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ABSTRACT 
 
 
Hysterectomy is commonly performed but there is scant evidence concerning 
appropriate follow-up by vaginal vault cytology testing.   
 
This observational, retrospective cohort study, using routinely collected data, linked 
women’s entire cervical screening histories with their operation details and 
subsequent vault cytology test results, to establish:  Which women are having 
hysterectomies?  What was the indication?  Which were followed-up?  How did they 
differ from those who were not? 
 
6,141 women underwent hysterectomy; an incidence of 23/10,000 women/pa.  
11.61% had malignancy, 3% had CIN and 82.9% had benign disease.  Median age 
was 48 years, women were of greater deprivation and different ethnicity from the 
background population.   
 
Post-operatively 1,016 (16.5%) had vault cytology testing.  Those having CIN at 
total hysterectomy should have vault cytology but only 63% had any, of these less 
than 10% had it according to protocol. 
 
Many factors were associated with having vault cytology (younger, less deprived, 
non-benign diagnosis and abnormal index cytology) but few clinically meaningful.  
Only 2.9% of vault cytology tests were abnormal. 
 
Efforts to identify and eradicate inappropriate use of vault tests should swiftly lead to 
savings.  Although national guidelines are targeting the right women, it is 
recommended that all vaginal vault cytology should be undertaken in secondary 
care hereafter. 
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ONS  Office for National Statistics (see above) 
p value probability value 
    
Pap test  Papanicolaou test for cellular changes in the cervical tissue 
PCO  Primary Care Organisation 
PCT  Primary Care Trust 
PhD  Doctor of Philosophy 
PIAG  Patient Information Advisory Group  
RCGP  The Royal College of General Practitioners 
RCOG  The Royal College of Obstetricians and Gynaecologists 
SHA  Strategic Health Authority 
SCAG  Security and Confidentiality Advisory Group of HES 
SPSS  Statistical computer package designed for Social Sciences research 
SNOMED Systemised Nomenclature of Medicine 
SNOMED CT SNOMED Clinical Terms subset 
UK  United Kingdom 
UKTC  UK Terminology Centre 
USA   United States of America 
VIN  Vulval Intraepithelial Neoplasia 
VaIN  Vaginal Intraepithelial Neoplasia 
WHO  World Health Organization 
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CHAPTER ONE:  INTRODUCTION 
 
In the United Kingdom, around 20% of the female population undergo surgical 
removal of the uterus during their lifetime.1’2  This major operation is known as a 
‘hysterectomy’.  Over 98% women who have their uterus surgically removed also 
have the cervix uteri or ‘neck’ of the uterus removed at the same time, a ‘total 
hysterectomy’,3 this leaves the vagina as a pouch with a blind end at the site of 
amputation of the cervix, the ‘vaginal vault’.  This thesis will consider data on a 
cohort of women who have had a hysterectomy operation and whether or not they 
are followed up after surgery by cytological screening of the vaginal vault. 
 
There are now several effective and less invasive alternatives to hysterectomy 
available to women and their Gynaecologists4; however, approximately 38,000 
hysterectomy procedures were undertaken in England in 2007-8 (most recent data) 
and 600,000 in the USA, making it one of the most frequently performed major 
surgical procedures.5;6  Over 90% of hysterectomy operations are known to be 
performed for benign indications,7 such as the presence of fibroids and 
dysfunctional uterine bleeding (DUB).4  The remaining operations are performed for 
removal of malignancies (endometrial, cervical, vaginal and ovarian), and 
additionally to remove Cervical Intraepithelial Neoplasia (CIN), a condition which 
may be a precursor to invasive cervical cancer.8   
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Even though it is performed often, hysterectomy is not without risk:  a large cohort 
study (the VALUE study) recorded an operative complication rate of 3.5% and a 
post-operative complication rate of 9%, with 1% requiring a return trip to the 
operating theatre.1  The Royal College of Obstetricians and Gynaecologists of the 
UK has estimated operative mortality from hysterectomy in the UK as being around 
one in 4,000 women.9  These figures are significantly lower than those reported in 
other older studies.10;11  This may reflect the fact that the ‘VALUE’ study was based 
upon self report by Gynaecologists and is not comprehensive; thus the study is 
believed to reflect around 45% of all hysterectomy operations in the UK from 1994 
to 1995, alternatively the situation has substantially improved over time. 
 
Previously it had been noted that an inverse gradient in social class and incidence 
of hysterectomy existed, in the UK,2;12 meaning that as women become more 
deprived their risk of undergoing hysterectomy increases.13;14  However, it is not 
known if this social class gradient persists with respect to follow-up.  Several large 
cohort studies have examined the indications for hysterectomy in the UK, however 
none has published any details of subsequent follow-up by means of the vaginal 
vault cytology test.1;2 
 
Total hysterectomy is usually a reason for ceasing routine cervical screening as the 
cervix is no longer present.  The aim of the UK National Health Service Cervical 
Screening Programme (NHSCSP) is to prevent cervical cancer, however, it does 
offer some guidance about use of vault testing post-hysterectomy.15,16   
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No international consensus exists on the appropriate cytological screening in 
women who have undergone a total hysterectomy, as evidence for the appropriate 
use of vaginal vault cytology tests (vault smears) post-hysterectomy and the 
optimum period of follow-up is sparse.  Cervical smear tests are known to cause 
anxiety to users and have a financial cost to the NHS.17  There is no reason to 
presume that this does not also apply to vault smears also.   
 
A vaginal vault cytology test or 'vault smear' is an exfoliative cytological sample 
taken from the blind end of the vagina in a similar way to the taking of a cervical 
Papanicolaou cytology test (See Chapter 2.3 for further explanation).  The sample is 
stained and a slide produced in a Cytopathology laboratory according to standard 
procedures and this slide may be examined under a microscope and then 
‘classified’ according to internationally agreed criteria.  
 
The classification of vaginal vault cytology tests is based on the same classification 
system as cervical cytology tests, with suitable additions to describe vaginal 
abnormalities.  The classification currently used is the British Society for Clinical 
Cytology (BSCC) and NHSCSP terminology.18  Recommended follow-up by means 
of vault smear tests after hysterectomy depends upon histology results at the time of 
hysterectomy (Figure 1). 
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The majority of published studies in this area, recommend the use of vaginal 
cytology in the follow-up of women who have had a hysterectomy subsequent to the 
diagnosis of an invasive tumour of the cervix, or where invasive disease is an 
incidental finding at hysterectomy.19-21  However, with respect to follow-up after 
hysterectomy for benign indications the literature is less clear.22;23  A systematic 
review of the literature could not identify any robust data to establish the benefit and 
effectiveness of follow-up, by ‘vault smears’ or ‘vault cytology’, of women who have 
had a hysterectomy for benign indications (see Chapter 2.3.2 for further 
information).24 
 
The available evidence does, however, suggest that the vaginal vault cytology test 
has a very low positive predictive value when used as a screening tool for the 
presence of residual abnormality after CIN in the absence of symptoms or clinical 
signs or for screening for Vaginal Intraepithelial Neoplasia (VaIN).22;23;25  Therefore, 
most commentators recommend that the use of vault cytology tests for post-
hysterectomy follow-up is only required for women who have had a histological 
diagnosis of CIN III or frank malignancy.19-21  Even then, vaginal vault cytology tests 
should be limited to those who present with symptoms or in whom an abnormality is 
detected clinically.26   
 
Half of all vault smear tests are conducted in the primary care setting in the UK but 
primary healthcare professionals’ knowledge about the role of the test is poor,27 
professionals whose knowledge about the test was best, performed the test least 
often.27  
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Only one significant abnormality was detected in an audit of over 4,000 specimens 
taken in Primary Care28 and vault smear tests in asymptomatic women can have a 
high false positive rate.22  One American study compared the results of vault 
cytology tests with cervical cytology tests, in matched controls, and noted that there 
was a significantly reduced risk of test abnormality in those followed up post-
hysterectomy.29   
 
Figure 1 lists the current NHSCSP guidelines for appropriate use of vaginal vault 
cytology in the UK.16 
 
Figure 1:  Current national guidelines for the routine use of vaginal vault cytology16 
 
"Women who have had a hysterectomy with CIN present are potentially at risk of 
developing vaginal intraepithelial neoplasia (VaIN) and invasive vaginal disease.  
There is no clear evidence that colposcopy increases the detection of disease on 
follow-up.  Expert consensus opinion recommends that: 
 
(i) for women on routine recall for at least 10 years prior to hysterectomy and no 
CIN in the sample at hysterectomy, no vault cytology is required. 
 
(ii) for women with less that 10 years' routine recall and no CIN at hysterectomy, 
a sample should be taken from the vault six months after surgery and there 
should be no further cytology follow-up if it is negative. 
 
(iii)  for women with completely excised CIN at hysterectomy, a sample should 
be taken from the vault at six and 18 months after surgery and there should be 
no further cytology follow-up if both are negative. 
 
(iv)  for women with incomplete or uncertain excision of CIN follow-up should be 
conducted as if the cervix were still in situ (i.e. as for low and high risk follow-up). 
 
It should be emphasised that these clinical guidelines for follow-up of women 
treated by hysterectomy are not part of the cervical screening programme and 
data on cytology from vault samples are not collected routinely." 
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Several large-scale national cohort studies have reported the socioeconomic 
distribution of patients undergoing hysterectomy12 and distribution of hysterectomy 
type (vaginal versus abdominal).1  However, no large, robust studies have been 
undertaken to establish actual patterns of follow-up, by means of vault smear tests, 
after hysterectomy.  We do not have any recent representative data on variability in 
follow up; compliance with national guidelines is, at present, also unknown.  Until we 
understand what actually is taking place, how much variability exists and why, it is 
difficult to suggest improvements, even though preliminary work suggests that 
vaginal vault cytology testing may be taking place inappropriately.28 
 
No international consensus exists as to the most appropriate follow up by vault 
smear test after hysterectomy;29 the UK guidelines that exist are not based upon 
robust ‘gold-standard’ evidence.16  With increasing pressure on diagnostic and 
treatment services every year, the identification of inappropriate usage of and 
evaluation of diagnostic services is more important than ever.  Thus there is a need 
for an adequately powered study to consider the issue of inappropriate use of 
vaginal vault cytology testing, the outcome of which may be used to inform national 
guidelines and encourage the teaching of best practice. 
 
The research reported in this thesis intends to fill a void in current knowledge 
concerning which women undergo hysterectomy operations and why and then 
describing the appropriateness, or otherwise, of any subsequent follow up. 
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In future national guidelines should be truly evidence based so that clinicians may 
be better able to inform their patients about the benefits and costs of screening 
using vaginal vault cytology tests.  To achieve this, a data linkage study of routinely 
collected datasets was undertaken and is now described in the forthcoming 
chapters:   
 
 Chapter two explores the background literature; a summary of what is 
already known about hysterectomy, cervical screening, use of vault cytology 
testing and some information about the chosen study methodology.   
 Chapter three explains the study methodology in detail, starting with the 
ethical approvals, then outlining the various data sources and concluding with 
the plan of data analysis. 
 Chapter four outlines the processes involved in extracting the study data from 
the source material, linking the databases and then anonymising the data. 
 Chapter five explains how the study data were validated and coded, in 
readiness for analysis. 
 Chapter six describes the results of the study; starting with demographic data 
of the whole cohort, then looking at women’s cervical screening histories, 
then considering what happened at hysterectomy and finally examining any 
subsequent follow-up by means of vaginal vault cytology.   
 Chapter seven explores the results by discussing the whole project and 
examining the results and analysis, and attempting to explain the findings.   
 Chapter eight includes the study conclusion and recommendations. 
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SUMMARY OF INTRODUCTORY CHAPTER  
The aim of this study is to describe the variation in hysterectomy rates and any 
subsequent follow-up by use of the vaginal vault cytology test, in women from the 
West Midlands region of the UK. 
 
To achieve this it is necessary to find out more information about those women that 
are undergoing hysterectomy operations:  Who are they?  Why do they undergo 
surgery?  Is this related to their cervical screening history?  What happens to them 
when they are in hospital?  What was the final diagnosis from their operation?  For 
those who had a total hysterectomy:  Were they subsequently followed up by means 
of vaginal vault cytology?  Was this done according to national guidelines and are 
there differences between those who were screened appropriately and those who 
were screened inappropriately? 
 
A novel data linkage study was undertaken to establish this information and is 
reported herein.    
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CHAPTER TWO:  BACKGROUND 
 
INTRODUCTION TO CHAPTER 
This chapter considers briefly how the ‘research question’ developed then 
summarises the relevant literature, including:  information about hysterectomy 
operations, cervical cancer, cervical cancer screening programmes nationally and 
internationally and also the role of vaginal vault cytology testing after total 
hysterectomy.  Work undertaken by the author in preparation for this thesis is also 
included.  The chapter then explains the chosen research question and justifies the 
methodology selected to answer it by reference to the literature and concludes with 
the stated aims and objectives of this project. 
 
The origin of the research question 
This research arose from an audit undertaken at Birmingham Women's Hospital 
(BWH) NHS Trust Cytopathology laboratory, in 2000 (reported in a MSc thesis).27  
The audit considered the results of all vaginal vault cytology tests (vault smears) 
analysed there.  Over the five-year period, February 1995 – January 2000, 5,080 
vault cytology tests were processed:  of these, 2,278 (44.80%) were generated in 
Primary Care, (Table 1), only one (0.02%) revealed any serious abnormality 
indicative of malignancy, forty four (0.87%) showed minor abnormalities or 
borderline changes, five (0.10%) contained endometrial cells, which implied that the 
hysterectomy had not been complete and 112 (2.20%) were deemed to be 
unsatisfactory for interpretation.27 
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These vault cytology tests represented over 2% of the workload of the 
Cytopathology department during this period (n=50,000 tests per annum, 250,000 in 
five years). 
 
Table 1.  Origin of vault cytology tests 1995 – 200027 
Source of vault tests 
 
Total number of 
tests 
% of total 
Out-patient clinics 2,623 51.70 
Primary care 2,278 44.80 
Private hospitals / clinics 71 1.40 
Family planning clinics 54 1.10 
Hospital in-patients 28 0.55 
Genitourinary clinics 26 0.51 
TOTAL 5,080 100.00  
 
These results led staff at the Cytopathology department to question why so many 
tests were being performed and if this was an appropriate use of resources.  The 
vault cytology tests, particularly those from Primary Care, had poor detection rates, 
and thus the suspicion was raised that some tests were being undertaken 
inappropriately and not within the framework of national guidelines. 
 
This led to a programme of work including:  a questionnaire survey of healthcare 
professionals who undertake vault cytology testing, to establish their knowledge and 
behaviours, a systematic review of the relevant literature and a larger scale, audit of 
the records at BWH pathology department.24;27;30  The conclusions suggested that 
there is a significant knowledge gap concerning vaginal vault cytology testing, in 
particular with respect to their use in primary care and the appropriateness of this. 
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2.1  HYSTERECTOMY  
 
A clear distinction between, and understanding of, the various types of hysterectomy 
operation, and the risks and benefits of each, is essential if unambiguous messages 
are to be conveyed to primary care staff about requirements for ongoing cytological 
surveillance in women post-hysterectomy.   
 
2.1.1  The hysterectomy operation and its variants 
 
History of the hysterectomy operation 
In the United Kingdom (UK) currently around 20% of the female population undergo 
surgical removal of the uterus during their lifetime2,31,32 this operation is known as a 
‘hysterectomy’ operation from Greek origin:  hysteros = uterus or womb, ectomy = 
removal.  Figure 2a & b illustrate the female pelvis and the organs that are usually 
removed during hysterectomy.  
 
Geoffrey Chamberlain notes that hysterectomy had been performed before the 
advent of anaesthesia but was ‘highly dangerous’; vaginal hysterectomy was noted 
to be somewhat safer and a successful vaginal hysterectomy was undertaken in 
Guy’s Hospital, London in 1827.33 Even with advances in anaesthesia it was only 
the introduction of the ‘head down’ operating position in the 1890’s that pelvic 
surgery became safer and a realistic surgical option.   
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Figure 2a. & 2b.  Female genital organs* 
 
Roy Porter comments that the subsequent surge in the numbers of hysterectomy 
operations in the 19th century was an “abuse of gynaecological surgery to control 
women” and that this was an operation performed by male surgeons who were all 
too keen to remove the uterus.34 
 
 
 
 Total hysterectomy involves surgical removal of the uterus (womb) and cervix, leaving 
the vagina as a closed tube, deep in the female pelvis.  Commonly the ovaries and 
fallopian tubes are removed at the same time.  If the cervix is not removed this is called 
a ‘sub-total’ hysterectomy. 
        *  Modified by the author, from NHS Direct, with permission 
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In the twentieth century the ‘total’ hysterectomy became increasingly popular (see 
below) and overtook the ‘sub-total’ operation as gynaecologists realised that cancer 
could occur in the remaining cervical stump.33  By the time of the First World War, 
abdominal hysterectomy was becoming the most commonly performed major 
gynaecological operation in the UK.  However, as surgery frequently took place in 
the patients’ own home, the outcome was highly variable.33 
 
As antibiotics were introduced into routine surgical practice after the Second World 
War, hospitals became the natural home of surgery and as anaesthetic techniques 
improved so did the outcome of all types of major surgery.33  From the 1960s 
onwards hysterectomy became routine surgery in most hospitals.35 
 
Subtotal or Total hysterectomy? 
Over 98% women who have their uterus surgically removed, in the UK, also have 
the cervix uteri or ‘neck’ of the uterus removed at the same time (called a ‘total’ 
hysterectomy).4  This leaves the vagina as a pouch with a blind end at the site of 
amputation of the cervix (Figure 2a & 2b), this pouch is called the ‘vaginal vault’.  A 
partial or sub-total hysterectomy leaves the cervix in position and just removes the 
main body of the uterus.  A radical hysterectomy involves removal of the vagina and 
the surrounding pelvic tissues and is usually reserved for the surgical management 
of malignancy.  Any type of hysterectomy is frequently accompanied by removal of 
the Fallopian tubes and the ovaries; known as a ‘bilateral salpingooophrectomy’, 
commonly abbreviated to BSO.4  
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Subtotal hysterectomy has seen something of a recurrence in popularity, particularly 
in the USA, since the late 1990s, this has coincided with an expansion of 
laparoscopic technologies,36 as the most risky part of laparoscopic hysterectomy is 
excision of the cervix and control of subsequent vaginal bleeding.36  However, 
laparoscopic hysterectomy is still only a practised routinely by a small number of 
surgeons and does not account for all of the increase.36   
 
In Denmark a large study (The Danish National Patient Register 2001) looked at 
hysterectomy over an 11-year period and noted that the number of abdominal 
hysterectomies had declined by 38% but the number of subtotal procedures had 
increased by a factor of 4.5x37 this trend has not been reported in the literature in 
the UK. 
 
A suggested reason for undertaking a subtotal procedure is that the cervical 
remnant may assist with supporting the pelvic floor, however, a large randomised 
controlled trial does not support this.38  There are several known disadvantages of 
leaving a cervical remnant, including risk of persistent vaginal bleeding, cervical 
mucus discharge, cervical prolapse and the enduring risk of cervical neoplasia 
leading to a requirement for continued cytological surveillance.36  Conversely, there 
have been claims than sexual satisfaction could be enhanced by cervical 
preservation, however, these have not been supported by any objective, high 
quality, evidence.36  Subtotal abdominal hysterectomy may be quicker and easier  to 
perform than a total hysterectomy, but these are probably the only genuine 
benefits.39
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Since the 1980s many new treatments have evolved which have reduced the 
reliance on hysterectomy to treat various benign gynaecological disorders.  These 
include assorted methods of destroying the lining of the uterus – the endometrium 
(ablative techniques), and innovative methods to obliterate the blood supply to 
benign tumours (embolisation techniques).  However, hysterectomy remains the 
preferred procedure for removing pelvic tissue as it permanently and irreversibly 
removes the potential for future malignant gynaecological disease.33 
 
Abdominal or vaginal hysterectomy? 
A hysterectomy operation may be undertaken through the traditional surgical route 
of a vertical abdominal incision; however a ‘Pfannenstiel’ incision, made horizontally 
across the lower abdomen, is the route of choice for most gynaecologists, both 
approaches are termed ‘abdominal hysterectomy’.  Increasing in popularity, 
particularly in the last decade are less invasive approaches including vaginal 
surgery and laparoscopic (keyhole) techniques.4  Vaginal surgery offers the 
prospect of faster return to normal activity, shorter duration of hospital stay and 
reduced risk of post-operative infections, whereas abdominal surgery allows greater 
access to the pelvis for the removal of large tumours and for extensive surgery (as 
in the case of malignant disease).32  Laparoscopic hysterectomy requires greater 
surgical expertise and takes longer than the other methods but offers the shortest 
recovery times.32 
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Incidence of hysterectomy 
Incidence and prevalence of hysterectomy has varied widely over the years and 
over geographic location:  during the mid 1970s up to 50% of women in California 
had undergone the operation (prevalence) whereas at that time in Scotland it was 
20%.4  Hysterectomy has been declining in popularity in more recent years:  
estimates from the 1980s suggest that 100,000 women underwent the procedure 
annually; in England in 2002 - 2003 there were some 42,500 operations, whereas in 
2007-08 there were 38,300 (Table 2).  However, it is still one of the most commonly 
performed major operations as it is the definitive procedure for cure of many 
conditions.   
 
In the USA around half a million women still undergo the procedure annually36 but 
there remains significant variation between countries.  Table 2 summarises the 
available international data. 
 
Thus, at least a million women currently alive in the UK have had a hysterectomy 
procedure undertaken.  With an ageing population this number will continue to rise, 
even though operation rates have been decreasing.  As such it is important to 
establish if women need any form of ongoing cytological surveillance post-
hysterectomy and, if so, on whom should it be undertaken. 
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Table 2.  Incidence of hysterectomy worldwide40 
Country Number 
p.a. 
Rate Year of 
latest data 
Source & Notes 
England 38,328 13 per 10,000 2007-08 HES via DOH website. The Information 
Centre, England only, 2007-085 
England 74,000 26 per 10,000 1994-95 Dept of Health. HES England 1994-95 
Vol 1 London HMSO 199641 
UK 100,000 35 per 10,000 1989 Vessey & Villard. Oxford Family 
Planning study, incidence of 20% by age 
55yrs2 
France 60,000 21 per 10,000 1997 Cosson.  Retrospective case notes 
review42 
Denmark 5,000 19 per 10,000 1998 Moller37 and Gimbel.14  Danish national 
patient register, sample of discharge 
summaries 
Italy - 37 per 10,000 1997 Materia E.  Residents of Rome, hospital 
discharge records43 
Finland 8,663 64 per 10,000 
women  aged 
over 35 years 
1988 Luoto.44  Finish hospital discharge 
register and 1987 population census, 
significant socio-economic variation   
Norway - 12 per 10,000 
women 
1982 McPherson.45  National government data
Australia 30,000 45 per 10,000 2001-02 Australian council for safety and quality 
in healthcare, from national hospital 
morbidity data46 
USA 550,000 56 per 10,000 
women 
1997 Farquhar C.  National discharge data 
sample of 20% of US hospitals 1990-
19973.  Life prevalence 33%, up to 43% 
in Utah47 
 
 
Socioeconomic factors in hysterectomy incidence 
It has been observed in the UK1;2 and internationally13;14;48;49 that, during the 1980s 
and 1990s, hysterectomy was more commonly undertaken in women of ‘lower 
socioeconomic class’ or women who were more ‘deprived’, the reasons for this 
generated debate in the 1980’s and included (amongst others), associations with 
pre-cancerous cervical change and increased promiscuity in those of lower social 
class leading to more hysterectomy operations1;50.   
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However, some exceptions to this pattern have been observed, particularly in 
Finland and in Los Angeles USA where more affluent women have undergone the 
operation more frequently, particularly for benign disease, this phenomenon seems 
to be associated with the higher availability of private gynaecology services to 
women of higher social class.44;50;51 
 
Summary 
Although the hysterectomy operation has attracted controversy because of its rise 
and fall in popularity,52 it remains a very common procedure in the Western world.  
Consequently, all primary healthcare professionals will have patients who have 
already had, or will in future undergo, hysterectomy.  Subtotal hysterectomy leaves 
part, or all, of the cervix in place whereas a total hysterectomy includes full removal.  
This has implications for any post-hysterectomy cytological surveillance. 
 
 
2.1.2 Indications for hysterectomy, past and present 
 
Over 90% of hysterectomy procedures are performed to cure benign conditions, 
despite the rise in very effective alternative treatment options, the majority 
undertaken for conditions which generate excessive menstrual blood loss, (see 
Table 4).53  Excessive menstruation or ‘menorrhagia’ may be a major problem and 
some women become clinically anaemic and have their normal activities curtailed by 
it.  Menorrhagia is the commonest cause of iron deficiency anaemia in the western 
world.4  
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In many women, no underlying disease process is detected and the term 
‘dysfunctional uterine bleeding’ (DUB) is used to describe the phenomenon of 
menstrual blood loss of a volume deemed unacceptable by patients, although 
various other definitions exist.   
 
Other causes of excessive menstrual blood loss include defects in the process of 
blood clotting i.e. Von Willebrand’s disease, pelvic infections, the presence of a 
foreign body in the uterus i.e. a copper containing intrauterine contraceptive device 
(IUCD) or adenomyosis (a condition where endometrial tissue is detected deep in 
the musculature of the uterus).54  
 
Other benign indications for hysterectomy include the presence of fibroid disease 
(smooth muscle, non malignant tumours) and endometrial polyps, both of which 
may present with excessive menstruation or because of pressure effects on other 
organs, or prolapse of the uterus and/or surrounding structures. 
 
Pre-malignant disease makes a contribution to the incidence of hysterectomy:  since 
the advent of routine cervical screening (see section 2.2) pre-invasive disease of the 
cervix is detected and treated in a variety of ways, depending on severity.  To treat 
more serious or recurrent disease definitively a total hysterectomy, with excision of 
some vaginal tissue can be performed. 
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Malignancy of the vulva, vagina, cervix, uterus or adnexal structures (fallopian 
tubes, ovaries or ligaments) are all indications for hysterectomy; often more radical 
variants of the operation are performed to ensure a clear margin of tissue, free from 
any invasive disease, and thus minimise the opportunity for metastatic spread 
subsequent to surgery.8   
 
Table 3  summarises the latest information concerning the incidence and mortality of 
the various types of gynaecological malignancy in the UK and latest estimates for 
the United States of America.  It may be seen that cancer of the uterus (including 
endometrial and cancer of the body of the uterus) is the most common malignancy, 
closely followed by ovarian cancer, with vaginal cancer being very rare (six cases 
per million women). 
 
Routinely collected statistics can be used to provide annual data incidence of 
hysterectomy in the UK, however, it is only by looking for emerging trends over time 
that we can understand what is actually happening to patients over their life course. 
 
Table 3.  Incidence of gynaecological malignancy55;56 
Site of 
malignancy 
UK incidence 
 2005 (actual) 
per 100,000* 
UK mortality 
 2006 (actual) 
per 100,000* 
USA incidence 
(estimated) 
per 100,000* 
USA mortality  
(estimated) 
per 100,000* 
Uterus 17.9 3.5 13.75 1.37 
Ovary 17.4 10.1 7.0 4.72 
Cervix 8.4 2.4 8.2 2.5 
Vulva 2.3 0.6 1.2 0.3 
Vagina 0.6 0.2 0.7 0.3 
*incidences per 100,000 women (not head of population).  
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The last major survey of hysterectomy in the UK was published in 2002:  the 
‘VALUE’ study objectives were to describe hysterectomies performed in 1994 and 
1995, their patients, surgery and short term outcomes.1  The study collated data 
from about 45% of the operations during that year (n= 37,298) by self report from 
gynaecologists through England, Wales and Northern Ireland.  Table 4 summarises 
these data and includes comparative data from an American study of a sample of 
national hospital discharge data covering 1990-1997.3   
 
Table 4.  Indications for hysterectomy (excluding malignancy)1,3;57 
Indication* UK  
% of all 
USA  
% 
Notes 
Dysfunctional uterine bleeding (DUB) 43.46 13.46
Fibroids 17.74 40.53
Difference reflects variation in 
coding between these two 
diagnoses 
Prolapse 18.96 18.13 Very similar rates 
Endometriosis / Adenomyosis 6.71 14.33 USA only stated endometriosis so some of their cases will be in DUB 
Pelvic mass (excluding malignancy) 4.06
Other 8.00
13.60 USA data did not have a pelvic mass category 
 
Both authors noted that the large number of hysterectomies for fibroid disease and 
abnormal bleeding in the absence of malignancy were areas where operative 
incidence may be reduced in future, with the advent of endometrial ablative 
techniques and the licensing of a novel progesterone releasing intra-uterine system 
(Mirena® IUS) providing less destructive alternatives than major surgery.1;3 
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2.1.3  Outcomes and risks of surgery  
Hysterectomy rarely leads to peri-operative death in the UK with a quoted incidence 
of just 1 in 4,000 operations,9 however, major post operative and long term 
complications are more frequent.  Table 5 summarises the most recent literature 
concerning complications of hysterectomy with approximate frequencies; estimates 
suggest that severe operative complications occur in 4.4% of hysterectomies.1;57  
Likelihood of complications increases with advancing age and presence of any co-
morbidities. 
 
Iversen and colleagues58 used the RCGP oral contraception cohort study, of 23,000 
women with over 20 years of follow-up on average, to establish that in the medium 
to long term hysterectomy was not associated with an increased risk of all cause 
mortality or with death from cardiovascular or malignant disease when compared to 
women who did not have a hysterectomy.58  
 
It is a key aspect of high quality, contemporary, clinical practice that patients 
undergoing major surgery are provided with unambiguous information about the 
indication for surgery and the potential risks and benefits from it.  In addition, 
patients should be offered a full discussion, with their surgeon, about all other 
available treatment options:  hysterectomy inevitably has some significant risks 
associated with it, although it is usually regarded as ‘routine surgery’ and the risks to 
any one individual are low.9 
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Complications that matter to most patients include changes in their quality of life, 
sexual function, pelvic pain, bowel and urinary function and vaginal prolapse.32 
Overall quality of life for women who have been suffering from prolonged abnormal 
uterine bleeding (the commonest indication for hysterectomy) has been shown to be 
significantly improved at six months and two years after surgery.59  Thus although it 
is a major procedure with the potential for serious complications, most women who 
undergo a hysterectomy are happy with the outcome and gynaecologists regard it 
as highly effective, this may go some way to explaining why, despite many viable 
alternatives, it remains such a popular operation.39 
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Table 5.  Complications of hysterectomy operations 
Operative complications Frequency  Notes or source of data 
Intra-operative death 0.025% Nil reported in latest series1;9 
Major haemorrhage 2.27% 
Damage to pelvic organs / viscera 0.73% 
Respiratory / Cardiac complication 0.35% 
Need to return to theatre 0.76% 
All operative complications 3.50% 
 
 
Maresh, Value study1 
Post operative complications   
Death (within six weeks) 0.04% 
Severe cases (includes death, thrombosis, 
myocardial infarction, renal failure, stroke, 
septicaemia, necrotising fascitis, secondary 
haemorrhage, fistula, ureteric obstruction, 
visceral damage and late return to theatre) 
1.03% 
Not severe cases (wound problems, all 
infections, pelvis or urinary tract related, 
incontinence, adhesions, bowel obstruction, 
anaemia, anaesthetic problems, pyrexia, nerve 
entrapment, depression, psychiatric symptoms 
or sleeping difficulties.)   
7.67% 
All 8.59% 
 
Maresh, Value study1 
Long term complications57;60   
Altered sexual function Nil  Farrell61 old studies had 
negative findings but high 
quality research consistently 
reports improvement 
Altered bowel function (including constipation) 5.0% Thakar62 Most studies 
retrospective, no conclusive 
evidence of causation 
Altered urinary tract function Up to 20% Vierhout63  Most studies 
retrospective, and again no 
conclusive evidence of 
causation 
Vaginal vault prolapse 0.2 – 1.0% Barrington64 
All pelvic prolapse 5% Blandon65 
Quality of life Improved 
for most 
Kupperman59 
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2.2  CERVICAL CANCER AND THE NATIONAL SCREENING PROGRAMME 
 
Follow up after hysterectomy using the vaginal vault cytology test uses the same 
techniques, technology and NHS systems as those already established to screen for 
cervical cancer.  This section will thus outline the aetiology and natural history of 
cervical cancer and the justification and implementation of national and international 
screening programmes as this has implications for the delivery of vaginal vault 
cytological testing. 
 
2.2.1  The natural history of cervical cancer 
 
Cervical cancer (carcinoma of the cervix) has been known since ancient Egyptian 
times, when it was treated by cautery.33  It is currently the third commonest cancer 
in women worldwide, after breast and bowel.66;67  In the UK currently it is the 11th 
commonest cancer of women; this significant difference is due primarily to the highly 
successful national screening programme used to detect pre-invasive squamous 
disease of the cervix and treat it before it develops into malignancy.15;68  Cervical 
cancer deaths worldwide occur mainly in the developing world (80%) where, in 
many regions, it is the commonest cancer affecting women.66 
 
Cervical cancer can take several forms; squamous cell type is the commonest (at 
least 90%) which tend to occur in the squamo-columnar junction of the cervix, then 
adenocarcinomas or tumours ‘of glandular origin’ comprising the rest, (less than 
10%), tending to occur within the cervical canal.8   
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Where no effective screening programmes exist, the incidence of cervical cancer 
rates have remained relatively constant over time:  incidence rises rapidly in the age 
group 25-40 years then reaches a plateau and eventually decreases a little in 
women over the age of 70 years.66  However, where changes occur in sexual 
behaviour of populations (increasing numbers of sexual partners) a rise in incidence 
occurs in younger age groups.66 
 
Squamous cervical cancer has a well established ‘natural history’ whereby early 
changes in cervical tissue may progress to invasive disease.  This pre-cancerous 
stage is known as Cervical Intraepithelial Neoplasia (CIN) and is categorised in 
three main stages (CINI, CINII and CINIII), illustrated in Figure 3.  It is possible for 
any of these stages to regress but the more advanced the disease, the less likely 
that this spontaneous regression will occur.  Currently it is estimated that, if left 
untreated, approximately 90% of changes induced by infection with human 
Papilloma virus (HPV) will regress spontaneously within 12-36 months as the 
human immune system eliminates the virus, see Figure 3 and section 2.2.2 for 
explanation of the role of HPV.69   
 
Although estimates vary widely, up to 80% of CIN I will probably regress 
spontaneously if left untreated66;70 whereas approximately 30% of CIN III will.  
Having any such abnormality significantly increases the risk of developing cervical 
cancer over background rates.   
  
- 27 - 
Rate of natural progression through these stages usually takes several years.  A 
study by McIndoe and colleagues (which could never be repeated for ethical 
reasons), considered 131 women who had been diagnosed with CINIII and he 
followed them up, without treatment, for several years; after 20 years 36% had 
developed invasive disease. 71 
 
Nomenclature concerning CIN and dyskaryosis is confusing to those who do not use 
it regularly, Table 6 includes three different histological schemes; the Bethesda 
scheme,72 introduced to simply the classification, is not widely supported in the UK, 
where ‘scheme 2’ is in use.  The term carcinoma in situ is no longer in favour but is 
found in much of the literature in this area and the reader needs to understand 
where it sits in the order of disease progression.   
 
Figure 3.  Progression of cervical cellular changes in CIN* 
 
 
*  Adapted, by the author, from GSK ‘notes for speakers’, with permission 
Time: YearsMonths 
Normal  
epithelium 
HPV infection;
koilocytosis 
CIN I CIN II CIN III 
CIN I 57%      CIN II 43%     CIN III 32% 
Approximate likelihood of spontaneous regression 
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An exfoliative test to detect cellular changes that may be indicative of CIN was 
developed by George Papanicolaou (1883 - 1962).  In 1941 he published a 
definitive paper about his work on identification of cervical cancer in cells scraped 
from the walls of the vagina and cervix.73  In 1947 a spatula (Ayre’s) was produced 
to obtain an optimum exfoliative sample of cells and the cervical ‘smear test’ or ‘Pap’ 
test was gradually adopted.35 
 
The nomenclature used for describing abnormalities detected by these screening 
tests has varied over time and there have been problems with intra-observer 
variation in classification.  The correlation between results obtained by means of 
screening tests and the histological results obtained from biopsy is variable.70  The 
term dyskaryosis is applied to abnormal screening tests but mild dyskaryosis does 
not translate perfectly to mild dysplasia or CIN I, although they are associated.  
Thus direct comparison of cytological test results and histological description of 
biopsy specimens is not technically accurate.72 
 
Table 6.  Terminology for describing squamous cell lesions* 
Scheme 1 Scheme 2 Bethesda 
- HPV changes 
Mild dysplasia CIN I 
Low grade lesions 
Moderate dysplasia CIN II 
Severe dysplasia 
Carcinoma in situ 
CIN III 
High grade lesions 
*  NB.  These terms, across the three schemes, are not interchangeable but are aligned  
            to allow for meaningful comparisons 
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2.2.2  Risk factors for developing CIN 
 
There are several factors associated with a risk of developing the pre-invasive 
stages of cervical cancer.  The first, and most critical of these, is undoubtedly the 
presence of infection with an oncogenic strain of the Human Papilloma Virus (HPV) 
at some time.66;69  Believed to be an essential step in disease progression, this 
family of small DNA viruses has over a hundred known sub-types, of which, forty 
have been associated with cervical and other lower genital tract cancers (vulval, 
vaginal and anal in women and penile and anal cancers in men).  Transmitted via 
skin to skin or sexual contact69 they are highly prevalent74 and it is estimated that up 
to 70% of women have been infected at some time.75  Most infection is 
asymptomatic and routine testing for HPV is not currently available in the UK.74;76 
 
Recently two highly effective vaccines have been launched to protect people against 
two oncogenic subtypes of HPV (16 & 18) which are responsible for triggering over 
70% of cervical cancers.69  National immunisation programmes are now underway 
in many Western countries to ensure that all girls under the age of 18 are 
immunised.77;78  It is envisaged that this intervention has great potential to reduce 
deaths from cervical cancer, although it will take many years for this to be realised 
due to the slowly progressing nature of the disease and that these girls are currently 
very young.77  There is a strong argument for women who are HPV naive but are 
older than 18yrs of age, being vaccinated, however cost-effectiveness concerns 
have tended to age-limit public programmes.79 
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Other factors that increase the likelihood of developing pre-malignant disease of the 
cervix include:  greater social deprivation, poor uptake of cervical screening 
opportunities, presence of HIV infection, smoking, long term use of oral 
contraceptives, higher parity and higher numbers of pregnancies, early age of first 
intercourse and multiple sexual partners.80  Cervical cancer survival is strongly 
related to screening history as ‘screen detected’ disease is usually found at an 
earlier stage than disease that presents symptomatically.  Survival is also related to 
access to optimal cancer care and, until 2000, this was uneven throughout the 
UK.67;81 
 
2.2.3 The NHS Cervical Screening Programme (NHSCSP) 
 
Cervical screening in the UK, using the Papanicolaou smear test, began to be 
adopted by doctors in the 1960s and by the mid-1980s many women were having 
regular tests done opportunistically by their General Practitioner, but there was 
concern that those at greatest risk of cervical cancer were not being tested.82  In 
addition, it was suspected that those with positive screening results were not being 
followed-up and treated effectively or consistently across the country.82  
Consequently, the NHS Cervical Screening Programme (NHSCSP) was established 
in 1988, when the Department of Health instructed all health authorities to introduce 
computerised call/recall systems and to meet certain quality standards.82   
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There is a large body of scientific evidence which states that both the incidence and 
mortality from squamous cancer of the cervix can be reduced by well-organised 
screening programmes.66  Indeed, in the UK alone, it is now estimated that 5,000 
lives are saved annually by the cervical screening programme15 (4,500 in England) 
and that the programme is directly responsible for the 42% drop in the annual 
incidence of cervical cancer observed between 1988 and 1997.   
 
The single most important factor in this improvement is the significant increase in 
screening coverage: in 1988/89 only 44% of the target population of women aged 
25-64 were screened every five years, in the late 1990’s 85% of the same target 
population were being screened.  However, since 2000, this proportion has been 
falling, and although coverage in women over 50 years has been sustained at over 
80%, in younger women five-yearly screening levels are below 79% and the three 
and a half yearly target for women under 50 years is achieved in less than 70%.15  
 
The stated aim of the NHSCSP is to reduce deaths from cervical cancer.83  It is 
funded by regional health authorities, from their overall budgets.82  The national cost 
is estimated at approximately £132 million per annum, or £34 per woman 
screened.82  The actual number of women screened in 2007/08 was 3,223,239, an 
increase of over 50,000 on the previous year.  The number of tests that were 
inadequate for interpretation fell by around 50,000, thus there has been a 
considerable improvement in efficiency and coverage.15 
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The proportion of tests that are taken in Primary Care has slowly been increasing, in 
2003 it was 92.1% but in 2007/08 it was 93.8%.  Overall the total number of tests 
taken has fallen (as inadequate rates fall, fewer women needed to have repeat 
tests), but the decrease appears greater from secondary care.15 
 
Women who have abnormalities detected are either referred to a local colposcopy 
service for further investigation or a repeat test is advised.  Table 7 summarises the 
various test results and recommended actions, these are nationally set.  Of those 
referred to colposcopy:  17% are because of persistently borderline changes, 31% 
for mild dyskaryosis, 14% moderate and 14% severe disease.  Less than 1% are 
referred for potential invasive cancer and 1% for potential glandular cancer.15 
 
Table 7.  Management of abnormal cervical cytology results84 
Screening test result Histology Action recommended 
Normal 0.1% CIN II-III Repeat 3 / 5yrs depending on age 
Inflammatory 6.0% CIN II-III Repeat 6m 
Borderline nuclear changes 20-37% CIN II-III Repeat 6m 
Mild dyskaryosis 50% CIN II-III Refer colposcopy 
Moderate dyskaryosis 50-75% CIN II-III Refer colposcopy 
Severe dyskaryosis 80-90% CIN II-III Refer colposcopy 
Severe dyskaryosis ‘positive’ 
or ‘malignant cells’ 
5% invasive disease Refer colposcopy 
Invasion suspected 50% Invasion Refer colposcopy - Urgent 
Abnormal glandular cells Possible adenocarcinoma of 
the cervix or endometrium 
Refer colposcopy - Urgent 
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Since 2005, further to successful regional trials, a novel approach to the processing 
of cytological samples from the cervix was introduced throughout the UK:  Liquid 
Based Cytology (LBC) has been implemented nationally since 2007 and has already 
led to a reduction in the number of inadequate samples generated.85  
 
LBC represents a combination of a new sampling device (a soft brush that is rotated 
over the transformation zone), a new transport medium (a suspension into which 
either the entire brush head or the cells from the brush are deposited) and an 
automated system for the processing of samples.85  All primary healthcare 
professionals who routinely take cervical cytology had to be re-trained to learn this 
new technique; however, training did not include sampling of the vaginal vault.  The 
soft brush sampling device does not lend itself to this variant of the test as well as 
the Aylesbury spatula used to. 
 
With the reduction in numbers of tests being processed, Cytopathology laboratories 
have been actively trying to reduce the time taken to process samples and generate 
the result; over the past five years this has improved with 49% of results being 
available within a fortnight and 83% within four weeks, compared with only 70% in 
2003/04.15   
 
In England and Wales the age-standardised incidence of cervical cancer in the 
1970s and 1980s remained between 14 and 16 per 100,000 (excluding some 
specific cohort effects);67 in 2000 it was below nine per 100,000.   
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Although overall coverage of the screening programme is very good there has been 
a noticeable decline in the proportion of younger women attending for screening.  
There is concern that if coverage of screening falls further then there will be a 
concomitant rise in cervical cancer in the future and significant efforts are being 
made, both nationally and locally, to recruit younger women back to screening 
programmes.15;86  
 
Since the death of a young, UK celebrity in 2008, from cervical cancer, and the 
introduction of the national HPV vaccination programme in the same year, there has 
been considerable media attention on the subject of cervical cancer.  The ‘Jade 
Goody effect’ appears to have had a substantial impact on increasing uptake of 
screening in women aged 25-30 years, however formal data is awaited.87 
 
In any screening programme resources may be used inappropriately.  Vaginal vault 
cytology tests should not normally be paid for under the auspices of the national 
cervical screening programme.  By definition, they are not a screening test for pre-
invasive disease of the cervix, as no cervical tissue remains.  A cytology test taken 
from cervical remnants after less radical surgery should not be called a ‘vault smear’ 
or ‘vault cytology’ as this could cause confusion in the interpretation of the slide; it is 
still a cervical cytology test.   
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2.2.4  Screening for cervical cancer:  The international perspective 
 
The World Health Organisation recommends that any screening test should only be 
adopted and implemented if it fulfils several criteria.  These criteria, identified and 
publicised by Wilson and Junger,88 suggest that ‘screening’ is a process of 
identifying individuals who are at sufficiently high risk of a specific condition to justify 
further investigation or treatment.   
 
Screening tests are systematically offered to a population who have not sought 
medical attention or do not display symptoms of the condition which is being tested.  
The aim of screening programmes are to benefit the individuals being tested:  thus 
there is an ethical imperative to ensure that any screening tests are sensitive, 
specific, cost effective and acceptable to patients and to minimize the potential for 
harm.  It is also important that patients realise that screening tests are fallible and 
that false negatives will occur. 
 
We know the natural history of cervical cancer; there is often a long time between 
first detectable cellular changes and progression to serious disease, particularly with 
respect to squamous cell carcinoma.  Inevitably many women will be identified as 
being at risk of disease when in reality only a small number would ever go on to 
develop cervical cancer, thus many women will be unnecessarily worried and further 
investigated due to an abnormal test result.   
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To minimise this harm a balance must be struck between over testing, and thus 
inevitably having more false positive results, and screening too infrequently and 
missing genuine cases. 
 
To run a successful cervical screening programme issues to be tackled include: 
funding and resources, training of healthcare practitioners, provision of quality 
assured laboratories, referral and treatment pathways, national monitoring systems 
for ‘call and recall’ and education of the population to ensure participation.66   
 
Worldwide there are significant variations in approaches to screening for cervical 
cancer:  In most affluent nations screening exists but there is wide variation in how 
this is undertaken, by whom and how often.66  Deaths from cervical cancer in 
developed countries occur mostly in women who have never been screened and the 
greatest mortality is in women aged over 50.  The reader is directed to the 
International Agency for Research on Cancer (IARC), of the World Health 
Organisation (WHO), handbook on cancer prevention series, volume 10 which 
collates world wide data on this subject of cervical cancer.66 
 
The European Union recommended cervical screening in all member states, in 
1987, and issued quality assurance guidelines in 1993.  However, coverage is still 
variable ranging from comprehensive programmes with good coverage in Denmark, 
Finland, Norway and Spain through to pilot programmes in Eire, Greece and 
France.66   
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Age of screening is also variable with Luxembourg starting screening sexually active 
girls of 15 years but Finland, Sweden and Netherlands starting at 30 years.  
Cessation of screening occurs between 59 and 69 years.66  Screening is undertaken 
in both primary and secondary care and five-year coverage (i.e. the proportion of the 
eligible population having at least one screening test within five years) ranges from 
40% in Spain to over 90% of women in Finland.66 
 
In the USA provision of cervical screening is variable and depends upon personal 
circumstances with the well-insured being offered annual screening as part of 
routine health checks but the uninsured dependent on State programmes which 
vary widely; many women are not eligible.  In Canada there is universal coverage of 
cervical cancer screening which is devolved to provinces to administer; most 
screening has been opportunistic although this is changing as organised 
programmes with call and recall are introduced.  In Australia cytological testing has 
been available from the 1960s with a national screening programme being 
introduced in 1995 on a two-year screening interval (18 – 69 years).  In Africa 
screening is difficult to achieve because of competing healthcare needs of the 
population and a lack of resources, additionally, the higher prevalence of HIV 
infection is a profound problem, which in turn impacts upon the incidence of cervical 
cancer.66 
 
Universal availability of screening for cervical cancer is an international health aim, 
as there are profound variations in practice.  
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2.3  VAGINAL VAULT CYTOLOGY TESTS (VAULT SMEARS) 
 
Screening after total hysterectomy by examining a cytological sample taken from the 
scarred region of the vagina where the cervix used to be located (the vault), is used 
variably by clinicians.  This section defines the anatomy, explains the national 
guidelines and testing process and explores the current evidence for use of the test 
in clinical practice. 
 
 
2.3.1  What is a vaginal vault cytology test (vault smear)? 
 
Total hysterectomy includes removal of the cervix-uteri (called the cervix hereafter), 
and leaves the vagina as a blind ending pouch; this pouch is known as the vaginal 
vault.  Since the cervix has been removed completely there is no possibility of the 
development of a primary cervical cancer and thus no indication for routine cervical 
screening.  Papanicolaou (Pap) tests of the vaginal vault are a means of detecting 
recurrent invasive or pre-invasive disease of the lower female genital tract (Vaginal 
Intra-epithelial Neoplasia – VaIN) in women who no longer have a cervix.31  Subtotal 
hysterectomy is an indication for continued participation in the routine cervical 
screening programme, however, as explained in Section 2.1.1, subtotal surgery is 
undertaken in less than 3% of the hysterectomies performed in the UK.1 
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2.3.2 Indications for undertaking vault cytology tests 
 
2.3.2.1  National guidelines89,16,83 
Screening using vaginal vault cytology tests fall outside the NHSCSP (see section 
2.2.3 for details of NHSCSP), as they are not used to prevent cervical cancer.  
However, there are some guidelines relating to appropriate use, these are listed in 
Figure 4 and apply to both primary and secondary care clinicians. 
 
Figure 4.  Summary of NHSCSP guidance:  use of vaginal vault cytology16 
 
-  For women on routine recall for at least ten year prior to hysterectomy and no CIN 
in the sample at hysterectomy, no vault cytology is required. 
 
-  For women with less than ten years routine recall and no CIN at hysterectomy, a 
sample should be taken from the vault six months after surgery and there should be 
no further cytology follow-up if it is negative. 
 
-  For women with completely excised CIN at hysterectomy, a sample should be 
taken from the vault at six and eighteen months after surgery and there should be 
no further cytological follow-up if both are negative.   
 
-  For women with incomplete or uncertain excision of CIN, follow-up should be 
conducted as if the cervix were still in situ. 
 
 
 
Thus, national guidelines suggest only a limited role for vaginal vault cytology tests.  
However, these guidelines are largely based on expert opinion and do not specify 
what further role vault cytology testing should have in the follow up of women 
following abnormal results or following a hysterectomy where malignancy was 
detected.  This is currently left to the discretion of the treating clinician. 
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2.3.2.2  A systematic review of the literature:  the use of vaginal vault cytology tests  
In view of the lack of ‘gold standard’, prospective, randomised controlled trial 
evidence underpinning the national NHSCSP guidelines concerning vault cytology 
tests, a full systematic review of literature was undertaken by the author (as PI) and 
departmental colleagues, and reported in full in the British Journal of Obstetrics and 
Gynaecology in 2006.24 
 
The aim of the review, performed to Cochrane standards, was to establish the 
evidence base for the use of vaginal vault cytology subsequent to hysterectomy for 
benign or pre-cancerous conditions.  This was done by identifying all studies that 
reported the follow-up of a series of patients treated by hysterectomy for reasons 
other than malignancy, and contained data to enable the effectiveness of vault 
smears in identifying VaIN to be estimated.  Papers were ‘eligible’ for inclusion if 
they reported on a population of women who had undergone a hysterectomy and at 
least some of the population had vault cytology tests. Case reports or expert opinion 
were excluded. 
 
Results of the systematic review: 
The review identified 526 citations but after eligibility and validity assessment only 
19 remained.20;22;23;43;71;90-98;98;98-103  All 19 utilised a form of cohort design, one 
included a control group.103  The included papers were published between 1963 and 
2000 in 16 different journals, with 11 published prior to 1990 (58%).  There were no 
papers concentrating exclusively on women who had CIN I or CIN II, the majority of 
papers considered follow up after carcinoma-in-situ or CIN III.   
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Appendix A includes the full published paper including the main data table and 
Figure 5 is the PRISMA diagram of the review process.104 
 
Figure 5.  PRISMA Diagram of systematic review104 
 
 
526 records for consideration  
73 other records: 
66 records identified from 
bibliographies 
7 from experts in the field 
122 Full text of articles 
screened for study eligibility 
441 records actually screened 85 duplicate 
records excluded 
20 records of studies eligible for 
inclusion in systematic review 
453 records identified by 
electronic database 
searching 
319 excluded by 
title and abstract 
102 ineligible 
records excluded  
19 Unique studies eligible for 
inclusion in narrative systematic 
review, none suitable for meta-
analysis 
1 record 
excluded: dual 
publication  
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The better quality studies had a combined study population of 11,656 
hysterectomies of which 6,543 were for benign disease, 76 for CIN I/II and 5,037 for 
CIN III.  Nevertheless, incompleteness of follow up and recording of data prohibited 
any meta-analysis of the data and thus it was not possible to provide robust 
estimates of the value of the vaginal vault cytology test in the follow up of women 
who have had a hysterectomy for reasons other than malignancy. 
 
There was little good quality evidence concerning the role of vaginal vault cytology 
tests and there were insufficient data to enable the calculation of robust aggregated 
assessments of the sensitivity or specificity of the test.  Most of the observed events 
occurred within the first two years of follow-up; 46 of the 48 documented abnormal 
tests occurred within two years of hysterectomy.  Of the six best quality studies, two 
considered data from women who had a hysterectomy for benign indications or CIN 
I/II and four studies considered women who had CIN III.  
 
The aggregated data from studies following-up over 6,800 women after 
hysterectomy for benign indications, CIN I and CIN II showed that despite up to 50 
years follow-up, no cases of subsequent vaginal cancer were identified.  Only one 
case of vaginal cancer was observed, three years after hysterectomy, in the cohort 
of 3,569 women having hysterectomy for changes of CIN III.  Unfortunately, all the 
studies following up women after hysterectomy with CIN III had significant 
methodological or reporting flaws.  
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Thus the conclusions were that primary vaginal cancer is very rare and does not 
warrant any screening programme and that the current UK guidelines (Figure 4) 
seem sensible.24  The study also confirmed the need for definitive research to 
determine the appropriate duration and frequency of vaginal vault cytology tests 
after hysterectomy, for reasons other than cancer.  As it is not practical to undertake 
a prospective randomised controlled trial (because vaginal cancer is rare and such a 
trial would have considerable ethical implications), epidemiological techniques offer 
the most practical approach to answering some of these questions.   
 
There is currently no evidence to suggest that there is demonstrable benefit in 
screening after hysterectomy for benign disease24;105 and there is no evidence to 
support changing current guidelines for screening after CIN I/II.  Screening after CIN 
III for five years was proposed by some authors, however, the data indicated that 
95% (46 of 48) of all abnormal tests occurred within two years of hysterectomy and 
only one case of vaginal cancer was identified in all of the reported series.  
 
The value of the vaginal vault cytology test as a screening tool after hysterectomy 
for reasons other than existing cancer is not supported by the existing literature. 
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2.3.3  When are vault cytology tests being undertaken? 
 
2.3.3.1  Questionnaire survey of primary healthcare professionals 
This study aimed to establish primary care professionals’ (GPs and Practice Nurses) 
knowledge and perceived behaviour relating to the use of vault cytology tests and 
has been fully reported in Cytopathology.30  
 
Results of questionnaire survey 
This postal questionnaire survey achieved a response rate of 68.6% (n=291) with 
practice nurses having a higher response rate than GPs (p=0.007).  The frequency 
of performing vault cytology tests was assessed by self-report and nurses took 
significantly more tests than doctors (p<0.001).  There was no significant difference 
in knowledge between doctors and nurses or between male and female 
respondents.  However, a comparison of the ‘knowledge score’ against the reported 
frequency of performing vault cytology tests suggested an inverse relationship; 
those with higher scores (better knowledge) undertaking the test least often 
(Kruskall Wallis 2=10.87, df =5, p=0.054).  
 
Conclusions of questionnaire survey 
Vaginal vault cytology tests incur a cost both to the NHS and the patient.  Those 
practitioners with higher knowledge scores tended to report performing fewer tests.  
If all primary care professionals had practised according to current guidelines the 
number of vault cytology tests undertaken would have been reduced.  
  
- 45 - 
The modification of professional behaviour is not simple, however, this study  
suggested that a simple educational intervention (a letter was sent from the 
laboratory to every registered sample taker) could result in a reduction in the 
numbers of vault cytology tests being performed; thus leading to savings in both 
resources and the emotional cost to patients.30   
 
 
2.3.3.2  Audit of histopathology records at Birmingham Women's Hospital 
This large audit work was undertaken as a pilot project for this thesis and is awaiting 
publication in Cytopathology; Appendix B includes the paper that was sent out to 
review.28  
 
Background 
The Pathology Department and Cytology Laboratory at the Birmingham Women's 
Hospital Health Care NHS Trust (BWH) has had comprehensive computerised 
records since 1995.  These comprise the personal and contact details of patients, 
clinical details, and results of all their histological and cytological specimens.  The 
study aimed to assess whether current national guidance on who should have a 
vault cytology test was being followed by:  identifying women who had hysterectomy 
operations 1995 - 2005, describing their demographics, describing any subsequent 
vault cytology tests and determining whether or not these were in accordance with 
national guidelines. 
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An electronic search of the computerised records for the period 1st April 1995 to 
31st March 2005, was run, looking for the topography (T) codes identifying 
hysterectomy samples.  Patient identifiers were then used to identify and link any 
other relevant department records.  The records were also searched to identify vault 
cytology tests by means of a laboratory based 'text' code. 
 
Results 
There were 8,457 records of separate vaginal vault cytology tests during the study 
period representing 3,164 different women.  The number of vault cytology tests per 
woman ranged from one to 17, with 47% of women having just one test and over 
87% having five or fewer during the ten-year study period (mean=3.06, median=2).  
Age at vault cytology followed a near normal distribution (range: 17 to 95 years, 
median=52 years).   The median age of women having vault cytology tests 
increased over time (Pearson correlation=0.922, p<0.001). 
 
General Practice was the most frequent setting for vault cytology tests, followed by 
gynaecology outpatient clinics.  The origin of vault cytology tests varied over time 
with a greater decline in numbers from general practice, other community settings 
and outpatient clinics than from the colposcopy service:  GP and community 
sources versus all other vault cytology tests, χ2 for linear trend=4.8 (9df, p=0.028); 
ward, theatre and out patient tests versus all other settings, χ2 (linear trend)=139.53 
(9df, p<0.0001); colposcopy versus all other sources, χ2 (linear trend)=87.33 (9df, 
p<0.0001). 
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There was a downward trend in total numbers of vault tests analysed each year.  
Abnormalities were detected in 8.9% of tests, with malignancy being detected in 
less than 0.1%.  The 'unsatisfactory sample' rate of 10.7% compared favourably 
with the in-house 'unsatisfactory' rate of 11.6% during the study period.  
 
Dyskaryosis was reported in just 4.4% of the samples, and invasion was suspected 
in less than 0.1%.  The eight tests indicating malignancy were performed on four 
women, one of whom had fourteen vault tests taken during the ten-year study 
period, four of them indicating malignancy.  The pattern of results suggests that not 
only were fewer tests being done, as the years passed, but that lower grade 
abnormalities were being detected. 
 
General Practice and the community setting had particularly low detection rates for 
significant abnormality over the decade:  no malignancies and only two severe 
abnormalities were detected from almost four thousand vault cytology tests taken in 
primary care.  ‘Abnormal’ tests (borderline, mild, moderate, severe or malignancy) 
represented only 2.8% (113) of the total, with the majority (n=73) of these being 
'borderline' results; whereas for the hospital settings (clinics, wards and operating 
theatres) the proportion of 'abnormal' test results was 14.5% (n=616).   
 
All the cytology results that indicated cancers (n=8, from four women) were detected 
in tests taken in gynaecology or colposcopy clinics and all were in women aged over 
60.  Of the 93 samples, in 39 women, that demonstrated 'severe' abnormalities, only 
three were taken in the community setting.   
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Summary of audit 
There was a steady fall in the number of vault cytology tests processed annually; 
this was particularly noticeable from primary care and gynaecology out-patient 
clinics.  The average age of women having vault cytology tests appeared to be 
increasing over time and the most significant abnormalities were, nearly all, 
detected in secondary care settings. 
 
The decline in the number of vault cytology tests during this period was far greater 
than the decline in the number of cervical cytology tests and could not be explained 
by national or local trends.  Within the ten year study period, research undertaken 
by the authors (2001-2003) may have increased primary care practitioners 
awareness about inappropriate use of vault cytology tests,30 and may have 
contributed to the decline in vault tests undertaken in the community. 
 
There was a very low rate of cellular abnormalities detected by testing; the vast 
majority of results were normal or of no clinical significance:  over 84% did not 
demonstrate any significant abnormality, 10.7% were unsatisfactory for 
interpretation.  Of those that did demonstrate an abnormality (382=4.4%), most were 
either mild or moderate changes (n=281).  Only 1.2% of all the tests (101 from 8,457 
tests) from 1.4% of all the women (43 from 3,164 women) demonstrated a serious 
abnormality.  These results suggest that vault cytology tests were not being 
restricted to higher risk women.   
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In this population, this test appears to have had poor detection rates for disease.  In 
particular, tests being done in the community setting were highly unlikely to detect 
any significant abnormalities, thus calling into question the usefulness of the vault 
cytology test in the community. 
 
Thus, it would appear that use of vaginal vault cytology tests has been declining, 
this appears appropriate given the poor detection rates for disease, particularly in 
asymptomatic women following hysterectomy for benign indications.   
 
It was concluded that to establish the true value of vaginal vault cytology tests it 
would be necessary to access more comprehensive data about women's entire 
screening histories, their hysterectomy pathology results and the results of any 
subsequent vault cytology tests.28  Then vault cytology tests could then be assessed 
for their appropriateness and conclusions drawn. 
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2.4  DEVELOPING AN APPROPRIATE STUDY DESIGN TO RESOLVE THE QUESTION 
OF:  WHEN SHOULD VAGINAL VAULT CYTOLOGY TESTS BE USED? 
 
2.4.1  Summary of the literature and justification of methodology 
 
When the findings of the systematic review were published it was evident that there 
was a dearth of high-quality evidence concerning appropriate use of the vaginal 
vault cytology test in both primary and secondary care.  The available literature was 
sparse and of poor quality for the purpose of determining when vaginal vault 
cytology should be used; national guidelines are thus based on inadequate 
evidence. 
 
What has been established is that primary care clinicians (doctors and nurses) know 
little about the test and most clinicians appear to use them inappropriately,30 taking 
twice as many as the guidelines recommend in those who start having tests but then 
not taking vault cytology tests at all in a significant proportion of women who, the 
guidelines suggest, should be screened.30 
 
Guidelines are known to improve care and standardise behaviour between 
clinicians106 however, changes in guidelines are difficult to implement and there are 
many examples of patients receiving inappropriate care in the presence of 
guidelines.107;107;108 
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Vaginal cancer is a rare malignancy and none of the evidence that has been 
collated suggests that vaginal vault cytology would make an appropriate national 
screening tool.  Any study to investigate this matter further would require large 
numbers of women.   
 
A population based or ‘epidemiological’ approach to look at women who undergo a 
hysterectomy was deemed to be the most appropriate next step in answering the 
research question 'when should vault cytology tests be performed post 
hysterectomy?' 
 
The basis of this research should be an observational cohort of women undergoing 
total hysterectomy, for any indication, reviewing their cervical cytology prior to 
surgery and then establishing if they subsequently undergo vaginal vault cytology 
following hysterectomy.  This would provide valuable information as to current 
practice on a larger scale than that reviewed by the audit and would give more 
generalisable results.  By describing an up-to-date cohort of women undergoing 
hysterectomy and their diagnoses at surgery, supplemented by information from 
their entire cervical screening histories, this research would provide a unique insight 
into this subject and provide the high quality evidence that is currently lacking.  
Chapter 3 explains the chosen study methodology in detail. 
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2.4.2  Population based data sets 
 
Developments in technology have meant that there are now multiple databases 
available, providing secondary sources of data. That is information not collected for 
the explicit purpose of the research.109  The great advantage of such data is that 
they already exist and thus research can be conducted more swiftly and cost-
effectively than undertaking novel research or establishing new, large scale cohort 
studies.  
 
To obtain enough data for a cohort of sufficient numbers of women, having had a 
hysterectomy, to generate meaningful and generalisable results, routinely collected 
data offered the most pragmatic solution in this project.  However all routine health 
statistics are vulnerable to variable data quality and the subsequent risk of bias.10  
Additionally the lack of control over the data puts the researcher in a position where 
it may be impossible to validate the data they are using, whereas in novel research 
the researcher usually has a large degree of control over data quality and the choice 
of data items recorded.109  
 
The three datasets chosen for extraction and subsequent linkage in this study each 
offered access to unique data items and the two national databases are known to be 
of high quality with rigorous quality assurance in place.110;111  Other databases were 
considered including primary care databases i.e. the General Practice Research 
Database (GPRD)112 which is the largest database of a longitudinal medical records, 
encompassing 4 million UK patients in approximately 500 GP surgeries.   
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Also considered was EPIC: an organisation which is responsible for international 
data (France, Italy, Germany, Belgium, Czech Republic and Australia with Korea 
and Spain) via  Cegedim Strategic Data (CSD) and The Health Improvement 
Network (THIN), another longitudinal primary care database in the UK.113  These 
data sources would have provided excellent data about co-morbidities and lifestyle 
of patients but were all rejected because Hospital Episode Statistics offered the 
most comprehensive detail about the hospital admission (operation and diagnostic 
detail) and the cervical screening database held the most reliable and 
comprehensive cytology call and recall data.  
 
Hospital Episode Statistics 
Hospital Episode Statistics (HES) is a national database of patient admissions and 
appointments in hospitals, in each of the devolved countries of the United 
Kingdom.114  The data is collected by the individual NHS trusts and coded before 
being uploaded to HES.  Chapter 3 includes further detail about the data held within 
HES and how it may be accessed. 
 
The data held by HES has been created by data entry clerks or ‘coders’ based in 
every NHS Hospital in the UK.  They classify each episode of hospital attendance 
and record precise details of:  patient demographics, the date, type and location of 
the episode, diagnostic and treatment codes.115;116  
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The NHS Classifications Service 'delivers national clinical classifications standards 
and guidance for the NHS clinical coding profession'.  They provide an education, 
training and formal accreditation programme for clinical coders and are developing a 
national clinical coding strategy alongside the Health Informatics Programme.  It 
takes approximately two years for a person to become an ‘Accredited Clinical 
Coder', and has its own Continuing Professional Development programme.   
 
Thus the quality of the data recorded is regarded highly and is used as the basis of 
payments and funding as well as a valuable source of audit and research 
material.117 
 
Cervical screening data – ‘Exeter’ 
The suite of software which holds all cervical screening data in the UK has evolved 
from a programme called ‘Exeter’ and thus is colloquially known as such.  Data are 
uploaded from Cytopathology laboratories around the country to regional ‘hubs’ and 
then finally collated to the ‘Open Exeter’ computer system which can be 
interrogated.  Because there are several steps in the process there are several 
opportunities for the process to break down, however rigorous safety and back-up 
processes are in place and quality assurance systems in place to ensure data are 
recorded uniformly throughout the UK.111  
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Hospital histopathology records 
Individual hospitals use various computerised databases to store information about 
their histopathological specimens.  Typical (but not universal) information recorded 
includes patient identifiers (name, hospital number, NHS number, date of birth, 
address), sample identifiers (description, typographical and morphological codes, a 
sample unique number), dates of samples (when obtained, when received at lab, 
when processed or reported) and details of the clinician reporting the sample.   
 
Unfortunately there is no NHS wide consensus on which software to use, or even on 
how to code specimens – some use free text coding, others use Systemised 
Nomenclature of Medicine (SNOMED) codes, or its one of its predecessors.  Thus 
the choice of hospital laboratory data to supplement and validate the data from HES 
and Exeter was taken with caution as the quality of data that may be obtained was 
uncertain until it was received. 
 
 
2.4.3  Record linkage  
 
Record linkage encompasses the concept of collating disparate records, to generate 
new datasets, for a defined purpose.118  Various techniques have been used over 
the past 40 years, which mirror the advances in routinely collected data systems.118  
There have been hugely complex systems devised to link data based on patient 
names or date of birth.119;120  
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One of the major decisions that impacts on the quality and completeness of any 
linked data, is whether or not data matching has to be perfect (all-or-none) or 
probabilistic (varying degrees of probability of a correct match).  The advent of the 
new NHS number121 as a personal, unique identifier has made data linkage far more 
accessible to researchers as, where it is used consistently and the validity of the 
NHS number is checked, then it provides the ideal linkage item and perfect 
matching can be the standard.118 
 
For this study the two main databases (HES and Exeter) were known to contain 
NHS number as well as other highly specific identifiers (Date of birth and postcode) 
thus the study was designed to preserve patient confidentiality as far as possible by 
not using patient names at all.  Thus linkage would be performed first on perfect 
matching of NHS number, and where this did not exist perfect matching of date of 
birth and postcode could be used as surrogate identifiers.  The decision whether to 
include any probabilistic matching had to be taken at the stage of data collection 
when it became evident that a small number of minor (single integer) differences 
between records existed, thus a very limited application of this method was also 
used. 
 
The use of postcode as a patient identifier is a well established identifier in linkage 
studies in the UK as the Royal Mail allocates a postcode to a group of no more than 
80 properties.122   
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There are over 28 million postcodes currently valid in the UK123, although for a 
research study is it theoretically possible to have neighbours from one street as 
participants and as such cannot be used as a unique identifier. 
 
Date of birth is a useful identifier in small to intermediate sized population studies 
as, for a given population; there are thousands of possible dates of birth.  However, 
with large datasets (>1,000 records) it becomes increasingly likely that date of birth 
will not be unique.  When used in conjunction with other identifiers it is a very useful 
item as it is frequently recorded and allows for age to be calculated. 
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2.5  SUMMARY AND STATEMENT OF STUDY AIMS AND OBJECTIVES 
 
Thus, the literature concerning hysterectomy is extensive, with references to this 
major operation being undertaken even prior to the advent of general anaesthesia.  
Incidence of hysterectomy has varied over time, at the time of writing, it is estimated 
that approximately 20% of women in the UK undergo a hysterectomy during their 
lifetime, however fewer operations are being performed each year as less invasive 
technologies are developed which reduce the requirement for major surgery and it is 
reasonable to assume that this lifetime incidence will gradually decline. 
 
There are various methods of undertaking a hysterectomy; for the purposes of this 
study it is important to be mindful that a total hysterectomy involves removal of the 
uterine cervix, whereas sub-total hysterectomy does not.  
 
Screening for pre-invasive disease of the cervix, using exfoliative cytology, has been 
highly successful in reducing the incidence of cervical cancer in those countries that 
have adopted it; the UK programme is one of the most successful in the world 
because it achieves full population coverage and has high uptake rates. 
 
After a hysterectomy, follow up by the use of vaginal vault cytology is not 
recommended for the majority of women; only those whose histology reveals CIN at 
surgery or who have not had at least 10 years of screening prior to surgery should 
have further testing.  These national recommendations are, of necessity, based on 
‘expert opinion’ as little high quality evidence exists. 
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It has been suggested that some vaginal vault cytology is being undertaken 
inappropriately, particularly in primary care.  Thus this study aimed to identify a 
cohort of women undergoing hysterectomy and consider their entire screening 
history both before surgery and subsequently, to establish if this suggestion is true 
and to quantify the problem. 
 
A retrospective record linkage study was designed so that women having 
undergone a hysterectomy could be identified from routinely collected Hospital 
Episode Statistics and then their entire screening histories could be obtained from 
Open Exeter and merged.  Supplementary data being obtained from individual 
histopathology laboratories, where possible.  This design was chosen as being a 
pragmatic way to obtain the maximum amount of high quality routinely collected 
data within a relatively short period of time. 
 
Thus the aims of this study were established as: 
 
Primary:  To describe the variation in both hysterectomy rates and subsequent 
follow-up by use of the vaginal vault cytology test, in the West Midlands region. 
 
Secondary:  To inform the development of national guidelines by generating high 
quality evidence of current practice with respect to vaginal vault cytology and 
assessing its appropriateness. 
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The study objectives were thus set:  
 
Primary Objectives 
 To estimate incidence rates for hysterectomy operations in the West 
Midlands region of the UK 
 To describe variations in incidence of hysterectomy and establish those 
factors associated with variability 
 To describe the current indications for hysterectomy in West Midlands 
 To describe cervical screening patterns prior to hysterectomy 
 To establish the current pattern of follow-up after total hysterectomy by 
means of vaginal vault cytology test 
 To describe the results of vaginal vault cytology with respect to histology at 
hysterectomy and establish those factors associated with having an abnormal 
result 
 To assess if vaginal vault cytology is being undertaken appropriately and 
establish those factors associated with inappropriate usage 
 
 
Secondary Objectives 
 To provide high quality evidence to inform national guidelines. 
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CHAPTER THREE:  STUDY METHODOLOGY AND DATA SOURCES 
 
INTRODUCTION TO CHAPTER 
This chapter explains the development of the detail of the study protocol and 
justifies the chosen methodology with particular emphasis on the use of confidential 
patient data without explicit consent.  The chapter then outlines the methodology 
used throughout the project, explores the three different sources of patient data and 
explains the various processes and approvals navigated to permit access to such 
confidential data.  Details of how this data was securely stored and subsequently 
managed are also summarised.  The chapter concludes with an overview of the 
planned statistical analysis and a justification of the statistical methods applied. 
 
 
3.1  STUDY DEVELOPMENT AND ETHICAL APPROVALS 
 
3.1.1  Developing the study protocol 
 
To answer the initial research question of ‘when should vault smears be 
undertaken?’ it was necessary to consider a population of women who may be 
eligible to have a vault cytology test (vault smear) i.e. women who had their cervix 
surgically removed at a hysterectomy operation.   
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Thus it was necessary to identify a cohort of women having had a hysterectomy 
undertaken in a specified time frame and to establish the reasons for that surgery.  
Hospital Episode Statistics (HES) was the natural choice for access to this 
information (see section 3.2). 
 
The West Midlands region was chosen as a good proxy for the whole of the UK 
population, representing 10% of England and Wales, or 11% of England,124 with 
ethnic diversity second only to London.125  It was predicted that this would provide 
almost 5,000 women who had a hysterectomy operation, generating a large enough 
sample to ensure that various subgroups could be studied further (see section 3.5.1 
for sample size calculations).126  
 
A woman’s histology result following hysterectomy may not accurately reflect her 
cervical screening prior to surgery if she had colposcopic treatment in advance of 
definitive surgery.  Thus it was important to access each patient's cervical screening 
history, for at least 10 years prior to hysterectomy.  This data would be provided 
from the regional screening databases, colloquially known and hereafter referred to 
as 'Exeter' databases, of which, 10 represent the West Midlands population. 
 
Finally, to add more sophisticated data about diagnosis at hysterectomy, to confirm 
that the operation included removal of the cervix and to validate the HES and Exeter 
data, some of the individual hospital pathology laboratories would have their data 
about the patients pathology results scrutinised.127  Figure 6 summarises the study 
protocol in addition to all approvals. 
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Figure 6.  Simplified schematic of study approvals and timing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
University of Birmingham agree to act as Sponsor 
Ref:  RG 05-150, December 2004 
National Research Register entry: N0138173331 
NCCRCD Project funding - Researcher Development 
Award. Ref: PAS/RDA/01/05/093 on 19th July 2005 
PIAG provisional approval - 8th December 2005 
Full approval - 7th March 2006  Ref: 4-05(e)/2005 
HES - SCAG Approval - 11th April 2006 
Ref:  ET0693 
Data extract received 
May 2006 
Exeter 10 Databases approvals granted between 
June - October 2006 
First data October 2006 
Paper based only 
Exeter - re-apply centrally for access to same data 
via West Midlands Cancer Intelligence Unit 
Electronic data June / 
July 2007 
19 Hospitals applied to; honorary contracts, awarded 
from 16.  January - November 2007 
Obtain data  
November 2007 - April 
2008 
Merging of all data sets and verification, then full 
anonymisation confirmed December 2008 
Final, fully anonymised dataset analyzed, 
January - June 2009 
West Mids MREC Approval granted on 27th April 
2005 Ref: 05/MRE07/27 
Research protocol 
published December 
2007 
  
- 64 - 
3.1.2  Ethical issues arising from the use of confidential patient data without 
informed consent 
 
Justification for not seeking individual patient consent:  A key principle of the study 
was the necessity to access confidential, individual-patient data to allow for data 
'linkage' to be performed between the different sources.  This meant access to 
details of patient’s unique NHS number, date of birth and postcode of home 
residence.  Due to the large numbers of women in the study, individual patient 
consent could not pragmatically be obtained and so there were many necessary, 
and appropriate, ethics approval processes to be navigated before the study could 
commence data collection. 
 
Historically, research ethics committees have had to consider all aspects of 
research applications to ensure that patient safety and dignity is preserved whilst 
supporting research activity within the NHS.  However, after the Health and Social 
Care Act (H&SCA) 2001 was implemented, the Patient Information and Advisory 
Group (PIAG) took on the role of regulating researcher access to confidential patient 
information without individual patient consent. 
 
Significant ethical issues arise from the decision to undertake any research that 
uses confidential information without involving the patient directly in the consent 
process.   
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The principle of obtaining informed consent prior to commencing research is 
commendable; however, some research has the potential to cause harm to the 
patient if consent is sought i.e. by revealing poor prognostic information or by 
contacting the seriously ill or approaching relatives of recently deceased patients.  
There is always a balance between potential benefits and harms; one of the key 
roles of research ethics committees is to weigh-up this decision-making process. 
 
When conducting large scale, population studies, there are practical considerations 
that must also be considered; to contact and obtain informed consent from over 
5,000 women would make this study prohibitively expensive, time consuming and 
ultimately impractical.  Additionally, we know that people who consent to 
involvement in research trials are often not truly representative of the populations 
from which they are selected.128;129  To generate research findings which are truly 
valid and representative of whole populations an adequately sized sample is 
essential. 
 
Justification for specific data items:  This study required several identifying items of 
data to allow for reliable data linkage to take place.  The identifying items were 
chosen specifically to maximise predicted matching whilst minimising the degree of 
‘breach of confidentiality’ i.e. patient’s full name and address was not requested but 
postcode of home address, date of birth and NHS number were. 
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Postcode:  This indicator, assigned by The Royal Mail to facilitate efficient mail 
delivery, is representative of an address block and includes up to 80 private 
addresses (usually less than half this number), anyone can access address details 
on supplying a postcode and so it is not a secure anonymous source.  There are 
just over 1.5 million postcodes in use in the UK representing 27 million addresses, 
with some addresses having their own postcode (usually if their volume of post is in 
excess of 500 items daily i.e. businesses and large institutions).123 
 
Date of birth: This indicator is not specific enough to use in isolation because, in a 
given area, many women will have the same date of birth, i.e. for women of 
childbearing age:  13 – 50 = 37 years x 365.25 possible days of year giving 
approximately 13,500 possible dates of birth.  Although use of this indicator allows 
for age data to be subsequently calculated.  When used in conjunction with 
postcode, date of birth is increasingly helpful as a patient identifier. 
 
NHS Number:  The new or modern NHS number comprises 10 digits.  The first nine 
are the individual patient identifier and the tenth is a ‘check digit’ used to confirm the 
number’s validity.  The check digit is calculated using the Modulus 11 algorithm, 
Appendix C includes details of how this algorithm is applied:  there are four steps in 
the calculation which is too complex to be verified without working through the 
process carefully.  
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NHS number can be used by any registered NHS employee to identify a patient by 
performing a straightforward electronic search.  It is intended that every person in 
the UK should have their own, unique NHS number which is the link to their entire 
medical record.121  NHS number has been, since 2002, allocated at birth, although 
for the women in this study most would have had their NHS number allocated during 
their lifetime when the NHS changed from an older system of NHS numbering 
during the late 1990's.121  Although using NHS number is ‘more’ anonymous than a 
patient’s name, it is still only represents ‘partial’ or ‘pseudo’ anonymisation. 
 
Environmental impact:  To minimise breach of individual patient confidentiality, and 
minimise paper waste, the study was designed to be 'paper light' i.e. to generate the 
minimum amount of paper wherever possible, and specifically not to generate any 
paperwork containing patient identifiable data.  Because the project was based in a 
large university department it was not possible to calculate a project specific ‘carbon 
footprint’.  However, email and computer communication was used in preference to 
mailing; scanning and screen reading of documents undertaken as standard and 
travel was kept to a minimum. 
 
Pseudo anonymisation stage:  It was a condition of one of the approvals (section 
3.1.6) that once initial linkage of data from HES and the Exeter cervical screening 
data had taken place, that data would be 'pseudo anonymised' to leave just NHS 
number as an identifier, so that when the data were taken from The University of 
Birmingham out to individual hospitals, the opportunity for breach of confidentiality 
would be minimised.   
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This was weighed against the inevitable reduction in data matching that could take 
place at hospitals by using just one indicator and deemed to be an acceptable 
compromise. 
 
Full anonymisation and long term confidentiality:  This was to be undertaken and 
verified once the data gathering was complete.  Analysis could not begin until the 
data was fully anonymised.  None of the outputs from this research can use any 
individual patient identifiers, thus ongoing patient confidentiality is assured.  
Appendix D includes a copy of the study System Level Security Policy which was 
developed in conjunction with the University of Birmingham Caldicott Guardian, 
information technology advisors and in line with guidance issued by the Security 
Advisory Group of HES. 
 
 
3.1.3 Overview of all study approvals 
 
The stages of necessary approvals are summarised in the flowchart:  Figure 5.  
Appendices E1 – E5 contain a sample of the applications.  Subsequent to the 
University of Birmingham agreeing to act as study Sponsor.   
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Approvals had to be sought from the following: Centre for Research Ethics 
(COREC, Appendix E1), now known as the National Research Ethics Service 
(NRES), the Patient Information Advisory Group (PIAG, Appendix E2), the Hospital 
Episode Statistics Safety and Confidentiality Advisory Group (HES, SCAG, 
Appendix E3). 
 
Once the required data had been obtained from HES, then the ten local database 
controllers for cervical screening were approached for their permission to access 
data and obtain an extract.  Appendix E4 includes an example of a letter of 
application.  Finally, the 19 individual NHS hospitals in which hysterectomy 
operations were undertaken, had to be approached and the relevant consultant 
Histopathologists and their respective Research and Development (R&D) 
Departments' permission had to be sought for access to hospital data.  Appendix E5 
includes an example of one such application. 
 
 
3.1.4  Prior approval:  University of Birmingham willingness to act as sponsor 
 
The University of Birmingham (UoB) has clear procedures with respect to 
applications for research ethics approval and research funding, to ensure that:  
research governance principles are followed; indemnity is in place to cover the study 
and appropriate accommodation and resources exist to support the research 
activity.  This process grants a study ‘Confirmation of Sponsorship and Indemnity’ 
by the University’. 
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Subsequently the study was registered with the National Research Register 
Reference N0138173331130 and although this resource is now archived, all studies 
registered with it are still available via the National Institute of Health Research 
(NIHR) National Research Register (NRR) archive.131  
 
 
3.1.5  MREC approval 
 
Ethical approval for the study was granted by West Midlands Research Ethics 
Committee via the National Research Ethics Service (NRES) of the National Patient 
Safety Agency (NPSA) of the NHS on 27th April 2005.  Appendix E1 contains a 
copy of the application form and subsequent correspondence confirming ethical 
approval. 
 
 
3.1.6  Obtaining Patient Information Advisory Group (PIAG) approval 
 
Section 60 of the Health and Social Care Act (H&SCA) 2001 enables the Secretary 
of State to support and regulate the use of confidential patient information 'in the 
interest of patients or the wider public good'.  Section 60132 essentially permits the 
temporary setting aside of the ‘common law’ duty of confidentiality for the use of 
medical records for specific purposes.  However, it does not set aside the 
requirements of the Data Protection Act 1998 (DPA98).133;134 
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Parliament agreed to the creation of this Act to ensure that any 'patient identifiable' 
information that was needed to support essential NHS activities could be used 
without informed patient consent, where there was no 'reasonably practicable 
alternative'.  The Patient Information Advisory Group (PIAG) was established 
subsequent to the introduction of this Act of Parliament to manage the demand from 
researchers for access to this information.135  Since 2008, an amendment to the 
Health and Social Care Act (2008) established a new statutory body, the National 
Information Governance Board for Health and Social Care (NIGB) to replace PIAG 
which was abolished on 31 December 2008.136  However, for the purposes of this 
study PIAG was the body responsible for granting approval. 
 
Acceptable use of patient data according to PIAG included:  preventative medicine, 
medical diagnosis, medical research, provision of care and treatment, management 
of health and social care services, informing individuals about their physical or 
mental health or condition, the diagnosis of their condition or their care or 
treatment.135  PIAG used to meet quarterly to review received applications and if 
there were practicable ways identified of gaining patient consent or using 
anonymised information, then an application would be refused.  
 
Two main types of approval existed, namely 'class' and 'specific' support:  'Specific 
approval' was only ever granted for two areas:  communicable disease and other 
risks to public health and also medical purposes related to the diagnosis or 
treatment of neoplasia i.e. activities carried out by cancer registries.   
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'Class support' was possible for a variety of activities and it was under this heading 
that permission was sought.  Application was made to PIAG, in November 2005, 
under sections iv and v, see Figure 7. 
 
Figure 7.  PIAG rules for Class support 
 
 
 
 
At first reading, PIAG recommended increased patient participation in the research 
project, despite user input into the study protocol and so INVOLVE,137 a national 
advisory body which aimed "to promote and support active public involvement in 
NHS, public health and social care research”, was contacted.  INVOLVE believed 
that involving members of the public leads to research that is more relevant to 
people’s needs and concerns, more reliable and more likely to be useful.137  
Essentially the organisation promoted the involvement of the public in the research 
process thus leading to improvement in the way that research is undertaken.  
However INVOLVE had no relevant groups based in the Midlands at the time of 
application and, although helpful and supportive of the project aims, they were 
unable to suggest ways of increasing user involvement beyond what had already 
taken place in the protocol development stage. 
iv. To link patient identifiable information obtained from more than one 
source in order to validate the completeness or quality of the information or 
to avoid the impairment of the quality of the data by unintentionally 
including the same information more than once.   
 
v. To process patient identifiable information for the purpose of auditing, 
monitoring and analysing patient care and treatment. 
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It was subsequently decided, with the support of PIAG, to publicise details of the 
research project throughout the West Midlands in freely available research 
publications.  These were routinely distributed to healthcare organisations including 
GP surgeries, so that anyone (public or professional) could approach the author 
either for exclusion from the database (during the brief stage where data was 
identifiable) or for further information. 
 
PIAG additionally stipulated that at the stage of requesting data from hospital 
histopathology laboratories, NHS number alone should be used as an identifier to 
minimise the opportunity for breaching confidentiality. 
 
PIAG gave their full approval to the study, once these modifications had been 
incorporated, on 7th March 2006 - Ref: 4-05(e)/2005.  Appendix E2 contains a copy 
of the successful application and relevant correspondence.  
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3.2  HOSPITAL EPISODE STATISTICS (HES) 
 
3.2.1  Background:  What is Hospital Episode Statistics Database (HES)? 
 
Hospital Episode Statistics (HES) is a national database containing approximately 
13 million records of patient admissions or appointments (episodes) for each ‘data 
year’ (1 April to 31 March) detailing the patient care that is provided by NHS 
hospitals in England.138  Extracts from these data can be provided for any time from 
1989 onwards.  Data for NHS hospitals in Northern Ireland, Scotland and Wales are 
similarly collected and are available separately.  Northgate Information Solutions is 
the independent company that manages the HES database. 
 
Each HES record may contain over 50 items of information collected directly by 
hospital providers, including demographic details relating to the patient, diagnoses 
and surgical procedure codes.  In addition, the central database provides a number 
of derived items from this supplied data i.e. using patient postcodes several 
indicators are added such as Super Output Areas (SOA) and Primary Care Trust 
(PCT) of residence. 
 
To obtain an extract from HES that contains fields that potentially identify a patient 
or their hospital consultant then the application requires approval from the Security 
and Confidentiality Advisory Group (SCAG) at HES before it can be processed.  
This is to ensure that high standards of data security are in place and that the 
information is being used for legitimate, ethically approved research projects.   
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Once a request is approved by SCAG, the Department of Health authorises 
Northgate Information Solutions to proceed with producing the data extract, for 
which a fee is payable. 
 
3.2.2  The data held in HES and applying for access to it 
 
For each hospital episode, in addition to each patient’s demographic and NHS 
registration details, data about the diagnosis that was attributed to the patient and 
the details of any procedures that were undertaken are documented in coded form.  
Every hospital consultant and GP surgery has a unique code which is recorded 
along with coded details of Heath Authority and Primary Care Trust of the patient 
and the organisation where they were seen.  Dates of hospital admission and 
discharge and duration of stay are also recorded, making this a unique resource. 
 
Any data that needs to be later retrieved and analysed first has to be summarised 
and coded.  Various coding systems are in use in HES data to permit comparisons 
over time and against international standards.  The data held by HES has been 
created by data entry clerks or ‘coders’ based in every NHS Hospital in the UK.  
They classify every episode of hospital attendance and record precise details of:  
patient demographics, the date, type and location of the episode, diagnostic and 
treatment codes.115  
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3.2.2.1  ICD 10 – An overview 
The illnesses, diseases and injuries experienced by patients are currently recorded 
in HES using the International Statistical Classification of Diseases and Related 
Health Problems - Tenth Revision (ICD-10), published by the World Health 
Organization (WHO).139  ICD-10 was endorsed by the Forty-third World Health 
Assembly in May 1990 and came into general use from 1994.  The classification is 
the latest in a series which has its origins in the 1853, when the first international 
statistical congress was convened in Brussels by Dr William Farr, the Registrar 
General and Medical Statistician for England and Wales and has been steadily 
evolving ever since.140  However, the first known ‘modern’ systematic classification 
of disease dates back to 1700:  The London Bills of Mortality was an attempt to 
estimate the proportion of live born infants, who died before the age of six years, 
and it listed 13 classes of disease. 
 
ICD-10 is presented as three volumes or divisions:   
 the tabular list, including the actual classification at three and four character 
levels and classification of neoplasms 
 the instruction manual, a collection of notes and historical material  
 the alphabetical index140 
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Information about an individual patient's diagnosis at a very specific level, which has 
been recorded in their case notes by the clinician treating them, is later translated 
into ICD-10 codes by a ‘clinical coder’.  Thus it should be possible to compare 
conditions consistently, not only within HES but internationally, wherever ICD-10 is 
used.   
 
Thus, ICD has become the international standard diagnostic classification for all 
general epidemiological and many health management purposes.  It is used on 
many types of vital records including death certificates and hospital records.  In 
addition to enabling the storage and retrieval of diagnostic information for clinical 
and epidemiological purposes, these records also provide the basis for the 
compilation of national mortality and morbidity statistics by WHO Member 
States.139;140 
 
ICD-10 codes comprise a single alphabetic letter followed by two or more digits, with 
a decimal point between the second and third (e.g. C53.1 Malignant neoplasm of 
cervix uteri, exocervix).  As there are many thousands of variations at the 4-
character level (where all three digits are used) it is common practice to summarise 
at the 3-character level (e.g. C53 Malignant neoplasm of cervix uteri).  Diagnosis 
tables are freely available for download at both the 3-character and the more 
detailed 4-character levels and are presented in code order.139  Table 8 summarises 
the 'chapter headings'. 
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Table 8.  ICD-10 Chapters 
Chapter Blocks Title 
I A00-B99 Certain infectious and parasitic diseases 
II C00-D48 Neoplasms 
III D50-D89 Diseases of the blood and blood-forming organs and certain disorders 
involving the immune mechanism 
IV E00-E90 Endocrine, nutritional and metabolic diseases 
V F00-F99 Mental and behavioural disorders 
VI G00-G99 Diseases of the nervous system 
VII H00-H59 Diseases of the eye and adnexa 
VIII H60-H95 Diseases of the ear and mastoid process 
IX I00-I99 Diseases of the circulatory system 
X J00-J99 Diseases of the respiratory system 
XI K00-K93 Diseases of the digestive system 
XII L00-L99 Diseases of the skin and subcutaneous tissue 
XIII M00-M99 Diseases of the musculoskeletal system and connective tissue 
XIV N00-N99 Diseases of the genitourinary system 
XV O00-O99 Pregnancy, childbirth and the puerperium 
XVI P00-P96 Certain conditions originating in the perinatal period 
XVII Q00-Q99 Congenital malformations, deformations and chromosomal abnormalities 
XVIII R00-R99 Symptoms, signs and abnormal clinical and laboratory findings, not 
elsewhere classified 
XIX S00-T98 Injury, poisoning and certain other consequences of external causes 
XX V01-Y98 External causes of morbidity and mortality 
XXI Z00-Z99 Factors influencing health status and contact with health services 
XXII U00-U99 Codes for special purposes 
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The primary diagnosis in HES is defined as 'the main condition treated or 
investigated during the relevant episode of healthcare'.  Where a definitive diagnosis 
cannot be applied then a code describing the main symptom, abnormal finding or 
problem is used.  The HES database also stores up to 13 additional, ‘secondary’ 
diagnoses (only six prior to 2002-03), which describe other conditions the patient 
may have.  The hospital will enter only codes necessary to describe the patient's 
condition, thus most records have far fewer than the maximum permitted 14 codes. 
 
3.2.2.2  The UK classification of Operative Procedures (OPCS-4) and SNOMED CT. 
An 'operation' usually comprises several separate procedures that, when put 
together, have a specific planned outcome (i.e. many operations involve making an 
abdominal incision but only hysterectomy operations involve excision of the uterus).  
Operations can be relatively simple or very complex, there are different ways in 
which a named operation can be performed, such as using endoscopic surgical 
techniques.  These different aspects of each operation are currently recorded 
separately in HES using the UK Classification of Operative Procedures (OPCS-
4).141 
 
HES records store up to 12 OPCS-4 codes recorded for each episode, (four prior to 
2002-03).  The 'main operation', which is the first one listed in a HES record, is 
normally the most resource intensive procedure performed.  Any additional OPCS-4 
codes (where they occur) are known as 'secondary procedures'.  
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OPCS-4 codes consist of a letter followed by three figures. The letters denote the 23 
'chapters' of the classification; each chapter dealing with a different part, or 'system' 
of the body.  There are around 6,000 codes available but for many purposes it is 
acceptable to group codes at the 3-character level.  However, where more precision 
is required the sub-division indicated by the final character adds further detail; a 
point is used to separate the 3-character 'group' code from the final integer, i.e. Q01 
= Excision of cervix uteri, but for more detail Q01.3 = Excision of cervix uteri, 
Excision of lesion of cervix uteri. 
 
Data is freely available at the 3 and 4-character levels, providing counts of main 
operations.141  Table 9 gives the name of each of the chapters; for the purposes of 
this study chapter Q, the upper female genital tract, is where hysterectomy 
operations are classified. 
 
There is an alternative newer coding system called SNOMED CT® which is currently 
being developed and it is envisaged that this will supersede OPCS (and several 
other classifications) in the next few years, however currently OPCS is the NHS 
standard.  SNOMED CT is a clinical terminology - the “Systematised Nomenclature 
of Medicine”.   
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Table 9.  OPCS Chapters 
Prefix Chapter Prefix Chapter 
A Nervous System  N Male Genital Organs  
 
B Endocrine System and Breast  P Lower Female Genital Tract  
 
C Eye  Q Upper Female Genital Tract  
 
D Ear  R Female Genital Tract associated with 
pregnancy, childbirth and puerperium 
E Respiratory Tract  S Skin  
 
F Mouth  T Soft Tissue  
 
G Upper Digestive Tract  V Bones and Joints of Skull and Spine  
 
H Lower Digestive Tract  W Other Bones and Joints  
 
J Other Abdominal Organs  X Miscellaneous Operations  
 
K Heart  Y Subsidiary Classification of Methods 
of Operation  
L Arteries and Veins  Z Subsidiary Classification of Sites of 
Operation 
M Urinary  
 
 
SNOMED CT It is a common computerized language that will eventually be used by 
all computers in the NHS to facilitate communications between healthcare 
professionals in clear and unambiguous terms.  It will be the language of the NHS 
Care Records Service and will reduce potential for differing interpretations of 
information and the possibility of errors resulting from traditional paper records.142 
 
SNOMED CT was a joint development between the NHS and the College of 
American Pathologists (CAP) to improve and safeguard patient care by using an 
agreed terminology.  It has greater depth and coverage of healthcare than the 
current systems that it is planned to replace.   
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Great efforts are being made to ensure that older codes will be accurately translated 
into SNOMED CT when the changes are rolled out so that valuable, historic data will 
not be ‘lost’.  It should, ultimately, enable clinicians, researchers and patients to 
share and exchange healthcare and clinical knowledge worldwide.   
 
In April 2007 the International Health Terminology Standards Development 
Organisation (IHTSDO) acquired the intellectual property rights of SNOMED Clinical 
Terms (SNOMED CT).  By acquiring the SNOMED CT standard the IHTSDO will 
help to ensure the continued maintenance and evolution of SNOMED CT as well as 
its availability on an international scale.142   
 
3.2.2.3  Consultant codes 
This comprises an individual Consultant's General Medical Council (GMC) 
registration number and as such can be used to identify each specialist individually 
by cross-referencing against the GMC website.143 
 
 
3.2.3  The Security and Confidentiality Advisory Group of HES 
 
3.2.3.1  Applying to The Security and Confidentiality Advisory Group (SCAG) 
A written application was submitted to Northgate Information Solutions SCAG in 
early December 2005.  However, the headquarters of this organisation are based in 
Hemel Hempstead and the, now infamous, fire at Buncefield Oil Depot destroyed 
their offices on 11th December 2005.   
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The application was re-submitted in January 2006 and by 23rd February 2006 a 
preliminary decision was reached.  Impressive testimony to their back-up disaster 
planning that it took so little time.  Full approval was granted on 11th April 2006.  
(Appendix E3). 
 
3.2.3.2  Study ‘Security Policy’ 
SCAG stipulated that the study should have a clearly defined 'security policy', 
including explicit consent from the Caldicott Guardian at The University of 
Birmingham.  This necessitated getting specific approval from the University of 
Birmingham Data Controller: Dr Carolyn Pike, Director of Legal Services and 
University Data Protection Officer, who assumes the role of Caldicott Guardian 
when necessary. 
 
A comprehensive system level security policy (SLSP) was drawn up (Appendix D), 
which defined standard practices to secure all patient identifiable electronic data 
used by the study.  A specified security manger was named as were all persons 
who may have access to confidential data. 
 
In summary, the only electronic format which would contain patient identifiable data 
would be one stand-alone lap-top computer with an associated external hard drive.  
These would both be password protected and their confidential data encrypted.  
When not in use they would be stored in a locked cupboard, located in a locked 
office in a secure department.  The wireless networking capacity of the lap-top was 
disabled and regular internal audit arrangements were put in place. 
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Disaster recovery processes were also implemented with bi-weekly back-up copies 
(also password protected) of any new or changed data being created and stored in 
a fire-proof safe that was physically remote from the study office.  It was planned 
that when patient identifiable data was removed from the hardware, supervised 
'secure wiping' would be undertaken and signed off accordingly. 
 
The data extract was received from HES in May 2005 and consisted of a single disc 
containing text files. 
 
  
- 85 - 
3.3  'EXETER' AND THE NATIONAL HEALTH SERVICE INFORMATION 
AUTHORITY 
 
Cervical screening by means of the Papanicolaou cytology test was introduced ad 
hoc throughout the UK during the 1970s but only became a nationally co-ordinated, 
standardised, scheme in the late 1980s (see Chapter 2).  The ‘Exeter’ suite of 
software was developed to manage the ‘call and recall’ of women in this first 
national screening programme.  It has evolved significantly over time but colloquially 
remains known as ‘Exeter’ and will be referred to as such hereafter. 
 
 
3.3.1  Background:  What is ‘Exeter’ / The NHSIA? 
 
The NHS Information Authority (NHSIA) was a ‘special health authority’ formed in 
1999 to develop and deliver national information technology services to the NHS.  
The NHSIA ceased activity on 1st April 2005 and its work was taken over by two 
other organisations:  NHS Connecting for Health and the Health and Social Care 
Information Centre. 
 
NHS Connecting for Health is the organisation responsible for supporting the NHS 
computer programmes, systems and networks.  Thus it covers a wide range of 
services and resources in primary and secondary care.   
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These include: referral systems (Choose and Book), Records (NHS Care Records 
Service) imaging storage and transmission (Picture Archiving and Communications 
System, PACS) the NHS Strategic Tracing Service plus new regional programmes 
for information technology.  The NHS Strategic Tracing service (NSTS) is a 
database of all the people and NHS organisations within the NHS which can be 
searched.  One of their objectives is to provide up to date NHS numbers on patients. 
 
The Health and Social Care Information Centre describes itself as “the leading 
provider of information for health and social care”.  It was formed from the merger of 
some aspects of the NHSIA and the former Department of Health 'Statistics Unit' 
and they aim 'to be the leaders in collecting, analysing and distributing facts and 
figures for the various health and social care communities in the UK'.144  
 
As these organisations have evolved, the cervical screening data remains and has 
passed through various different versions of software.  Currently, cervical smear 
screening data is still held in multiple ‘stand alone’ databases which then download 
their information to regional cancer registries.  Ten of these databases cover the 
West Midlands region and Appendix F summarises their details.  At each site, a 
named ‘Data Controller’ can allow access to the information held therein and allow 
certain outputs to be created.  These outputs include reports of full screening 
histories on selected cases, which may be searched for by various means, including 
NHS number, postcode and date of birth (although not all three simultaneously).  
However, these reports can only take the form of printed documents, and as such, 
for research on the scale planned this would not have been a suitable outcome. 
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3.3.2  Open Exeter 
 
‘Open Exeter’ is a remote access, highly secure, system for accessing the ‘Exeter’ 
databases across the national network.  The West Midlands Cancer Intelligence 
Unit (WMCIU) has permission to use the Open Exeter system to extract cervical 
screening records and so it is possible, if an individual obtains permission from each 
database controller individually, to access screening data electronically.  However, 
this system is relatively new and obtaining permission is notoriously difficult.  
 
It took 12-months to obtain all the necessary permissions to access data via Open 
Exeter, but permission was finally granted in June 2007 with data collection 
undertaken throughout June and July 2007.  An example of an application is in 
Appendix E4. 
 
Data was extracted by searching the database in batches of up to 40 records at a 
time, using NHS number alone (See Chapter 4 for further explanation).  For some 
women, their NHS number or other records were in the system but they had no 
cytology test results recorded.  Their demographic details were downloaded and 
saved separately from the main database.  Many of these were women, born before 
1/1/1923, were never routinely called to the national cervical screening programme 
(i.e. they were over the age of 60 by the time of the first national call). 
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3.4  LOCAL HOSPITAL HISTOPATHOLOGY AND CYTOPATHOLOGY DATABASES 
 
There are 19 hospitals that have access to histopathology laboratories which 
process and analyse cervical cytology and gynaecological specimens, in the West 
Midlands Strategic Health Authority area.  Each of these was approached for 
permission to undertake the third stage of data collection.  Full permission was 
ultimately granted from 15 with two refusing outright and two asking for application 
to be deferred due to staffing problems.  However data collection actually took place 
at just four sites as the value of this data source was called into question during the 
course of the study (Chapters 4.6 and 5.4). 
 
 
3.4.1  The role of pathology laboratories 
 
Hospital pathology laboratories are responsible for receiving organic samples, then 
cataloguing, processing, analysing and reporting them in a consistent, valid and 
reproducible way.  There are very strict quality assurance systems in place in all 
NHS laboratories, which are accredited nationally via Clinical Pathology 
Accreditation (CPA) and the National External Quality Assurance Schemes 
(NEQAS) as well as via strict internal audit and quality control.145   There has, 
historically, been great variation in investment in pathology services and although 
steps are being taken to standardise laboratories and their computerised systems 
this is still far from ideal.146 
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3.4.2  Access to histopathology laboratory data 
 
Table 10 includes details of all the hospitals in the West Midlands that hold 
histopathological specimens from hysterectomy operations; these were all 
approached for access to their computerised records.  The response from each is 
also summarised.  Details, of a typical application, is available at Appendix E5.  
Hereafter discussion about hospitals will be anonymised to preserve confidentiality 
of patients and clinicians. 
 
The various laboratories used several different IT systems to store and manage 
their samples.  This raised concerns about how comparable data was going to be.  
However, consistent across all databases were the presence of some patient 
identifying items including full name and date of birth.  Unfortunately, it transpired 
that NHS number was not used consistently, despite a clear intention to do so (all 
included it in their database).145  Thus, because of the stipulation by PIAG that only 
NHS number could be used to identify patients at hospital level, (a form of 
pseudoanonymisation), the study had no access to patient names to facilitate more 
effective linkage of the hospital’s data. 
 
A major difficulty was that clinical coding of the samples across hospitals used 
several different systems:  either various versions of SNOMED or its predecessor, 
SNOP (Systemised Nomenclature of Pathology).  Unfortunately these different 
coding systems were not comparable for the purposes of this research.  See 
chapters 4.6 and 5.4 for further discussion. 
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Table 10.  Summary of hospitals in West Midlands region approached for data 
Hospital & NHS Trust 
(alphabetical)* 
Notes and decision 
The Alexandra Hospital, 
Worcestershire Acute Hospitals 
NHS Trust 
Permission granted and full R&D approval. 
Burton Queens Hospital NHS 
Trust 
Consultant on long term sick leave, no-one covering her work, 
no-one able to give permission. 
City Hospital NHS Trust 
 
Full R&D and laboratory approval granted. 
University Hospitals Coventry & 
Warwickshire NHS Trust 
Cost issues a worry as grossly understaffed and funded, but 
‘happy to be involved in research if guaranteed no cost to the 
laboratory’.  
George Eliot Hospital NHS 
Trust 
Consultant on maternity leave until June 2008, no-one to 
cover or give permission.  
Heartlands Hospital, Heart of 
England NHS Foundation Trust 
Full approval granted which incorporated Solihull and Good 
Hope under one new NHS trust but two laboratories.  
Hereford County Hospitals NHS 
Trust 
Full permission granted after attending their R&D meeting in 
person.   
Good Hope Hospital NHS Trust Very helpful, full agreement, however lead consultant retired 
during the study.  Full R&D and laboratory approval granted.    
New Cross Hospital, Royal 
Wolverhampton Hospitals NHS 
Trust 
Full R&D and laboratory approval granted. 
University Hospital of North 
Staffs NHS Trust 
Full R&D and laboratory approval granted. 
The Princess Royal Hospital, 
Shrewsbury & Telford  Hospital 
NHS Trust 
Full R&D and laboratory approval granted. 
Russell’s Hall Hospital, Dudley 
Group of Hospitals NHS Trust 
Informal permission granted swiftly; R&D approval delayed 
but granted. 
Sandwell District General 
Hospital 
Full R&D and laboratory approval granted. 
Shrewsbury and Telford 
Hospital NHS Trust 
Lead Histopathologist agreed, said no other permission 
needed but as part of same trust as Princess Royal, full R&D 
approval was granted. 
Staffordshire General Hospital, 
Mid Staffordshire General 
Hospitals NHS Trust 
Full R&D and laboratory approval granted. 
Walsall Manor Hospitals NHS 
Trust 
Full R&D and laboratory approval granted. 
Warwick Hospital, South 
Warwickshire General Hospital 
NHS Trust 
Head of Department not interested, declined further 
discussion. 
Birmingham Women's Hospital, 
Birmingham Women's 
Healthcare NHS Trust 
Full R&D and laboratory approval granted. 
Worcester Royal Hospital, 
Worcestershire Acute Hospitals 
NHS Trust 
Permission granted via lead Histopathologist.  Full R&D 
approval later granted via The Alexandra hospital (one trust). 
*  NB Study results are presented anonymously, study numbers do not relate to alphabetical order. 
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3.5  ANALYSIS PLAN 
 
This study collated routinely collected data from multiple sources, as has been 
described.  Hospital Episodes Statistics database initially provided details of all 
women who underwent a hysterectomy operation in the West Midlands region 
during 2002-03, their hospital coding for diagnosis, operations undertaken and 
comprehensive details of the admission.  The ‘Exeter databases’ provided their 
entire cervical screening histories and any vault cytology data and the hospital 
laboratories provided some supplementary information about diagnosis. 
 
 
3.5.1  Sample size calculations 
 
This was to be a pragmatic sample of all women in the West Midlands region who 
underwent a hysterectomy operation in a specified time period thus there was no 
control over the size of the cohort, other than to use a longer time frame.  However, 
sample size (power) calculations were undertaken during the protocol development 
to ensure the study would have sufficient power to detect important differences. 
 
The key groups of women for analysis would be specified by their main histology 
result at the time of surgery (benign disease / cervical intraepithelial neoplasia (CIN) 
/ malignancy) as this would determine their recommended follow up post-operatively 
by means of vaginal vault cytology tests, according to national guidelines.   
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Table 11 was used to provide the estimated proportions on the basis of previous 
research by the authors.28 
 
Assumptions:   
 4,500 hysterectomy operations performed annually in West Midlands 
region147 
 80% of hysterectomies undertaken for entirely benign indications1 
 10% for CIN2 
 5% for cancer2 
 5% would be sub-total hysterectomy operations (any cause) and will thus be 
excluded from final analysis concerning vaginal vault cytology as the cervix 
would remain and so screening should continue according to national cervical 
screening guidelines (approximately 225 cases excluded).28 
 
For the benign histology group, a sample of 1,800 women would be sufficient to 
estimate prevalence of follow up to within +/-1% (95% CI); for the CIN and cancer 
groups the estimate would be to within +/-4% (95%CI).  Thus the anticipated sample 
would be more than adequate and did not need to be expanded further. 
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Table 11.  Estimated numbers of women in each histology category for sample size 
calculations 
* with 5% excluded from calculation as sub-total hysterectomy operations. 
 
 
3.5.2  Overview of planned analysis  
 
Details of statistical tests actually used at each stage of analysis are provided in the 
results section (Chapter 6) along with the results obtained.  Appropriate statistical 
tests were determined after assessment of data distribution and sample sizes and 
the choice of test affirmed by a statistician.  Figure 8 summarises the planned 
analysis in a visual format. 
 
Descriptive data was generated using queries in Microsoft Access 2003® SP2 and 
using Pivot Tables in Microsoft Excel 2003® with some descriptive work and all 
further statistical analysis undertaken using SPSSv15.  Descriptions typically 
included mean (with standard error) for normal data or median values with ranges 
and interquartile ranges and an assessment of skewness for non-normally 
distributed data, confidence intervals of proportions were calculated and presented 
where relevant.   
 Sub-Total* 
(Excluded) 
Benign CIN All 
Cancers 
Totals 
Not followed up by 
vault cytology 
(controls) 
N/A 3,240
90%
90  
20%
23 
10% 
3,353
Followed-up by vault 
cytology (cases) 
N/A 360
10%
360
80%
202 
90% 
922
Totals 225
5%
3,600  
80% 
450
10%
225 
5% 
4,275
(95%)*
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3.5.3  Justification of statistical methods 
 
The data was analysed in four main sections and presented in tabular, graphical 
and text format as appropriate.   The Kolmogorov-Smirnov test for normality was 
applied to establish if data was normally distributed, where relevant.  Table 12 
summarises the main statistical tests used in the analysis.148 
 
3.5.3.1  Which women had hysterectomy operations? 
Demographic factors were explored:  Comparison of the whole study population 
against the West Midlands and England populations with respect to age, Index of 
Multiple Deprivation 2007 (IMD07) and ethnicity was undertaken initially and the 
results tabulated.  Age was divided into five-year bands and ethnicity into six key 
groups (and later dichotomised) to permit meaningful comparisons and deprivation 
split into quintiles.  Cross tabulations were undertaken for the various groups and χ2 
test applied with degrees of freedom (df) and significance values (p) stated. 
 
Incidence rates for hysterectomy were calculated using population data (2001 
census data).  The numbers of screening tests undertaken were explored then 
divided into cervical tests pre-operatively and post-operatively (vault and cervical). 
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Figure 8:  Planned Analysis of study database 
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Dates, results, infection, recall, 
suspension, total number, 
operation type 
Hysterectomy Operation: 
Date, operation type, results, 
duration of stay, location of 
surgery 
Event dates
Index test 
Full history 
(algorithm) 
Vault vs Cervical 
cytology test 
Appropriate vs 
Inappropriate use 
Cancer v CIN v 
benign diagnosis 
Total vs Sub-total 
operation type 
Process Groups for comparison Analysis
Descriptive analysis of testing and 
summarised pre-operative screening history.  
Explore each factor compared with age, 
deprivation and ethnicity to establish 
associations and correlations. 
Descriptive analysis of operation type and 
exploration of age, deprivation, ethnicity and 
duration of hospital stay. 
Descriptive analysis of diagnosis at surgery 
and exploration of age, deprivation, 
ethnicity, duration of hospital stay and result 
of index test to establish associations.   
Regression analysis of relevant factors. 
Descriptive analysis of use of vault cytology 
and exploration of age, deprivation, 
ethnicity, duration of hospital stay, result of 
index test, operation type and operative 
diagnosis to establish associations.   
Regression analysis of relevant factors. 
Descriptive analysis of factors associated 
with inappropriate use of vault cytology 
following benign and pre-malignant 
indications.   
Regression analysis of these factors. 
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3.5.3.2  Why did women have a hysterectomy operation?  Cervical cytology results 
prior to surgery 
Pre-hysterectomy cervical cytology data was explored with respect to age, 
deprivation and ethnicity.  The last test before hysterectomy was explored in some 
depth, the ‘Index’ test, and women were divided by their result at this test into four 
main groups (cancer, dyskaryosis, normal or other).  Comparisons were then made 
between the groups in terms of age, deprivation and ethnicity using Kruskal-Wallis 
χ2 as the non parametric equivalent to a one way analysis of variance (ANOVA).  
Correlation between increasing age and increasing number of tests pre-operatively 
was assessed using Spearman coefficient. 
 
The Wilcoxon signed ranks test was used to compare distributions of predicted total 
numbers of tests, by age band, against actual distribution observed, as this was an 
example of comparing differences in paired observations. 
 
All the pre-operative screening data was coded according to 'per protocol' and 'non-
protocol' patterns using an algorithm constructed by the cancer registry in the West 
Midlands (see Chapter 4.4 for further explanation); this was to ensure standardised 
results to facilitate future analysis and collaboration.  Using this complex 
classification, women were further grouped into those having had a history of 
entirely normal screening or various combinations of abnormal cytology with two 
variations of sub-classification applied:  a 13-group and a 4-group coding, to permit 
different types of analysis.  This permitted comparisons between groups with 
respect to age at surgery, deprivation score and ethnicity.  
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3.5.3.3  What happened at hysterectomy?  The surgical diagnosis 
The reasons for hysterectomy were explored, with the diagnosis, obtained from HES 
records, being used as a proxy for reason for surgery.  The diagnosis was explored 
with respect to deprivation score, age, ethnicity, index cytology test result, duration 
of stay and overall cervical screening pattern.  Each of these was considered further 
by histology type:  benign, CIN (further subdivided into CIN I, II & III) and malignant.  
 
Regression analysis techniques are usually applied where statistical associations 
exist, to predict the value of one variable from knowledge of the others.  Multivariate 
logistic regression analysis (where there are several variables in the model) was 
undertaken to establish if any factors were associated with type of hysterectomy 
operation (total or sub-total).   
 
The first stage was formulation of a baseline model which took no account of any 
association among the variables (Step 0 in SPSS outputs).  It provided a 
comparison for the evaluation of the final model.  The backward likelihood method of 
regression analysis was undertaken because variables were selected which were 
predicted to be responsible for the observed outcome.  This model gradually 
removed variables which were not actually associated, until the final model was 
obtained. 
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Table 12.  Summary of main statistical tests used during analysis148 
Statistical 
Test 
Data 
Type 
Example of use Notes  
χ2 non 
parametric 
Comparison of study population 
deprivation with reference populations or 
proportions of each ethnic grouping 
To compare associations 
between rows / columns. 
Degrees of freedom must 
be stated 
Kolmogorov-
Smirnov test 
for normality 
continuous establishing if distribution of age in study 
population was normal 
 
Spearman 
rank 
correlation 
continuous Used to establish if a relationship exists 
between two continuous variables 
 
Kruskal-
Wallis χ2 
Test 
non 
parametric 
To detect associations between a non 
normally distributed variable and a 
categorical one i.e. ethnicity and age 
The non-parametric 
alternative to a one way 
ANOVA 
McNemar  non-
parametric  
Test for equal proportions of index smear 
result compared with diagnosis at surgery 
Test for agreement in 
paired data 
One way 
ANOVA 
parametric 
test 
Result of index test compared with age  
Wilcoxon 
signed rank 
non 
parametric 
Distribution of expected tests per age 
band compared with observed distribution 
The non-parametric 
alternative to a paired t-test 
Pearson χ2 
 
non-
parametric 
Deprivation quintiles compared with 
operation type 
 
Logistic 
regression 
analysis: 
backwards, 
stepwise 
non-
parametric 
To establish a model for predicting 
factors associated with having 
inappropriate vault cytology subsequent 
to hysterectomy for benign indications 
Backwards method used 
where variables are 
predicted to be important in 
the final model 
 
 
The analysis was also planned to be run in a forward fashion, to act as a check that 
any findings were valid and the most appropriate was reported.  Nagelkerke R2 is a 
measure of the ‘goodness of fit’ of the regression analysis model and was reported 
for all regression analysis.  It is a modified variant of the Cox and Snell R2 which 
can, by definition, never reach a correlation of 1, whereas the Nagelkerke R2 can 
reach 1 and as such is now a favoured means of reporting regression analysis in 
SPSS.149 
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3.5.3.4  Post operative follow up:  vault cytology or no vault cytology? 
The numbers of women, of each histology type, having some follow up by means of 
a vault smear test subsequent to their surgery were described, again with respect to 
their age bands and deprivation scores. 
 
Multivariate logistic regression analysis was then undertaken on those women who 
were followed up by means of post operative vault cytology and those who were not 
(binomial).  This was to determine those factors, in addition to histology or operation 
type, that influenced whether or not a woman was followed up in this way.   
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3.6  SUMMARY OF CHAPTER 
 
Chapter three has explained the overall study methodology and given prominence 
to ethical concerns about use of confidential patient data without consent.  
 
HES was chosen to provide the data about hospital admissions as it is an 
established, high quality national data resource and uses the internationally 
accepted ICD10 diagnostic coding and OPCS4 operative coding. 
 
The ‘Exeter’ software, used to record cervical screening history for the UK 
population, was interrogated to provide screening histories for the study population 
as it is the only national repository of screening data.  Access to this data was 
eventually obtained via the West Midlands Cancer Intelligence Unit where the ‘Open 
Exeter’ system could be accessed. 
 
Hospital histopathology data was found to be problematic, as the various hospital 
laboratories use widely different software to record their data.  Although 19 hospitals 
were approached and permission granted from 15, data was eventually only 
retrieved from four. 
 
The order of the statistical analysis and presentation of the results has been outlined 
along with justification of the statistical tests to be applied.  These results will be 
presented in chapter 6. 
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CHAPTER FOUR:  DATA EXTRACTION, LINKAGE AND 
ANONYMISATION 
 
 
INTRODUCTION TO CHAPTER 
This chapter considers the various processes involved in obtaining and managing 
the preliminary data, preparing it for linkage, the actual data linkage process and 
then subsequent anonymisation.  These stages followed a logical progression and 
as such the chapter is process orientated.  Boxes and flowcharts are used to guide 
the reader through the various stages and to facilitate understanding whilst 
attempting to avoid excessive use of technical jargon or formulae.  Appendices G 
and H contain supplementary information. 
 
4.1  DATA FROM HOSPITAL EPISODE STATISTICS (HES) 
 
The HES data extract was supplied by Northgate Information Solutions, as two ‘pipe 
delimited text files’, see example Figure 9, essentially data items separated by a 
‘pipe’ or ‘|’.  These were uploaded, on receipt, to a securely password protected 
laptop computer, which had its wireless networking capability disabled.  Then the 
files were converted into Excel spreadsheets, with columns separating the data 
items. 
 
Figure 9.  An anonymised (#) example of two records from the HES files 
   
########|Z|#########9|2|08082002|13082002|19|502|502|1|C541|M801|||||||||||||09082002|0908
2002|||||||||||1|Q074|Q221|||||||||||4|RXK01|00CSFY0021|00CSFY|06CSFY|5MJ|WS## 
###|5MX|Y07|Q27|C#######|M88007|29707326 
########|Z|########2|2|09052002|17052002|19|502|502|1|C541|M801|||||||||||||10052002||||||||||||
1|Q074||||||||||||7|RXK01|00CSFF0013|00CSFF|06CSFF|5MJ|B## 
###|5MX|Y07|Q27|C#######|M88007|29669254 
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4.1.1 Summary of HES Data 
 
Full detail of the data validation process is included throughout Chapter 5; however 
Table 13 gives a summary of all the supplied items for each participant and a brief 
explanation of each. 
 
 
4.1.2 HES Data preparation prior to obtaining cervical screening histories 
 
Searching the 'Exeter' database system, which holds cervical screening data, for the 
records required in this study, using NHS number alone was recommended by local 
data controllers as being the most efficient technique. The Exeter databases were 
originally developed for internal use and were not designed to facilitate external 
audit, as such data search facilities are strictly limited to certain combinations of 
input data and certain formats.  Due to the confidential nature of the data, clear 
guidance exists which specifies that 'no programming may be undertaken by 
external researchers'. 
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Table 13.  Summary of supplied HES data items (operation data) 
No. Code Explanation 
1 DOB Date of birth  
2 ETHNOS Ethnic group of patient 
3 NEWNHSNO New NHS number 
4 SEX Gender 
5 ADMIDATE Date of admission to hospital  
6 DISDATE Date of discharge from hospital 
7 DISDEST Discharge destination (i.e. home or another hospital) 
8 MAINSPEF Speciality of consultant  
9 TRETSPEF Treatment speciality of consultant 
10 EPITYPE Type of admission (general or obstetric) 
11 - 24 DIAG01 - 14 Diagnosis ICD10 (International Classification of Diseases 10th 
revision) code - up to 14 per admission  
25 - 36 OPDATE01 - 12 Date of operation - up to 12 per admission 
37 OPERSTAT Whether or not an operation was carried out 
38 - 49 OPERTN01 - 12 Classification of Surgical Operations and Procedures (OPCS4) code 
- up to 12 per admission.  OPERTN01 should be the main operation 
50 POSOPDUR Number of days in hospital after main operation 
51 SITETRET Hospital where operation conducted 
52 OACODE Super output area of residence 
53 OACODE6 Shortened super output area of residence 
54 WARD91 Electoral ward of residence 
55 RESPCT Primary Care Trust (PCT) of residence 
56 HOMEADD Patients home postcode 
57 PCTTREAT PCT where treatment occurred 
58 ROTREAT Region where treatment occurred 
59 STHATRET Strategic HA where treatment occurred 
60 CONSULT General Medical Council number of the responsible consultant 
61 GPPRAC General Practitioner surgeries code 
62 EPIKEY A unique record identifier created by HES 
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A ‘batch search’ facility may be employed in Exeter, where more than one NHS 
number can be searched for concurrently, the resulting output is a full record for 
each woman.  To undertake these batch searches NHS numbers had to be 
converted to a defined format; 'Comma Separated Variable' or CSV files (Figure). 
 
There were 5,882 NHS numbers listed from 6,168 records in the original HES 
database, however a few were duplicated:  to identify the duplicate entries a simple 
Excel formula was used (Figure 10). 
 
 
Figure 10.  Excel formulae used in preparation for data extraction 
 
 
 
Handling of 'Duplicate Entries' 
46 NHS number entries were present more than once, with 19 instances of two 
records, one instance of three entries and one instance of five entries for that NHS 
number.  The additional entries were identified and removed from the list of NHS 
numbers to be used for Exeter matching, to prevent duplication of record extraction.  
 
To produce a comma delimited or 'comma separated variable = CSV' file: 
Text:  make this cell the same as NHS no but add a comma afterwards 
Code version = A#&"," 
 
To identify duplicate entries where only small numbers of duplicates are 
predicted: 
Text version:  if cell in this row contains ‘NHS no’ which is identical to 'NHS no' in 
cell directly above, then copy the NHS number to a new column, if not leave new 
column blank.  Then sort column to visualise all duplicate NHS numbers. 
Code version:  =IF (A#=A#-1,B#) 
 
To identify duplicate entries where larger numbers of duplicates are predicted: 
Text version:  as above but then repeat formula in a new column as many times 
as needed to extract all duplicates.   
Code version:  as above.   
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This left 5,857 unique NHS numbers for matching and 26 lines of data referring to a 
person already eligible for matching.  These cases fell into several categories and 
are identified in Table 14.  The various types of duplicate are as follows: 
 
 Those for whom there was an entire identical duplicate entry but with two 
HESIDs applied:  perfect duplicate. 
 Those that referred to the same admission but were not identical entries:  
imperfect duplicate. 
 Cases where a woman had more than one operation during her one hospital 
admission:  one admission, more than one operation. 
 Those that referred to more than one admission but where both were coded 
as a hysterectomy (greater than a month apart):  two admissions. 
 Those where the woman was re-admitted within a short space of time (less 
than one month) after surgery, most likely as a result of operative 
complications:  re-admission. 
 
For the duplicated records, given the small numbers a decision was made on the 
validity of each record individually, however, certain rules were applied consistently.  
Essentially in the case of perfect duplicates one record was deleted, for imperfect 
duplicates the most informative data line was retained or where totally different sets 
of codes were used the different data was collated (as the differences only applied 
to operation and diagnosis codes), for more than one admission the main procedure 
(including a hysterectomy) was be taken as the index record.  A simple code was 
added to the file to this effect).  Figure 11 demonstrates this process.  
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Table 14.  Identification of type of duplicate records 
NHS No. No entries Reason 
4#######75 2 Perfect Duplicate 
4#######68 2 Perfect Duplicate 
4#######93 2 Perfect Duplicate 
4#######62 2 Imperfect Duplicate 
4#######59 2 Re-admission  
4#######79 2 2 Admissions  
4#######99 2 Perfect Duplicate 
4#######43 2 2 Admissions 
4#######08 5 1 Admission, >1 Op 
4#######45 2 1 Admission, >1 Op 
4#######90 2 Re-admission  
4#######74 2 1 Admission, >1 Op 
4#######53 2 Imperfect Duplicate 
6#######73 2 2 Admissions 
6#######01 2 Imperfect Duplicate 
6#######04 2 2 Admissions 
6#######49 3 1 Admission, >1 Op and 1 Perfect Duplicate 
6#######98 2 Perfect Duplicate 
6#######14 2 Imperfect Duplicate 
6#######86 2 Perfect Duplicate 
6#######37 2 Perfect Duplicate 
   Totals    
 
 
21 women 
46 entries 
Perfect Duplicate       = 8     Imperfect Duplicate   = 4  
1 Admission, >1 Op   = 4     2 Admissions            = 4 
Readmission             = 2 
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Figure 11.  Flowchart of HES data preparation prior to Exeter batch search   
 
 
 
 
No NHS Number 
Of the remaining women who did not have a valid NHS number (N=286), home 
postcodes and date of birth were available for searching instead. 
 
When NHS number and postcode were examined, a further duplicate record was 
identified which occurred three times.  There were several instances of two women 
having the same date of birth and two instances of women having the same 
postcode, as one might anticipate, but only one perfect duplicate was present and 
as such was treated as the duplicate entries above.  Thus there were N=284 women 
with a postcode and DOB combination, but without a NHS number.  
6,168 records 
from HES 
286 with no valid NHS 
number - individual DOB 
and postcode search in 
Exeter required 
5,857 unique 
NHS numbers - 
suitable for 
Exeter batch 
facility search 
5,882 records with a valid 
NHS number 
26 records either 
duplicated or 
referring to second 
procedures; 
deleted or merged 
284 unique NHS 
numbers identified 
from individual 
search of postcode 
and DOB 
2 records perfectly 
duplicated 
identified from date 
of birth and 
postcode, deleted 
Thus study population N = 6,141 women who underwent a hysterectomy (5,857 + 284) 
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Searching on NHS number and DOB had to be done individually but any records 
that were thus identified then had the NHS number added manually, to facilitate the 
third stage of data collection at the individual hospitals.  Under the terms of PIAG 
approval, only new NHS number could be used at the hospitals - a form of 
‘pseudoanonymisation’. 
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4.2  EXTRACTING STUDY DATA FROM 'OPEN EXETER' 
 
4.2.1 Background and security 
 
It was necessary for an honorary contract to be set up between the author and the 
West Midlands Cancer Intelligence Unit (WMCIU), and enhanced police clearance 
obtained as the data processed at the WMCIU is highly confidential.  Appendix G 
includes details of these security measures. 
 
A unique researcher ID and password were provided to enable access to the 
department computer network and to ensure generation of a clear audit trail.  
Additionally a separate, personalised log in and password were provided for use 
specifically with Open Exeter, authorised centrally as a further safeguard against 
fraudulent application or use. 
 
The 'batch search’ facility permitted searching of all ten local databases serving the 
West Midlands; hence the need for prior express permission from all ten data 
controllers for access to their data.  If any had disagreed then the study could not 
have used this resource. 
 
Theoretically, up-to 100 NHS number searches could be set to run concurrently.  
However, staff at WMCIU had previously established that, in practice, the system 
was laborious when more than 20 numbers were used in a batch search, so much 
so that that it became very slow and eventually 'crashed'.   
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As data extraction for this study proceeded it became evident that, when optimum 
conditions were in place, 40 NHS numbers at a time could be searched on without 
precipitating processing problems.  This data was immediately fed back to the data 
controller who implemented a policy change as a consequence. 
 
 
4.2.2 Methodology of data extraction 
 
Figure 12 is a flowchart which demonstrates the process steps necessary for 
searching using the batch download facility.  It incorporates the numbers of records 
relating to each process step but is only applicable to women having valid modern 
NHS numbers; these did represent the great majority of study participants. 
 
The output of each successful match was collated automatically into one file per 
batch search, which could be immediately viewed in Excel as a comma separated 
variable (CSV) file.  Each was immediately converted into an Excel workbook 
containing all the relevant data, ready for collating and analysis.  These workbooks 
included one line for every cytology test that the individual women had ever had 
(each duplicating all the demographic and registration data) so a search of 40 
women could produce in excess of 200 lines of data as some women had over 20 
results recorded.  A standardised method of saving these small files was applied to 
ensure consistency and reproducibility.  
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Figure 12.  Process steps for obtaining data using batch search facility in Open 
Exeter (women with valid NHS numbers) 
 
 
For every batch of up to 40 records searched, manual validation was undertaken on 
at least one matched NHS number.  The date of birth and postcode were compared 
with the date of birth and postcode from HES, thus manual double checking was 
undertaken on approximately 3% of the records.  In all cases the match was perfect 
(100%). 
Select ‘cytology history batch 
download facility’ - extended search 
Log on to Open 
Exeter secure system 
Log on to WMCIU 
secure system 
If no cytology records identified, 
subsequent manual search for 
each separate NHS number   
                                       (n=103)
Import small list of comma delimited 
NHS numbers into search field and 
run ‘batch search’           (n = 5,857) 
Successful search generates CSV 
file with a line per cytology test: 
converted to Excel spreadsheet and 
a sample manually validated 
                                          (n=5,754) 
No match found - either 
resident outside 
screening region or 
wrong NHS number 
recorded        (n=6) 
NHS number matched 
but no cytology 
recorded, Word file 
generated   
                       (n=97) 
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When a batch search could not match a NHS number this was flagged up and later 
manually searched.  Sometimes a manually input NHS number search would reveal 
the record to be present; in these cases the record was added to the database and 
the failure of the batch search noted to feedback to the data-controller. 
 
In several cases the NHS number was known to the database but there was no 
record of a woman having ever had any cervical cytology tests; these women did 
not have any data to be output into Excel and so their demographic details had to be 
output to a Word file for collation later.  These women, who had never had a smear 
test, were often noted to be older than the typical study population.  This was not 
surprising; women born prior to 1/1/1923 were never routinely called to participate in 
the national cervical screening programme as they were already ‘too old’ when the 
programme was launched i.e. women over 84 years at the time of data extraction or 
over 81 years old during the year 2002-03 when the hysterectomies were 
undertaken.  Additionally it is known that some women consistently decline the 
opportunity for cervical screening within the NHS for a wide range of reasons.150 
 
Finally, a small number of NHS numbers could not be matched at all – there were 
several plausible reasons for this:  the woman may be resident outside the region 
(having moved after her hysterectomy operation), the NHS number had been 
wrongly recorded in HES or that some inaccuracies were included in the cytology 
data.  There was no way to establish which, if any, of these plausible explanations 
applied.  
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The ‘batch search’ use of NHS number meant that, of the HES database of 6,141 
women, the 284 without a valid NHS number (4.6% of the total) could not be 
searched for this way.  Thus individual manual searches of the relevant databases, 
using date of birth as the search variable with postcode then used for verification, 
was undertaken.  Figure 13 summarises the process: 
 
Figure 13.  Process steps for obtaining data using batch search facility in Open 
Exeter (women without valid NHS numbers) 
 
 
Select ‘cytology history’, ‘female 
gender’, select which of the 10 
databases to search (n=284) 
Log on to Open 
Exeter secure system 
Log on to WMCIU 
secure system  
If no postcode match identified, search 
manually for only one integer errors in 
postcode or evidence of having 
previously lived at this postcode 
Search on DOB to generate list then 
manually check matched records to 
match postcode 
Successful search produces a 
perfect match with postcode  
No match found - 
either resident outside 
region or wrong DOB 
or postcode recorded    
 
                      (n=61) 
NHS number matched 
but no smears recorded 
- either patient choice 
or age precluded from 
national screening  
                           (n=18) 
CSV file with a line per 
smear test - save as 
an Excel spreadsheet 
for each matched 
woman       
                       (n=205) 
No match? 
Repeat cycle 
with different 
database 
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Table 15.  Exeter data, format of the output Excel file 
Name  Explanation 
NHS number New 10 digit 
Name  Title Forename Surname (text string) 
POS/DOUBT Of uncertain significance, rarely used, historic field 
Q code PCT identifying code  
Address Full address as a text string, finishing with postcode 
Date of birth In the format dd/mm/yyyy 
Age In years, at date of data extraction (July 2007)  
GP GP name, address and postcode as a text string 
GP Local Code 3 or 4 digit national code 
#* Smear number for that woman 
Test date* In the format dd.mm.yyyy 
Reporting Lab Text entry giving code or name of lab 
Slide number* Various types of numbering in use depending on lab, inconsistent 
Result* Numeric code - see separate table for description** 
Infection* A code added if suspicion of infection noted, see separate table for detail** 
Action Code* Cytology lab action code - numeric, see separate table for description** 
Repeat Months* Number of months until repeat smear advised - and recall set for 
GP Local Code Not always present - a numeric (up to 4 digit) code  
Responsible 
PCSA 
Name of PCT or Health Authority 
Date Deducted Date removed from recall 
Reason for 
Movement 
Reason for this removal from recall 
Date of Death Date Exeter has recorded for death of patient (not commonly used) 
New PCSA Name Of uncertain significance, rarely used, historic field 
Recall date Date that recall has been most recently set i.e. on the basis of most recent 
smear result 
Notes* Available for free text notes 
Free Text Second field available for free text or a spare column 
Recall Type Routine or Cancelled from further recall 
Recall Status No action / Cancelled / Non-respondent / GP informed 
Notify Date* Date of notification of no-respondent status or GP informed 
*  Unique data item to each record 
**  See Chapter 5.3, validation of Exeter data for relevant table 
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4.2.3  Cytology history output 
 
The entire cytology history for each participant was output into an Excel workbook 
and each line of the database contained the data summarised in Table 15.  The 
table also highlights that some data is unique to each record (i.e. the details of that 
smear) but that for women having more than one smear ever, a significant amount 
of data was duplicated. 
 
 
4.2.4  Managing the extracted data 
 
The data, having been extracted into many small Excel files (N =171), required 
collation into one database thus the following data management stages were 
undertaken, summarised in Figure 14: 
1. The 171 small Excel workbooks were merged to create one very large master 
workbook (5,754 NHS numbers). 
2. Women without an NHS number, who had a perfect match or a one integer 
error in their postcode (current address or a previously recorded address) 
and perfect match of their date of birth, were appended to the main workbook 
(205 women), their NHS numbers were added from Exeter. 
3. Records from all study participants who had never had a smear test were 
then manually transferred from Word into an Excel spreadsheet mirroring the 
main database, which was then appended to the main workbook (N= 115), 
their NHS numbers were also added from Exeter.  
  
- 116 - 
4. A small number of women could not be matched at all thus they had no 
records within the Exeter system (N=67).  It was not possible to say whether 
or not they had ever had any cytology but for the purposes of the study it was 
assumed they had not. 
 
Figure 14.  Summary of data management HES and Exeter 
 
6,141 women in final 
study database 
284 without a valid 
NHS number  
5,754 
women 
had 
cervical 
screening 
records 
5,857 records with a 
valid NHS number 
6 records 
did not 
have a 
match in 
Exeter 
205 
women 
had 
cervical 
screening 
records 
61 records 
did not 
have a 
match in 
Exeter 
Thus study population N = 6,141:   5,959 had cervical screening, 115 did not have 
cervical screening recorded but 67 did not have a record in the Exeter database and thus 
their screening history is uncertain.  For the purposes of this study they are presumed not 
to have had any screening. 
97 
recorded 
in Exeter 
but never 
had any 
cervical 
screening 
18 
recorded 
in Exeter 
but never 
had any 
cervical 
screening 
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The resulting Excel file included 36,649 lines of data on 6,074 (6141 - 67) women.  
Excel is able to handle approximately 65,000 lines of data in 256 columns for each 
line, but, if there are a lot of formulae containing cells included, this number is 
decreased.   
 
The next step was to convert this long table of data, which included many lines of 
information for some women (one line representing every cytology test each woman 
had ever had), into a table containing only one line of data for each woman. 
 
Excel was used to manage this process:  data was sorted into NHS number order, 
those women never having any cytology had their missing values completed.  Then 
the data was sorted into cytology test number order and then a formula applied 30 
times to copy the cytology details from the rows below to the current row, thereby 
effectively ‘moving up’ the data.  Figure 15 gives the formula used. 
 
 
Figure 15.  Generating one line of data for each study participant 
 
 
 
 
 
 
 
 
 
 
 
 
To move cytology data from the next row of the spreadsheet up to spare cells on 
this row, only if the row below applies to the same person as this row: 
Text:  make this cell contain the same data as the cell specified if the cells both 
relate to the same NHS number, if not then insert a missing value code.. 
Code version = IF (A2=A#(?#,*))   
where # represents the relevant row number, ? the relevant column letter and * 
the relevant missing value 0 for date, 99 for result and 999 for number of months 
to repeat cytology advised)  
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Due to the file size limitations of Excel this process had to be undertaken in batches 
and all the files collated.  Once complete, all rows containing data on the first 
cytology test a woman had ever had, also contained her entire cytology record and 
thus these were extracted to create a new, complete database whereby each 
woman was represented by just one line of data. 
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4.3  MERGING THE DATASETS:  FIRST STAGE, HES AND EXETER  
 
Before merging of the HES and Exeter datasets could be undertaken, extensive 
data validation was necessary.  This process is explained in some detail in Chapter 
5; validation ensured that there were no unnecessary gaps in the data and 
avoidable errors could be identified and rectified to permit optimal matching.  
 
In summary, the validated HES dataset contained 6,141 women of which all had 
valid dates of birth and postcodes and 6,055 had valid NHS numbers (98.9%).  A 
decision was made to delete those fields which contained absolutely no data: DIAG 
12/13/14, OPDATE 11/12. OPERTN11/12.  All date fields were confirmed as such 
or converted into ‘dates’ in both Access and Excel and any missing discharge dates 
were calculated from duration of stay post operatively.  Age at the day of surgery 
was calculated thus:  (Operation date - Date of birth)/365.25.   
 
The final, validated Exeter dataset included 6,065 records, of which, 6,064 had valid 
NHS numbers (the missing one matched HES on DOB and postcode perfectly).  
Postcode and date of birth were present in all 6,065.  Empty columns and two 
containing free text were deleted:  the 'Notes' column contained 88 entries, all 
relating to removal from recall but there was no standard format or information,  the 
'Free Text' column contained just 4 entries. 
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Given the very high percentage of records with an NHS number by the time of 
matching (Figure) and with the knowledge that NHS numbers had already been 
validated by HES, the first merge was simply done on the basis of this.  Running a 
merge query in Access 2003® provided an identical match of 98.65% of the records 
first time; this is similar to levels achieved within the WMQARC.151 
 
This preliminary data merging was an obligate step before coding of entire 
screening histories could take place (section 4.4) as date of hysterectomy had to be 
added to the cervical screening histories. 
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4.4  CLASSIFICATION OF LIFETIME SCREENING HISTORIES USING THE WEST 
MIDLANDS CANCER INTELLIGENCE UNIT QUALITY ASSURANCE REFERENCE 
CENTRE ALGORITHM. 
 
4.4.1 Background and data preparation 
 
It was important for the analysis of the final database to be able to classify and 
categorise the data in reproducible and standardised ways to allow for comparison 
with other populations.  It was suggested that a pre-existing algorithm, recently 
developed by the West Midlands Cancer Intelligence Unit Quality Assurance 
Reference Centre (WMQARC) at Birmingham, for coding lifetime screening histories 
in women who developed cervical cancer, could be adopted for our purposes.111 
 
This algorithm is fully reported in the Journal of Medical Screening, by Bagnall et 
al.111  In essence, it is an Access® based visual basic programme which considers a 
woman’s entire screening up until an ‘event’ date, in the case of the study the ‘date 
of hysterectomy’ and attempts to classify it in a logical, standardised, reproducible 
way.  The syntax was generated ‘in-house’ at WMQARC and as such it was 
relatively straightforward to substitute the ‘event date’ from that of a cancer 
diagnosis to an operation date.  However, it did mean that preliminary data matching 
was essential so that the date of hysterectomy could be included.  
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To be able to run the algorithm on the study data a specific format of cytology 
results was required and a set of assumptions about the population had to be made.  
These assumptions may be seen in full at Appendix H but, in summary, only women 
who have ever had screening at the appropriate age were included, tests taken in 
the private or in hospital sector were disregarded, apart from those near the recall 
date to ensure subsequent primary care follow-up is correct.  Tests recommending 
referral were only included if they were taken at the ‘usual’ screening intervals; this 
was to assess how good the call-recall system was at detecting problems.  Thus 
opportunistic testing, when a woman may present with other problems, was 
disregarded. 
 
 
4.4.2 Running the algorithm 
 
From a prepared Excel file containing a line for each screening test ever undergone 
by every woman in the study, the programme was run successfully.  There were two 
outputs from the algorithm, provided in a simple Excel table with the patient 
identifiers DOB and new NHS number attached:  The first was ‘screening status’; a 
code indicating proximity of the last cytology test to the hysterectomy date, as 
outlined in Table 16.  This measure was of uncertain relevance to the study as it 
assumed that the hysterectomy was related to the cervical cytology, however it was 
included for interest and possible analysis.  
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Table 16.  Summary of Screening Status classifications 
Classification Meaning # 
I Interval - hysterectomy occurred in between routine cytology 
testing 
4,089
SD Screen Detected - hysterectomy was within 6 months of a 
routine abnormal cytology test  
62
SDD Screen Detected Delayed - hysterectomy occurred more than 
6months after an abnormal cytology test 
115
LP Lapsed - used to attend for screening but by time of 
hysterectomy was overdue 
453
D Defaulter - missed routine cytology tests despite reminders 190
DBI Diagnosed Before Invitation - hysterectomy occurred  before 
first invitation to routine cytology screening 
2
NA Non Attender - never attended for any cytology screening 
despite being eligible 
101
NE Never Eligible - above eligible age for screening via national 
programme 
1,043
 Total 
 
6,055
 
 
The second output was a ‘summary code’ for the entire Screening History, there are 
theoretically up to 4,320 of these five integer codes (6 x 5 x 6 x 6 x 4 integers).  
Figure 16 gives a few examples of this code to illustrate its complexity.   
 
Each integer of the screening history code had a distinct meaning, these are 
explained further in Chapter 5.5.4.4.  Essentially the process works through a 
flowchart, with 5 layers, each layer adding an integer to the code.  Thus the coding 
is quite sophisticated.  However, grouping of codes was possible to permit 
meaningful analysis.  
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Figure 16.  Examples of Screening History codes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.3 Merging the algorithm data 
 
The additional columns generated from running the algorithm could simply be added 
to the Excel version of the HES data as it mirrored it exactly.  The NHS number and 
date of birth were added again but then removed after accurate merging of the 
columns to the HES database had been validated. 
 
01113:   Last cervical cytology test negative, taken less than six months before 
operation, but at some stage has had inadequate smears 
 
10000:  Never attended for a cervical cytology test despite being eligible and being 
called by the national programme 
 
53112:  Hysterectomy was undertaken at over 65 years of age, the last recorded 
cytology test was 5-10 years ago but she had all normal cytology tests throughout 
her screening history 
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4.5  FINAL MERGING OF HES AND EXETER DATA, DEALING WITH 
DISCREPANCIES 
 
Where NHS numbers were missing in HES, then Exeter had been searched for 
postcode and DOB matches.  Perfect matches of both identifiers were accepted and 
automatically included.  A small number of women with DOB matches had moved 
house some time between 2002/03 (when they had their surgery) and their most 
recent cytology test recorded in Exeter (up to June 2007), but one of their previous 
postcodes did match perfectly.   
 
A small number of women, without an NHS number, had perfect DOB matches but 
had a postcode with an error in one integer.  A decision was made to include these 
records as an imperfect match.  No other imperfect matches were considered for 
inclusion.  One record had no NHS number in either HES or Exeter but matched 
perfectly on DOB and Postcode and so a false NHS number of 9999999999 was 
allocated. 
 
Once the algorithm data had been added to HES then the final merging of these 
datasets could take place.  The merge query was run in Access 2003® then manual 
validation was undertaken on a random sample of 100 of the matched records.  
Random number tables were used to select row numbers and the author validated 
NHS number (100% accurate), date of birth (100% match) and postcode details.   
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There were several postcode discrepancies but when records were reviewed 
carefully this was either due to single digit transcription errors (an infrequent 
finding), or women had moved house following their hysterectomy and Exeter only 
searches on the most ‘up to date’ postcode for a woman.  Table 17 summarises 
how data discrepancies were handled. 
 
Then, for the small number of records in HES with the NHS number missing, date of 
birth and postcode were used to match the records using further merge queries.  
The merged data was turned into a new table using a ‘make table’ query in Access.  
This resulted in a table of 6,141 rows (each representing one woman) and 203 
columns of data.  83 of these new records did not have any Exeter data included 
because there was no record of these women in the Exeter database.  Throughout 
all these stages data was securely and frequently backed-up, in accordance with the 
study security protocol (Appendix D). 
 
Finally, it was essential to apply a unique study identifier for each woman; had NHS 
numbers been universal in the HES data this could have been used even though it 
would have had to have been later removed at anonymisation.  HES had already 
added its own unique number, the ‘EPIKEY’ to each admission, however, a small 
number of women had two EPIKEY numbers relating to more than one admission 
and so it was decided to add a completely new, unique study number which could 
be retained after anonymisation took place. 
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Table 17.  Managing data discrepancies 
Item HES 
6,141 
Exeter 
6,065 
Algorithm
6,055 
Notes for dealing with matching discrepancy 
NHS 
number 
 
6,067 6,064 6,055 The 6,067 in HES had all been verified to be true 
NHS numbers.  The Exeter data set only 
contained one entry that did not have an NHS 
number.  Those records in HES with no NHS 
number were supplemented with the NHS 
number from Exeter when this had been found. 
There were eventually 6 records with an NHS 
number from HES that could not be matched with 
an Exeter record, whereas there were 80 without 
NHS numbers that could not be found. 
 
D.O.B. 
 
6,141 
 
6.065 6,055 Both HES and Exeter data were complete but the 
Exeter data was taken to be more reliable in case 
of conflict because a woman's normal cervical 
screening is undertaken on the basis of her age.  
 
Postcode 
 
6,141 
 
6,064 Not 
included 
HES data related to the hysterectomy operation 
whereas the Exeter postcodes related to the 
most recent recorded address (from July 2007) in 
their smear records so there were a few 
differences.  The HES data was used because all 
these are validated (i.e. genuine) postcodes and 
relate to the time point of interest of the study. 
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4.6  HOSPITAL HISTOPATHOLOGY DATA 
 
4.6.1 Obtaining hospitals data  
 
To obtain data from the histopathology laboratories of the hospitals, PIAG stipulated 
that only the NHS number could be used as an identifier.  Thus a simple data file 
was generated, from HES, of the study participants NHS numbers (where known) 
and the corresponding hospital where surgery had been undertaken.  This file was 
taken to each of the chosen hospitals to obtain the data that they held concerning 
hysterectomy operations. 
 
Three hospitals were all under the auspices of one NHS Foundation Trust by the 
data collection stage of the study.  Thus a file was generated representing 829 
women who were either recorded as having surgery in one of these hospitals or who 
lived within the postcode boundaries for routine care of those hospitals. 
 
Hospital A 
The intention had been to run a search on NHS number, at each of these trusts.  
However, at hospital A the laboratory manager advised that this would not be 
reliable as NHS number was not being used consistently in 2002-2003.  A search 
was devised for all ‘hysterectomy’ specimens; it transpired that Hospital A was still 
using an outdated coding system for their samples – ‘SNOP’.  The Systemised 
Nomenclature of Pathology (SNOP) was a forerunner to the more widely used 
SNOMED codes (See Chapter 5.4 for further explanation).   
  
- 129 - 
The first search generated less than 140 records of hysterectomy specimens 
(Hospital A had over 400 according to HES) and so a wider search was undertaken 
of their entire database, this was subsequently interrogated for details of any 
gynaecological specimens generated during the required timeframe. 
 
The resulting database initially included over 3,200 items; these contained duplicate 
records and single records spanning several lines thus giving the impression of 
being additional records.  This data was then pseudoanonymised and cleansed to 
remove non-consultant samples, samples generated in the community, male 
patients (there were several) and samples taken in outpatient clinics.  The final data 
set contained 923 lines of data and a merge query, in Access, found a perfect match 
for 383 of these women. 
 
To validate this matching, a manual sample of 50 records was checked, 
unfortunately in 5 (10%) errors were found, usually where more than one sample 
was matched to a study patient, obviously only one could be the hysterectomy 
specimen.  One had the SNOP code for an endometrial biopsy on a date prior to 
hysterectomy and the remaining 44 included many uterus specimen codes on the 
correct day but also codes for just cervix or just endometrium on the day of surgery.  
Thus the data was difficult to collate and did not seem to be standardised between 
patients.  At an individual patient level however the laboratory could generate a 
comprehensive report of all specimens received.  
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Hospitals B and C  
The same process had to be repeated at Hospital B, which had the histopathology 
data for Hospital C too.  Although they use SNOMED coding there was confusion by 
staff as to which version was being used, and no key was available.  There was also 
concern raised by staff that NHS number was ‘not used reliably enough’ to permit a 
valid search on the basis of this alone.   
 
On this occasion, over 2,000 records were obtained.  However the searches could 
not generate operation or sample dates on batch searching and so the output was 
of limited value as it was not possible to identify date order of samples and correlate 
these with operation dates.  Additionally a lot of the data seemed incomplete with 
missing or incomplete morphology codes applied on 15% of the samples.  As with 
hospital A, at an individual patient level it was possible to generate a comprehensive 
output of all histopathology reports and these included dates, however, these also 
included patient names and addresses and as such were not permissible for use in 
this study. 
 
Hospital D 
The process at Hospital D, a separate NHS Trust, was similarly troublesome with a 
search of their records for what the staff believed to be hysterectomy samples.  This 
generated data on 214 women during the study period, whereas HES thought just 
168 had a hysterectomy, of these the overlap was 127 women (75.5% of the HES 
cohort).   
 
  
- 131 - 
Decision making with respect to hospital level data 
These hospital databases provided a powerful example of the limitations of routinely 
collected data.  They functioned well for the requirements of the individual hospitals, 
having a comprehensive list of samples and sample identifying codes which 
permitted clinicians to access a separate ‘hard copy register’ of sample reports, for 
individual patients where there was no restriction on use of patient identifiers.  
However, for our purposes the data was of limited value. 
 
Serious contemplation and study of the preliminary data that had been extracted 
was undertaken and several strategies attempted to increase the quality and 
matching potential.  As some hospitals had refused access to their data and 814 
study participants could not have their hospital identified, this level of data was 
never going to have been applied to all of the study population.  However, it was 
frustrating to have access to data that was not suitable for matching. 
 
After extracting data from just four hospitals the process was stopped as it was 
evident that there would be little to gain from persevering.  The restrictions imposed 
by PIAG with respect to lack of patient identifiers proved to be the key limiting factor 
and a decision was reluctantly taken to not pursue this source of data.   
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4.6.2  Combining hospitals data with study database 
 
The quality of the obtained hospitals data was variable and only applied to a small 
proportion of the study population, thus it was decided that it was more appropriate 
to keep this data separate rather than attempt to merge it with the main study data 
which was felt to be of high quality.  The hospitals data was managed in Access, 
which permitted small subsets of data to be extracted and then converted to SPSS if 
necessary.  No detailed statistical analysis could subsequently be undertaken on the 
hospitals’ data. 
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4.7  ANONYMISING THE STUDY DATABASE 
 
Once the final database of 6,141 women had been constructed and verified and the 
various key data items validated (see Chapter 5) then the three essential patient 
identifiers were removed i.e. date of birth, home postcode and new NHS number.   
 
The secure removal of the identifiers was verified externally, as per study Security 
Policy (Appendix D) and PIAG was notified.  Finally, the fully anonymised data could 
be transferred to a networked PC for analysis.  All complex statistical analysis was 
performed in SPSS v 15.0, some of the descriptive work was undertaken in Excel 
2003. 
 
A back up copy of the database, including study identifiers prior to anonymisation 
was retained in a secure store (as per security protocol) for disaster management 
purposes only. 
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4.8  SUMMARY OF CHAPTER 
 
This chapter has taken the reader through the many, necessary, steps in the 
process of obtaining data from the various datasets and highlighted some of the 
difficulties navigated.  Using databases that were never designed for this style of 
interrogation highlighted some of their limitations whereas the bulk searching of 
NHS numbers in Exeter was an example of a good search facility that was seriously 
limited by a lack of computing power. 
 
Despite efforts to use automated searching wherever possible it was inevitable that 
a small, but substantial, portion of data had to be searched for in more laborious 
ways.  The ability to validate NHS number (See Appendix C) means that its use will 
inevitably increase; once NHS numbers are used universally through all NHS and 
related databases, these obstacles will disappear.  Missing and duplicate records 
were dealt with systematically and the rules applied have been justified. 
 
Several conversions of the various types of data had to take place from text files to 
Excel spreadsheets and then to Access relational databases.  Both these computing 
applications were used for different stages of the extraction and linkage:  Excel was 
particularly helpful for converting long lists of cervical screening test results to one 
line of data per study participant.  Access, with its ability to run ‘merge’ and ‘make-
table’ queries was invaluable for linking the datasets, without the need for writing a 
bespoke computer program.   
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The final merged database, from HES and Exeter, was of high quality and populated 
with a wide range of data on each study participant’s hospital stay, operation type 
and outcome, her entire cervical screening history and a coding of this.  However, 
the data obtained from hospital histopathology laboratories was very disappointing 
and, after efforts to improve the quality failed, this resource was no longer pursued.  
Full anonymisation of the study database was confirmed and analysis could then 
begin. 
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CHAPTER FIVE:  DATA VALIDATION AND CODING 
 
 
INTRODUCTION TO CHAPTER 
The chapter deals with the preliminary management of the various items of data, 
once they had been successfully extracted from their respective sources.  This 
management and subsequent manipulation was necessary to ensure the data were 
free from errors and duplication; a vital process step before merging the data sets to 
maximise matching and ensure that numbers of mismatched items would be 
minimised  
 
The sets of data are considered in the order they were obtained i.e. HES data 
concerning the hospital admission for hysterectomy, ‘Exeter’ data concerning 
women’s entire cervical screening histories and finally the hospital laboratory data . 
 
Once the final dataset had been created and anonymised (as has already been 
outlined in Chapter 4) it was necessary to classify and code some data to allow for 
meaningful comparisons and statistical analysis; coding is described towards the 
end of the chapter. 
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5.1  VALIDATION METHODS 
 
Data validation tests are generally applied to ensure that data conforms to specific 
rules.  In data collection systems, where the researcher has control over the raw 
data, simple validation rules can be applied to inputting forms to ensure that data is 
in the correct format or that entered values are plausible (i.e. not accepting dates of 
birth prior to 1st January 1899).  However, when using routinely collected datasets, 
the researcher does not have initial ownership of the data inputting stage and so 
validation of routinely collated data is essential to confirm that all data items are 
genuine, accurate and contain no obvious errors.109;152  
 
Phases of data validation often include:  
1.  Missing values:  These may be a single integer missing or a whole entry skipped.  
It is important to quantify these and then to standardise them into different types i.e. 
whether missing through human error or if this is genuinely unknown information.  It 
may be important to know this distinction during subsequent data coding.  It may be 
possible to ‘fill in the gaps’ especially where data has been duplicated (i.e. in the 
case of a repeated test) or where another data source can be accessed. 
 
2.  Invalid data:  This may take many forms; it may represent the wrong number of 
characters (i.e. in a postcode), impossible values (i.e. age >115, or 'hysterectomy 
operation' in a male) or simple typographical error (i.e. test type recorded as ‘valt’ 
instead of ‘vault’).  Some may have to be excluded from analysis; other items may 
be amenable to correction. 
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3.  Consistent data:  Checking for consistency may be helpful to confirm if data has 
been transferred effectively:  if there are particularly unexpected findings i.e. no 
births in a particular year or no operations performed in one hospital in a given 
month.  This acts as an ‘alert’ that a problem may have occurred at some stage and 
the data requires closer scrutiny.  Further investigation may reveal operator errors or 
programming errors in data linkage. 
 
These three main approaches were applied to all the received study data and are 
outlined below, with specific mention being made of instances where there were 
problems identified with the data. 
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5.2  HES DATA VALIDATION 
 
The requested data extract was received from Northgate Information Solutions on a 
CD-Rom containing a text file of two data sets, in pipe delimited style (see Chapter 
4.1 for explanation), which was converted to Excel for preliminary validation. 
 
5.2.1  Summary of all the received data 
 
Table 18 summarises all the different received 'fields' or headings in the main data 
file from HES, the number of included records for each and the degree to which the 
data was complete and valid.  Records with 100% valid entries are in bold type.   
 
It may be seen that postcode and date of birth were present in 100% of cases but 
new NHS number was present for 95.4%.  The names of fields used were those 
supplied by HES and are compatible with all HES outputs.  There is a brief 
explanation of each in the table, however, further explanation may be found in then 
next section. 
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Table 18:  Summary table of all the received HES data items   
No. Code What the code is for Valid Incomplete 
or invalid 
Missing 
or not 
recorded
1 DOB Date of birth (date field) 6,168 0 0
2 ETHNOS Ethnic Group of patient 4,226 1,942 0
3 NEWNHSNO New NHS Number 5,882 1 285
4 SEX Gender (all female) 6,168 0 0
5 ADMIDATE Date of admission to hospital (date) 6,168 0 0
6 DISDATE Date of discharge from hospital (date) 6,120 42 0
7 DISDEST Discharged destination 6,120 47 1
8 MAINSPEF Speciality of consultant  6,168 0 0
9 TRETSPEF Treatment speciality of consultant 6,168 0 0
10 EPITYPE Type of admission 6,168 0 0
11 DIAG01 6,168 0 0
12 DIAG02 6,163 0 5
13 DIAG03 1,325 0 4,843
14 DIAG04 518 0 5,650
15 DIAG05 197 0 5,971
16 DIAG06 84 0 6,084
17 DIAG07 31 0 6,137
18 DIAG08 10 0 6,158
19 DIAG09 4 0 6,164
20 DIAG10 2 0 6,166
21 DIAG11 1 0 6,167
22 DIAG12 * 0 0 6,168
23 DIAG13 * 0 0 6,168
24 DIAG14 *  0 0 6,168
25 OPDATE01 6,163 5 0
26 OPDATE02 4,965 31 1,172
27 OPDATE03 1,814 15 4,339
28 OPDATE04 638 7 5,523
29 OPDATE05 157 0 6,011
30 OPDATE06 50 0 6,118
31 OPDATE07 18 0 6,150
32 OPDATE08 6 0 6,162
33 OPDATE09 3 0 6,165
Diagnosis code:  up 
to 14 per admission 
for each woman 
ICD10 codes 
Date of operation: 
up to 12 dates per 
episode for each 
woman 
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34 OPDATE10 1 0 6,167
35 OPDATE11 * 0 0 6,168
36 OPDATE12 * 
 
0 0 6,168
37 OPERSTAT Was operation carried out or not 5,736 429 3
38 OPERTN01 6,168 0 0
39 OPERTN02 4,998 0 1,163
40 OPERTN03 1,829 1 4,338
41 OPERTN04 645 0 5,516
42 OPERTN05 157 0 6,011
43 OPERTN06 50 0 6,118
44 OPERTN07 18 0 6,150
45 OPERTN08 6 0 6,162
46 OPERTN09 3 0 6,165
47 OPERTN10 1 0 6,167
48 OPERTN11 * 0 0 6,168
49 OPERTN12 *  0 0 6,168
50 POSOPDUR Days in hospital after main surgery 6,163 0 5
51 SITETRET Hospital where operation conducted 5,354 102 712
52 OACODE Super Output area (SOA) of residence 6,168 0 0
53 OACODE6 6-character SOA of residence 6,168 0 0
54 WARD91 Electoral ward of residence 6,128 40 0
55 RESPCT PCT of residence 6,168 0 0
56 HOMEADD Patients home postcode 6,168 0 0
57 PCTTREAT PCT where treatment occurred 6,168 0 0
58 ROTREAT Region where treatment occurred 6,168 0 0
59 STHATRET Strategic HA where treatment occurred 6,168 0 0
60 CONSULT GMC number identifying consultants 6,167 1 0
61 GPPRAC General Practitioner surgeries code 6,157 11 0
62 EPIKEY A record identifier (unique) created by 
HES 
6,168 0 0
* Seven fields contained no data at all and thus were omitted from further analysis. 
 
 
Operation code:  OPCS4 
(Classification of Surgical 
Operations and Procedures) 
codes with the full-stop, that 
is usually located between 
the 2nd and 3rd digits, 
omitted   
 
OPERTN01 should 
represent the main 
operation that was carried 
out 
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5.2.2   Expanded validation data on some fields 
 
DOB = Date of birth:  This was a complete data set, which was important to the 
study as this was one of the three linkage items.  Of interest, 10 women were aged 
over 90 at the time of their surgery (i.e. DOB prior to 1912) and two women were 
aged under the age of 20 at the time of surgery (i.e. DOB after 1982).  No dates of 
birth were implausible and thus this field was taken to be completely accurate and 
used as the basis for all subsequent age related calculations. 
 
ETHNOS = Ethnic Group of patient:  From 2001 HES ethnicity codes were 
changed to conform to the 2001 census classification.  Unfortunately ethnicity was 
recorded somewhat erratically during 2002-2003 and only 68.5% of women had this 
recorded.  The great majority of women were White British (86.4%) but there was 
representation from every ethnic grouping amongst the study population.  Table 19 
has a summary of all supplied ethnicity data. 
 
DISDEST - Discharged from hospital destination:  This field gave information 
about the place that patient intended to go to on leaving hospital.  Table 20 
summarises the validation of this field, it may be seen that ten patients were 
recorded as having died during the admission but 47 (0.76%) had discharge 
information missing.  The great majority were discharged to their usual place of 
residence. 
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Table 19:  Summary of supplied ethnicity data 
HES 
Code 
Meaning Code for 
analysis 
N % 
 
(6,168) 
% of coded 
women 
(4,226) 
A British (White) 0 3,653 58.9 86.4
B Irish (White) 1 28 0.5 0.7
C Any other White background 2 174 2.8 4.1
D White & Black Caribbean (mixed) 3 12 0.2 0.3
E White and Black African (mixed) 4 1 0.0 0.0
F White & Asian (mixed) 5 1 0.0 0.0
G Any other Mixed background 6 1 0.0 0.0
H Indian (Asian or Asian British) 7 120 1.9 2.8
J Pakistani (Asian or Asian British) 8 72 1.2 1.7
K Bangladeshi (Asian or Asian British) 10 7 0.1 0.2
L Any other Asian background 11 10 0.2 0.2
M Caribbean (Black or Black British) 12 91 1.5 2.2
N African (Black or Black British) 13 15 0.2 0.4
P Any other Black background 14 13 0.2 3.1
R Chinese (other ethnic group) 15 11 0.2 0.3
S Any other ethnic group 16 17 0.3 0.4
 Subtotal of classified ethnic group  4,226 68.5 100
X (not a genuine code) 26 4.2 
Z Not stated / missing 1,165 18.9 
0 (not a genuine code) 635 10.3 
1 (not a genuine code) 22 0.4 
2 (not a genuine code) 3 0.0 
9 (not a genuine code) 
 
 
 
99 
91 1.5 
 Subtotal of unclassified ethnic group  1,942 31.5 
Total  6,168 100  
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Table 20:  Summary of destination information 
Value Meanings of codes ( all possible) Number % 
19 Usual place of residence (incl. no fixed abode) = home 6,048 98.05
29 Temporary place of residence (i.e. hotels, schools) 25 4.05
38 Penal establishment - police station 1 0.02
49 NHS other hospital provider - high security psychiatric unit 1 0.02
51 NHS other hospital provider - ward for general patients or 
younger physically disabled. 
18 2.92
52 NHS other hospital provider - ward for maternity patients or 
neonates 
1 0.02
54 NHS run nursing home, residential care home or group home 3 0.05
65 Local Authority Part 3 residential accommodation - where care 
is provided 
11 0.18
79 Patient died 10 0.16
84-89 Non NHS institutions 2 0.03
98 Not applicable 47 0.76
39 not a genuine code 1 0.02
Total 6,168 100
 
 
MAINSPEF = Speciality of consultant, the medical speciality that the consultant is 
contracted under, during period of care and TRETSPEF = Treatment speciality of 
consultant during period of care:  these two fields would usually be the same.  
Table 21 indicates that there were only a few minor differences between the groups, 
with the vast majority of cases being under the care of gynaecologists or 
obstetricians. 
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Table 21:  Summary of MAINSPEF and TREATSPEF validation 
Code Meaning Number  
MAINSPEF 
% Number 
TRETSPEF 
% 
100 General surgery 64 1.04 63 1.02
101 Urology 13 0.21 13 0.21
300 General Medicine 6 0.10 2 0.03
370 Medical oncology 1 0.02 1 0.02
501 Obstetrics 25 0.39 24 0.39
502 Gynaecology  6,058 98.22 5,745 93.14
& TREFSPEF = MAINSPEF  320 5.19
800 Clinical oncology (Radiotherapy) 1 0.02 0 0
Total  6,168 100 6,168 100
 
 
 
EPITYPE = Type of inpatient episode:  This was useful to identify those women 
who underwent an emergency hysterectomy during or just after childbirth, the data 
was complete with only 25 women being coded as having had a ‘delivery’ episode 
and is consistent with 25 women being under the care of an Obstetrician (Table 21). 
 
DIAG = ICD10 diagnosis codes:139  These codes were crucial to permit coding 
women for analysis on the basis of their diagnosis.  Although up to 14 are 
permissible in HES, the majority of women had just two codes, see Section 3.2.2.1 
for further detail about ICD10. 
 
OPDATE = Operation date:  dates of all procedures undertaken whilst an in-
patient.  This permitted duration of hospital stay to be calculated.   
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OPERSTAT = Operation status code:  this confirmed that a surgical procedure 
was carried out.  Of interest, 428 women had a code suggesting that no operation 
occurred (Table 22), but all of these had documented operation codes.  There were 
no invalid codes and only one entry was missing but in view of the large number of 
obviously erroneous entries this field was not used further. 
 
Table 22:  Operative status:  Did surgery take place?  
Value Meaning Number 
1 One or more operation carried out 5,736 
8 Not applicable - no operation carried out  428 
9 Not known - no data entered  1 
- Missing data  3 
 
 
 
OPERTN = Operation code:  These fields are the OPCS4 (UK Classification of 
Surgical Operations and Procedures) codes,153 however the usual full-stop between 
the 2nd and 3rd digits in this code had been omitted by HES.  Chapter 3.2.2.2 has 
already outlined the structure and content of OPCS4 codes.126  OPERTN01 in HES 
is intended to represent the ‘main’ operative procedure that was undertaken and all 
6,168 records included a valid code in this field.  All the codes included in the other 
fields were found to be valid (Table 18).  In total, HES had 13,875 OPCS4 codes 
documented for these 6,168 cases. 
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POSOPDUR = Post operative duration of stay:  The number of days from the 
date of operation to date of discharge from that hospital, these were whole or part 
days recorded in all but 5 cases.  However, those five cases did have dates for 
hospital discharge and operation dates so this field was calculated and input 
manually.  Of concern, however, was that 114 records suggested that women were 
discharged on the day of surgery (see Table 23) and seven women were in hospital 
for 40 days or more.  Whilst the longer duration of hospital stay is plausible if a 
woman experienced surgical complications or had severe disease, to be discharged 
home following major surgery, within 24 hours, seems highly improbable and would 
suggest miscoding of either the operation or the discharge date/destination. 
 
SITETRET = Site of the treatment:  a code for the individual hospitals where 
surgery had occurred, thus, more specific than just coding the relevant NHS Trust.  
Hospitals are only identified by a code in this thesis, to preserve confidentiality of 
both patients and clinicians.  Table 24 summarises these data and illustrates several 
problems that were identified:  Firstly, three hospitals within the region, which 
definitely have gynaecology departments and at which hysterectomy operations are 
known to occur, did not have any operations recorded for the study period.  
However, there were 712 instances of missing or just one-digit codes being applied 
and this coincides closely with the approximate number of cases that would have 
been anticipated as being undertaken at these three sites.  Crude postcode data 
supported the hypothesis that cases from these particular hospitals may have just 
had this coding omitted but a decision was made not to ‘assign’ women to a given 
hospital but to work with and analyse just the supplied hospitals data. 
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Table 23:  Duration of hospital stay, post operatively 
No days N Collated No days N Collated 
Missing 5 5 20 4 
0 114 114 21 6 
1 40 22 4 
2 85 
125 
23 5 
3 872 24 2 
4 1,936 25 2 
5 1,605 26 2 
6 636 
5,049 
27 3 
7 335 28 4 
8 184 29 2 
34 
9 90 31 3 
10 53 
662 
32 1 
11 44 34 1 
12 33 38 1 
6 
13 18 40 1 
14 23 42 1 
15 15 47 2 
16 10 50 1 
17 6 51 1 
18 10 81 1 
19 7 
166 
  
7 
 
 
A major University Hospital NHS Trust in the West Midlands has no department of 
gynaecology or obstetrics on site at either of its two hospitals (these being located at 
a nearby women’s hospital), however, a small number of operations (18) were 
performed here and these may represent cases of emergency surgery or a 
hysterectomy being undertaken as part of more major bowel surgery. 
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Table 24:  Hospital at which hysterectomy was performed 
Hospital Code No  
samples 
% total 
N=6,168 
1 245 3.97 
2 167 2.71 
3 216 3.50 
4 408 6.61 
5 169 2.74 
6 375 6.08 
7 413 6.70 
8 649 10.52 
University Hospital, no gynaecology on site 18 0.29 
9 366 5.93 
10 414 6.71 
Odd finding as Gynaecology on site 0 0 
11 224 3.63 
12 274 4.44 
13 352 5.71 
14 157 2.55 
15 368 5.97 
Maternity hospital only, same trust as 16 6
16 412
 
6.78 
Odd finding as Gynaecology on site 0 0 
Total of cases within the region 5,215 84.55 
Out of area 10 hospitals 121 1.96 
Code does not exist 84 1.36 
Private provider / incomplete  18 0.29 
Missing data or one digit only 712 11.54 
Total incomplete or outside region 935 15.45 
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121 operations were coded as being conducted out of the region; the great majority 
(113) were hospitals that border the West Midlands (i.e. Gloucester, Oxford, Derby 
and East Cheshire) and may represent cases referred to tertiary centres or an 
expression of patient choice.  For those recorded as being significantly outside the 
region it is possible that women had relocated but their hospital records had not 
been updated or that emergency surgery was undertaken during a vacation. 
 
OACODE / OACODE(6) = Census output area:  This code was applied by HES 
and was based on the home postcode of the patient and thus is a derived field.  
Both the full (10 integer) and restricted (six integer) codes are supplied.  Output 
Areas (OAs) are small geographical areas that cover similar population sizes, 
according to the 2001 census and are as socially homogeneous as possible.154 
There are 165,665 OAs in England.  The six character version includes three two-
letter codes combined i.e. CCDDWW (CC = county, DD = district, WW=ward). 
 
RESPCT = Patients Primary Care Trust of residence:  This is another HES 
derived code, by applying patient postcode of usual residence.  All these codes start 
with five then two letters representing the various PCTs (Table 25).  Some of these 
subsequently changed in 2006. 
 
HOMEADD = Full UK Postcode:  Postcode of patient's recorded home address, 
using the eight alphanumeric style, where spaces are used to ‘pad out’ shorter 
postcodes.123  Table 26 summarises the various regions, it may be seen that 20 
women lived outside the traditional West Midlands boundary (designated with a *). 
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Table 25:  PCT Codes and numbers of study participants 
Code PCT Name N  Code PCT Name N  
5CN Herefordshire 185 5MG Oldbury and Smethwick 93
5D1 Solihull 192 5MH Rowley Regis and Tipton 129
5DQ Burntwood, Lichfield and 
Tamworth 
208 5MJ Wednesbury and West Bromwich 153
5DT North East Oxfordshire 110 5MK Telford and Wrekin 188
5HR Staffordshire Moorlands 119 5ML East Staffordshire 139
5HT Dudley South 224 5MM Cannock Chase 231
5HV Dudley Beacon and Castle 145 5MN South Western Staffordshire 260
5HW Newcastle-under-Lyme 104 5MP North Warwickshire 287
5M1 South Birmingham 499 5MQ South Warwickshire 269
5M2 Shropshire County 292 5MR Redditch and Bromsgrove 193
5M3 Walsall Teaching 366 5MT South Worcestershire 302
5M9 Rugby 84 5MV Wolverhampton City 211
5MD Coventry Teaching 315 5MW North Birmingham 186
5ME North Stoke 119 5MX Heart of Birmingham 213
5MF South Stoke 102 5MY Eastern Birmingham 250
Totals 6,168
 
 
Table 26:  West Midlands postcode regions and numbers of study participants123 
Postcode Location Number Postcode Location Number (N) 
B Birmingham 2,087 OX* Oxford 7
CV Coventry 872 SK* Stockport 3
CW* Crewe 7 ST Stoke 654
DE Derby 108 SY Shrewsbury 218
DY Dudley 482 TF Telford 237
GL Gloucester 7 WR Worcester 294
HR Hereford 173 WS Walsall / Lichfield 661
LE* Leicester 3 WV Wolverhampton 355
Totals 6,168
* Italics represent postcodes outside the West Midlands region.  
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PCTTREAT = Primary Care Trust of treatment:  A derived code based on the 
hospital providing surgery.  All codes start with ‘5’ then two letters representing the 
local Primary Care Trusts (PCT) as summarised in Table 27. 
 
ROTREAT = Region of treatment:  A field recording geographical location of 
treatment; this was a main regional classification, summarised in Table 28. 
 
STHTRET = Strategic Health Authority (SHA) of treatment.  Summarised in 
Table 29, a small number of SHAs were geographically remote from the West 
Midlands. 
 
CONSULT = The GMC Code (number): This identifies the responsible consultant 
individually.  There was only one code for a missing data item, the rest were valid 
GMC codes.143  These have not been summarised but there were 6167 valid codes 
representing 233 different doctors. 
 
GPPRAC = Registered GP Practice of patient:  This code allows the practice to 
be notified about any treatment administered.  However the registered GP may not 
be the same as the referring GP.  6,157 women had valid GP practice codes, two 
were registered with Ministry of Defence (MoD) doctors and nine did not have this 
data recorded. 
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Table 27:  Primary Care Trust of treatment 
Code PCT Name N  Notes 
5AA South Manchester 2 out of area 
5AL Central Derby 15 out of area 
5CL Central Manchester 1 out of area 
5CN Herefordshire 167  
5DD Morecombe Bay** 1 out of area 
5DW Oxford City 20 out of area 
5EJ Leicester City West 5 out of area 
5F5 Salford 1 out of area 
5F7 Stockport 2 out of area 
5FA Ashfield** 1 significantly out of area 
5H1 Hammersmith and Fulham** 1 significantly out of area 
5H4 Central Cheshire 3 out of area 
5H5 Eastern Cheshire 33 out of area 
5HT Dudley South 367  
5K3 Swindon** 2 significantly out of area 
5KT Central Cornwall** 1 significantly out of area 
5KW Cheltenham and Tewkesbury 51 out of area 
5M1 South Birmingham 667  
5M2 Shropshire County 434  
5M3 Walsall Teaching 352  
5MD Coventry Teaching 408  
5MF South Stoke 418  
5ML East Staffordshire 157  
5MN South Western Staffordshire 384  
5MP North Warwickshire 269  
5MQ South Warwickshire 215  
5MT South Worcestershire 544  
5MV Wolverhampton City 301  
5MW North Birmingham 434  
5MX Heart of Birmingham 911  
5C6 Invalid code  1 only one miscoded entry 
Totals 6,168  
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Table 28:  Region of treatment 
Code Region Number 
Y02 Trent 20
Y07 West Midlands 6,030
Y08 North West 42
Y10 London 2
Y11 South East 20
Y12 South West 54
Total 6,168
 
 
 
Table 29:  Strategic Health Authority of treatment 
Code Strategic Health Authority N  
Q04 North West London 1 
Q06 North East London 1 
Q13 Cumbria and Lancashire 1 
Q14 Greater Manchester 6 
Q15 Cheshire & Merseyside 36 
Q16 Thames Valley 20 
Q20 Avon, Gloucestershire and Wiltshire 53 
Q21 South West Peninsula 1 
Q24 Trent 16 
Q25 Leicestershire, Northamptonshire and Rutland 5 
Q26 Shropshire and Staffordshire 1,393 
Q27 Birmingham and the Black Country 3,031 
Q28 Coventry, Warwickshire, Herefordshire, Worcestershire 1,604 
Total 6,168 
 
 
Thus, overall the HES data was comprehensive and valid with the few notable 
exceptions of relevance to this study being ethnicity and hospital of treatment. 
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5.3  EXETER DATA  
 
Chapter 4 has already outlined the processes involved in extracting and combining 
all the Exeter data into one large spreadsheet of 6,065 women, created from the 
36,469 lines of cytology results data.   
 
Validating this new database was less complex than the validation required for HES 
data as there were fewer variables and Exeter has some inbuilt validation i.e. as age 
is the trigger that sets call and recall to the various national screening programmes 
then date of birth is a mandatory field.  NHS number is also a pre-requisite, thus it is 
difficult to add any data to Exeter files without having a valid NHS number. 
 
When a woman had undergone at least one cytology screening test in her lifetime 
the ‘Exeter’ database held all the data items, summarised within Table 30, for each 
separate test.  Thus, theoretically, a single woman could have over thirty records if 
she had ever had any abnormal tests with early recall recommended.   
 
Currently, in England, a woman who only has negative cytology tests would usually 
have a maximum of 11 tests in her lifetime,83 however guidelines have changed 
over the years since the screening programme started and have varied around the 
UK and so some women could, theoretically have had up to 15 consecutive normal 
cytology test results (three yearly from 20 - 65 years).  
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Table 30 also shows which items were unique and which were duplicated on all 
tests recorded for a given woman.  Some completely irrelevant data items have not 
been included and some of those items included were subsequently discarded from 
the database prior to analysis (indicated by ‘R’). 
 
A few of these data items warrant further explanation:  Table 31 includes details of 
all possible cytology results codes, subsequent recommended action and details of 
those codes representing any infection detected.  Every test should have had a 
result code and an action code documented, but infection codes were only applied if 
relevant with the default being a blank cell representing ‘no infection detected’. 
 
Thus, it may be seen from Table 31, that the overall cytology results gave an 
inadequate specimen rate of 6.31%, borderline results represented 4.05% with the 
likelihood of a normal (negative) result being 85%.  Infection was uncommon, with 
only 3.07% of tests having an infection code added; candida (fungal) infection was 
most prevalent, being noted in 1.77% of all tests. 
 
Address and postcode 
The Exeter system does not hold postcode as a separate field, thus to establish the 
patient’s postcode from the address string it was necessary to use special functions 
in Excel:  the address ‘string’ took the form of one line with commas separating the 
address items thus the string was split using the ‘Text to Columns’ function, with the 
comma as the separating variable.  Then the postcode column could be extracted, 
ready for use in linkage and to apply a deprivation classification.  
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Table 30:  Exeter data items for each recorded cytology test 
Title Notes Unique = U 
Duplicated = D 
Irrelevant = R 
Number 
of items* 
(N=6,065) 
% 
NHS number New 10 digit D 6,064 99.98
Name  Title Forename Surname (string) D 6,065 100
Q code PCT Code D 6,053 99.80
Address Full address (string) inc postcode D 6,060 99.92
Date of birth ‘dd/mm/yyyy’ format D 6,065 100
Age In years, at time of data extraction D 6,065 100
GP GP name, address, postcode (string) D 6,054 99.82
GP Local Code 3 or 4 digit, (string) D 6,015 99.18
# Smear number  D 6,065 100
Test date ‘dd.mm.yyyy’ format U 5,810 5,810
Reporting Lab Text field U - -
Slide number Various formats, depending on 
hospital processing the test 
U - -
Result Numeric code - see later for 
description 
U 5,810 95.80
Infection A coded added if suspicion of infection 
noted  
U 174 2.87
Action Code Cytology lab action code - numeric, 
see separate table for description 
U 5,810 95.80
Repeat Months Number of months until repeat smear 
advised 
U 4,433 73.09
GP Local Code Numeric (up to 4-digit) code  D 6,065 100
Date Deducted Date removed from recall R 59 0.97
Reason for 
Movement 
Reason for this removal from recall U 59 0.97
Date of Death Date Exeter has for death of patient U 343 5.66
Recall date Date for recall on the basis of most 
recent smear result 
U 5,594 98.17
Notes Option for free text (string) U - -
Recall Type Routine or Cancelled from further 
recall 
U 5,594 98.17
Recall Status No action / Cancelled / Non-
respondent / GP informed 
D 5,594 98.17
Notify Date Date of notification of no-respondent 
status or GP informed 
R - -
* The ‘number of items’ field refers to the database of 6,065 women.  Demographic data related to 
the most recent screening test, however, the result related to the first recorded cytology test only. 
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Table 31:  Explanation of data items in cytology extract 
Details of cytology ‘Results Codes’ 
Results Code Interpretation   N = 36,213
1 Inadequate Specimen 2,284
2  Negative 30,772
3  Mild Dyskaryosis (CIN 1) 851
4 Severe Dyskaryosis (CIN 3) 411
5 Severe Dyskaryosis / Possible Invasive Carcinoma 48
6 Possible Glandular Neoplasia 87
7 Moderate Dyskaryosis (CIN 2) 295
8 / B Borderline 1,465
Details of cytology ‘Action Codes’ 
Action 
Code 
Description N = 36,213
A To be used for all cases where the next test is to be performed at 
the normal (routine) recall interval for the health authority 
responsible for the women 
25,882
R To be used for all cases in which a further smear is recommended 
in an interval less than the routine recall interval of the DHA 
8,110
S To be used for all cases where a referral to a gynaecologist is 
recommended and for those smears from patients under the care of 
a gynaecologist or other relevant specialist 
2,211
H Record the result and do not change current recall details 10
Cytology infection code descriptions 
Code Description N = 1,113
1 Trichomonas present 52
2 Candida present 640
3 Wart virus present 248
5 Actinomyces present 44
6 / 7 Other infection (to be specified) present 129
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Dates 
To convert dates from non-standard formats from Exeter to standard formats for 
analysis the “Text to Columns” function in Excel was applied with ‘delimiting’ left 
blank and the ‘DMY’ option selected.  This process was used for every date field to 
ensure that date fields were compatible. 
 
Overall the quality of the cervical screening data obtained from the QARC was 
excellent; the data was comprehensive and contemporaneous and of better quality 
than had been anticipated. 
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5.4  HOSPITALS’ DATA 
 
The hospitals in the study area used a variety of software programmes to store and 
archive their histopathology data.  Three NHS trusts, representing four distinct 
hospitals were selected for use at this stage of the project, representing a diverse 
range of affluence and population density:  Hospital A located in an affluent suburb 
of Birmingham (hospital 10 in Table 24 and Chapter 6).  Hospital B located in a 
more densely populated urban setting also included data from Hospital C which is 
part of the same NHS Trust and located in another affluent suburb (combined as 
hospital 7 in Table 24).  Finally, Hospital D, located in a small town centre, covered 
a largely rural population (hospital 2 in Table 24).   
 
A wide range of variety of computer programmes are used by hospital pathology 
laboratories to manage their patient records ranging from bespoke programmes 
developed locally 20 years ago through to Windows based spreadsheets or 
relational databases.  Table 32 summarises the data held at each of these sites that 
was made available to this study. 
 
The Systematized Nomenclature of Pathology (SNOP) was developed in the 1960s 
by the College of American Pathologists (CAP) and American Cancer Society (ACS) 
as a coding system for pathological specimens.142  There were two groups of codes, 
the Morphology or M codes to describe form and structure of the specimen (the 
diagnosis) with the Typography or T codes used to describe the anatomical region 
or body part that the sample came from.   
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The pathology laboratory at Hospital A had retained SNOP coding from the 1970s 
and never transferred their records over to the newer SNOMED system.  The recent 
merger with the NHS Trust of hospitals B and C meant that at the time of data 
extraction the transfer was being planned.  This use of an old coding scheme 
produced difficulties with respect to aggregating data; conversion algorithms were 
being developed at the time, but these were not yet ready for use.  
 
Table 32 includes a summary of the data that were extracted from the hospitals 
including the numbers of records compared with the numbers of HES cases, the 
proportion of records including NHS number and some notes. 
 
All the laboratories were confident that their own systems would allow a clinician to 
access reports, for a named patient, to determine the diagnosis from a specific 
specimen.  However, the generalisability of the data across groups of patients for 
audit purposes was questionable.  Standardisation of recording was not assured. 
 
Thus, the hospitals’ data was of variable quality; coding was not consistent and was 
not usually compatible with the other data.  After attempting to identify practical 
solutions to these problems a decision was made not to interrogate the data further 
or attempt to validate and integrate it, but to accept that the study would be 
essentially limited to the HES and Exeter data already obtained.  Chapter 4.6.1 has 
outlined in greater detail the justification for this decision. 
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Table 32.  Summary of hospital laboratory data obtained  
Unit 
 
Number of HES cases 
Hospital A  
 
412 
Hospitals B & C 
 
412 
Hospital C 
 
164 
Records obtained 923 2,103 215 
DOB    
Postcode X X X 
NHS No  (93.2%)  (99%)  (83%) 
Hospital No    
Date received at lab X X X 
Date reported  X  
Sample ID    
Clinician   X 
Source of specimen   X 
Tissue Type - T code    
Number of possible T 
Codes 
2 6 6 
Procedure at which 
obtained 
X X X 
Result - M code    - free text only 
Number of possible M 
codes 
2 6 6 
Free text  X X 
Notes 
 
 
Telepath with Excel 
output, file of 3,236 
lines generated with 
data on ALL women 
who had any gynae 
procedure during 
the study year.  Had 
to be cleansed 
significantly but 
resulting file of 923 
still impossible to 
match with great 
accuracy. 
Telepath with Excel 
output.  Another 
large file of 4,450 
lines representing 
3,834 NHS 
numbers. 
Matching erratic. 
Excel file generated 
by lab: 2,377 
records, once 
converted to one 
woman per line 
these related to 
almost the same 
number of women in 
HES database, but 
did not match well 
also morphology  
results not coded - 
just free text. 
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5.5  CODING OF FINAL MERGED DATABASE  
 
Before full analysis of the database could be undertaken, various key data items 
needed to be grouped and coded or re-coded to permit meaningful statistical 
testing.  The following section outlines the major areas of re-coding that were 
undertaken and attempts to justify the categories and groupings that were applied.  
Particular attention is given to the most significant diagnosis attributed to each study 
participant at time of hysterectomy; what type of hysterectomy she underwent (total 
or subtotal); whether or not she had cervical screening prior to surgery (‘screening 
history’); whether or not she had any follow-up vault cytology and if this was 
appropriate according to national guidelines. 
 
5.5.1  Postcode and the addition of deprivation indices 
 
Postcode is a highly specific identifier of a patient’s address and deprivation score.  
The 6,141 supplied postcodes were in ‘Postcode 8’ format, meaning that every 
postcode was made up of eight characters including spaces so the University of 
Birmingham would be recorded as 'B15--2TT', but the Bullring shopping centre in 
central Birmingham is recorded as 'B5---4BU', where - represents a space.   
 
Before deprivation indices could be derived from these postcodes the spaces had to 
be removed; achieved using the ‘Find and Replace’ function in Excel.  Then, using 
the Midlands Research Practices Consortium (MidREC) postcode database (2.5 
million entries, in Access), the fields listed in Table 33 were added via a ‘merge 
query’, as a set of new columns with an entry for each postcode provided.   
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The postcode database is a resource that is regularly updated by staff from MidREC 
based at the University of Birmingham and is derived from the National Statistics 
website and National Administrative code service. 
 
Table 33.  Deprivation and geographical indices derived from postcode 
Code Name Notes 
SOA1 Super Output Area 1 The 'lower layer Super Output Area code’ for each 
postcode (Eng & Wales) 
SOAPopCt SOA Population Count Actual number of inhabitants of that SOA in 2007 
IMD07Score IMD2007 Score Index of Multiple Deprivation 2007 actual score 
IMD07Rk IMD2007 rank Index of Multiple Deprivation 2007 rank 
Town01Score Townsend 01 score Townsend 2001 actual score 
Town01Quin Townsend 01 Quintile Townsend 2001 quintile 
Town01Rk Townsend 01 Rank Townsend 2001 rank 
 
 
The decision was taken to use IMD07 rather than Townsend scores throughout this 
study as IMD is now regarded as being a more sophisticated measure.155  Index of 
multiple deprivation 2007 (IMD07) is a comprehensive, robust measure which uses 
seven main indices to assess deprivation:  Income, Employment, Health & 
Disability, Education, Barriers to Housing & Services, Living Environment and 
Crime, which together incorporate 38 items.156   
 
IMD07 works at the level of Lower Super Output Areas (LSOAs).  There are 32,482 
of these LSOA's in England, each with an average population of 1,500 people 
(range 1000 - 3000).  The LSOA ranked 1 is the most deprived in England, with the 
one ranked 32,482 the least deprived.   
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This latest index is based on information from the 2001 census and on the latest 
available data, in some cases averaged from 2003-2005.157  As the most detailed 
deprivation indicator available it is used to highlight variation between areas and 
provides a relative (rather than absolute) ranking, thus the score is not linear.  Of 
note, IMD07 is not an index of affluence, but of deprivation, thus a high ranking 
score does not necessarily mean an affluent area, rather that there is an absence of 
deprivation, a subtle but important difference.  Detailed IMD data is available for the 
West Midlands region.158 
 
 
5.5.2  Diagnosis coding 
 
The ICD10 codes from HES (DIAG codes) provided the study population with a set 
of specific diagnoses at the time of surgery and this permitted women to be 
classified into having benign (non-cancerous), intermediate (pre-malignant or 
borderline malignant) or malignant (invasive) disease.  Section 5.2.2 outlined the 
numbers of codes; the majority of women had just two but the maximum for any 
study participant was 11.  Table 34 summarises the first level re-coding that was 
undertaken, whereby all the DIAG codes were grouped into one of 15 categories, 
these were then grouped and reclassified into a simpler grouping for each individual 
woman whereby the ‘worst’ of her various diagnosis codes was taken and used to 
put her into one of four diagnosis bands; benign, pre-invasive, malignant disease or 
unknown.  Appendix J includes further detail of the re-coding. 
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Table 34.  First level re-coding of HES diagnosis codes  
ICD10 Section Recode options  Notes 
A - B: Certain infectious and 
parasitic diseases  
1: Of no interest to study 
2: HIV malignancy 
17: Gynae, infection 
Sexually transmitted diseases 
were put with gynaecological 
diseases but HIV related 
malignancy was allocated to 
section 2 to allow for comparisons 
with other malignancies 
C - D50: Neoplasms 
 
2: Non-gynae malignant 
5: Non-gynae, benign 
12: Gynae malignant 
15: Gynae benign 
This whole chapter allocated to 
new growths, both malignant and 
benign:  C51-C58 malignant 
neoplasms of female genital 
organs:  D39= neoplasm of 
uncertain behaviour of the female 
D50 - 99: Diseases of the blood 1: Of no interest to study 
E:        Endocrine, nutritional and 
           metabolic diseases 
1: Of no interest to study 
F:        Mental and behavioural  1: Of no interest to study 
G:       Nervous system 1: Of no interest to study 
H:       Eye & Ear 1: Of no interest to study 
I - J :   Circulation & respiratory 1: Of no interest to study 
K:        Digestive 1: Of no interest to study 
L - M:  Skin & Muscle 1: Of no interest to study 
 
 
 
 
All grouped as of being unrelated 
to the study and as such excluded 
from analysis/comparisons 
N:        Genitourinary 1: Of no interest to study 
16: Gynae, inflammation 
18: Gynae, bleeding 
19: Gynae, other 
 
N70-98 all other gynaecological 
diagnoses 
O:       Obstetric 10: Obstetric general 
15: Gynae benign 
19: Miscarriages (other 
gynae) 
O01.9 Chorioadenoma 
(hydatidiform mole) was one 
specific example of a benign 
obsetric tumour 
Q:       Congenital 1: Of no interest to study  
R :       Not otherwise classified 88: Non diagnostic 
S - T:   Injury etc 88: Non diagnostic 
W - Y: 'External causes' 88:  Non diagnostic 
Z:        Factors influencing health  
            contacts 
88: Non diagnostic 
 
Descriptive terms, not diagnosis 
thus no contribution toward study 
aims 
           Missing data 99: Missing For blank cells 
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5.5.3  Operation type coding 
 
It was important, if the aims of the study were to be realised, to establish which type 
of hysterectomy each woman had undergone:  a sub-total hysterectomy, when 
some of the cervix is retained at time of surgery, is an indication for continued 
participation in the national cervical screening programme.  Whereas, a total 
hysterectomy, where all the cervix is excised, means that a woman is no longer 
eligible for continued participation in cervical screening; she may however, fit the 
criteria for follow-up by means of vaginal vault cytology. 
 
The OPERTN codes in HES, which utilise OPCS4 (see section 3.2.2.2), were used 
to determine which operation was performed on each woman and a code applied 
accordingly.  However, before allocation into hysterectomy type could be 
undertaken, it was necessary to first establish which operation codes may be of 
relevance to the study and so all the OPERTN codes were recoded, in SPSS, into 
one of the following operation groupings:  breast, gastrointestinal, genitourinary, 
vaginal or prolapse, other gynaecological, obstetric or other.  Table 35 summarises 
this re-coding. 
 
All women had their ‘hysterectomy’ operation code established and classified into 
one of the following three groups:  total hysterectomy (to include abdominal, vaginal 
or laparoscopically assisted), sub-total hysterectomy and unknown (where OPCS 
coding was generic and did not specify operation variant). 
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Table 35.  Re-coding of OPCS codes 
Meaning of grouped OPCS codes Number % of all codes 
Breast surgery 11 0.08
Abdominal or GI tract surgery 1,408 10.80
Genito-urinary or bladder surgery 401 3.08
Vaginal or prolapse surgery 1,130 8.67
Gynaecological surgery 10,057 77.14
Obstetric surgery 31 0.24
Total of useful codes (1-6) 13,038 100
 
 
For women who had several operation codes it was sometimes possible to allocate 
them manually to the total or sub-total hysterectomy groups from the ‘unknown’ 
category to ‘total’, by establishing either that the cervix was excised or that vaginal 
surgery had taken place.  However, a small proportion of cases remained where it 
was impossible to be certain; these were retained in the study population but were 
treated as a separate group for some of the analysis (specified in the Results, 
Chapter 6). 
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5.5.4  Cytology screening history 
 
5.5.4.1  Total number of cytology tests 
The first step in classification of each woman’s personal screening history was to 
establish how many cytology tests she had undergone.  It was assumed, for the 
purposes of the study, that if a woman could not be found on the Exeter system, 
despite electronic and extensive manual searching, that she did not have any 
cervical screening history.  However, many women who definitely never had any 
cytology were included in the Exeter system because this suite of software is used 
for many different healthcare applications, not just the national cervical screening 
programme.  
 
For women not recorded in Exeter, it was possible that some were relatively new 
immigrants to the UK when they developed problems necessitating gynaecological 
surgery.  As such they may not have been fully registered on the Exeter system, 
although new registration with any GP surgery should automatically trigger 
registration.  
 
Some operations would have been undertaken as emergencies i.e. whilst women 
away from home, and it is known that a number of illegal immigrants in the UK 
deliberately try to stay ‘below the radar’ of Primary Care services and just present 
directly to secondary care when they have acute healthcare needs. 
  
- 170 - 
A simple count of all the tests ever recorded for each woman was made and used 
as a reference for further classifications. 
 
5.5.4.2  Differentiation between pre and post operative cytology  
By using each woman’s first operation date as the critical ‘event’ date it was 
possible to compare the date of every cytology test with this and allocate it to being 
pre or post operative.  It was then possible to count how many of each type of test 
every woman had ever had. 
 
5.5.4.3  Last smear before operation - ‘Index test’: 
This was determined using the operative date, as above, and this test was renamed 
the ‘index’ test i.e. the test that may have indicated a need for surgery. 
 
5.5.4.4  Full screening history prior to surgery:  WMQARC algorithm classification 
There were a wide range of cervical screening history patterns evident in the data, 
too many to allow for meaningful comparisons and so a decision was made to use a 
pre-existing algorithm, developed by the West Midlands Cancer Intelligence Unit, 
Quality Assurance Reference Centre (WMQARC).  It was anticipated that use of this 
coding would allow for future collaborative working. 
 
This algorithm was applied to the data as described in Chapter 4.  The resulting two 
new columns of data included a ‘screening status’ code which outlined at what stage 
the event (hysterectomy) had occurred in relation to the routine screening 
programme (eight categories) and a ‘screening history’ code.   
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This screening history code was a five integer categorisation with each integer 
representing a different ‘layer’.  Details of this algorithm are outlined in Journal of 
Medical Screening, 2006.111  In essence the main ‘layers’ are: whether or not a 
woman had ever attended for screening, when the index smear was taken in 
relation to the hysterectomy operation and what the result of that test was, then all 
the tests in the entire history are considered to see if any have been abnormal (and 
to what degree) and if a woman has ever been suspended from the programme. 
 
The 6,141 women from the merged HES/Exeter database all had their Exeter data 
run through the algorithm.  This resulted in 228 different screening codes being 
applied.  This was too complex to allow for meaningful analysis and so it was 
essential to re-code.  These 228 codes were strings of integers rather than 
meaningful numbers thus the strings were split into their 5 component integers; in 
the case of four integer strings, a zero was used as the first integer (Table 36).  
 
Table 36.  Description of 5 integers of screening history classification 
Integer Meaning Options 
1st Whether or not ever attended for screening and if age is related to 
this 
0 - 5, 9 
2nd Time of the most recent screening smear test compared to 
hysterectomy operation 
1 - 5 
3rd The Index test - description of the last test prior to hysterectomy 1 - 6 
4th All other smear tests - were any bad enough for recall to be 
suspended? 
1 - 6 
5th Either, if 4th not bad, were they ever abnormal OR if 4th bad, what 
type? 
1 - 4 
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An important step was to identify those groups of women who had had abnormal 
cytology results just prior to hysterectomy (index test) or ever, and then to be able to 
compare them with those who had never had abnormal cytology.   
 
Rather than use the classification to establish which women had ever attended for 
screening, the study database permitted quicker classification thus the first integer 
of the code was not of great relevance.   
 
The timing of the index smear in relation to the hysterectomy could be examined 
separately by just using integer two (no need for re-coding).  Thus the third integer 
was used for the first block of re-coding, to split women thus: 
 Group 1 - Index smear significantly abnormal 
 Group 2 - Index smear uncertain (borderline, inadequate, glandular) 
 Group 3 - Index test normal 
 Group 4 - Never had any tests done 
 
Then the fourth and fifth integers were used to establish the remainder of the 
screening history and women could finally be categorised into the 13 groups, 
summarised in Table 37; a more complete table of this recoding is available as 
Appendix K. 
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Table 37.  Summary of re-coding of screening history before hysterectomy 
Main 
Group 
Full 
Code 
Explanation 
 
11 Index abnormal, previous history includes abnormal tests 
13 Index abnormal, previous history only ever normal 
18 Index abnormal, previous history includes tests of uncertain significance 
 
1 
19 Index abnormal, only one test pre-op 
31 Index normal, previous history includes abnormal tests 
33 Index normal, previous history all normal 
38 Index normal, previous history includes tests of uncertain significance 
 
2 
39 Index normal, only one test pre-op 
81 Index of uncertain significance, previous history includes abnormal tests 
83 Index of uncertain significance, previous history only ever normal 
88 Index of uncertain significance, previous history includes uncertain test results
 
3 
89 Index of uncertain significance, only 1 pre-operative test 
4 99 Never had any pre-op testing, or at least nil recorded in Exeter or too old to 
have ever been detected in programme (even if did have smears) 
 
 
5.5.5  Vaginal vault cytology testing and its appropriateness 
 
Once women had been categorised in to their hysterectomy type, severity of 
disease at time of hysterectomy and whether or not each of their cytology tests took 
place prior or subsequent to surgery, it was possible to give each participant a code 
for the appropriateness, or otherwise, of her having vault cytology testing.   
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Table 38 summarises the two levels of ‘appropriateness’ categorisation used; a 
‘crude’ set of categories, having three groups and a ‘complex’ set, having five 
groups and also the number of women falling into each category.  The table also 
includes a ‘group’ code which refers to the main diagnosis and whether or not any 
post-operative cytology testing took place. 
 
 
5.5.6  Other data items generated or coded 
 
Age at operation 
Age, in years, on the day of surgery was calculated as the difference between 
operation date and date of birth, divided by 365.25.  As well as being available as a 
discrete number, age was grouped into five-year bands, with the extremes being 
<20 years and >90 years, giving 16 categories for use in some of the analysis. 
 
Ethnicity 
Ethnicity was further coded, from the 16 main groups originally supplied by HES, to 
a simpler six grouping system (white, mixed, Asian, black, Chinese, other) to 
facilitate some analysis as the numbers of women in the various sub-groups was 
very small.  Indeed it was further necessary to divide women into White, non-white 
and not specified, for some analysis. 
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Table 38.  Summary of diagnosis and cytology coding to establish appropriateness 
of post operative cytology 
Subgroup  
(Operation type and main diagnosis) 
Group 
code 
Crude 
code* 
Complex 
code** 
Total Hysterectomies = 5,697 
Malignancy, no post op cytology A 9 30 
Malignancy, post op vault smear tests done B 9 31 
CIN or Carcinoma in situ, no post op cytology C 0 20 
CIN or Carcinoma in situ, post op vault smear tests 
done exact to protocol 
D 1 21 
CIN or Carcinoma in situ, post op vault smear tests 
done but too many (>2 in 2yrs) 
D 1 22 
CIN or Carcinoma in situ, post op vault smear tests 
done but too few (1 only in 2yrs) 
D 1 23 
CIN or Carcinoma in situ, post op vault smear tests 
done but outside recommended window (>18m) 
D 1 24 
Benign disease, no post op cytology E 1 11 
Benign disease, no post op cytology, <10yr FUp 
before op (age less than 35yrs) 
E 1 12 
Benign disease, post op vault smear tests done          
thus inappropriate 
F 0 10 
Benign disease, post op vault smear tests done:  
<10yr FUp before op (age less than 35yrs), just one 
smear so appropriate but post 2004 guidelines 
F 0 15 
Benign disease, post op vault smear tests done:  
<10yr FUp before op (age less than 35yrs) but >1 
smear so still inappropriate 
F 0 16 
Unknown diagnosis, no post op cytology G 9 80 
Unknown diagnosis, post op vault smear tests done H 9 81 
Subtotal Hysterectomies or unspecified total = 444 
Malignancy, no post op cytology J 9 98 
Malignancy, post op cytology tests done K 9 99 
CIN or Carcinoma in situ, no post op cytology L 0 90 
CIN or Carcinoma in situ, post op cytology tests done M 1 91 
Benign disease, no post op cytology N 0 90 
Benign disease, post op cytology tests done P 1 91 
Unknown diagnosis, no post op cytology Q 9 98 
Unknown diagnosis, post op cytology tests done R 9 99 
*  1= Correct, 0 = Not to protocol, 9 = N/A         
** 1# = Benign, 2# = CIN, 3# = Cancer, 8# = Unknown, 9# = Not vault 
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5.6  SUMMARY OF CHAPTER 
 
This chapter has outlined how the study data was managed:  validation of the data 
from HES included calculating missing dates i.e. of duration of hospital stay post-
operatively and decision making concerning handling of errors or missing data i.e. 
erroneous coding of site of treatment for three of the hospitals in the West Midlands.  
One significant concern during data validation was the lack of consistency in 
recording a patient’s self-declared ethnicity; this was only present in 68.5% of 
records from HES.  Apart from this notable exception, the data from HES was felt to 
be comprehensive and valid. 
 
The data received from the ‘Exeter’ sources was similarly of high quality and 
comprehensive, however a lot of irrelevant data was obtained which was discarded.  
Obtaining valid postcodes was challenging, as it was not held as a separate field, 
rather as a string at the end of the patient’s address.  However, once extracted from 
this string of data it was present consistently and accurately. 
 
The data obtained from some of the hospitals was very disappointing.  There was 
no standardisation across the various sites with respect to software used or even 
coding of data.  Some sites used out-dated nomenclature and although ‘translation’ 
was considered, a decision was made that comparisons between hospitals should 
not be attempted as the data was too unreliable.   
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Overall the quality of data from HES and Exeter exceeded the expectations of the 
study protocol, however the hospital level data was poor for the purposes of this 
study and the decision was made not to attempt to incorporate this into the main 
database as it may invalidate the study findings. 
 
Coding of several data items was undertaken prior to commencement of any 
analysis.  In particular, transforming the national coding for operations (OPCS) and 
diagnosis (ICD10) into groups relevant to the aims of the study had to be performed.  
Entire cytology screening history was considered and summarised with tests being 
classified into having occurred pre or post hysterectomy.  
 
An algorithm designed for use in the WMQARC was applied to women’s entire 
screening histories, this generated a complex series of codes and so these were 
further categorised according to the study aims to permit appropriate comparisons.   
 
Finally, data concerning vaginal vault cytology was scrutinised and an assessment 
of ‘appropriateness’ according to national guidelines was made.  Thus, every 
woman had a set of data which was available for interrogation which summarised 
her hysterectomy operation (i.e. when, where, what type of operation, what was the 
final diagnosis?), her entire cervical screening history before surgery (i.e. how many 
tests and when were they done, what were the results of each?) and any screening 
in the four years subsequent to surgery (i.e. how many tests performed, what were 
the test results, was screening undertaken in accordance with national guidelines?).  
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CHAPTER SIX:  RESULTS 
 
INTRODUCTION TO CHAPTER 
This chapter presents the results of the analysis of the study database, which are 
relevant to the study aims, and summarises the main study findings in four main 
sections.  Starting with an overview of the demographics of the whole study 
population:  'who' the study participants were including their age, deprivation, 
ethnicity and cervical screening history prior to surgery.  Then exploring 'Why' these 
women underwent a hysterectomy operation; examining their entire cervical 
screening history prior to surgery and focussing on the last test preoperatively (the 
index test).  
 
The chapter then goes on to establish what the operative diagnosis was, for each 
woman, what type of hysterectomy operation she had and exploring the factors 
influencing this.  The analysis concludes, by exploring 'What happened next' by 
looking at those women who had vaginal vault cytology tests subsequent to surgery.  
This sub-group is contrasted with the rest of the study population to establish 
whether or not this testing was appropriate or justified, according to national 
guidelines.  Figure 17 illustrates and summarises these four main stages of analysis 
including the main groups that are examined and the comparisons undertaken at 
each stage.  Figure 17 also demonstrated how all the data are all related 
chronologically through the ‘patient journey’.  Section numbers included in this figure 
relate to the main chapter sections to facilitate navigation. 
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Finally, the chapter summary brings together some of the key findings of the four 
main stages of the analysis. 
 
Throughout the chapter, the value of ‘p’ is always stated, rather than assuming any 
particular value to be ‘statistically significant’.159  The clinical significance or 
relevance of all findings and the potential for bias are then discussed in the 
subsequent chapter.  Percentages are usually quoted to two decimal places, 
whereas other calculations and statistical test results are quoted to three decimal 
places.  Degrees of freedom are expressed as #df throughout.  Confidence intervals 
(CI) around proportions represent the 95% range and were calculated using the 
exact method throughout; they always quoted to at least two decimal places, if they 
are given in a table, they are usually omitted from the text, for clarity. 
 
Wherever box plots are used throughout the chapter, the horizontal line represents 
the median, the boxes represent the interquartile range (IQR), the bars represent 
the upper quartile plus (IQR x 1.5) and the lower quartile minus (IQR x 1.5).149  For 
histograms the vertical axis (y) is the count or total unless otherwise specified.   
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Figure 17.  Summary diagram of analysis.  Including section numbers in parenthesis 
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(6.4)  Post operative 
cytology: 
Dates, results, infection, recall, 
suspension, total number, 
operation type 
(6.3)  Hysterectomy 
Operation: 
Date, operation type, results, 
duration of stay, location of 
surgery,   
Event dates
Index test 
Full history 
(algorithm) 
Vault v Cervical 
cytology test 
Appropriate vs 
Inappropriate use 
Cancer v CIN v 
benign diagnosis 
Total vs Sub-total 
operation type 
Process Groups for comparison Analysis
Descriptive analysis of overall testing, Index 
test and summarised full preoperative 
screening history.  Explore each of these 
factors compared with age, deprivation and 
ethnicity to establish associations and 
correlations. 
Descriptive analysis of operation type and 
exploration of age, deprivation, ethnicity and 
duration of hospital stay to establish 
associations. 
Descriptive analysis of diagnosis at surgery 
and exploration of age, deprivation, 
ethnicity, duration of hospital stay, result of 
index test and full screening history to 
establish associations.  Regression analysis 
of these factors. 
Descriptive analysis of use of post operative 
testing and more specifically vault cytology 
and exploration of age, deprivation, 
ethnicity, duration of hospital stay, result of 
index test, full screening history, operation 
type and operative diagnosis to establish 
associations.  Regression analysis of these 
factors. 
Descriptive analysis of factors associated 
with appropriate use of vault cytology in 
women having a total hysterectomy for 
benign and pre-malignant indications.  
Regression analysis of these factors. 
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6.1  CHARACTERISTICS OF THE STUDY POPULATION:  DEMOGRAPHIC 
INFORMATION ABOUT WOMEN HAVING A HYSTERECTOMY OPERATION 
 
6.1.1  Summary of demographic data 
 
Table 39 summarises the key demographic characteristics of the study population of 
6,141 women who were resident in the West Midlands area and who had a 
hysterectomy performed between 1st April 2002 and 31st March 2003.  The rest of 
section 6.1 examines these further. 
 
Table 39.  Summary of demographic characteristics of study population  
Population 
Variable 
Results Notes 
Incidence of 
hysterectomy 
23 per 10,000 women, per 
annum (crude and 
adjusted rates) 
Equates to approximately 7 cases per annum 
for a typical GP surgery.  Age adjustment did 
not substantially alter the overall rate 22.81 vs 
22.96 per 10,000pa.  Thus crude rates used 
throughout.  Significant variation in incidence, 
according to age, peak of 63 per 10,000pa in 
the 45-49 years old group. 
Age of population 
at date of operation 
N = 6,141 
Range: 17 - 94yrs 
Mean 51.12,  SD 13.11 
Median 48.38,  
IQR = 18.21 
Not normally distributed, skew to right, 
Skewness = 0.606.  Kolmogorov-Smirnov = 
0.088, df 6,141, p<0.001. 
 
Deprivation (IMD07) 
Quintiles: 
1. (Deprived) =1,628 
2.                  = 1,210 
3.                  = 1,295 
4.                  = 1,177 
5.                  =  831 
Study population very 
similar to West Mids in 
terms of deprivation. 
However, significantly 
different from England as a 
whole. 
 
IMD07 quintiles of study population were 
compared with the population of England (χ2 = 
263.577, 4 df, p<0.001)   
Worsening deprivation was associated with 
increased incidence of hysterectomy, age 
adjusted trend = -0.99, p = 0.001, most 
deprived 25.17 per 10,000pa, least deprived 
19.97 per 10,000pa. 
Ethnicity 
N = 4,213 
White = 3,842  
Mixed = 15 
Asian = 209 
Black = 119 
Other = 28 
White British = 86.4%, 
very similar to West 
Midlands (86.5%).  
Asian under represented  
Black over represented 
(p<0.001). 
Ethnicity data only available for 69% of 
population.  Even allowing for inter hospital 
variability in coding significant differences 
between the various ethnic groups existed.  
Incidence of hysterectomy varied by ethnicity 
(White 19.67, Asian 15.68, Black 28.01 using 
provided data only) Age adjustment made little 
difference.  Crude data presented hereafter. 
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Table 39 cont: 
Number of cervical 
cytology tests ever 
N = 6,141 
36,151 tests 
Range 0 - 31 tests 
Mean = 5.89 
Median = 6,  IQR = 4 - 7 
Skewness = 1.050 
338 women never had any 
23 women ≥ 20  
A woman who completes full screening 
according to current guidelines (25-65yrs) 
could have up to twelve tests performed but 
few women do because of pregnancies and 
also the screening programme only became 
nationally implemented in the late 1980s.  90% 
undertaken in primary care. 
Distribution skewed to the right. 
Number of cytology 
tests preoperatively  
N = 5,787 
 
34,174 tests in 5,787 
women 
Range 1 - 25 tests 
Mean = 5.91 
Median = 5  IQR = 4 - 7 
94.5% of all cytology tests recorded on this 
population were undertaken pre-operatively. 
Number of cytology 
tests post 
hysterectomy 
N = 1,016  
1,977 tests in 1,016 
women, 
Range 1 - 10 tests 
Mean = 1.95 
Median = 1  IQR = 1 - 2 
16 only had post op testing 
National guidelines concerning use of post 
operative cytology do not apply to women who 
had malignant disease, just benign or 
completely excised pre-invasive. 
Duration of hospital 
stay post operatively 
N = 6,136 
 
Range = 0 - 81 days  
Mean = 5.06 days 
SD = 3.115 
SEM = 0.04 
Median = 5 
Mode = 4,  IQR = 4 - 5 
Skewness = 6.781 
Mean duration of entire in-patient stay = 5.9 
days, thus less than one day in hospital 
preoperatively, on average. 
Destination on 
discharge from 
hospital 
N = 6,099 
Home = 6,027 
Died = 10  
98% discharged to usual 
place of residence. 
10 died (0.16%) 
 
A supplementary database from HES 
suggested that 70 women from the study 
cohort had died during their first year after 
surgery.  However this could not be 
independently verified as there were no linking 
identifiers supplied and no cause of death 
supplied. 
 
 
 
 
Thus it may be seen that our cohort had a hysterectomy incidence of 23 per 10,000 
women per annum.  They are representative of the West Midlands region in terms of 
overall ethnicity and deprivation.  The average age of the population is consistent 
with that of women typically undergoing a hysterectomy operation1 in the UK, and 
overall these women participated in national cervical screening at a level that seems 
consistent with national guidelines.  
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6.1.2  Incidence of hysterectomy operation in the West Midlands 
 
There were 6,141 women resident in the West Midlands region that underwent 
some form of hysterectomy operation in the study period (1st April 2002 – 31st 
March 2003) as summarised in Table 39.  The total population of the West Midlands 
region in 2001, from the last census data, was 5,267,308.  Women comprised 
2,692,197 (51.1%).124 
 
Thus, the crude annual incidence of hysterectomy was 0.23% (0.222 - 0.234), or 23 
hysterectomies per 10,000 women per annum (0.12% or 12 hysterectomies per 
10,000 head of population, male and female).   
 
It is reasonable to anticipate that a typical GP surgery, of around 6,000 patients,160 
could anticipate seven women having a hysterectomy operation in any given year.  
Thus, the cumulative number of women potentially being eligible for post-operative 
follow-up in such a typical size surgery, could be in excess of a hundred women, 
and up to two hundred (seven women per annum, for several decades).124 
 
 
6.1.3  Age of population 
 
The mean age of the 6,141 women, on the day of their hysterectomy operation, was 
51.12 years, with a range of 17 - 94 years (SD 13.118yrs).  The median age was 
48.38 years, with the distribution skewed to the right, see Figure 18, which has the 
women grouped into five-year bands, for clarity.   
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Figure 18  Age at operation  
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The Kolmogorov-Smirnov test for normality was applied to the age data and 
confirmed that population age is not normally distributed (Test statistic = 0.088, df 
6,141, p<0.001). 
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The age specific incidence rates for hysterectomy were calculated using the West 
Midlands population figures from the 2001 census as a baseline.124  Table 40 
includes these data, it may be seen that the age specific incidence varied from 0.1 
per 10,000 women in the youngest group (which only included two women) to 63 
per 10,000 in the 45-49 year old group, where the peak incidence has been 
illustrated in Figure 18. 
 
 
Table 40.  Age specific incidence of hysterectomy (crude incidences) 
Group Age range Study W Mids 
Population 
(Women) 
England 
population  
(Women) 
WMids as a 
percentage 
of England 
population 
WMids Crude 
Incidence 
per 10,000 
women* 
1 16-19 2 131,644 1,177,991 11.18 0.15
2 20-24 9 155,028 1,483,873 10.45 0.58
3 25-29 94 165,778 1,665,176 9.96 5.67
4 30-34 373 198,808 1,928,557 10.31 18.76
5 35-39 755 202,026 1,965,187 10.28 37.37
6 40-44 1,094 180,620 1,741,553 10.37 60.57
7 45-49 1,057 166,914 1,569,632 10.63 63.33
8 50-54 719 180,109 1,705,408 10.56 39.92
9 55-59 535 156,627 1,405,973 11.14 34.16
10 60-64 443 134,727 1,217,373 11.07 32.88
11 65-69 378 122,347 1,119,370 10.93 30.90
12 70-74 330 115,793 1,062,021 10.90 28.50
13 75-79 205 103,283 957,878 10.78 19.85
14 80-84 106 74,903 696,973 10.75 14.15
15 85-89 33 45,171 444,118 10.17 7.31
16 >90 8 23,585 244,884 9.63 3.39
Totals  6,141 2,692,197 25,216,687 10.68 22.81
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The study population of women all lived in the West Midlands region, however to 
ensure generalisability of the study data to the UK, the cohort was age standardised 
(Direct method)161 to the population of England using the most recent census data 
(2001) which is also included in Table 2.  The age standardised incidence rate for 
hysterectomy was 22.96 per 10,000, compared with a crude rate of 22.81, thus the 
difference was small and crude rates are used hereafter. 
 
 
 
6.1.4  Deprivation of the study population and incidence of hysterectomy 
 
Postcode for all the study participants was available from HES and was used to 
apply a deprivation score for each woman prior to anonymisation.  The Index of 
Multiple Derivation 2007 (IMD07), published by the Department for Communities 
and Local Government late in 2007, covers the whole of England and was selected 
for use in this project as being the most robust index available.157  The reader is 
reminded that IMD07 is not a measure of affluence, only deprivation and although it 
is plausible that women living in areas having a very low deprivation score will be 
more affluent, this does not necessarily follow (see Section 5.5.1). 
 
The IMD07 scores were re-coded into the reference quintiles for England and 
compared using χ2 test, giving a score of 263.577, (4 df) and a highly significant 
p<0.001  Thus the study population was considerably more deprived than the UK 
population generally, summarised in Table 41, where quintile one indicates the most 
deprived. 
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This finding is also true of the West Midlands region, which contains 3,482 lower 
super output areas (LSOAs), of which 27.3% are in the most deprived quintile in the 
UK, i.e. there is more deprivation in the West Midlands region than in the UK as a 
whole.158  Thus, the study population was compared with the West Midlands 
reference population:  χ2 score 4.192 (4df), p>0.1 which did not suggest a significant 
difference between the populations, thus the study population was similar to the 
West Midlands resident population in terms of deprivation.   
 
Table 41.  IMD Quintiles for study population   
England 
Quintile 
England 
(reference) 
Study 
Population 
% Study 
(95% CI) 
% West 
Mids  
 
Crude 
Incidence 
Per 10,000  
1  most deprived 1,228.2 1,628 26.51 
(25.41-27.61)
27.28 30
2 1,228.2 1,210 19.70
(18.71-20.69)
19.59 23
3 1,228.2 1,295 21.09
(20.07-22.11)
20.36 24
4 1,228.2 1,177 19.17
(18.19-20.15)
18.81 22
5  least deprived 1,228.2 831 13.53
(12.67-14.39)
13.96 16
Total / Aggregated - 6,141 100 100 23
 
 
The overall incidence of surgery has been established to be 23 per 10,000 women; 
for the various quintiles this was then calculated separately and included in Table 
41.  It may be seen that women in the most deprived quintile were almost twice as 
likely to have a hysterectomy as those in the least affluent when compared with 
England as a whole i.e. 30 per 10,000 compared with 16, per 10,000.   
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To ensure that the observations were valid, age adjustment (Direct method) of the 
deprivation data was undertaken, Table 42 summarises these data.  Although the 
differences were less pronounced, the previously observed trend was still clearly 
evident, that women from more deprived areas were significantly more likely to have 
hysterectomy operations than those from less deprived areas (25 per 10,000 vs 20 
per 10,000, test for trend, Pearson = -0.991, p=0.001). 
 
 
Table 42.  IMD Quintiles for study population (age standardised) 
Age range 
 
Study Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
16-19 2 1 0 0 0 1
20-24 9 5 3 0 0 1
25-29 94 40 21 19 8 6
30-34 373 128 84 76 53 32
35-39 755 246 163 153 116 77
40-44 1,094 320 220 216 197 141
45-49 1,057 304 199 216 204 134
50-54 719 162 137 148 158 114
55-59 535 93 92 120 124 106
60-64 443 99 68 123 85 68
65-74 708 142 153 153 152 108
75-79 205 48 41 39 56 21
80-84 106 28 22 24 16 16
85-89 33 10 5 8 6 4
>90 8 2 2 0 2 2
Overall 6,141 1,628 1,210 1,295 1,177 831
Age 
adjusted 
per 10,000  
22.96 25.17 24.04 22.93 21.95 19.97
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6.1.5  Ethnicity of study population 
 
6.1.5.1  Overview of ethnicity 
Data on ethnicity of the study population was available from the hospital records 
(HES) for 4,213 women, representing 68.6% of the population.  Of the third of the 
women with missing data 1,154 had truly missing data but 774 had invalid codes 
applied (12.6%).  Table 43 summarises the collated ethnicity data and also gives the 
ethnic breakdown of the West Midlands resident population (male and female) in 
2001, England and the UK along with the study population.  The population data 
were derived from the last national census in 2001.124 
 
6.1.5.2  Ethnicity compared with baseline and UK data 
Self declared 'Ethnicity' in the study population was compared with West Midland 
figures using Chi squared (χ2) tests.  This confirmed that the observed differences 
exceeded conventional levels of statistical significance (p<0.05) for most of the 
ethnic classifications.  In particular, those describing themselves as being of ‘other 
White’ background and Caribbean were over represented in the study population, 
whereas all Asian groups were under represented.  The proportion of White British 
women was almost identical to that locally and they comprised the largest ethnic 
group (86.4% of study, 86.5% in West Midlands). 
 
It may be seen that the proportion of women of each ethnic group, undergoing 
hysterectomy, when compared with the ethnic make-up of the general population, is 
different, Table 43.  The χ2 value for all the groupings was 404.4 (14df, P<0.001), 
thus differences do exist.  
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Table 43.  Self declared ethnicity for study population at time of surgery 
Ethnic group 
Study N 
%  Coded 
N=4,213 
CI 
%  Total 
N=6,141 
CI 
West 
Mids 
(2001) 
% 
England 
(2001) 
 
% 
UK 
(2001) 
 
% 
χ2 
W Mids 
χ2 
W Mids 
Grouped 
British (White)  
                      3,641 
86.42 
85.39–87.45 
59.29 
58.06 -60.52 
86.5 86.99 0.004 
Irish (White) 
                          28 
0.66 
0.42 – 0.90 
0.46 
0.29 -0.63 
1.39 1.27 16.142# 
Any other White 
background      173 
4.11 
3.51 – 4.71 
2.82 
2.41 -3.23 
1.2 2.66
92.11
294.251# 
2.035
White & Black 
Caribbean (mix) 12 
0.28 
0.12 – 0.44 
0.20 
0.09 – 0.31 
0.76 0.47
White and Black 
African (mixed)    1 
0.02 
-0.02 - 0.06 
0.02 
0 - 0.06 
0.07 0.16
13.930*# 
 
White & Asian 
(mixed)                 1 
0.02 
-0.02 - 0.06 
0.02 
0 - 0.06 
0.34 0.37 12.455# 
Any other Mixed 
background          1 
0.02 
-0.02 - 0.06 
0.02 
0 - 0.06 
0.22 0.31
1.25
7.416# 
32.637*#
Indian (Asian or 
Asian British)    120 
2.84 
2.35 – 3.35 
1.95 
1.60 – 2.30 
3.39 2.09 1.94 3.828 
Pakistani (Asian or 
Asian British)      72 
1.71 
1.32 – 2.10 
1.17 
0.90 – 1.44 
2.93 1.44 1.37 21.785# 
Bangladeshi   
                             7 
0.17 
0.05 – 0.29 
0.11 
0.03 – 0.19 
0.60 0.56 0.52 13.316# 
Any other Asian 
background        10 
0.24 
0.09 – 0.39 
0.16 
0.06 – 0.26 
0.40 0.48 0.45 2.833 
32.748*#
Caribbean (Black 
or Black British)  91 
2.16 
1.72 – 2.60 
1.48 
1.18 – 1.78 
1.56 1.14 1.04 9.467# 
African (Black or 
Black British)      15 
0.36 
0.18 – 0.54 
0.24 
0.12 – 0.36 
0.23 0.97 0.90 2.853 
Any other Black 
background        13 
0.31 
0.14 – 0.48 
0.21 
0.10 – 0.32 
0.19 0.19 0.18 3.062 
14.812#
Chinese (other  
ethnic group)      11 
0.26 
0.11 – 0.41 
0.18 
0.07 – 0.29 
0.31 0.45 0.46 0.341 0.341
Other 
                          17 
0.40 
0.21 – 0.59 
0.28 
0.15 – 0.14 
0.27 0.44 0.43 2.722 2.722
Sub-Total, non 
white                371 
8.81 
7.95 – 9.67 
6.04
5.44 –6.64
10.91 9.08 7.29  
Totals 
                    4,213 
- - - - 404.403  
(14 df) 
p<0.001 
85.2954
(5df) 
p<0.001
* Cells containing less than 5 were merged appropriately to facilitate analysis 
# χ2  <0.05 with 1df for that individual comparison i.e. exceeding conventional statistical significance  
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To attempt to counteract potential variability between different hospitals coders in 
the recording of patient's ethnicity data, the six main ethnic groups were merged and 
then re-compared.  It was found that although the differences between the study 
population and the West Midlands residents were smaller than differences with the 
UK population, they were all still present and remained highly significant (see final 
column of Table 43).  Thus the χ2 value for the collated groups was 85.295 (5df, 
p<0.001).  These six main groups were used for the remainder of the analysis. 
 
White British women comprised the overwhelming majority of the study population;  
Figure 19 excludes them to facilitate interpretation of the prevalence of the other 
ethnic groups.  The West Midlands region represents the baseline population from 
which these women are drawn; however, data for the whole England is also 
included for comparison.   
 
 
6.1.5.3  Incidence of hysterectomy for the main ethnic groups (crude and adjusted) 
The crude likelihood of women from the main ethnic groups having a hysterectomy 
operation was calculated, Table 44 demonstrates the wide variation that was noted, 
with the Black women being more likely than any other group of women to have had 
a hysterectomy.  In those ethnic groups with very small numbers it is difficult to 
make meaningful comment.  This particular table was devised on the assumption 
that women whose ethnicity was stated (4,213) were in the same proportions as the 
ethnic distribution of the whole study population (6,141).   
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Table 44.  Incidence of hysterectomy by ethnic group* 
Ethnic group Study 
N 
Study % N = 
4,213 
UK data 
 
UK data 
(2001) % 
Incidence 
per 10,000 
UK 
White (all groups) 3,842 91.19
90.33 – 92.05
54,153,898 92.12 23 
Mixed races 15 0.36
0.18 – 0.54
677,117 1.52 5 
Asian (all) 209 4.96
4.30 – 5.62
2,331,423 3.97 29 
Black (all) 119 2.82
2.32 – 3.32
1,148,738 1.95 33 
Chinese (other ethnic) 11 0.26
0.11 – 0.41
247,403 0.42 14 
Other 17 0.40
0.21 – 0.59
230,615 0.39 24 
Sub-total of non white  371 8.8
7.95 – 9.67
4,635,296 7.88 25 
Totals / Aggregate 
 
4,213 100 58,789,194 100 23 
* NB These data assume that the ethnicity of the whole study population is in the same proportions 
as those where it was stated. 
 
 
Age standardisation (direct method) of the incidence of hysterectomy in the three 
largest ethnic groups was undertaken Table 45 & Figure 19).  This was calculated 
only on the given data, rather than assuming the proportions.  Invariably rates of 
hysterectomy were lower (as a third of the study population are excluded), however, 
valid between group comparisons may still be made.  The difference between crude 
and age standardised incidence rates were very small for White and Black ethnic 
groups (White: 19.67 vs. 19.50  Black: 28.01 vs. 28.03); for the Asian population this 
was slightly greater (15.68 vs. 16.39).  In view of these findings no further 
adjustment for age was used. 
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Table 45:  Age standardised incidence for some ethnic groups 
Group Age 
range 
Study 
Population 
total 
Study 
Ethnicity 
stated 
West Mids
 
White Asian Black* 
1 16-19 2 2 131,644 2 0 0
2 20-24 9 6 155,028 6 0 0
3 25-29 94 74 165,778 70 0 2
4 30-34 373 275 198,808 255 12 7
5 35-39 755 535 202,026 479 22 28
6 40-44 1,094 719 180,620 635 44 31
7 45-49 1,057 690 166,914 597 57 22
8 50-54 719 498 180,109 445 35 13
9 55-59 535 365 156,627 347 13 4
10 60-64 443 311 134,727 293 14 2
11 65-69 378 258 122,347 244 6 6
12 70-74 330 228 115,793 223 3 2
13 75-79 205 146 103,283 142 2 2
14 80-84 106 77 74,903 75 1 0
15 85-89 33 24 45,171 24 0 0
16 >90 8 5 23,585 5 0 0
Totals 6,141 4,213 2,692,197 3,842 209 119
Crude Incidence Rate per 10,000** 19.67 15.68 28.01
Direct Standardised Incidence Rate per 10,000*** 19.50 16.39 28.03
*The categories of ‘other’ and ‘mixed’ ethnicity have been deliberately omitted from the table as 
numbers were too small to allow for meaningful comparisons. 
** As a third of the study population did not have ethnicity stated these figures will be significantly 
lower than the’ true’ values but do allow for comparison between crude and standardised rates. 
***Direct standardisation against the population of England, 2001 census. 
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Figure 19.  Study participants and background population compared by ethnic 
classification 
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* Excluding White British for clarity 
 
 
6.1.6  Overall number of cervical cytology tests 
 
6.1.6.1. Total numbers of cytology tests 
6,141 women had 36,151 cytology tests taken and recorded under the national 
cervical screening programme.  With a range of 0 to 31 tests per woman there was 
considerable variation which, to a certain extent, had been anticipated as older 
women should have had time to have more tests than younger under the national 
programme.  With a median and mean number of tests of six per woman, and a 
mode of five, the distribution was skewed to the right (Figure 20, positive skew). 
  
- 195 - 
Figure 20 .  Total number of screening tests 
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Of note 90% (CI 89.25 – 90.75%) of women had less than 11 cytology tests and 
99.6% had less than 20; 23 women having between 20 and 31 tests done.  Table 46 
includes data on total numbers of tests broken down into 5-year bands and 
illustrates that there is significant variability in the mean number, with the younger 
women having less time to have ever had any tests, and the eldest women being 
too old for the national screening programme and women aged from 40-50 having 
had the maximal opportunity for routine screening. 
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Table 46.  Total number of tests for each age band of women 
Band Age Range  
(yrs) 
Number of 
women 
Mean 
number of 
tests 
Median n. 
of tests 
Range Standard 
error 
1 <20 2 0 0 0  - 
2 21-25 9 4.56 4 0 - 9 1.100 
3 26-30 94 4.48 4 0 - 19 0.336 
4 31-35 373 5.79 5 0 - 20 0.180 
5 36-40 755 6.58 6 0 - 27 0.126 
6 41-45 1,094 6.67 6 0 - 24 0.103 
7 46-50 1,057 6.52 6 0 - 23 0.098 
8 51-55 719 6.40 6 0 - 21 0.122 
9 56-60 535 6.74 6 0 - 31 0.163 
10 61-65 443 6.17 6 0 - 18 0.145 
11 66-70 378 4.95 5 0 - 27 0.156 
12 71-75 330 3.36 3 0 - 17 0.149 
13 76-80 205 1.93 2 0 - 15 0.139 
14 81-85 106 1.03 0 0 - 9 0.158 
15 86-90 33 0.48 0 0 - 4 0.169 
16 >90 8 0.25 0 0 - 2 0.250 
 
6.1.6.2 Numbers of test pre and post hysterectomy 
The tests were then divided into those taken before the main operation date and 
those taken afterwards:  34,236 were before (94.70%, range 0 - 23 tests) and 1,977 
afterwards (5.47%, range 0 - 10), illustrated in Figure 21. 
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Those women having cytology tests done after hysterectomy, and who had a total 
hysterectomy (i.e. removal of the cervix uteri) had vaginal vault smear tests or, more 
correctly, vaginal vault cytology tests taken.  These have specific guidelines for their 
use.  Alternatively, women who had retained all or part of their cervix should have 
remained within the NHS national screening programme and should have had 
follow-up cytology according to those guidelines, (section 6.4 separates the study 
population based upon the type of hysterectomy).   
 
Figure 21.  Graph of all cytology tests (pre and post surgery) 
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6.1.7  Duration of hospital stay post operatively 
 
The duration of post operative hospital stay was available for 6,136 women and 
ranged from 0 - 81 days, with a mean duration of 5.06 days (median 5, mode 4 
days, inter quartile range (IQR) 4-5 days), Figure 22.  107 women apparently were 
discharged the same day as their surgery (1.74%, 1.41 – 2.07) and a further 121 
(1.97%, 1.62 – 2.32) remained in hospital for one or two days.  Only 36 women 
remained in hospital post operatively for longer than three weeks (0.59%, 0.40 – 
0.78). 
 
Total duration of inpatient stay (average = 5.90 days) was calculated as the 
difference between admission and discharge dates, this differed from post operative 
stay by the time spent in hospital prior to surgery; this preoperative time averaged 
0.87 days and ranged from 0- 72 days with two obviously miscoded dates (giving 
negative numbers) omitted from the analysis.   
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Figure 22.  Graph of duration of inpatient stay following surgery 
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Of the women discharged within two days of surgery there was insufficient recording 
of ethnicity to undertaken meaningful analysis:  Of the 228, only 108 had ethnicity 
codes, of these, 13.9% were of Asian descent and 9.3% were black suggesting 
these groups may be over-represented.   
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When grouped into early discharge, (less than three days), normal (3-8days) and 
late (>8days), there were some differences noted between the groups:  living in a 
less deprived area was associated with early hospital discharge (Pearson χ2= 
17.715, 8df, p=0.023) also being younger was associated with earlier discharge 
(Pearson χ2= 345.992, 30df, p=<0.001).  These are explored further in subsequent 
sections (6.1.9.3-4). 
 
 
6.1.8  Destination on discharge from hospital and in patient deaths 
 
HES data includes where patients state they are going to, on discharge from 
hospital.  Within the study population, in the great majority of cases, this was to their 
usual place of residence (98.14%).  Temporary accommodation was used by 25 
women, one went to prison, another to a high security psychiatric unit and ten died 
(Table 47).  When the original data was supplied by HES they also supplied an un-
linked file which included details of 70 women (1.14%) from the cohort who had died 
in the year following their surgery.  However, no identifiers were supplied and as 
such the data could not be further used or analysed.   
 
Patient deaths 
Those ten women who died were considered further: six had their ethnicity 
recorded, five were white British and one was coded as being ‘white and Black 
Caribbean mixed’.  Their median age was 69.66 years with the youngest being just 
37 years, the eldest was 83 years.   
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Table 47.  Destination on discharge from hospital for study population 
Meanings of codes (all possible) N %, CI Crude 
rate per 
10,000 
Usual place of residence (incl. no fixed abode)  6,027 98.14, 97.86 – 98.42 9,814.36
Temporary place of residence (i.e. hotels, schools) 25 0.41, 0.28 – 0.54 40.71
Penal establishment:  police station 1 0.02, 0 – 0.05 1.63
NHS other hospital provider:  high security psychiatric 1 0.02, 0 – 0.05 1.63
NHS ward:  general or younger physically disabled. 18 0.29, 0.18 – 0.40 29.31
NHS ward:  maternity patients or neonates 1 0.02, 0 – 0.05 1.63
NHS run nursing home, residential care or group home 3 0.05, 0 – 0.10 4.89
Local Authority residential accommodation 11 0.18, 0.09 – 0.27 17.91
Patient died  10 0.16, 0.08 – 0.24 16.28
Non NHS institutions i.e. private provider 2 0.03, 0 – 0.07 3.26
Not applicable 42 0.68, 0.51 – 0.85 68.39
Total 6,141  10,000
 
 
The hospital stay of women who died was generally protracted, with a median of 
eight and a half days but a range of two to fifty days.  They spanned the whole 
range of deprivation with women in all five quintiles.  Five had cancer as their main 
diagnoses, four had undergone a hysterectomy for benign indications and one did 
not have diagnosis information recorded.  Four of the five cancers were 
disseminated disease with secondary spread recorded, two ovarian, one 
endometrium, one bladder and one where the primary was unknown.   
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There was not extensive data available concerning underlying medical conditions, 
but of the five cases without malignant disease one had pneumonia, one had 
chronic obstructive airways disease and one had severe underlying medical 
problems (hydrocephalus and quadriplegia) but there were two women who had a 
diagnosis of prolapse recorded and no other information. 
 
Thus five deaths in cases of benign disease gave an operative mortality of 5 in 
5,090 or one per 1,000.  For malignant disease it was 5 in 713, or seven per 
thousand.  There were no deaths in cases of CIN. 
 
 
6.1.9  Selected demographic factors for further description 
 
6.1.9.1  Age at time of surgery compared with deprivation  
Actual age at time of surgery was compared with IMD07 deprivation score; 
Spearman correlation = 0.129, p<0.001.  Thus with increasing quintile (i.e. with 
decreasing deprivation) there was a small but significant increase in age at time of 
surgery, as demonstrated in the box plot at Figure 23.   
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Figure 23.  Age range for each deprivation quintile (1 = most deprived)) 
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6.1.9.2  Age at time of surgery compared with ethnicity 
Age was compared with ethnic grouping (6 groups:  White, mixed, Asian, Black, 
Chinese, other stated) to look for an associations between increasing age and the 
various ethnic groups.  The Kruskal-Wallis Test was used as the non-parametric 
alternative to a one way ANOVA:  Kruskal-Wallis test statistic = 38.604 (5df, 
p<0.001), thus there was a highly significant association.  The women of self 
declared ‘Mixed and Black’ ethnic origin were younger than the ‘White’ women, with 
‘Chinese’, ‘Other’ and ‘Asian’ being in-between.  This is illustrated in Figure 24. 
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Figure 24.  Mean age of the various ethnic groups  
 
 
6.1.9.3  Duration of post operative stay compared with age at operation 
Further to the observation in 6.1.7 that when classified into early, normal and 
delayed discharge, there were some differences between groups, the data were 
further explored to establish the validity of those findings:  The duration of stay post 
operatively was compared with the age at time of surgery as it was predicted that 
older women may required a longer period of post operative recovery:  Spearman 
correlation = 0.215, 2-tailed significance p=<0.001, thus a highly significant 
correlation exists with increasing age and increasing duration of stay.  The analysis 
was repeated with just those women who remained in hospital for more than 6 days 
(N=872):  Spearman = 0.153 p=<0.0001, a weaker correlation than with the more 
conventional duration of stay. 
Error bars represent 
95% CI of mean 
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6.1.9.4  Duration of hospital stay compared with deprivation  
Further to the observations in 6.1.7, the actual IMD07 (deprivation) score for each 
woman was compared with the actual duration of her post operative hospital stay:  
Spearman correlation = -0.026, p=0.042, a small negative correlation.  Thus Kruskal 
Wallis test was then applied to the deprivation quintiles:  χ2=8.318 4df, p=0.081 
which demonstrated that there were no meaningful differences between quintiles.  
 
When those women whose post operative duration of stay was deemed to be 
‘normal’ were excluded (up to 6 days) there was still no meaningful associations 
detected (Spearman correlation = -0.054, p=0.111). 
 
 
6.1.10  Summary of section 6.1   
 
This first section has examined the demographic details of the study population and 
has established that the crude and age standardised hysterectomy incidence is 23 
per 10,000 women per annum in the West Midlands region.  Surgery occurred at a 
median age of 48 years but with a wide range of 17 to 94 years.  Thus, age specific 
incidence rates varied widely, with a peak of 63 per 10,000 women aged 45-49 
years. 
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Hysterectomy incidence varied by ethnicity:  hysterectomy was most commonly 
performed in Black women, having an incidence of 33 per 10,000 pa (assuming true 
study distribution of ethnicity in proportion to that provided).  Ethnicity was recorded 
for 68.6% of the study population and all groups were represented.  
 
Deprivation (IMD07) was also established to be associated with variability in 
incidence of hysterectomy:  the most deprived quintile had an age standardised 
incidence of 25 per 10,000 compared with 20 per 10,000 in the least deprived.  The 
West Midlands region is more deprived than the UK generally and thus although the 
study population was more deprived that the UK, compared to the regional data it 
was found to be very representative of women locally. 
 
The study population had a mean and median of six cytology tests undertaken 
(range 0-31) including pre and post operative cytology.  Duration of hospital stay 
varied from 0 to 81days but the median was 5.  Ten women died during their 
admission, five of these had malignant disease (four were coded as having 
disseminated disease).  Of the other five, three had co-morbidity.  This gave a death 
rate of one per thousand for benign indications and seven per thousand for 
malignancy.  A positive correlation was noted between increased age and increased 
duration of hospital stay. 
 
There was also an association noted between increasing deprivation and 
decreasing age at time of surgery. 
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6.2  CERVICAL SCREENING HISTORY OF STUDY POPULATION:  
WHY DID THESE WOMEN NEED A HYSTERECTOMY OPERATION? 
 
 
6.2.1  Cervical screening history overview 
 
The personal screening records for the 6,141 participants were examined for trends:  
these varied from women never having any screening to a small number of women 
who underwent very intensive testing spanning several decades.  Table 48 
summarises the screening data which are then explored in more detail in the 
following sections: 
 
Table 48.  Description of collated cytology screening data 
   
Variable 
 
   
Results 
   
Notes 
Number of 
cervical cytology 
tests ever 
36,151 tests in 6,141 women 
Range 0 - 31 tests 
Median = 6 
IQR = 4 - 7 
Skewness = 1.050 
338 women never had any tests 
23 women had 20 or more 
A woman who completes full screening 
according to current guidelines (25-65yrs) 
would have approximately seven tests 
although 12 are possible in a woman who 
is fully compliant with screening recall 
dates and who does not have any 
pregnancies.  Distribution skewed to the 
right. 
Number of tests 
preoperatively  
34,174 tests in 5,787 women 
Range 1 - 25 tests 
Median = 5 
IQR = 4 - 7 
Skewness = 0.920 
Distribution mirrors that of total numbers of 
tests.  354 never had preoperative testing 
Number of tests 
post  
hysterectomy  
1,977 tests in 1,016 women, 
Range 1 - 10 tests 
Median = 1 
IQR = 1 - 2 
Skewness = 4.102 
 
National guidelines concerning use of post 
operative cytology do not apply to women 
who had malignant disease, just benign or 
pre-invasive.  Exponential decay in 
numbers. 
16 only had post op testing. 
Diagnosis at pre-
op ‘index’ cervical 
cytology 
test 
 
Normal or inadequate = 5,311 
Dyskaryosis = 161 
Invasive disease = 18 
Borderline / other = 297  
No test = 354 
 
91.77% of index results normal or 
inadequate. 
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The group of women who never had any cervical cytology screening preoperatively 
was examined:  these 354 women spanned the whole range of age, deprivation and 
ethnicity.  There was no association detected between ethnicity and never having 
had cervical screening, this information was present for a similar proportion as the 
whole study (66.95%, 62.84 – 71.06 vs 68.6%, 67.63 – 69.57).  Age greater than 70 
was associated with not being tested as anticipated because the national screening 
programme was only introduced in 1984,15 Wilcoxon Z = -15.167 (p<0.001).   
 
 
6.2.2  Summary of the index cervical cytology test 
 
The final cervical screening test prior to hysterectomy was termed the ‘Index’ test 
and it is plausible that the result of this test had some bearing on the decision to 
undertake a hysterectomy operation.  Thus, the index test was examined in some 
detail, whereas all the other screening tests that each woman underwent were 
summarised into an overall code for analysis. 
 
6.2.2.1  Overview of index test result 
Table 49 summarises the result of the index cervical screening tests for all the 
women:  83.8% were completely normal and only 2.7% were graded as inadequate, 
which is significantly below the national average for cervical screening prior to 
2002.28  
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Table 49.  The results of the final cytology test taken before surgery (the Index test) 
Result of index test Frequency % (CI)  
No preoperative test 354 5.76 (5.27 – 6.25)  
Inadequate 165 2.69 (2.35 – 3.03)  
Normal 5,146 83.80 (83.03 – 84.57)  
Mild Dyskaryosis 43 0.70 (0.52 – 0.88)  
Moderate Dyskaryosis 43 0.70 (0.52 – 0.88)  
Severe Dyskaryosis 75 1.22 (0.99 – 1.45)  
Severe, probable invasion 18 0.29 (0.18 – 0.4)  
Glandular cells 52 0.85 (0.66 – 1.04)  
Borderline changes only 129 2.10 (1.80 – 2.40)  
Other 116 1.89 (1.60 - 2.18)  
Total 6,141 100.0  
 
 
6.2.2.2  Result of Index cervical cytology test compared with age 
The result from the last test before surgery (4 bands, see Table 50) was compared 
with actual age at the time of surgery and confirmed that age was strongly    
associated with the index test result (Kruskall Wallis χ2 =280.530 3df, p=<0.001).   
Thus women having a cancer diagnosis tended to be older than those having 
dyskaryosis. 
 
Table 50.  Index cervical cytology (4 groups) by mean age 
Index test result N Mean age (yrs) SD 
Cancer 18 48.89 11.120 
Dyskaryosis 161 43.54 10.466 
Benign 5,146 50.35 12.088 
Other 816 57.47 17.156 
Total 6,141 51.12 13.118 
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This strong association was confirmed with the Kruskal Wallis test:  χ2 test statistic 
including ‘other’ group = 179.132, 3df (p <0.001) or excluding ‘other’ group Kruskal 
Wallis χ2 = 56.599, 2df, p<0.001.  Figure 25 illustrates this finding; although there is 
a lot of overlap in the age ranges for each result, the mean ages are clearly 
different. 
 
Table 51 summarises the raw age data, broken into the 5-year age bands, for the 
Index test result and shows that the majority of women had normal index cytology 
results and these were mostly performed between the ages of 30 and 75 years.  
The most seriously abnormal findings were in women aged 30 to 70 years.  There 
were very few abnormal test results from any women over the age of 70 years. 
 
Figure 25.  Age at surgery for various index cytology results 
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Table 51.  5 year age bands compared with result of index cytology test 
Result of Index cervical cytology test*  
Cancer Dyskaryosis Benign Other Total  
5 year  
bands 
Inva 
sive 
Mild Mod Severe Normal Gland 
ular 
Border 
line 
Inad N/K 
 
No 
test 
 
<20 0 0 0 0 0 0 0 0 0 2 2
20-24.99 0 0 0 1 6 0 0 1 0 1 9
25-29.99 0 0 3 5 70 1 4 3 2 6 94
30-34.99 2 6 7 14 287 5 12 19 7 14 373
35-39.99 3 8 9 16 648 5 20 20 6 20 755
40-44.99 2 15 12 12 971 8 17 22 8 27 1,094
45-49.99 2 6 4 9 942 4 22 29 14 25 1,057
50-54.99 3 1 2 3 633 6 16 24 9 22 719
55-59.99 3 5 0 6 455 12 15 18 8 13 535
60-64.99 2 1 5 4 376 6 10 12 9 18 443
65-69.99 1 1 1 3 326 2 5 5 13 21 378
70-74.99 0 0 0 1 250 2 4 3 30 40 330
75-79.99 0 0 0 1 135 1 2 4 8 54 205
80-84.99 0 0 0 0 40 0 1 5 2 58 106
85-89.99 0 0 0 0 7 0 1 0 0 25 33
>90 0 0 0 0 0 0 0 0 0 8 8
Subtotal  161 5,146 816  
Total 18 43 43 75 5,146 52 129 165 116 354 6,141
*  A full listing and explanation of all cytology results groups is given in table 14 in Chapter 5.  The not 
known (N/K) group has been added where the given code was erroneous. 
 
 
6.2.2.3  Result of index test compared with deprivation score 
When result of the Index test was compared with the deprivation quintile of the 
patient a significant difference was detected:  Kruskal-Wallis χ2 = 22.223 (1 df, 
p=<0.001), Table 52 includes these data.  
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It may be seen that with increasing affluence, the likelihood of the last cytology test 
before surgery being abnormal decreased and the likelihood of a normal test result 
increased.  The association between deprivation and abnormal cervical screening 
has been established previously.66 
 
Table 52.  Index cervical cytology result by deprivation quintile 
Quintile Abnormal Index 
     N        %   (CI) 
Normal Index 
     N            %      (CI) 
Total 
 
1.  Most Deprived   75 5.44 (4.43 – 6.45) 1,303 94.56 (93.55 – 95.57) 1,378
2.                  35 3.35 (2.43 – 4.27) 1,010 96.65 (95.73 – 97.57) 1,045
3.               27 2.38 (1.64 – 3.12) 1,107 97.62 (96.88 – 98.36) 1,134
4.                 27 2.60 (1.79 – 3.41) 1,013 97.40 (96.59 – 98.21) 1,040
5.  Least Deprived 15 2.06 (1.19 – 2.93) 713 97.94 (97.07 – 98.81) 728
Totals 179 3.36 (2.95 – 3.77) 5,146 96.64 (96.23 – 97.05) 5,325
 
 
6.2.2.4  Result of Index test compared with ethnic group 
When results of the relevant index tests (i.e. excluding those who did not have an 
index or for whom their index test was of uncertain significance) were compared 
with ethnicity (6-group classification) of the patient, no meaningful difference was 
detected:  Kruskal-Wallis χ2 =5.224 (5 df, p=0.389), Table 53 summarises these 
data.  As numbers of invasive disease detected at index test were so small it was 
inappropriate to draw conclusions. 
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Table 53.  Index cytology test result by ethnicity 
Ethnic      
group 
Benign (%, CI) Dyskaryosis Invasive Total 
valid 
Other 
results 
Total 
White 3,242 (84.38, 82.23-85.53) 89 11 3,342 500 3,842
Mixed 11 (73.33, 50.95-95.71) 1 0 12 3 15
Asian 173 (82.78, 77.66-87.90) 6 0 179 30 209
Black 95 (79.83, 72.62 – 87.04) 4 1 100 19 119
Chinese 9 (81.82, 59.03-100) 0 1 10 1 11
Other 11 (64.71, 41.99-87.43) 1 0 12 5 17
Totals 3,541 (84.05, 82.94-85.16) 101 13 3,655 558 4,213
 
 
6.2.3  Summary of preoperative cervical screening history 
 
6.2.3.1  Number of preoperative cervical screening tests compared with age 
 
The number of cytology tests performed preoperatively was compared with each 
woman’s’ age and, as would be expected, there was a highly significant correlation 
noted:  Spearman correlation = -0.216, p<0.001.  However, that was a simplistic 
comparison which did not consider how many tests a woman would have been 
anticipated to have had, at any given age, assuming that all of her tests were normal 
and took place at approximately the correct time. 
 
Thus an effort was made to predict how many cervical screening tests a woman 
should have undergone at any given age.   
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Until 2004, there was significant regional variation throughout the UK in terms of 
how often screening was occurring, despite the national screening programme 
being introduced in 1988 and ad-hoc screening occurring from the late 1960’s, but 
the minimum stated target was one test every five years, from 20 - 65 years.83  This 
provided an ‘expected’ minimum recommended figure for use as a baseline for 
comparisons and is based upon the screening guidelines that were in place in 
England prior to the changes introduced in 2004.84   
 
Additionally, the estimates reflect the fact that older women may never have been 
offered the opportunity to be screened properly through their lifetime and very 
elderly ladies in particular would be expected to have had very few tests.   
 
Table 54 summarises, what the authors suggests, are the realistically ‘expected’ 
minimum numbers of tests and these were applied for the purposes of analysis.  
This table also gives details of the observed numbers of cytology tests for the 
various age bands. 
 
If current guidelines were applied rigorously (three yearly 25 – 50 years, five yearly 
until 65 years) then a woman could have up to 12 normal tests by the time she is 
aged 65.  However, women often have gaps in their screening when pregnant or 
when relocating, additionally few have the discipline to book their routine follow-up 
exactly when it falls due, thus an ‘expected minimum’ was generated to serve as an 
educated approximation. 
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Table 54.  Anticipated numbers of screening tests for each age band 
Age band at 
surgery  
(2002-03) 
Expected 
number of 
tests for 
age band 
Number of 
women per 
band 
Mean 
number of 
tests 
Observed range Observed 
total 
<20 0 2 0 0 0
20-24.99 1 9 3.11 0 - 7 28
25-29.99 2 94 3.89 0 - 12 366
30-34.99 3 373 5.35 0 - 17 1,994
35-39.99 4 755 6.14 0 - 22 4,633
40-44.99 5 1,094 6.29 0 - 22 6,881
45-49.99 6 1,057 6.20 0 - 22 6,548
50-54.99 7 719 6.08 0 - 20 4,372
55-59.99 7 535 6.37 0 - 25 3,406
60-64.99 7 443 5.87 0 - 17 2,600
65-69.99 7 378 4.80 0 - 21 1,812
70-74.99 6 330 3.22 0 - 17 1,061
75-79.99 5 205 1.77 0 - 13 362
80-84.99 4 106 0.83 0 - 9 87
85-89.99 2 33 0.46 0 - 4 15
>90 1 8 0 0 0
Total -  6,141 - - 34,165
 
 
Table 55 summarises the anticipated numbers of women having each number of 
tests for the purposes of analysis.  
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Table 55.  Expected minimum number of cervical cytology tests 
Expected number of tests Number of women % 
0 2 0.03 
1 17 0.28 
2 127 2.07 
3 373 6.07 
4 861 14.02 
5 1,299 21.15 
6 1,387 22.59 
7 2,075 33.79 
Total 6,141 100.0 
 
 
The Wilcoxon rank sum test statistic, for paired observations, was applied to these 
data (the actual observed number of tests compared with the expected minimum), Z 
= -4.525, was highly statistically significant (p<0.001).  This suggested that although 
the total ‘realistically expected’ number of tests was similar to the ‘observed’ total 
number i.e. total tests observed = 34,165, total expected = 34,176 (a difference of 
only 0.03%), the age distribution of these tests was significantly different.   
 
Thus, women were having testing at a younger age than we had predicted.  This is 
illustrated in Figure 26.  This would imply that the study population (women having a 
hysterectomy) have different screening histories from women who do not require a 
hysterectomy. 
 
 
  
- 217 - 
Figure 26.  Observed and expected numbers of preoperative cervical cytology tests 
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Figure 27 illustrates the numbers of women having cervical cytology tests 
preoperatively divided into five year age bands; the extreme ages were excluded as 
there were too few women to allow for meaningful comparisons.  However, it can be 
seen that the profile of the histograms does vary as age increases, corresponding to 
the increase in number of tests according to the national screening programme but 
then tailing off in those women too old to have ever participated. 
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Figure 27.  Number of screening tests preoperatively for various age bands 
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6.2.3.2  Number of preoperative screening tests compared with deprivation 
A small negative correlation between the total number of screening tests 
preoperatively and the overall IMD07 deprivation score was established:  Spearman 
coefficient = -0.058, (p<0.001), Figure 28.  In view of the very small value, the 
importance of this observation in clinical practice is doubtful.  
 
 
Figure 28.  Number of preoperative screening tests, by deprivation quintile 
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6.2.3.3  Number of preoperative cervical screening tests compared with ethnicity  
There was a significant association noted between ethnicity of the patients and the 
number of smears they had preoperatively:  Kruskal Wallis test statistic = 30.053, 
(5df, p=<0.001).  White women tended to have more screening tests than the other 
ethnic groups; in particular they had more tests than the mixed and Chinese groups 
as illustrated in Figure 29. 
 
 
Figure 29.  Ethnicity compared with number of preoperative cytology tests  
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6.2.4  WMCIU Screening Algorithm 
 
6.2.4.1  Overview of screening history 
The data obtained from the screening coding algorithm was re-coded as described 
in Chapter 5 and summarised in Table 56 and Figure 30, allowing for sub-group 
comparisons.  The algorithm coded as ‘abnormal’, results that were regarded as 
being of uncertain significance, thus the numbers differ slightly between the two sets 
of comparisons.  Additionally the algorithm discarded any cytology undertaken in 
hospitals thus it applies to a smaller subset than the analysis on the raw data.  In 
general numbers are sufficient to draw meaningful conclusions,. 
 
Table 56.  Groupings from WMCIU Screening algorithm - summary 
Groups (four then 13 band groupings) N % 95% CI  
1 - Index smear abnormal 605 9.85 9.22 – 10.48
2 - Index smear normal 5,020 81.75 80.94 – 82.56
3 - Index uncertain 136 2.21 1.90 – 2.52
4 - Never had a smear 380 6.19 5.68 – 6.70
 6,414 100.00
11 - Index abnormal, previous abnormal 187 3.05 2.69 – 3.41
13 - Index abnormal, previous only normal 197 3.21 2.84 – 3.58
18 - Index abnormal, previous uncertain 195 3.18 2.81 – 3.55
19 - Index abnormal, no prior tests 26 0.42 0.28 – 0.56
31 - Index normal, previous abnormal 1,017 16.56 15.78 – 17.34
33 - Index normal, previous only normal 2,819 45.90 44.85 – 46.95
38 - Index normal, previous uncertain 971 15.81 15.04 – 16.58
39 - Index normal, no prior tests 213 3.47 3.09 – 3.85
81 - Index uncertain, previous abnormal 35 0.57 0.41 – 0.73
83 - Index uncertain, previous only normal 54 0.88 0.68 – 1.08
88 - Index uncertain, previous uncertain 40 0.65 0.48 – 0.82
89 - Index uncertain, no prior tests 7 0.11 0.04 – 0.18
99 - Never had preoperative testing 380 6.19 5.68 – 6.70
 6,141 100.00
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Figure 30.  Frequencies of screening histories 
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6.2.4.2  Screening history compared with age at operation 
Age was compared with the screening history groups from Table 56, to look for an 
association between increasing age and the various screening histories.  The 
Kruskal-Wallis Test was used, as the non-parametric alternative to a one way 
ANOVA:  Kruskal-Wallis test statistic for the 13-group banding = 436.747 (12df, 
p<0.001), Kruskal-Wallis test statistic for the 4-group banding = 287.961 (4df, 
p<0.001), thus there was a highly significant association, as illustrated in Figure 31, 
with those who never had any testing being older than those who had normal results 
and those with abnormal results being the youngest. 
 
Figure 31.  Screening History (4-group) compared with age at operation  
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6.2.4.3  Screening history compared with deprivation score 
Deprivation quintile and score were compared with the screening history groups, as 
in Table 56, to look for any association.  Kruskal-Wallis test statistic for the 13-group 
banding = 43.037 (12df, p<0.001) and Kruskal-Wallis test statistic for the 4-group 
banding = 28.148 (3df, p<0.001), thus there was a significant association between 
absolute IMD07 score and overall screening history.  This is illustrated in Figure 32 
and demonstrates that those with abnormal index tests had a higher level of 
deprivation than those with normal test results.  This is consistent with the findings 
previously presented in Table 52. 
 
 
Figure 32.  Deprivation scores of the screening history groups  
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6.2.4.4  Screening history compared with ethnicity 
The screening history (4-group) was examined against the grouped ethnicity data 
where available, as summarised in Table 57.  Then the proportions of women in 
each of the four bands were split into white or non-white to permit meaningful 
analysis and χ2 was calculated:  Pearson χ2 (for the four groups in Table 57, based 
on the index result) = 5.785 (3df, p=0.1213) thus suggesting that there were no 
meaningful differences in screening history according to ethnic group.   
 
Table 57.  Ethnic groups and Index Screening test (algorithm) 
Ethnic group  4 Group 
Screening 
History White Mixed Asian Black Chinese Other Total 
Index 
Abnormal 371 5* 18 12 1* 2* 409
Index 
Normal 3,160 8 177 89 8 11 3,453
Index 
Uncertain 89 0* 4* 3* 1* 1* 98
No preop 
testing 222 2* 10 15 1* 3* 253
Totals 3,842 15 209 119 11 17 4,213
* Many cells containing <5 expected frequency thus χ2 not valid 
 
 
However, Table 58 includes the four and 13 group classifications of screening 
history and it may be seen that whilst some sub-groups had a proportion of White 
British women similar to the overall population, a few had quite different proportions.   
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Further comparisons were made to explore this observation:  rather than consider 
the index test in isolation, the screening history prior to the index was explored (thus 
from Table 57 groups 11, 31, 81 were compared with groups 13, 33, 83).  Pearson 
χ2 = 6.373 (1df, p=0.012), thus suggesting that there may be some difference 
between these groups and that results from former screening history may also be 
associated with ethnicity.  
 
Table 58.  Screening history classifications and ethnicity 
Groups (4 and 13 group classifications) White Non 
white 
% White (CI) 
 
Total 
1  Index Abnormal 371 38 90.71 (87.90 – 93.52) 409
2  Index Normal 3,160 293 91.51 (90.58  92.44) 3,453
3 Index Uncertain 89 9 90.82 (85.10 – 96.54 ) 98
4  No pre-op testing 222 31 87.75 (83.71 – 91.79) 253
    
11  Index abnormal, previous abnormal 120 7 94.49 (90.52 – 98.46) 127
13  Index abnormal, previous only normal 128 11 92.09 (87.60 – 96.58) 139
18  Index abnormal, previous uncertain 111 17 86.72 (80.84 – 92.60) 128
19  Index abnormal, no prior tests 12 3 80.00 (59.76 - 100) 15
31  Index normal, previous abnormal 695 44 94.05 (92.34 – 95.76) 739
33  Index normal, previous only normal 1,753 160 91.64 (90.4 – 92.88) 1,913
38  Index normal, previous uncertain 586 67 89.74 (87.41 – 92.07) 653
39  Index normal, no prior tests 126 22 85.14 (79.41 - 90.87) 148
81  Index uncertain, previous abnormal 24 0 100.00  24
83  Index uncertain, previous only normal 36 5 87.80 (77.78 – 97.82) 41
88  Index uncertain, previous uncertain 24 3 88.89 (77.04 – 100) 27
89  Index uncertain, no prior tests 5 1 83.33 (63.74 – 100) 6
99  Never had pre-operative testing 222 31 87.75 (83.71 – 91.79) 253
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When women who had only ever had an entirely normal screening (group 33), were 
compared with all other women who had undergone some screening there was no 
meaningful difference detected:  Pearson χ2=0.232 (1df, p=0.630).  This is 
consistent with the earlier findings from the raw data (section 6.2.2.4). 
 
 
 
6.2.5  Summary of section 6.2 
 
This section has considered women’s preoperative cervical screening.  Of the 6,141 
women, 5,787 (94.24%, 93.66 – 94.82) had some cervical screening (range 0 - 25 
tests); those who did not have any were most likely to be aged over 70 years.  
 
The last cervical screening test preoperatively, the ‘index’ test showed dyskaryosis 
or severe change in less than 3%, women with a more severe abnormality being 
older than those with dyskaryosis.  There was an association with increasing 
deprivation and worsening test results, however there were no associations with 
ethnicity and index test results. 
 
Overall screening histories of this population differ slightly from those of the general 
population in that they tended to have more tests performed at a younger age.  
White women had more screening than any other ethnic groups but coding of 
ethnicity was incomplete. 
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The application of the WMCIU algorithm, to code entire screening histories, 
permitted group comparisons and confirmed previous observations with respect to 
deprivation and age.  When ethnicity was examined a mixed set of observations 
was generated; overall the test results suggested that ethnicity was not strongly 
related to having screening tests or to any particular pattern of results. 
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6.3  OUTCOME OF HYSTERECTOMY:  WHAT WAS THE SURGICAL DIAGNOSIS? 
 
6.3.1  Hospital site of surgery 
 
6.3.1.1  Comparison between different hospitals 
Section 5.2.2 summarised the raw data obtained from the various hospitals (before 
the small number of duplicate entries were removed), and identified a concern that 
three hospitals in the region, which were known to have active departments of 
obstetrics and gynaecology, did not have any hysterectomy operations attributed to 
them.  However, there were noted to be missing or incomplete data on 712 women 
whose postcodes indicated that they would have been most likely to attend one of 
those three hospitals.  This represented 11.59% (CI 10.79 – 12.39) of the data but 
because of uncertainty about allocating women to a hospital, particularly those near 
postcode boundaries, they were omitted from hospital based comparisons.   
 
For the remaining hospitals, basic patient demographic factors were compared:  
median age at surgery, the proportion of women who were white, the median IMD07 
deprivation score and the median post operative duration (Table 59).  Also, because 
of the erratic ethnicity coding, the proportion of cases at each hospital that had their 
ethnicity coded was identified and the number of consultants at each site during the 
year was included. 
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Median age of hysterectomy did not differ greatly between hospitals (47 – 50 years).  
However, deprivation did vary widely across the region with median scores ranging 
from 9.2 to 43.7, illustrating the huge variability across the West Midlands.  (IMD 
scores for individual patients ranged from 1.24 to 80.34, lower scores indicate less 
deprived areas, whereas lower ranks equate to greater deprivation). 
 
Examining ethnicity coding illustrated clearly where some of the problems arose, 
with hospitals demonstrating a great variation in ethnicity coding; from 14% to 98% 
across the region.  Of note, the hospital that recorded ethnicity accurately in less 
than 14% did not have any women coded as being ‘white’.  Closer examination 
revealed that almost 85% of the records were erroneously coded using the same 
classification consistently, which, on the basis of regional trends, is likely to 
represent white women. 
 
The numbers of hysterectomies performed by, or under the care of, specific 
consultants varied widely; there were many instances of a consultant just having 
one or two cases in the year, but the nine most prolific surgeons were each 
responsible for over 100 hysterectomies.  The most prolific was responsible for 189 
cases, equating to almost four cases each week.  The number of consultants at 
each hospital varied, as did the number of hysterectomy operations. 
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Table 59.  Comparisons of hospital patient demographics 
Hospital 
code 
Number  % Total (CI) 
N=6,141 
Median 
age 
(yrs) 
Median  
deprivation 
(IMD07) 
Ethnicity 
recorded  
in HES % 
% White of 
those 
recorded 
Median  
post op 
stay (days) 
Number of 
clinicians 
1 245 3.99 (3.5 – 4.48) 48.08 19.61 60.41 97.97 5 11 
2 164 2.67 (2.27 – 3.07) 49.20 17.45 67.07 98.18 4 6 
3 216 3.52 (3.06 – 3.98) 49.85 9.82 82.41 97.75 5 8 
4 408 6.64 (6.02 – 7.26) 48.24 20.31 68.14 87.41 4 15 
5 168 2.74 (2.33 – 3.15) 50.23 13.71 70.24 99.15 5 6 
6 375 6.11 (5.51 – 6.71) 48.62 13.38 36.80 100.00 4 10 
7 412 6.71 (6.08 – 7.34) 49.79 29.49 97.82 87.34 4 15 
8 643 10.47 (9.70 – 11.24) 47.10 28.42 13.84 0 4 16 
9 366 5.96 (5.37 – 6.55) 50.38 25.00 94.26 95.36 4 10 
10 412 6.71 (6.08 – 7.34) 49.20 18.00 39.32 96.30 5 11 
11 224 3.65 (3.18 – 4.12) 47.04 43.68 58.48 36.64 4 14 
12 274 4.46 (3.94 – 4.98) 48.02 36.96 63.50 90.23 4 8 
13 352 5.73 (5.15 – 6.31) 47.54 30.69 93.47 92.10 5 10 
14 153 2.49 (2.10 – 2.88) 46.14 13.94 94.77 97.93 4 6 
15 368 5.99 (5.40 – 6.58) 47.68 13.61 83.42 99.67 4 8 
16 418 6.81 (6.18 – 7.44) 49.17 21.77 97.85 98.53 5 13 
mis-coded 943 15.36 (14.46 – 16.26) 48.58 17.47 79.43 96.13 5 46 
Population 
data 
6,141 100.00 48.38 24.59 68.60 91.19 5 days  
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6.3.1.2  Hospital based pathology data 
As explained previously, the data obtained from some of the hospital histopathology 
departments could not be used to validate HES data as there were insurmountable 
difficulties linking hospital records to those from HES and comparing data from one 
hospital with another.  This was substantially due to the fact that PIAG only 
permitted NHS number to be an identifier in this stage of the study and hospitals do 
not yet use this reliably and also because the laboratory coding was not consistent 
across sites. 
 
Where linkage was attempted a poor match was obtained and thus no conclusions 
could reliably be drawn from this data source. 
 
 
6.3.2  Operative procedures undertaken (OPCS4 codes) 
 
6.3.2.1  Overview of OPCS4 surgical procedure codes 
There were up to nine procedures listed per patient, with the majority of patients 
having at least two.  These were grouped into seven main sections to facilitate 
analysis.  Table 60 summarises these data. 
 
Reassuringly, every woman had a 'gynaecological surgery' code recorded at least 
once in her data (i.e. their hysterectomy operation code, which was one of the 
inclusion criteria for the data from HES), thus even those who had abdominal or 
breast surgery also underwent a gynaecological operation.   
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When blank, invalid or unhelpful codes were excluded, the range of useful codes 
was from one to nine per woman, with most having two.  Almost 86% of codes were 
gynaecological, 11% related to abdominal surgery with 3% concerning bladder or 
genitourinary surgery. 
 
Table 60.  Collated OPCS codes 
Meaning of 
grouped OPCS 
codes 
Diag  
1 
Diag 
2 
Diag 
3 
Diag 
4 
Diag 
5 
Diag 
6 - 9 
Total 
codes 
% of all codes 
CI 
Breast surgery 
2 1 6 2 0 0 11 0.08
0.03 – 0.13
Abdominal or GI 
tract surgery 
169 111 709 334 62 23 1,408 10.80
10.27 – 11.33
Genito-urinary or 
bladder surgery 
22 64 202 88 17 8 401 3.08
2.78 – 3.38
Vaginal or 
prolapse surgery 
675 354 75 21 2 3 1,130 8.67
8.19 – 9.15
Gynaecological 
surgery 
5,253 4,369 336 77 16 6 10,057 77.14
76.42 – 77.86
Obstetric surgery 
20 3 3 4 1 0 31 0.24
0.16 – 0.32
Other codes or 
blank cells 
0 1,239 4,810 5,615 6,043 24,524 42,231 N/A
Total of useful 
codes (1-6) 
6,141 4,902 1,331 526 98 40 13,038 100
 
 
6.3.2.2  Operation sub-type demographics  
The gynaecological surgery codes were then examined to establish what type of 
hysterectomy procedure had been undertaken i.e. a sub-total or total operation.  In a 
few cases it was impossible to distinguish the operation type from the OPCS code 
and so an ‘unknown’ group was also created. Table 61 summarises the key 
demographic comparisons between these three groups.   
  
- 234 - 
Table 61.  Summary of differences in demographic data between hysterectomy sub-types 
Comparator 
whole study population 
N = 6,141  
Total 
Hysterectomy 
N = 5,697 
% = 92.77 
 
Sub total 
Hysterectomy 
N = 436 
% = 7.10 
 
Unknown 
 
N = 8 
% = 0.13 
 
Statistical 
test 
Notes 
Age (6,141) 
Mean = 51.52 
Median = 48.38 
Skewness = 0.606 
IQR = 18.21 
 
Mean = 51.44 
Median = 48.88 
Skewness = 0.562 
IQR= 18.76 
 
Mean = 47.01 
Median = 45.166 
Skewness = 1.267 
IQR= 9.68 
 
Mean = 43.79 
Median = 41.409 
Skewness = 2.247 
IQR= 8.01 
 
Kruskal Wallis 
χ2=52.055, 
2df, p<0.001 
Thus there is a significant difference in 
age between the three subgroups with 
women having a total hysterectomy 
being somewhat older than the other two 
groups.  See Figure, below. 
Deprivation (6,141) 
Overall Mean = 24.59 
Median = 19.70 
Skewness =0.847 
IQR = 23.94 
 
Quintiles (N/%) 
1  1,628 / 26.51% 
2  1,210 / 19.70% 
3  1,295 / 21.09% 
4  1,177 / 19.17% 
5  831 / 13.53% 
 
Mean = 24.472 
Median = 19.640 
Skewness = 0.850 
IQR= 23.61 
 
 
1,490 / 91.52% 
1,139 / 94.13% 
1,205 / 93.05% 
1,086 / 92.27% 
777 / 93.50% 
 
Mean = 26.217 
Median = 20.490 
Skewness = 0.780 
IQR=27.56 
 
 
136 / 8.35% 
70 / 5.79% 
88 / 6.80% 
90 / 7.655 
52 / 6.26% 
 
Mean = 22.33 
Median = 18.84 
Skewness = 0.587 
IQR= 30.73 
 
 
2 / 0.12% 
1 / 0.08% 
2 / 0.15% 
1 / 0.08% 
2 / 0.24% 
 
Kruskal Wallis 
χ2=2.502 
2df, p=0.286 
 
 
 
Pearson  
χ2 = 9.891  
8df p=0.273  
(5cells count 
less than 5) 
 
There was no association established 
between operation type and deprivation 
score, either absolute or in quintiles.  
See Figure. 
 
 
Excluding unknown from the χ2 analysis 
confirms that there is no association 
detected between deprivation and 
operation type (Pearson χ2 = 8.649, 4df 
p=0.070). 
 
Ethnicity  (4,213) 
White: 3,842 / 91.19% 
Mixed: 15 / 0.365% 
Asian: 209 / 4.96% 
Black: 119 / 2.82% 
Chinese: 11 / 0.26% 
Other:  17 / 0.40% 
% 
3,583 / 93.26% 
13 / 86.67% 
196 / 93.78% 
102 / 85.71% 
8 / 72.73% 
16 / 94.12% 
% 
254 / 6.61% 
2 / 13.33% 
13 / 6.22% 
17 / 14.29% 
3 / 27.27% 
1 / 5.88% 
% 
5 / 0.13% 
0  
0 
0 
0 
0 
 
Pearson  
χ2 = 18.846  
5df p=0.002  
(3cells count 
less than 5) 
 
Thus there is an association between 
ethnicity and operation type. Including 
‘unknown’ in the analysis gave Pearson 
χ2 = 19.351, 10df p=0.036 but 9 cells 
count less than 5. 
 
Duration of post op 
stay (6,136) 
Median = 5 days 
Skewness = 6.781 
IQR = 4 - 5 
Range = 0 - 81  
 
 
 
Median = 5 
Skewness = 6.969 
IQR= 1 
Range = 0 - 81 
 
 
Median = 5 
Skewness = 4.225 
IQR= 2 
Range = 0 - 31 
 
 
Median = 6 
Skewness = 2.412 
IQR= 6 
Range = 4 - 29 
 
Kruskal Wallis 
χ2=5.966 
2df, p=0.051 
 
 
 
Thus no association between duration of 
post operative stay and type or 
operation.  Analysis excluding the 
‘unknown’ group confirms this:  Kruskal 
Wallis χ2=1.391 1df, p=0.238. 
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It may be seen that only eight women could not have their operation type 
established and 7.10% (n=436, CI 6.46 – 7.74) of women had a subtotal 
hysterectomy. 
 
The three groups differed in two main ways.  Firstly those women undergoing a sub 
total hysterectomy were younger than those having a total hysterectomy (Figure 33), 
with the unknown group being even younger.  Also in terms of their ethnicity (where 
stated) white women were more likely to have total hysterectomies when compared 
to black and Chinese women although numbers were very small.   
 
 
Figure 33.  Age at surgery compared with operation type 
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In terms of deprivation (Figure 34) and duration of stay post operatively, the three 
groups did not differ significantly, with total and subtotal surgery having a medial 
post operative duration of 5 days.  Considering women who were discharged within 
two days of surgery, no difference was found in the proportions having a total or 
other variant of hysterectomy. 
 
 
Figure 34.  Deprivation score compared with operation type 
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6.3.3  Diagnosis at time of operation 
 
6.3.3.1  Overview of operative diagnosis 
Each woman had between one and eleven valid ICD10 diagnostic codes recorded; 
each code was allocated to a group to allow for meaningful analysis (Table 62).  
There were over 11,000 codes in total; almost 20% were of no interest but 6% 
related directly to a gynaecological malignancy.   
 
Table 62.  Collated, grouped ICD10 codes 
Meaning of diagnosis codes  
 
Number  
(total) 
% of all 
codes 
CI 
No interest to project 1,168 10.28 9.72 – 10.84 
Neoplasm, malignant, non gynae 143 1.26 1.05 – 1.45 
Neoplasm, in-situ, non gynae 3 0.03 0 – 0.06 
Neoplasm, benign, non gynae 22 0.19 0.11 – 0.27  
Obstetric general 82 0.72 0.56 – 0.88 
Neoplasm, malignant gynae 676 5.95 5.52 – 6.38 
Neoplasm, in-situ, gynae 94 0.83 0.66 – 1.00 
Neoplasm, intraepithelial neoplasia, gynae 76 0.67 0.52 – 0.82 
Neoplasm, benign & unknown, gynae 1,902 16.74 16.05 – 17.43 
Other gynae diagnoses:  inflammation 407 3.58 3.24 – 3.92 
Other gynae diagnoses:  infection 0 0 0 
Other gynae diagnoses:  bleeding, menstrual, 
menopausal 
2,400 21.12 15.46 – 18.46 
Other gynae diagnoses:  NOS, endometriosis, prolapse, 
infertility, polyp, miscarriage 
3,339 29.39 28.55 – 30.23 
Descriptive terms only (not true diagnosis), non gynae 1,049 9.23 8.70 – 9.76 
Total number of codes 11,361 100  
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The 'worst' of all diagnoses was established, for each woman, by use of a basic 
ranking where, any malignancy was coded as being worst, then any intraepithelial 
neoplasia or carcinoma in-situ, followed by any benign disease and finally a 
selection of other codes that were not diagnostic were regarded as unclassifiable.   
 
Next, the regional raw screening data for the result of the last cervical screening test 
prior to hysterectomy (index) was considered:  if this took place within six months 
(180 days) of the operation then the diagnosis was regarded as being related to 
surgery and so that if serious cervical pathology was detected which was worse 
than the main diagnosis then the woman was classified to a more serious group.  
This reclassification was justified because it is possible for colposcopic treatment to 
remove all trace of CIN or in-situ disease but be severe enough for hysterectomy to 
be recommended, particularly if the patient has completed her family. 
 
Table 63.  Final 'worst diagnosis' per study participant classification 
Code Explanation N % CI 
1 Cancer or Malignancy 713 11.61 10.81 – 12.41
2 Intraepithelial neoplasia or carcinoma in-situ 184 3.00 2.57 – 3.43
3 Benign disease 5,090 82.89 81.95 – 83.83
9 Unclassifiable 154 2.51 2.12 – 2.90
 Total 6,141 100 
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The final 'worst diagnosis' (Table 63) was a combination of the worst of each 
woman’s recorded ICD10 codes and, if applicable, her cervical screening within six 
month of surgery.  In reality in only 28 cases did the screening result change the 
outcome (four from CIN to malignant, sixteen from benign to CIN, three from 
unclassifiable to CIN and five cases from unclassifiable to benign diagnosis). 
 
6.3.3.2  Operative diagnosis:  description of group demographics 
The three main diagnosis groups (benign, intraepithelial neoplasia and malignancy) 
were compared in terms of age, deprivation, ethnicity and duration of post operative 
stay.  Table 64  summarises the key demographic differences.  It may be seen that 
there was a significant association between age and diagnosis; Kruskal Wallis test 
statistic = 546.441, a large and highly significant result (2df, p<0.001).  Thus, 
women with malignant disease were significantly older than the other groups of 
women.  However there were no associations detected with respect to diagnosis 
and deprivation, (quintiles or raw data). 
 
Ethnicity was compared and demonstrated an association between being of White 
ethnicity and having a worse final diagnosis i.e. being non-white is associated with 
an increased likelihood of having a benign diagnosis, Pearson χ2=17.863 (2df, 
p<0.001).  Duration of post operative stay was examined and results confirmed that 
having a cancer diagnosis was positively associated with a longer duration of 
hospital admission, Kruskal Wallis = 428.010 (2df, p=<0.001).  However, even some 
of these cases were discharged within two days of surgery (n=25 or 6.6% of the 
women discharged very early).    
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Table 64.  Demographic summary worst diagnosis at hysterectomy 
Comparator 
whole study population 
N = 6,141  
 
Cancer / 
malignancy 
N = 713 
% = 11.61 
 
Intraepithelial 
neoplasia  
N = 184 
% = 3.00 
 
Benign 
N = 5,090 
% = 82.90 
 
Statistical test Notes 
(Unclassifiable = 154 or 2.51%) 
Age (6,141) 
Mean = 51.52 
Median = 48.38 
Skewness = 0.606 
IQR = 18.21 
 
Mean = 62.106 
Median = 62.776 
Skewness = -0.396 
IQR= 17.15 
 
Mean = 45.549 
Median = 42.800 
Skewness = 0.795 
IQR= 16.82 
 
Mean = 49.852 
Median = 47.288 
Skewness = 0.752 
IQR= 15.66  
 
Kruskal Wallis 
χ2=546.441 
2df, p= <0.001 
 
Thus a significant association exists 
with women having a cancer 
diagnosis generally being older than 
women in the other groups. 
Deprivation (6,141) 
Overall Mean = 24.59 
Median = 19.70 
Skewness =0.847 
IQR = 23.94 
 
Quintiles (N/%) 
1  1,628 / 26.51% 
2  1,210 / 19.70% 
3  1,295 / 21.09% 
4  1,177 / 19.17% 
5  831 / 13.53% 
 
Mean = 23.716 
Median = 18.620 
Skewness = 0.959 
IQR= 22.92 
 
 
175 / 11.04% 
137 / 11.63% 
153 / 12.11% 
145 / 12.63% 
103 / 12.63% 
 
Mean = 26.550 
Median = 23.050 
Skewness = 0.649 
IQR= 24.71 
 
 
56 / 3.54% 
45 / 3.82% 
37 / 2.93% 
28 / 2.43% 
18 / 2.21% 
 
Mean = 24.597 
Median = 19.650 
Skewness = 0.839 
IQR= 24.13 
 
 
1,353 / 85.29% 
995 / 84.53% 
1,073 / 84.96% 
975 / 84.93% 
694 / 85.15% 
 
Kruskal Wallis 
χ2=5.508 
2df, p=0.064 
 
 
 
Pearson  
χ2 =  8.858 
8 df p=0.354 
(0 cells less 
than 5) 
 
There was no important association 
established with diagnosis and 
deprivation. 
 
 
 
The analysis of quintiles rather than 
crude IMD07 score confirms that 
there is no strong association 
between deprivation and diagnosis.  
Ethnicity  (4,213) 
White: 3,842 / 91.19% 
Mixed: 15 / 0.365% 
Asian: 209 / 4.96% 
Black: 119 / 2.82% 
Chinese: 11 / 0.26% 
Other:  17 / 0.40% 
% 
492 / 13.06% 
2 / 13.33% 
12 / 5.91% 
4 / 3.48% 
2 / 25.00% 
2 / 12.50% 
% 
110 / 2.92% 
0 / 0% 
4 / 1.97% 
0 / 0% 
0 / 0% 
1 / 6.25% 
% 
3,166 / 84.02% 
13 / 86.67% 
187 / 92.12% 
111 / 96.52% 
6 / 75.00% 
13 / 81.25% 
 
Pearson  
χ2 = 25.320 
10 df p=0.005 
(7 cells count 
less than 5) 
There appeared to be an 
association between ethnicity and 
diagnosis but small numbers made 
interpretation difficult.  However, 
when the ethnicity was split into just 
‘white’ or ‘non white’ there were no 
low values and Pearson χ2 = 17.863 
2 df p=<0.001, highly significant. 
Duration of post op 
stay (6,136) 
Median = 5 days 
Skewness = 6.781 
IQR = 4 - 5 
Range = 0 - 81  
 
Median = 6 
Skewness = 3.716 
IQR = 3 
Range = 0 - 50 
 
Median = 4 
Skewness=11.316 
IQR = 1 
Range = 0 - 81 
 
Median = 4 
Skewness = 4.560 
IQR = 1 
Range = 0 - 42  
 
Kruskal Wallis 
χ2= 428.010 
2df, p= <0.001 
 
 
Thus women having the worse 
diagnosis tended to have a longer 
post operative stay overall. 
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6.3.3.3  Operative diagnosis compared with index cervical cytology result 
The most recent test before surgery (the index test) was compared with result at 
hysterectomy; there was a positive association between the two, with comparable 
results, highlighted in Table 65, giving a highly significant Pearson χ2=1,612.528 
(9df, p<0.001).  It must be noted that a cytology result of dyskaryosis is not the 
same as a histo-pathological diagnosis of CIN (see Chapter two, section 2.2.1 for 
full explanation). 
 
Table 65.  Worst diagnosis compared with index cervical cytology test 
Index smear result  
Probable 
invasion 
Dyskaryosis  
(mild - severe) 
Normal Unclassifiable Totals 
Cancer/Malignant 13 25 487 188 713
CIN/ In situ 3 83 67 31 184
Benign 2 42 4,471 575 5,090
H
ys
te
re
ct
om
y 
Unclassifiable 0 11 121 22 154
 Totals 18 161 5,146 816 6,141
 
The index result was then grouped into two basic blocks of normal or abnormal 
(including all dyskaryosis and invasive results); this was then compared with the 
worst diagnosis at surgery (split into normal or abnormal).  It had been postulated 
that these results would be strongly related with an abnormal index test providing a 
good predictor of an abnormal result at hysterectomy, however, this proved not to 
be the case:  McNemar test for equal proportions = 433.246, p=<0.001, Table 66, 
thus although there was an association, there is still substantial disagreement.  
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Table 66.  Comparison of Index cytology result with hysterectomy diagnosis 
Index result Abnormal 
hysterectomy 
Normal 
hysterectomy 
Total 
Index abnormal 124 44 168 
Index normal 554 4,71 5,025 
Total 678 4,515 5,193 
 
 
6.3.3.4  Operative diagnosis compared with preoperative screening history 
Having compared the index screening test, the main operation results groups were 
compared against the full cervical screening histories (from the WMCIU algorithm, 
section 6.2.4) to establish if there were any associations.  The algorithm coding had 
generated 13 groups (Table 56), however, those where the index test was uncertain 
were excluded from the analysis as numbers were so small and thus nine groups 
were compared, see Table 67. 
 
A cross tabulation of these data was performed and Pearson χ2=622.485 (16df, 
p=<0.001) thus suggesting that there are important differences between the various 
groups.  The Kruskall Wallis test was applied to the three diagnosis groups in each 
of the nine categories in Table 67 and again confirmed a significant association with 
the test statistic χ2=248.073 (8df, p=<0.001).  Women who had never been tested or 
had only had one test preoperatively were more likely to have a cancer diagnosis 
than the other groups, whereas for CIN the key factor was having had several 
abnormal tests. 
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Table 67.  Cervical screening entire history code compared with operative diagnosis 
Screening 
history 
 
Cancer 
N  
Cancer  
% 
CI 
CIN 
N / 
CIN 
% 
CI 
Benign 
N  
Benign 
% 
CI 
Total 
Index abn, prev 
abn 
25  14.12
8.99-19.25
41 23.16
16.95-29.37
111 62.71
55.59-69.83
177
Index abn, prev 
normal 
30  15.79
10.60-20.98
21 11.05
6.59-15.51
139 73.16
66.85-79.46 
190
Index abn, pre 
unknown 
20  10.75
6.30-15.20
29 15.59
10.38-20.80
137 73.66
67.33-79.99
186
Index abn, only 
one test 
6  24.0
7.26-40.74
5 20.00
4.32-35.68
14 56.0
36.54-75.46
25
Index normal, 
prev abn 
97  9.80
7.95-11.65
23 2.32
1.38-3.26
870 87.88
85.85-89.91
990
Index normal, 
prev normal 
304  10.99
9.82-12.16
29 1.05
0.67-1.43
2,433 87.96
86.75-89.17
2,766
Index normal, 
unknown 
65  6.90
5.28-8.52
11 1.17
0.48-1.86
866 91.93
90.19-93.67
942
Index normal, 
one test only 
48  22.75
17.09-28.41
7 3.32
0.90-5.74
156 73.93
68.01-79.85
211
Never tested 100  27.47
22.88-32.06
8 2.20
0.69-3.71
256 70.33
65.64-75.02
364
Totals 695  11.88 174 2.97 4,982 85.15 5,851
 
 
6.3.3.5  Operative diagnosis compared with type of operation 
The worst diagnosis at surgery was compared with type of operation (total 
hysterectomy or ‘other’) as it was postulated that women with a diagnosis of cancer 
would be more likely to undergo a total hysterectomy.  A cross tabulation of the data 
(Table 68) gave a Pearson χ2=16.458 (2df, p=<0.001), a result suggesting that there 
may be differences in operation type between the groups.   
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The Kruskall Wallis test was then applied to the three diagnosis groups however a 
significant association was not established this time with the test statistic χ2=15.292 
(2df, p=0.54).  Thus women who had a diagnosis of cancer or CIN were not 
particularly more likely to undergo a total hysterectomy rather than a subtotal 
variant. 
 
Table 68.  Hysterectomy type compared with operative diagnosis 
Operation 
type 
Cancer % 
CI 
CIN % 
CI 
Benign % 
CI 
Total 
 
Total 
hysterectomy 
678 12.21 
11.35-13.07 
181 3.26 
2.79-3.73 
4,695 84.53 
83.58-85.48 
5,554 
Other 
hysterectomy 
35 8.08 
5.51-10.65 
3 0.69 
0-1.47 
395 91.22 
88.55-93.89 
433 
Total 
 
713 11.91 
11.09-12.73 
184 3.07 
2.63-3.51 
5,090 85.02 
84.12-85.92 
5,987 
 
 
There were ten deaths in the study population during their hospital admission, five 
occurred in patients with a cancer diagnosis (5/713, 7 per 1,000) and five in patients 
with a benign diagnosis (5 from 5,090, 1 per 1,000). 
 
 
6.3.3.6  Regression analysis of factors associated with operation type 
To establish if there were any preoperative patient factors influencing the likelihood 
of having a total, rather than any other type of hysterectomy, logistic regression 
analysis was applied.  It was predicted that those factors most likely to be 
associated with operation type were the age of the woman (do older women have 
less follow-up than younger women?), her deprivation score, the index test result 
(does an abnormal index test make a certain operation type more likely?).   
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The result of the index test was categorised into three groups (normal, abnormal or 
uncertain significance, those never having an index test being excluded).  5,787 
women had data on all the variables and were included in the model.  Ethnicity was 
excluded as there were so many missing variables at the outset.  Table 69 
summarises the analysis run backwards, stepwise fashion.  
 
Thus it may be seen that the presence of an abnormal index test was a significant 
predictor of whether or not a woman has a total hysterectomy.  Age was the other 
significant factor in the model; with increasing age a woman is more likely to have a 
total hysterectomy.  However deprivation was not associated and was rejected from 
the model for the final step and is thus not reported in the table. 
 
 
Table 69.  Logistic regression analysis:  predictors of type of operation  
Variable** ß  S.E. of ß Sig. Odds 
ratio 
95% range  
for OR 
Age -0.033 0.005 0.000* 0.968 0.959 - 0.997 
Index test: Normal   0.004*   
Index test: Abnormal -2.178 0.714 0.002* 0.113 0.028 - 0.459 
Index test: Unknown -0.297 0.210 0.157 0.743 0.493 - 1.121 
Constant -0.924 0.226 0.000 0.397  
*  Significant.  **Deprivation is not reported as it was excluded from final step 
 
 
The Nagelkerke R Square (R2) = 0.030 thus this model only explains 3.0% of the 
likelihood of a woman having a total hysterectomy.   
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The overall percentage of women who have a total hysterectomy predicted by the 
model is 92.8%, but this is completely unchanged by the introduction on the 
variables and as such none of these factors has a significant bearing on the 
likelihood of any given operation type. 
 
When the model was run again with the addition of the simplified ethnicity data, 
(white or non-white) for the 3,976 women with all the variables included, it had no 
impact on the result.   
 
The model was also run using deprivation quintiles instead of deprivation scores, in 
case this impacted on the results, but it did not have any great impact (Nagelkerke 
R Square = 0.032, model prediction unchanged at 92.8%) and again deprivation 
was excluded from the final step. 
 
Thus although the presence of an abnormal index test result and increasing age are 
associated with subsequent operation type, these are weak predictors. 
 
 
6.3.4  Summary of section 6.3 
This section examined the hysterectomy procedures to establish which variant took 
place, the diagnosis and at which hospital.  This process identified the source of 
some of the problems with ethnicity coding as hospitals across the region varied 
widely (14-98%).   
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The number of operative procedures varied significantly, although, all hospitals 
identified as having departments of gynaecology, undertook over 150 operations 
during the year, but individual clinicians varied from 1 to 189 hysterectomies each.  
There were no clear associations between hospitals with more deprived patients 
and age at surgery or duration of post operative stay. 
 
There were differences noted between those women having total and sub-total 
hysterectomies with younger, non-white women being the most likely to undergo the 
subtotal variant, but no association noted with deprivation score or duration of 
hospital stay.  Having a normal index test result was weakly associated with 
operation type. 
 
The worst operative diagnosis was established: 11.61% had malignant disease, 
although this was not necessarily gynaecological.  3.00% had intraepithelial 
neoplasia or a carcinoma in situ, 2.51% were unclassifiable with the majority having 
a hysterectomy performed for benign indications.   
 
There were differences detected between the various diagnosis groups with cancer 
patients being older, more likely to be white and having a longer hospital stay, 
although the ethnicity data included small numbers.  The index cervical screening 
test result was positively correlated with the final diagnosis but was not a reliable 
predictor.   
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6.4  WHAT HAPPENS AFTER HYSTERECTOMY:  WHICH WOMEN HAVE VAGINAL 
VAULT CYTOLOGY TESTS? 
 
6.4.1  Overview of vault smear sub groups  
 
The data were then divided into operation type (total or subtotal hysterectomy), the 
overall worst diagnosis at time of surgery (benign disease, pre-invasive or malignant 
/ invasive disease) and whether or not women underwent post operative follow-up 
by means of vaginal vault cytology (vault smear testing).  Table 70 gives the 
numbers and percentages of women in each subgroup and Figure 35  illustrates the 
breakdown of the various groups in a more visual, flowchart format.   
 
Additionally a further classification as to whether or not women had vault cytology 
done according to national guidelines was applied – an assessment of 
‘appropriateness’.  This was done as an overview level and then a detailed level to 
allow for various types of subsequent analysis. 
 
It may be seen that the single largest group is that of women who had a total 
hysterectomy undertaken for benign indications and who subsequently did not go on 
to have any vault cytology (N=4,256), representing 69.30% of the study population.   
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For each of the main groups the proportion of women having vault smears was also 
calculated and it may be seen that this varied from 9.35% (women having had a 
total hysterectomy for benign disease) through to 100% in women who had either a 
sub-total operation or did not have hysterectomy type specified and where the 
operative diagnosis was carcinoma in situ or cervical intraepithelial neoplasia. 
 
The classification of post operative cytology into appropriate and inappropriate was 
complex, as screening guidelines have changed over time, the guidelines in place at 
the time of the hysterectomy (2002-2003) were used to apply a classification of 
appropriate or inappropriate, this is discussed further in Chapter 7.  No national 
guidelines exist concerning follow-up after malignant disease by means of vaginal 
vault cytology and so the data for women who had cancers were interesting but the 
significance was uncertain and they were not explored in depth. 
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Table 70.  Breakdown of numbers of women by hysterectomy type and vault smear testing  
Hysterectomy 
type 
Operative  
diagnosis 
N 
(%, CI) 
Followed 
up 
N % Vaults 
(CI) 
Subgroups N % 
 
No test  543 - 543 8.84 
Malignancy 678 (11.04, 10.26–11.82) Post op test 135 
19.91 
(16.90-22.92) - 135 2.20 
No test  67 - 67 1.09 
Vault cytology tests done exact to protocol 
(2 with normal results in 24m) 13 0.21 
Vault cytology tests done but too many  50 0.81 
Vault cytology tests done but too few  24 0.39 
Vault cytology tests done but too late  16 0.26 
CIN / 
Carcinoma 
in situ 
(C in-situ) 
181 
(2.95, 2.53–3.37) 
Post op test 
114 
62.98 
(55.95-70.01) 
Vault cytology tests done, results 
abnormal so no guidelines  11 0.18 
No post op cytology done correctly 3,958 64.45 No test  
4,256 No post op cytology but less than 10yrs 
cytology pre-hysterectomy so too few 298 4.85 
Vault cytology tests done; inappropriate 407 6.63 
Vault cytology tests done but <10yrs 
cervical cytology before op (age less than 
35yrs), just one test done so appropriate 
16 0.26 Benign 
4,695 
(76.45, 75.39–77.51) 
Post op test 
439 
9.35 
(8.52-10.18) 
Vault cytology tests done but had <10yr 
cervical cytology before op (age less than 
35yr) but >1 so still inappropriate 
16 0.26 
No test  114 - 114 1.86 
 
 
 
 
 
 
 
 
 
Total 
hysterectomy 
= 5,697 
Unknown 143 (2.33, 1.95–2.71) Post op test 29 
20.98 
(13.69-26.87) - 29 0.47 
No test  23 - 23 0.37 Malignancy 35 (0.57, 0.38–0.76) Post op test 12 
34.29 
(18.86-50.02) - 12 0.20 
No test  0 - 0 0.00 CIN / C in-
situ 
3 
(0.05, 0–0.11) Post op test 3 100 - 3 0.05 
No test  118 - 118 1.92 Benign 395 (6.43, 5.82–7.04) Post op test 277 
70.13 
(65.62-74.64) - 277 4.51 
No test  4 - 4 0.07 
 
Subtotal 
hysterectomy 
or type not 
specified 
= 444 
Unknown 11 (0.18, 0.07–0.29) Post op test 7 
63.64 
(35.21-92.07) - 7 0.11 
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Figure 35.  Flowchart of study participants grouped by operation type and overall diagnosis 
 
6,141 Women, resident in the West Midlands 
region, undergoing a hysterectomy 
operation:  April 2002 - March 2003 
299 
Post op 
cytology 
5,697 Total 
hysterectomy 
operations 
444 Sub-total operation or operation 
type not specified. 
395 Benign (277 had post op cytology 
tests, 118 did not) 
3 Pre invasive (all had post op cytology) 
35 Malignant (13 had post op cytology, 22 
did not) 
11 Diagnosis not specified (7 did have post 
op cytology, 4 did not) 
439  
Post op 
cytology 
(Vault) 
114 
Post op 
cytology 
(Vault) 
135 
Post op 
cytology 
(Vault) 
4,695 Benign 181 CIN or 
carcinoma in situ 
678 Malignancy 143 Unknown 
diagnosis 
145 
No Post op 
cytology 
29 
Post op 
cytology 
(Vault) 
4,256 No 
Post op 
cytology 
543 No 
Post op 
cytology 
114 No 
Post op 
cytology 
67 No 
Post op 
cytology 
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6.4.2  Post operative cytology subgroups:  description of demographics  
 
The demographic comparisons were made twice, firstly with the whole population of 
women who underwent post operative cytology and then just in those women who 
were known to have undergone a total hysterectomy as these women definitely did 
not have a cervix and thus their cytology was taken from the vaginal vault, these 
were the population of greatest relevance to the study aims. 
 
 
6.4.2.1  Whole population post operative cytology 
Table 71 summarises the demographic data of the two groups of women:  those 
who had post operative cytology testing and those who did not.  Several significant 
differences were observed with those having post operative cytology being slightly 
younger (Kruskal Wallis χ2 = 87.586, 1df, p=<0.001), less deprived (Kruskal Wallis χ2 
= 54.607, 1df, p=<0.001) and more likely to be non-white than the overall population 
(Pearson χ2 = 60.402 1df, p= <0.001).  There was also an association with shorter 
post operative hospital stay in this group, however the clinical significance of these 
observations is uncertain and discussed in Chapter 7. 
 
 
6.4.2.2  Total hysterectomy group vault cytology 
One of the key study aims was to establish the current pattern of follow-up post-
hysterectomy by means of vaginal vault cytology.   
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As only women who have undergone a total hysterectomy can undergo vaginal vault 
cytology it was important to extract this group from the main data.  For the rest of 
the comparisons and analysis in this chapter, the selected population of just 5,697 
women, who we were confident underwent a total hysterectomy, will be used. 
 
When all the analysis of demographic factors was run only on the group of women 
who had a total hysterectomy, compared with whether or not they under went vault 
cytology testing, it did not change the overall result of any of the observations 
outlined in section 6.4.2.1 above (i.e. those having post operative cytology were 
slightly younger, less deprived, more likely to be non-white and having a shorter 
post operative hospital stay), although the magnitude of some of the observations 
varied.  
 
Table 72 summarises all these comparisons; it may be seen that whilst the 
association with age was slightly weakened, the association with deprivation was 
strengthened.  There was no meaningful change in the results for ethnicity or 
duration of post operative stay. 
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Table 71.  Summary of differences in demographic data depending on post operative cytology status - whole population 
Comparator 
 
Whole study population 
N = 6,141  
Post operative 
cytology done 
 
N = 1,016 
% = 16.54 
 
No post 
operative 
cytology testing 
N = 5,125 
% = 83.46 
 
Statistical test Notes 
 
Age (6,141) 
Mean = 51.52 
Median = 48.38 
Skewness = 0.606 
IQR = 18.21 
 
Mean = 47.57 
Median = 45.84 
Skewness = 0.796 
IQR= 14.41 
 
Mean = 51.76 
Median = 49.07 
Skewness = 0.527 
IQR= 19.86 
 
Kruskal Wallis χ2 
= 87.586 
1df, p=<0.001 
 
Thus there was significant association; women who 
undergo post operative cytology testing tending to 
be younger than those who do not. 
Deprivation (6,141) 
Overall Mean = 24.59 
Median = 19.70 
Skewness = 0.847 
IQR = 23.94 
 
Quintiles (N/%) 
1  1,628 / 26.51% 
2  1,210 / 19.70% 
3  1,295 / 21.09% 
4  1,177 / 19.17% 
5  831 / 13.53% 
 
Mean = 28.19 
Median = 23.03 
Skewness = 0.631 
IQR = 29.19 
 
 
358 / 21.99% 
202 / 16.69% 
188 / 14.52% 
155 / 13.17% 
113 / 13.60% 
 
Mean = 23.87 
Median = 19.16 
Skewness = 0.867 
IQR = 23.26 
 
 
1,270 / 78.01% 
1,008 / 83.31% 
1,107 / 85.48% 
1,022 / 86.83% 
718 / 86.40% 
 
Kruskal Wallis χ2 
= 54.607 
1df, p=<0.001 
 
 
 
Pearson  
χ2 = 53.777 
4df, p=<0.001 
(0 count less 
than 5) 
 
There was an association established between 
deprivation score and post operative cytology 
testing, with those who did undergo post operative 
testing being somewhat less deprived than those 
who did not. 
 
Analysis of the quintiles confirmed that there was an 
association detected between deprivation and 
follow-up by means of cytology testing. 
 
Ethnicity  (4,213) 
White: 3,842 / 91.19% 
Mixed: 15 / 0.365% 
Asian: 209 / 4.96% 
Black: 119 / 2.82% 
Chinese: 11 / 0.26% 
Other:  17 / 0.40% 
 
536 / 13.95% 
1 / 6.67% 
54 / 25.84% 
45 / 37.82% 
3 / 27.27% 
5 / 29.41% 
 
3,306 / 86.05% 
14 / 93.33% 
155 / 74.16% 
74 / 62.19% 
8 / 72.73% 
12 / 70.59% 
 
Pearson  
χ2 = 74.599 
5df, p=<0.001 
(3 cells count 
less than 5) 
 
Thus there was an association is demonstrated 
between ethnicity and use of post operative cytology 
subsequent to hysterectomy.  To remove the effect 
of small numbers the analysis was re-run using just 
white/non-white and Pearson χ2 = 60.402 1df  
p= <0.001, confirming the finding. 
Duration of post op stay 
(6,136) 
Median = 5 days 
Skewness = 6.781 
IQR = 1 
Range = 0 - 81  
 
 
 
Median = 4 
Skewness = 12.448 
IQR = 2 
Range = 0 - 81 
 
 
Median = 5 
Skewness = 5.712 
IQR = 2 
Range = 0 - 50 
 
 
Kruskal Wallis 
χ2= 13.650 
1df, p=<0.001 
 
 
 
 
Thus an association was noted with those who had 
post operative cytology performed staying in 
hospital for a slightly shorter time than those who 
subsequently did not have testing. 
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Table 72.  Summary of differences in demographic data and vault cytology status - total hysterectomy only 
Comparator 
 
Total hysterectomy only 
N = 5,697 
Vault cytology 
done 
N = 716 
% = 12.57 
 
No vault 
cytology testing 
N = 4,976 
% = 87.34 
 
Statistical test Notes 
Only including those who underwent a total 
hysterectomy operation 
Age (5,697) 
Mean = 51.44 
Median = 48.88 
Skewness = 0.562 
IQR = 18.78 
 
Mean = 48.50 
Median = 46.93 
Skewness = 0.632 
IQR = 16.49 
 
Mean = 51.87 
Median = 49.17 
Skewness = 0.541 
IQR = 19.22 
 
Kruskal Wallis χ2 
= 34.446 
1df, p=<0.001 
 
Thus there was a significant association with 
women who undergo vault cytology testing tending 
to be younger than those who do not. 
Deprivation (5,697) 
Overall Mean = 24.48 
Median = 19.65 
Skewness = 0.849 
IQR = 23.61 
 
Quintiles (N/%) 
1  1,490 / 26.15% 
2  1,139 / 19.99% 
3  1,205 / 21.15% 
4  1,086 / 19.06% 
5  777 / 13.64% 
 
Mean = 29.46 
Median = 26.26 
Skewness = 0.510 
IQR = 28.84 
 
 
268 / 17.99% 
149 / 13.08% 
130 / 10.79% 
94 / 8.66% 
76 / 9.78% 
 
Mean = 23.77 
Median = 18.94 
Skewness = 0.896 
IQR = 22.87 
 
 
1,222 / 82.01% 
990 / 86.92% 
1,075 / 89.21% 
992 / 91.34% 
701 / 90.22% 
 
Kruskal Wallis χ2 
= 63.173 
1df, p=<0.001 
 
 
 
Pearson  
χ2 = 64.100 
4df, p=<0.001 
(0 count less 
than 5) 
 
There was an association established between 
deprivation score and vault cytology testing, with 
those who did undergo post operative testing being 
somewhat less deprived than those who did not. 
 
 
Analysis of the quintiles confirms that there was an 
association between deprivation score and follow-up 
by means of vault cytology testing. 
 
Ethnicity  (3,918) 
White: 3,583 / 91.45% 
Mixed: 13 / 0.33% 
Asian: 196 / 5.00% 
Black: 102 / 2.60% 
Chinese: 8 / 0.20% 
Other:  16 / 0.41% 
 
372 / 10.38% 
1 / 7.69% 
46 / 23.47% 
30 / 29.41% 
2 / 25.0% 
5 / 31.25% 
 
3,211 / 89.62% 
12 / 92.31% 
150 / 76.53% 
72 / 70.59% 
6 / 75.0% 
11 / 68.75% 
 
Pearson  
χ2 = 71.074 
5df, p=<0.001 
(3 cells count 
less than 5) 
 
There was an association demonstrated between 
ethnicity and use of vault cytology subsequent to 
hysterectomy.  To remove the effect of small 
numbers the analysis was re-run using just 
white/non-white and Pearson χ2 = 64.305 1 df p= 
<0.001, confirming the result. 
Duration of post op stay 
(5,692) 
Median = 5 days 
Skewness = 6.969 
IQR = 1 
Range = 0 - 81  
 
 
 
Median = 4 
Skewness = 9.339 
IQR = 3 
Range = 0 - 81 
 
 
Median = 5 
Skewness = 5.549 
IQR = 1 
Range = 0 - 50 
 
 
Kruskal Wallis χ2 
= 14.405 
1df, p=<0.001 
 
 
 
Thus an association was noted with those who 
subsequently had vault cytology done staying in 
hospital for a slightly shorter time than those who 
subsequently did not have testing. 
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6.4.3  Vault cytology status and cervical screening history  
 
Considering only those women who underwent a total hysterectomy, two sets of 
further comparisons were undertaken against the status of whether or not women 
underwent vaginal vault cytology testing subsequent to hysterectomy.  These were 
result of the index test and the classification of the entire cervical screening history. 
 
6.4.3.1  Index test compared with vault cytology status 
Initially, a cross tabulation of result of the index test, comparing whether or not 
women had any vault cytology subsequent to hysterectomy, was undertaken (Table 
73).  This gave a highly significant association; Pearson χ2 = 382.828, 3df, p=<0.001 
(with no cells counting less than 5).  Those women whose index result was of 
uncertain significance and those women who did not have any preoperative testing 
were subsequently excluded and the comparison rechecked and again, Pearson χ2 
= 345.399 1df p=<0.001 (0 cells count less than 5), thus there was an association 
between having an abnormal index test result and subsequently having vaginal vault 
cytology performed. 
 
Table 73.  Index test result compared with having vault smear tests 
Index test result Vault test No vault Total 
Index Abnormal 103 74 177 
Index Normal 520 4,236 4,756 
Index Uncertain 81 355 436 
No pre-op testing 13 315 328 
Totals 717 4,980 5,697 
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6.4.3.2  Entire screening history compared with vault cytology status 
The proportion of women in each of the 13 screening history bands was divided into 
whether or not they underwent vault cytology testing.  Table 74 summarises these 
data.  Cross tabulation gave a significant Pearson χ2 = 406.540 (12df p=<0.001, but 
4 cells counted less than 5). 
 
Table 74.  Entire screening history compared with vault cytology status 
Group Vault 
test 
No vault % Vault observed (CI) Total 
Index abnormal, previous abnormal 83 100 45.36  (38.15 – 52.57) 183
Index abnormal, previous only normal 57 125 31.32 (24.38 – 38.06) 182
Index abnormal, previous uncertain 68 120 36.17 (29.30 – 43.04) 188
Index abnormal, no prior tests 10 15 40.00 (20.80 – 59.20) 25
Index normal, previous abnormal 122 829 12.83 (10.70 – 14.96) 951
Index normal, previous only normal 233 2,359 8.99 (7.89 – 10.09) 2,592
Index normal, previous uncertain 93 806 10.34 (8.35 – 12.33) 899
Index normal, no prior tests 19 178 9.64 (5.52 – 13.76) 197
Index uncertain, previous abnormal 6 26 18.75 (5.23 – 13.76) 32
Index uncertain, previous only normal 5 45 10.00 (1.68 – 18.32) 50
Index uncertain, previous uncertain 3 35 7.89 (0 – 16.46) 38
Index uncertain, no prior tests 1 6 14.29 (0 – 40.22) 7
Never had preoperative testing 17 336 4.82 (2.59 – 7.05) 353
Totals 717 4,980 - 5,697
 
 
The ‘index uncertain’ and never preoperative tested groups were then excluded 
because of small numbers, for the remaining eight groups a Pearson χ2 = 369.972 
(7df p=<0.001, 1 cell count less than 5), thus still a highly significant finding so there 
were associations between different patterns of cervical screening and having vault 
cytology testing subsequent to total hysterectomy. 
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Then, some of the sub-groups were compared directly and demonstrated clear 
differences between the groups:  women who only ever had normal screening 
(n=2,592) were compared with those who repeatedly had abnormal screening 
(n=183) preoperatively, Pearson χ2 = 224.024 (1df p=<0.001).  
 
When repeated with the rest of the population compared as a third group (n=2,922) 
with those two groups again a significant difference was obtained with Pearson χ2 = 
213.444 (2df p=<0.001).  Thus, as the simple percentages in Table 74 would 
suggest, the likelihood of having vault cytology post operatively is associated with 
the results of preoperative screening history. 
 
 
6.4.4  Vault cytology status and operative diagnosis 
 
For those women who underwent a total hysterectomy, a cross tabulation of the final 
operative diagnosis (4 groups, Table 75) compared with whether or not women had 
any vault cytology subsequent to hysterectomy was undertaken) and this gave a 
highly significant result of Pearson χ2 = 503.311, 3df, p=<0.001 (0 cells count less 
than 5).  Those women whose operation result was of uncertain significance were 
subsequently excluded and the Pearson χ2 = 502.203, 2df p=<0.001 (0 cells count 
less than 5), thus confirming there was clearly a strong association between 
operative diagnosis and subsequently having vaginal vault cytology.  
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Table 75.  Summary of diagnosis at time of surgery and use of vault cytology 
Diagnosis Vault test No vault % Vault (CI) Total 
Cancer 135 543 19.91 (16.90 – 22.92) 678 
CIN 114 67 62.98 (55.95 – 70.71) 181 
Benign 439 4,256 9.35 (8.52 – 10.18) 4,695 
Uncertain 29 114 20.28 (13.69 – 26.87) 143 
Totals 717 4,980 12.59 (11.73 – 13.45) 5,697 
 
 
6.4.5  Factors associated with a woman having vault cytology post operatively 
 
One of the principal aims of the study was to establish which factors may be 
associated with a woman having cytology testing post operatively compared with not 
having any testing.  Having already investigated various possible factors 
independently (Table 72), logistic regression analysis was undertaken. 
 
6.4.5.1  Patient factors associated with having vault cytology 
It was postulated that those factors most likely to be associated with having vault 
cytology were the operation type (i.e. total hysterectomy where the cervix is 
removed or subtotal), the deprivation status of the patient, her age at hysterectomy, 
her diagnosis and what the result of her last cervical smear test was (the index 
result).  The operative diagnosis was categorised into four groups (benign, pre-
malignant, malignant and unknown) and the result of the index test into three groups 
(normal, CIN, invasive).  
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The analysis is reported in Table 76, run in backwards stepwise fashion, but when 
repeated with forward stepwise analysis the result was the same.  Women who 
never had any cytology were excluded from the analysis as were women who did 
not have a total hysterectomy and so there were 5,237 women included in the 
model.  As 87.1% of women never had any vault cytology this was the overall 
starting point. 
 
Table 76.  Predictors of having vault cytology tests in women undergoing total 
hysterectomy* 
Variable ß S.E. of ß Sig. Odds 
ratio 
95% range 
for OR 
Age -0.018 0.004 <0.000 0.982 0.974 - 0.989
Deprivation score 0.019 0.002 <0.000 1.019 1.014 - 1.025
Diagnosis: Benign - - <0.000 - -
Diagnosis: Uncertain 1.072 0.127 <0.000 2.921 2.278 - 3.745
Diagnosis: Cancer 0.924 0.125 <0.000 7.023 1.972 - 14.927
Diagnosis: Pre-malignant  2.326 0.192 <0.000 10.239 6.546 - 13.768
Index test: Normal - - <0.000 - -
Index test: Invasive  1.058 0.205 <0.000 2.882 1.928 - 4.308
Index test: Dyskaryosis 0.319 0.136 0.034 1.357 1.023 -1.801
Constant -1.890 0.215 <0.000 0.151 -
*  Backward, stepwise, logistic regression analysis 
 
 
It may be seen that all the suggested variables were significant predictors of 
whether or not a woman has post operative vault cytology.  Age was negatively 
associated, suggesting that younger women were more likely to have vault cytology 
than older women, however with an odds ratio of 0.98 this was of limited clinical 
usefulness.   
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Deprivation had an odds ratio of 1.019, thus for each point increase in IMD07 score 
there was a slightly increased likelihood of having vault cytology.  However, IMD07 
is not a linear scale and our study participants had scores of up to 80 and so the 
usefulness of this association may be questioned.  The odds ratios of an invasive 
test result at index cervical smear of 2.882 and of dyskaryosis of 1.357 were 
significantly more meaningful in practice. 
 
However, Nagelkerke R2 = 0.157 thus this model only explains 15.7% of the 
likelihood of a woman having post operative cytology.  Using a 50% cut off, the 
overall percentage of positive and negative (vault/no-vault) correctly predicted by 
the final fitted model was 88.20%. 
 
The analysis was then repeated including those women who were known to have a 
subtotal operation, as well as a total hysterectomy or in whom operation type could 
not be established.  There was sufficient data on 5,787 women and the results are 
reported in Table 77. 
 
Operation type was the most significant predictor of having post operative testing 
(Odds ratio of 17.986) and including it in the model increased the accuracy of the 
model (Nagelkerke R2 =0.282) thus this model now explains 28.2% of the likelihood 
of a woman having post operative cytology.   
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Table 77.  Regression analysis:  predictors of having post operative cytology tests 
for any woman undergoing a hysterectomy 
Variable ß S.E. of ß Sig. Odds 
ratio 
95% range 
for OR 
Operation type 2.890 0.118 <0.000 17.986 14.268 - 22.674
Age -0.021 0.004 <0.000 0.979 0.972 - 0.986
Deprivation  Score 0.016 0.002 <0.000 1.017 1.012 - 1.021
Diagnosis: Benign - - <0.000 - -
Diagnosis: Uncertain 0.757 0.217 <0.000 2.131 1.394 - 3.258
Diagnosis: Cancer 0.924 0.125 <0.000 2.520 1.972 - 3.220
Diagnosis: Pre-malignant  2.251 0.190 <0.000 9.493 6.546 - 13.768
Index test: Normal - - <0.000 - -
Index test: Invasive  1.106 0.194 <0.000 3.023 2.065 - 4.424
Index test: Dyskaryosis 0.319 0.136 0.019 1.376 1.054 -1.796
Constant -4.509 0.246 <0.000 0.011 -
 
 
However, the overall percentage predicted by the model is actually worse at 86.9%.  
Thus the original model applied only to women know to have had a total 
hysterectomy, is preferred. 
 
Regression analysis was then repeated using deprivation quintiles instead of 
deprivation score and also using age, banded into five-year groups.  Both models 
gave results very similar to the first model with slightly less accuracy and are not 
reported further. 
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6.4.5.2  Site of treatment associated with having vault cytology 
As patient factors had been explored extensively and were found to have only 
limited power to predict likelihood of having vault cytology post operatively, hospital 
factors were introduced into the analysis.  
 
The hospital for each total hysterectomy operation was included in the model, with 
the 17 main centres. that had been coded accurately. included.  Women were 
excluded if they had never had any cytology.  The reference category was taken to 
be a large tertiary referral centre.  This left 4,515 women available for inclusion in 
the analysis.   
 
Table 78 summarises the raw data concerning hospitals and vault cytology.  When 
regression analysis was re-run including hospital of treatment, it was noted to be 
significant in the model (Nagelkerke R2 = 0.198) although making little difference to 
the ability of the model to predict who does and does not have vault cytology.   
 
Cross tabulation was undertaken to investigate this association and gave Pearson χ2 
= 159.244 (15df, p<0.001).  Thus women appear to be more or less likely to have 
vault cytology depending on which hospital the hysterectomy is conducted at.  A 
range of 4.9% to 25.7% of cases having subsequent vault cytology was noted.  The 
reference institution had the highest rates; this was a tertiary referral centre for 
gynaecological oncology cases.  
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Table 78.  Vault cytology testing, by hospital of surgery, in women having a total 
hysterectomy 
Code for hospital of 
hysterectomy surgery 
Vault 
cytology  
% (CI) No vault 
cytology 
% Total 
1 (Reference institution)  142 25.72 (22.07 – 29.37) 410 74.28 552
2 34 15.25 (10.53 – 19.97) 189 84.75 223
3 7 5.11 (1.42 – 8.80) 130 94.89 137
4 19 9.79 (5.60 – 13.97) 175 90.21 194
5 72 20.63 (16.38 – 24.88) 277 79.37 349
6 30 9.23 (6.08 – 12.38) 295 90.77 325
7 17 12.14 (6.73 – 17.55) 123 87.86 140
8 54 15.04 (11.34 – 18.74) 305 84.96 359
9 25 7.69 (4.79 – 10.59) 300 92.31 325
10 45 12.61 (9.17 – 16.05) 312 87.39 357
11 37 21.76 (20.20 – 35.44) 133 78.24 170
12 52 21.58 (16.39 – 26.77) 189 78.42 241
13 55 17.19 (13.06 – 21.32) 265 82.81 320
14 7 4.90 (1.36 – 8.44) 136 95.10 143
15 19 5.99 (3.38 – 8.60) 298 94.01 317
16 35 9.28 (6.35 – 12.21) 342 90.72 377
Total (used in model) 650 14.35 (13.33 – 15.37) 3,879 85.66 4,529
Hospital outside region 
or no gynaecology on-
site or invalid code 
67 7.83 (6.03 – 9.63) 789 92.17 856
Total 717 13.31 (12.40 – 14.22) 4,668 86.68 5,385
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6.4.6  Adherence to national screening guidelines:  factors associated with 
appropriate use of vault cytology testing 
 
To establish if there were any factors influencing the likelihood of a woman having 
appropriate vaginal vault cytology, in addition to her diagnosis at surgery, logistic 
regression analysis was undertaken separately for the two groups of women where 
national guidelines clearly apply.  Thus, women having a total hysterectomy where 
the operative diagnosis is either benign disease (no vault smears) or CIN (2 vault 
smear tests in 2 years).  For the purposes of regression analysis no further 
classification was possible as the group of women having malignant disease was 
too small to allow for meaningful results. 
 
 
6.4.6.1  Appropriate use of vault smears:  women with a diagnosis of CIN at total 
hysterectomy 
Intraepithelial neoplasia was detected in 181 women at the time of total 
hysterectomy, of these 114 subsequently had post operative vault cytology (63.0%) 
which is in line with national screening guidelines, however 67 did not. 
 
Logistic regression analysis was undertaken on this subgroup of women who should 
all be having post operative vault cytology.  It was postulated that those factors most 
likely to be associated with these women having a vault test in accordance to 
guidelines were the age of the patient, deprivation status and the result of the index 
test (normal, abnormal or uncertain significance).  
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Table 79 summarises the analysis run backwards, stepwise fashion, excluding 
ethnicity as there were so many missing variables.   
 
Table 79.  Logistic regression analysis:  predictors of adherence to national 
guidelines for women having CIN 
Variable ß S.E. of ß Sig. Odds 
ratio 
95% range 
for OR 
Age -0.15 0.014 0.279 0.985 0.960 - 1.1012 **
Deprivation  Score 0.017 0.010 0.096 1.018 0.997 - 1.039
Index test: Normal - - 0.009* - -
Index test: Abnormal 1.101 0.361 0.001* 3.143 1.559 - 6.338
Index test: Unknown 0.507 0.493 0.304 1.661 0.631 - 4.368
Constant -0.434 0.359 0.227 0.648 
*  Significant 
 
 
Thus, it may be seen that only the presence of an abnormal index test was a 
significant predictor of whether or not a woman had any post operative vault 
cytology undertaken appropriately.  With an odds ratio of 3.143 for an abnormal 
result and 1.661 for a result of uncertain significance, Nagelkerke R2 = 0.110 thus, 
although helpful, this model only explains 11.0% of the likelihood of a woman having 
post operative cytology appropriately.   
 
The overall percentage of women adhering / not adhering to guidelines, predicted by 
the final model (using 50% cut off), was 67.6% compared with the 64.8% of women 
who were already in the ‘appropriate’ group on the basis of operative diagnosis 
alone. 
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6.4.6.2  Appropriate use of vault smears:  women with a diagnosis of benign disease 
at total hysterectomy 
4,695 women had a diagnosis of benign disease at the time of total hysterectomy, of 
these 4,256 did not have any post operative vault cytology (90.6%) which is in line 
with national screening guidelines84, however, 439 had subsequent vault cytology, 
outside of the guidelines. 
 
Binomial logistic regression analysis was undertaken of this subgroup of women 
who should not be having any vault cytology:  it was predicted that those factors 
most likely to be associated were the age of the patient, her deprivation status and 
ethnic group and the result of her last cervical smear test (index).  The result of the 
index test was categorised into three groups (normal, abnormal, uncertain 
significance).  
 
Table 80 summarises the analysis run backwards, stepwise fashion and excludes 
the ethnicity data (too many missing variables).  The analysis was also run using 
deprivation quintile but this did not impact on the outcome and is not reported 
further. 
 
Decreasing age, increasing deprivation score and worsening result of index cytology 
were all predictors of adherence to national guidelines, however only the presence 
of an abnormal index test had an odds ratio of more than 1.5 (Table 80).   
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Table 80.  Logistic regression analysis:  predictors of adherence to national 
guidelines for women having a benign diagnosis 
Variable ß S.E. of ß Sig. Odds 
ratio 
95% range 
for OR 
Age -0.018 0.005 <0.000* 0.982 0.973 - 0.991
Deprivation score 0.022 0.003 <0.000* 1.023 1.017 - 1.028
Index test: Normal <0.000*  
Index test:  Abnormal  1.313 0.335 <0.000* 3.718 1.926 - 7.174
Index test:  Unknown 0.300 0.182 0.099 1.350 0.945 - 1.930
Constant -1.999 0.253 0.0008 0.135 
*  Significant 
 
Although all the suggested variables were significant predictors of whether or not a 
woman has a post operative vault cytology, with Nagelkerke R2 =0.048 this model 
only explains 4.8% of the likelihood of a woman having post operative cytology, a 
very small proportion.  Using a 50% cut off, the overall percentage of adherence/non 
adherence to guidelines predicted by the final model is 90.3% and this was 
unchanged from the original (226 cases were excluded because of missing data).  
Thus, none of the factors significantly influences the likelihood of a woman having 
inappropriate vault cytology beyond the impact of her original operative diagnosis. 
 
The analysis was also run including the ethnicity data dichotomised into white and 
non-white (in view of the small numbers), but the outcome was the same with no 
difference in the prediction after all factors were accounted for (3,084 cases 
included), although the Nagelkerke R2 =0.078 thus explaining 7.8% of the likelihood 
of a woman having post operative cytology, but the overall percentage predicted by 
the final model was unchanged. 
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6.4.7  Factors associated with having an abnormal vault cytology result 
 
The final stage in the analysis was to examine the vaginal vault cytology test results 
more closely to determine which were ‘normal’ or ‘abnormal’ test results and to 
establish if there were any factors associated with an increased likelihood of having 
an abnormal result.  
 
Women who had a total hysterectomy (n=5,687) and who ever had a vault cytology 
test (n=717) were divided into those who only ever had normal cytology, those who 
had one or more abnormal results and those who had one or more uncertain results 
(where the remainder were normal).  They were then subdivided into groups based 
on numbers of vault tests that they ever had (one, two or more than two), and what 
that woman’s result at hysterectomy had been:  see Table 81. 
 
It may be seen (Table 81) that of the 717 women who underwent vault cytology, the 
great majority (79.50%, CI 76.55 – 82.45%) only ever had entirely normal results.  
However, 17.57% (14.78 – 20.36%) had at least one result which was of uncertain 
significance, but only a very small proportion, 2.93% (1.70 – 4.16%), ever had any 
abnormal vault smear results.  
 
When just those women who had greater than two vault tests in total were 
examined, women having abnormal or results of uncertain significance, appeared to 
have a greater total number of tests (range 3 - 10, 7 groups) than those women with 
normal results, Fishers Exact test (Monte Carlo method) = 34.399, 14df, p=<0.001. 
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Table 81.  Vault cytology results (total hysterectomy only) 
Diagnosis at hysterectomy Results per 
woman 
Number of 
vault tests Malignancy CIN/in-situ Benign Unknown 
Total 
number  
1 48 20 283 6 357
2  19 19 70 4 112
Normal 
results only 
N = 570 
>2, range 3 - 7 
median = 3.00 
33 38 23 7 101
1  1 2 1 0 4
2  0 0 3 0 3
Abnormal (1 
or more) N 
= 21 
>2, range 3 - 7 
median = 5.50 
1 8 2 3 14
1 5 1 11 0 17
2 8 2 21 1 32
Uncertain (1 
or more) N 
= 126 
>2, range 3 - 10 
median = 5.00 
20 24 25 8 77
Subtotal - 135 114 439 29 717
 Not tested 543 67 4,256 114 4,980
Totals - 678 181 4,695 143 5,697
 
 
Diagnosis at time hysterectomy is the basis for national screening guidelines 
concerning use of vaginal vault cytology in women who had CIN.  Cross tabulation 
of the final operative diagnosis (Cancer, CIN, benign) and the vault cytology result 
(normal, abnormal, uncertain) confirmed that a strong association existed:  Pearson 
χ2 = 35.874, 4 df p=<0.001 (2 cells count less than 5). 
 
Comparisons were then made between those women having normal and abnormal 
vault test results in terms of age, deprivation, ethnicity and duration of post operative 
hospital stay, in an effort to establish any demographic patient factors that may 
predict likelihood of a woman having abnormal vault cytology result.   
 
  - 271 - 
These findings are summarised in Table 82 which also includes, for ease of 
comparison (but not for analysis in view of small numbers), those women who had 
uncertain results and those who did not have vault cytology (shaded out).   
 
It may be seen that there were no meaningful, demographic, differences between 
those women having normal and abnormal vault cytology detected and thus multiple 
regression analysis was not undertaken. 
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Table 82.  Summary of differences in demographic data between those having differing vault test results 
Comparator 
All women having 
total hysterectomy 
N = 5,697  
No vault  
Cytology 
N = 4,980 
% = 87.41 
Vault cytology 
‘normal’ 
N = 570 
% = 10.01 
Vault cytology 
‘abnormal’ 
N = 21 
% = 0.37 
Vault cytology 
‘uncertain’ 
N = 126 
% = 2.21 
Statistical 
test 
(2 group 
comparisons) 
Notes 
(comparing just 
abnormal vs normal 
vault test results; 2 
group results) 
Age (5,697) 
Mean = 51.44 
Median = 48.88 
Skewness = 0.562 
IQR = 18.78  
 
Mean = 51.87 
Median = 49.17 
Skewness = 0.541 
IQR = 19.20 
 
Mean = 48.61 
Median = 47.67 
Skewness = 0.622 
IQR = 15.84 
 
Mean = 51.43 
Median = 47.07 
Skewness = 0.768 
IQR = 21.55  
 
Mean = 47.536 
Median = 44.244 
Skewness = 0.564 
IQR = 18.12 
 
Kruskal Wallis 
χ2= 0.278 
1df, p=0.598 
 
Although an association 
exists between age and 
having vault tests, when 
the analysis was done 
comparing just normal 
and abnormal groups 
the association 
disappeared.  
Deprivation (5,697) 
Overall Mean = 24.48 
Median = 19.65 
Skewness = 0.849 
IQR = 23.61 
Quintiles (N/%) 
1  1,490 / 26.15% 
2  1,139 / 19.99% 
3  1,205 / 21.15% 
4  1,086 / 19.06% 
5  777 / 13.64% 
 
Mean = 23.76 
Median = 18.91 
Skewness = 0.897 
IQR = 22.87 
 
1,222 / 82.01% 
990 / 86.92% 
1,075 / 89.21% 
992 / 91.34% 
701 / 90.22% 
 
Mean = 29.299 
Median = 25.640 
Skewness = 0.491 
IQR = 29.16 
 
212 / 14.23% 
115 / 10.10% 
105 / 8.71% 
76 / 7.00% 
62 / 8.00% 
 
Mean = 27.806 
Median = 25.400 
Skewness = 1.164 
IQR = 20.63 
 
6 / 0.40% 
6 / 0.53% 
6 / 0.50% 
1 / 0.09% 
2 / 0.26% 
 
Mean = 30.295 
Median = 26.960 
Skewness = 0.529 
IQR = 30.00 
 
50 / 3.36% 
28 / 2.46% 
19 / 1.58% 
17 / 1.56% 
12 / 1.54% 
 
Kruskal Wallis 
 χ2= 0.203 
1df, p=0.653 
 
Fishers exact 
= 1.176, 4df, 
p=0.900 
(2sided) 
 
There was no 
association established 
between deprivation 
score and having 
abnormal vault cytology. 
The analysis of quintiles 
rather than crude IMD07 
score confirms that no 
association was 
detected. 
Ethnicity  (3,918) 
White: 3,583 /91.45% 
Mixed: 13 / 0.33% 
Asian: 196 / 5.00% 
Black: 102 / 2.60% 
Chinese: 8 / 0.20% 
Other:  16 / 0.41% 
 
3,211 / 89.62% 
12 / 92.31% 
150 / 76.53% 
72 / 70.59% 
6 / 75.0% 
11 / 68.75% 
 
303 / 8.46% 
1 / 7.69% 
41 / 20.92% 
26 / 25.49% 
1 / 12.50% 
2 / 12.50% 
 
12 / 3.35% 
0 / 0% 
1 / 0.51% 
0 / 0% 
1 / 12.50% 
0 / 0% 
 
57 / 1.59% 
0 / 0% 
4 / 2.04% 
4 / 3.92% 
0 / 0% 
3 / 18.75% 
 
Fishers exact  
(for 2x2) 
 Sig 0.755 - 
0.345. 
Many cells had numbers 
<5 so analyses run on 
the white / non-white 
groups only; no 
association was 
detected. 
Duration of post op 
stay (5,692) 
Median = 5 days 
Skewness = 6.969 
IQR = 1 
Range = 0 - 81  
 
Median = 5 
Skewness = 5.549 
IQR = 1 
Range = 0 - 50 
 
Median = 4 
Skewness= 3.883 
IQR = 2 
Range = 0 - 38 
 
Median = 5 
Skewness = 0.272 
IQR = 2 
Range = 0 - 10  
 
Median = 5 
Skewness = 9.468 
IQR = 3 
Range = 0 - 81 
 
Kruskal Wallis 
χ2= 0.004 
1df, p=0.951 
There were no 
differences detected 
between those having 
normal and abnormal 
vault cytology. 
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6.4.8  Summary of section 6.4 
 
This final section of results considered the four years following surgery, when some 
women were followed up by post operative cytology.  Those with a subtotal 
hysterectomy should have remained in the national cervical screening programme 
and thus were excluded from the analysis.  Women having a total hysterectomy 
should only have had vaginal vault cytology testing if they had CIN or, in the case of 
malignancy, if their consultant had requested it. 
 
Vault cytology was undertaken inappropriately on 9.35% (CI 8.52 – 10.18) of those 
women having total hysterectomy for benign indications, and was inappropriately 
not undertaken on 37.02% of women with CIN.  Of those with CIN who were 
followed up, this was frequently not according to protocol specified intervals and 
only 13 women with CIN (of 181) had screening completely compatible with the 
recommended intervals, 11 had an abnormality on their first test so the guidelines 
ceased to apply. 
 
Operative diagnosis was the strongest predictor of having any subsequent vault 
cytology, which tended to occur in younger, less deprived non-white women who 
had an abnormal index test result.  Although age and deprivation were significantly 
associated with having vault cytology the odds ratios were very small and the 
clinical usefulness of this finding is limited. 
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Hospital site of surgery was found to be associated with having vault cytology but 
did not influence the overall predictive power of the regression model.  The 
reference institution (a tertiary referral centre) was the most likely to have patients 
who subsequently had vault cytology. 
 
Widespread inappropriate use of vault cytology testing was evident, however 
regression analysis failed to establish many associated factors, with presence of an 
abnormal index test as the only genuine predictor.   
 
Abnormal vault cytology test results were very uncommon with only 21 true 
abnormalities detected and only 2.93% (CI 1.70 - 4.16%) of those women who have 
vault cytology every having an abnormal result. 
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6.5  SUMMARY OF RESULTS CHAPTER 
 
This chapter has systematically considered the study data in four main sections with 
multiple comparisons.  Several graphs, figures and tables have been used in an 
attempt to present the data in a meaningful way and the explanation of the analysis 
has focussed on clinical importance of the findings. 
 
Study population demographics 
The overall study population demographics revealed an incidence of hysterectomy 
of 23 per 10,000, and a median age of surgery of 48 years.  Age standardisation 
had little bearing on these findings.  Age specific incidence rates varied, with the 
highest rate in women aged 44 – 49yrs (63 per 10,000 pa). 
 
Deprivation scores were very similar to the West Midlands region, which is 
somewhat more deprived than England overall.  Variability in hysterectomy 
incidence, by deprivation quintile, revealed a clear correlation between women living 
in more deprived areas being more likely to have a hysterectomy operation 
(incidence of 25 per 10,000 vs 20 per 10,000 for most and least deprived quintiles). 
 
Ethnicity, although only available for two thirds of the population, indicated that the 
study population had some differences from background population of the West 
Midlands region:  Caribbean and White women were over represented and Indian 
women were under represented.   
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Using age standardised data a significant difference was noted between the three 
main ethnic groups (White, Black and Asian). 
 
Ten women died during their hospital admission, five of whom had malignant 
disease.  This represented 0.16% of the study population or a mortality rate of 16 
per 100,000 hysterectomy operations. 
 
Cervical screening history 
Preoperative cervical screening was undertaken on 5,787 women (94.23%). Those 
ever tested underwent a median of five tests each, although this varied significantly 
by age.  Post operative cytology was performed on one in six of the whole cohort.  
The result of last cervical screening test before hysterectomy (the index test), 
suggested that severe changes were more common in younger women and 
abnormal test results were more likely in women living in more deprived regions.  
Ethnicity was not associated with index test result.  Overall women in the study 
tended to have more cytological screening than the general population when they 
were younger. 
 
Use of a complex algorithm from the WMQARC allowed entire screening histories to 
be classified and compared; findings corroborated the data on deprivation and 
ethnicity even though the groupings were undertaken slightly differently from that of 
the raw study data. 
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Outcome of hysterectomy 
Consideration of the different hospitals revealed some of the causes of poor 
ethnicity data with some hospitals clearly using invalid coding whereas others had 
up to 98% of patients ethnicity recorded.  Operation type was established for all but 
eight of the participants.  Sub-total surgery was more common in younger women 
and total hysterectomy was more common in white women.  11.61% of the study 
population had a hysterectomy for a malignancy (not necessarily gynaecological), 
3% for intraepithelial neoplasia of all types but the great majority had benign 
indications. 
 
Women with malignant disease were significantly older than the rest and white 
women were more likely to have a diagnosis of malignancy.  Regression analysis of 
those factors associated with having a total or subtotal type of hysterectomy 
revealed significant associations with age and result of the index test, however 
these only accounted for a small proportion of the total. 
 
Vault cytology 
Dividing the study participants according to hysterectomy type allowed post-
operative cytology to be classified as vault cytology or cervical screening.  The 
group of women who had total hysterectomies were then considered further.   
 
Vault cytology was undertaken on 9.35% of women, who had hysterectomies for 
benign disease, this was clearly inappropriate.   
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Of women having hysterectomy for carcinoma in situ or CIN only 63% had any vault 
cytology, thus in the group of women who are explicitly recommended to have some 
post operative testing, over a third do not have any.   
 
The women having CIN were examined more closely; in addition to those not being 
tested at all, of those who were tested, 24 only had one test, 16 had two tests but 
over too great a time frame (>2yrs), 50 had more than two consecutive normal 
results (so excessive testing) and just 13 (7.18%) were followed up exactly in 
accordance with the national guidelines.16 
 
When those women having benign disease were considered more closely, (Table 
70), and latest guidance applied, (including the suggestion that vault cytology be 
undertaken if a woman has less than 10 years of pre-hysterectomy cervical 
screening) the proportion having inappropriate testing became even worse, with 
inappropriate screening in 721 of 4,695 = 15.36%.   
 
Operative diagnosis was, appropriately, confirmed as the strongest predictor of 
having vault cytology.  Women who had vault cytology undertaken were more likely 
to be younger, less deprived and non-white than those who did not have vault 
testing.  Having an abnormal index test result was clearly associated with having 
post operative cytology as was having a history of any abnormal cytology 
preoperatively.   
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Logistic regression analysis demonstrated that age and deprivation score were also 
associated with having vault cytology but the odds ratios were very small and the 
clinical usefulness of this observation is in doubt.  Hospital of surgery was also a 
significant factor but overall impacted little on the fitted model. 
 
Regression analysis of those factors associated with inappropriate usage of vault 
cytology only identified index test result as being clinically important although age 
and deprivation score were related.  The only factor associated with having an 
abnormal vault test result was diagnosis at time of surgery, however with only 21 
definitely abnormal vault test results from 717 (2.93%) it was not possible to draw 
firm conclusions.  Regression analysis could not be undertaken in view of the small 
numbers. 
 
Overview of results 
Thus analysis of the study dataset confirms that hysterectomy is still commonly 
performed for benign indications in the West Midlands, ethnicity and deprivation are 
related to incidence of surgery.  Ten women died during their hospital admission, a 
mortality rate of 16 per 10,000 hysterectomy operations or one per 625 cases, five 
of these had malignant disease.  Preoperative screening history is associated with 
likelihood of having post operative vault cytology testing and women had a median 
of five cervical screening tests prior to hysterectomy.   
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Vault cytology testing is being undertaken inappropriately in a significant proportion 
of cases although the only factor of clinical importance associated was the presence 
of abnormal index cytology.  Less than 3%, of those tested, had abnormal results at 
vault cytology testing. 
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CHAPTER SEVEN:  DISCUSSION 
 
INTRODUCTION TO CHAPTER 
This chapter draws together all phases of the study, by first summarising the 
background to the research including key findings from the literature review and 
results of preliminary work undertaken by the author.  It then examines the study 
methodology and the limitations and challenges of this particular project.  The 
important study findings are considered next, presented in the same order as the 
results (Chapter 6), contextualising them and suggesting possible explanations.  
Finally, this chapter considers the implications of these findings in practice and 
makes recommendations for the future. 
 
 
7.1  BACKGROUND TO THE RESEARCH 
 
Hysterectomy is one of the most common major surgical operations undertaken on 
women, with approximately 20% of UK women undergoing this procedure during 
their lifetime.2  Any operation carries a degree of risk, even when undertaken in 
optimal conditions, consequently 8.5% of women experience a minor adverse event 
from hysterectomy and 4.4% a major one.57 
 
There are several variants of hysterectomy operations;32 key to this study is the 
differentiation between a total hysterectomy, which involves removal of the uterine 
cervix and sub-total hysterectomy which leaves the uterine cervix in situ.   
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Other variants of hysterectomy include the choice of surgical route i.e. abdominal, 
vaginal or laparoscopically assisted, and how much additional tissue is removed i.e. 
bilateral salpingooophrectomy involves removal of the Fallopian tubes and ovaries; 
radical hysterectomy includes removal of substantial portions of lymphatic tissue 
and other structures including para-cervical tissue. 
 
Cervical screening is well established in the UK with the aim of preventing cervical 
cancer, the NHS Cervical Screening Programme (NHSCSP) is one of the most 
successful programmes worldwide and is credited with a 42% reduction in the 
incidence of cervical cancer within a decade of its establishment.15   
 
Total hysterectomy is a reason for ceasing routine recall from the NSHCSP as the 
cervix is no longer present.  Follow-up after total hysterectomy by means of vaginal 
vault cytology (vault smears) is, however, recommended in certain circumstances:  
women who have had less than ten years routine cervical screening should have 
one vault cytology test and those who have CIN detected at surgery should have 
two, within 24 months of the operation.  If all test results are negative, screening 
should cease permanently as there is no cervical tissue in which CIN can develop.16  
Undertaking vault cytology testing of asymptomatic women outside these guidelines 
is to screen for vaginal cancer, a very rare malignancy which does not fit the criteria 
for any organised screening programme. 
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It has been suggested that vaginal vault cytology is sometimes being undertaken 
inappropriately, outside the recommendations of national guidelines, which is 
wasteful of resources and potentially harmful to women.30  There are also women 
for whom guidelines do not apply i.e. those who have a diagnosis of malignancy, 
where the specialist will dictate what they feel is the most appropriate follow-up on 
an individual patient basis.  Women who have abnormal vault cytology are 
subsequently treated according to local protocols.   
 
The existing literature concerning the indications for hysterectomy had not been 
updated for some time1 and the literature concerning use of vaginal vault cytology in 
follow-up after surgery was sparse when this study was conceived.  It was known 
that the great majority of women underwent hysterectomy for benign 
indications1;2;162 and that vault cytology was a matter of some considerable 
debate.24;27 
 
Current NHSCSP guidelines concerning vault cytology are based on expert opinion 
rather than gold standard research evidence; no randomised controlled trials have 
been undertaken.  The majority of published literature suggests that follow-up by 
means of vault cytology has a limited place in follow-up of those cases where 
women had a hysterectomy which revealed invasive or pre-invasive disease.71;91  
However, following hysterectomy for benign disease, the value of vault cytology is 
unproven. 22;24;101 
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This study aimed to establish which women were having hysterectomy operations, 
why and whether or not they subsequently had any vaginal vault cytology 
performed.  The study objectives are given again in Figure 36. 
 
Figure 36.  Study objectives 
 
 
Primary Objectives 
 To estimate incidence rates for hysterectomy operations, in the West Midlands 
region of the UK 
 To describe variations in incidence of hysterectomy and establish the factors 
associated with variability 
 To describe the current indications for hysterectomy in West Midlands 
 To describe cervical screening patterns prior to hysterectomy 
 To establish the current pattern of follow-up after total hysterectomy by means of 
vaginal vault cytology test 
 To describe the results of vaginal vault cytology with respect to histology at 
hysterectomy and establish the factors associated with having an abnormal result 
 To assess if vaginal vault cytology is being undertaken appropriately and establish 
the factors associated with inappropriate usage 
 
Secondary Objectives 
 To provide high quality evidence to inform national guidelines. 
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7.2  STUDY LIMITATIONS AND PECULIARITIES 
 
7.2.1 Justification for the study 
 
To establish which women were having vaginal vault cytology and why, it was first 
necessary to establish which women were having hysterectomy operations.  
Establishing which operations were total or subtotal hysterectomies enabled 
classification of women according to who should continue with routine cervical 
cytology, who should have vault cytology and who should cease to be screened.  
Hence, the concepts underpinning this study:  identifying a suitably large cohort of 
women who had a hysterectomy operation during a defined period, who could have 
their cervical and any subsequent vaginal vault cytology linked to their operative 
details so that patterns and trends could be established. 
 
 
7.2.2 Limitations and usefulness of routinely collected data in linkage studies 
 
Although increasingly common to undertake research using database linkage,163 
any study using routinely collected data is at risk of bias.  The priorities for those 
responsible for recording the raw data will be different from those of the researcher, 
the measurements and standards are outside the control of the researcher and 
completeness of data may not be known.  
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To link datasets that were not designed for the purpose risks a significant loss of 
data where no reliable matching occurs or where items from one database are not 
able to be transferred to the other.  The deliberate choice of NHS number, date of 
birth and UK postcode of residence in this study, was to utilise standardised, 
commonly recorded data, to facilitate optimal linkage.  Studies of this nature have 
been conducted ever since healthcare data has been reliably stored 
electronically.163;164 
 
The two key data sources are well established and respected.  Hospital Episode 
Statistics (HES)114 uses highly trained NHS Clinical Coders to upload data about 
every hospital admission or appointment, using a variety of internationally 
standardised coding systems to ensure that the data is of the highest possible 
quality.110;116;117  National cervical cancer screening programme data is a very rich 
resource including data for the past 35 years, and its data entry and coding is 
regarded as being of ‘high quality’.111 
 
 
7.2.3 Use of confidential patient data without individual consent 
 
The considerable ethical dilemmas that arose from using individual patient data 
without consent have been explored in Chapter 3.  In essence, to conduct a 
database linkage study of this scale it was not practicable to obtain individual patient 
consent.  
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The potential benefit from the research for all women, outweighed any theoretical 
risk of harm to a few, by a transient breach in patient confidentiality for the purposes 
of linking data.  A position that PIAG agreed with.  As soon as the study data was 
linked and verified, and before any analysis took place, anonymity was restored:  at 
first in part (pseudo anonymisation) and then, once hospital data had been obtained, 
full anonymisation with independent verification. 
 
To protect against frivolous use of confidential patient data, there are many 
necessary approvals which any legitimate researcher must obtain before being 
granted access to such data.  These processes, which were successfully navigated 
before the research could begin, ensured that the highest standards were applied 
and that the research concept had been independently verified by experts in the 
field of medical ethics. 
 
At the time of study development and data collection the body responsible for 
overseeing this process of allowing researchers access to confidential data, without 
patient consent, was PIAG.  However, subsequently PIAG has been subsumed into 
the National Information Governance Board (NIGB).136  
 
Efforts were made to advertise the study in local research publications as suggested 
by PIAG.  No-one came forward to ask that their details be removed from the study 
database and, as such, it is impossible to know if this was because the advertising 
did not reach the target audience or if it is because women were in complete 
agreement with the study aims and were happy for their data to be used.   
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Two lay persons were asked for their views during study development and their 
comments were integrated with the final protocol.  It is plausible that the resulting 
study paperwork and patient information generated by their input was the reason 
why no women sought to have their data removed from the study database.   
 
As patients were not approached for their individual consent, the study is completely 
inclusive and thus the findings should be generalisable.  However, there is a valid 
argument that, had the opportunity presented itself explicitly, there were some 
women who may have chosen to be excluded from the study.  These women may 
represent a discrete group for whom the normal ‘medical model’ of research and 
routine care does not apply.  As we had no way of identifying those women, direct 
comparisons of the findings of this work against other research that has obtained 
patient consent, should be undertaken with caution. 
 
The author of this thesis is a practising British doctor with enhanced Criminal 
Records Bureau clearance (CRB, an agency of the Home Office), employed by the 
NHS and funded by the NIHR to undertake this research in a well-respected 
academic institution.   
 
It was suggested that the maze of approvals and permissions necessary for access 
to the patient data (outlined in Chapter 3) was disproportionate and potentially 
wasteful of resources.  However, in view of subsequent national scandals 
concerning inappropriate use or loss of confidential data, it would appear that these 
were appropriate safeguards.165  
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The development of a unique study security policy (SLSP) was requested by the 
Security and Confidentiality Advisory Group (SCAG) of HES and its evolution 
involved close working with The University of Birmingham Caldicott Guardian.  This 
was a productive relationship which led to several initiatives being adopted which 
have subsequently become established as ‘good practice’ for all research 
undertaken at The University of Birmingham:  the use of removable hard drive 
storage devices which are smaller and easier to lock away than full personal 
computers; use of sophisticated encrypted removable storage when any sensitive 
material is to be transferred between computers and the principle that patient 
identifiable data should not leave the security restricted areas of the University. 
 
Secure wiping of media that contained patient identifiable data has been undertaken 
and verified, as per study protocol and there have not been any security breaches 
throughout the study period.  Other procedures i.e. ‘disaster recovery’ have, 
fortunately, not been required to date.   
 
7.2.4 Use of local hospital histopathology records 
 
Hospital’s histopathology data had been intended to be merged with the main study 
database, on a large sample of the study population.  This was to provide additional 
information, and to act as a cross-check of the quality of the coded data.  However, 
the significant variability in the quality and quantity of the data from laboratories was 
a cause of considerable concern.   
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The need to ensure patient confidentiality and only use NHS numbers (a study 
requirement stipulated by PIAG) meant that there was no way of obtaining more 
specific data or of searching more rigorously at the laboratories.  It transpired that, 
despite the intention that NHS number should be the key identifier for all patient 
records, some hospitals were still reliant on their own numbering or identification 
systems and as such their use of NHS number was erratic.  Had the study been 
able to use patient name or other specific identifiers or been permitted to use date of 
birth and postcode (which were already available) then the usefulness of hospitals’ 
data may have been amplified. 
 
Additionally, various hospitals used several variations of diagnostic and 
histopathological coding, which were not comparable.  It was reluctantly decided not 
to pursue this source of data as the results would have been of uncertain 
significance in the absence of independent validation.   
 
Fortunately, the data received from HES and Exeter was of significantly higher 
quality than had been anticipated.  Thus, if linkage had been undertaken on NHS 
number alone, just one automated search of Exeter data generated 5,754 records; a 
match of over 98% of those with NHS numbers and a match of over 93% of the 
whole study population.  This was because NHS number was present in 95.4% 
(5,857) of the 6,168 HES records, which had already been validated to ensure all 
were legitimate.   
  
- 291 - 
This is a significant improvement over older data linkage studies166 but is consistent 
with findings from a large-scale new project (The SAIL Databank) which has 
validated NHS number for use in multiple database linkages (specificity >99.8% and 
sensitivity >94.6%).167 
 
The final Exeter dataset, after a significant amount of manual searching and 
postcode and date of birth electronic searches, actually included data on 6,065 
women.  The final merged dataset, after all duplications were identified and 
removed, included information on 6,141 women, of which 6,055 had NHS numbers. 
 
 
7.2.5 The West Midlands as a choice of study population 
 
The West Midlands region is regarded as a reasonable proxy for the whole of 
England and Wales, representing approximately 10% of the population in terms of 
numbers and having ethnic diversity second only to London.  The region 
encompasses affluent and deprived wards and spans densely populated urban to 
isolated rural communities with a corresponding variety of hospitals.  These facts, 
and the practicality of conducting the study local to The University of Birmingham, 
justified the choice of study population on more than just pragmatic grounds. 
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7.2.6  Data validation 
 
It was a major undertaking to validate all the data received and re-code it to a 
standard that would permit statistical analysis.  This was partly because of the large 
number of different data items that were available for the analysis and also because 
of the need to group codes into practical but clinically relevant sections.  Early in the 
project, problems were encountered by the use of Microsoft Excel 2003®; this 
spreadsheet programme is limited to 65,536 rows of data and 256 columns.  The 
number and complexity of the transformations required to generate the final study 
database necessitated use of a high specification personal computer, multiple files 
open in parallel and a double width monitor with additional laptop screen.  Microsoft 
Access 2003® and SPSS® v15.1 software packages were also used at various 
stages in the validation and all the statistical analysis was ultimately undertaken in 
SPSS. 
 
Methodical validation of data required a range of strategies including identifying 
missing and duplicated data, establishing validity of outlying values and consistency 
of information.  In reality, the data obtained from Exeter and HES was of high 
quality.  The few areas of concern were:  recording of ethnicity, which was only 
present in two thirds of cases and some probable errors in recording the duration of 
hospital stay i.e. women discharged from hospital on the same day as they 
underwent major surgery, which would usually necessitate at least three or four 
days post operative recovery (HES data).  
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Hospital of treatment was another area of concern in the HES data:  121 operations 
were apparently conducted outside the region; most of these took place in counties 
bordering the West Midlands and may have reflected patient preference.  Three 
hospitals, which are known to have departments of Obstetrics and Gynaecology, did 
not have any hysterectomy operations recorded during the one-year study period.  
There were, however, 712 operations conducted where no valid hospital code was 
recorded.   Looking at the numbers of operations performed in the other hospitals, 
this was similar to the estimated numbers of cases in the ‘missing three’.  Crude 
postcode data supported this hypothesis, however, a decision was made not to 
‘assign’ women to a given hospital but to just analyse the supplied information. 
 
Exeter data was remarkably complete:  only one woman, from 6,065, did not have 
an NHS number, all women had date of birth and a registered GP and only five did 
not have a valid UK postcode.  For the 5,810 who had screening performed there 
was a date, test result and action code for each. 
 
 
7.2.6 WMCIU coding algorithm of screening histories 
 
The use of this Microsoft Access® visual basic programme, designed by the West 
Midlands Cancer Intelligence Unit (WMCIU) staff to classify women diagnosed with 
cancers into a screening history code, was a useful supplement to the study.   
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By modifying the algorithm, so that the date of surgery was substituted for the 
cancer diagnosis date, it then allocated women to a specific group representing all 
phases of their screening history.  The resulting 238 codes, in the population of 
6,141 women, were too extensive to permit meaningful comparisons.  Thus, further 
subgroups were created, resulting in a final coding of 13 variants.  The last 
screening test before surgery was the first discriminator (abnormal, normal, of 
uncertain significance or never tested) followed by the four main patterns of prior 
screening history (all normal, some abnormal, only one test ever or previous results 
of uncertain significance). 
 
There were some assumptions in the programming which were not relevant to our 
study population (i.e. women over the age of 65 were usually excluded and tests 
taken in hospital or the private sector disregarded), allocation to the 13 sub-groups 
serve to counter-balance these. 
 
 
7.2.8  Data coding and reclassification 
 
A variety of coding schemes were used by HES and Exeter to permit comparison of 
their data with that from other sources, some international coding (i.e. ICD10), some 
national (OPCS4) and some unique to that database.  Recoding some of these data 
was essential to permit appropriate comparisons. 
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7.3  DISCUSSION OF RESULTS 
 
7.3.1 Demographic composition of the study population:  which women had 
hysterectomy operations? 
 
Incidence of hysterectomy 
The 6,141 women included in this study were resident in the West Midlands region 
and all underwent a hysterectomy operation between 1st April 2002 and 31st March 
2003.  This equated to an annual, crude incidence of hysterectomy of 23 per 10,000 
women, thus the ‘average GP’ surgery of 6,000 patients would have approximately 
seven women each year undergoing this major operation.168 
 
Compared with the published literature this confirms that hysterectomy is declining 
in popularity, indeed there has been a halving in the number recorded annually in 
England over the past decade.5;126 
 
Age 
The study population were of a very wide age range; the youngest was only aged 17 
years at the time of her obstetric hysterectomy, having had a normal vaginal 
delivery, but subsequent uncontrolled post-partum haemorrhage necessitated an 
emergency hysterectomy (suggested by HES coding).  The eldest was 94 years at 
the time of surgery; she underwent a vaginal hysterectomy for repair of a vaginal 
prolapse. 
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The distribution of age was slightly skewed to the right, with a median age of 
surgery of 48.38 years but a mean of 51.12.  This is consistent with the 
‘perimenopause’ stage of a woman’s life when menstrual difficulties are 
commonplace, but is somewhat older than in the last reported major review of 
hysterectomy in the UK (operations in 1994-95) where the median age was 45 
years, although that study excluded cases of malignancy which may have increased 
our observed mean age.1  Also, this finding of increased mean age is compatible 
with the observed reduction in the numbers of operations performed over time, as 
the introduction of less invasive techniques for managing menstrual problems are 
likely to have the greatest application and benefit for women prior to their 
menopause transition. 
 
Age specific incidence rates for surgery varied widely with peak of 63 per 10,000 
women per annum, in the 45-49 year age group but very low rates in women under 
30.  In women aged 80-84 years the rate was 14 per 10,000 demonstrating that age 
is no barrier to surgery in otherwise healthy individuals.  Age standardisation of the 
study population did not make any meaningful difference to the incidence of 
hysterectomy and so crude rates were used throughout. 
 
Deprivation 
The study population was significantly more deprived than the population of England 
(p=<0.001) with 27% of the study population in the most deprived quintile and 14% 
in the least deprived.   
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However, deprivation of the study population was not significantly different from that 
of the West Midlands region, i.e. the women represented the full range of 
deprivation quintiles in approximately the same distribution as the general 
population of the area from which then came.   
 
The finding fits with from those of previous studies of the epidemiology of 
hysterectomy, where higher rates of surgery have been noted in women of lower 
social class.2  In the most recent cohort study it was suggested that women having 
higher levels of academic attainment are significantly less likely to have a 
hysterectomy than those with few qualifications.12  It is timely to acknowledge that, 
when compared with England as a whole, the West Midlands contain more areas of 
significant deprivation and as such, although there are many advantages in using 
this region, the study population cannot be entirely representative of the UK and 
thus the reader needs to be cognisant of this. 
 
Age standardisation of the deprivation data confirmed that, even accounting for the 
fact that younger women were more likely to be in the lower deprivation quintiles169, 
the observed differences in hysterectomy incidence were true with a range for 25 
per 10,000 in quintile one to 20 per 10,000 in quintile five (p=0.001). 
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Ethnicity 
The ethnic make-up of the study population, where this data was recorded, was 
significantly different from the background population:  although the proportion of 
white British was similar; women from Afro-Caribbean groups were over 
represented with women from Asian backgrounds being under represented.  This 
may be due to the fact that Afro-Caribbean women are more prone to significant 
fibroid disease with rates of up to 9x those in the general population.170  
 
Hysterectomy incidence was calculated for the main ethnic groups, age 
standardisation making little difference.  The crude rates ranged from 23 per 10,000 
in White women to 33 per 10,000 in Black women, numbers of Chinese, mixed and 
other races were too small to allow for meaningful comment.   
 
As ethnicity was recorded for only two thirds of the study population some caution 
should be taken when interpreting and extrapolating these findings. 
 
Duration of hospital stay 
The mean duration of hospital stay was five days, (mode = four days); consistent 
with findings of previous studies1 and fits with normal practice in that women who 
undergo routine hysterectomy surgery without complication are usually discharged 
on the fourth day.  There is the inevitable skew to the right as some women had 
complications and complex surgery, in addition to having underlying general medical 
problems, and may have required a far greater duration of admission.   
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The maximum hospital stay was 81 days post operatively.  However, 107 women 
were coded as being discharged on the same day as their surgery.  This was not 
related to transfer to another hospital and probably represents miscoding; the 
impact of this on the overall findings is likely to have been very small.  Within two 
days of surgery 228 had left hospital, ethnicity was recorded on just 47% of these, 
but the data suggested that Asian and Black women may be over represented in the 
‘early discharge’ group.  The diagnosis for these ‘early leavers’ covered the whole 
range with 15 malignancies represented. 
 
Destination on discharge from hospital 
On leaving hospital the vast majority of women went ‘home’ (98.14%).  Ten were 
noted as having died in hospital and a small number were transferred to other types 
of accommodation including one who went to prison to recuperate. 
 
Deaths in hospital 
Ten post operative deaths was higher than would have been anticipated using 
recognised complications rates1 for hysterectomy and giving a mortality rate of 1.6 
per 1,000 hysterectomy, or 0.16%, of the study population.  However, previous 
studies excluded women with malignancy and half of the deaths were in cancer 
patients (four of the five having disseminated disease).   
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When split by underlying diagnosis the mortality rates became 7 per 1,000 for 
hysterectomy in cases of malignancy and 1 per 1,000 for benign indications.  Two of 
the ‘benign’ cases had very little data recorded and it is possible that their discharge 
destination was miscoded which may have reduce the mortality rate further. 
 
Death is a rare outcome and this study was never powered to look at it in any detail 
but the observation does bear further investigation.  The Royal College of 
Obstetricians and Gynaecologists publishes guidance information for clinicians to 
use when obtaining informed consent from women prior to surgery; this states that 
there is an operative mortality of one in 4,000 cases.  Even if these are just 
applicable to hysterectomy for benign indications these study findings are four times 
worse and should prompt an appraisal of the current situation. 
 
 
7.3.2 Cervical screening history preoperatively:  why these women may have 
had surgery 
 
Overview 
The 6,141 women underwent 36,151 cytology tests between them, of which 34,174 
were prior to surgery and 1,977 after surgery.  In those women who had a sub total 
hysterectomy post operative tests were still cervical screening, but most were 
vaginal vault cytology tests. 
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Index test 
The index test was defined as the last cervical screening test prior to surgery, thus it 
usually took place within five years of the operation date.  It was examined in some 
detail because it is plausible that the test result may have had a bearing on the 
decision to proceed to surgery:  83.8% of index tests were essentially ‘normal’ 
results, which compares closely with the likelihood of having a normal test at any 
screening point in 2002-03.171  
 
Only 18 women were noted to have invasive disease at their index tests and 
dyskaryosis was detected in 161 women.  In 297 (4.84%) cases the result was 
borderline or some another result of uncertain significance, which is a little higher 
than the normal population.171  Having an abnormal index test result was associated 
with greater levels of deprivation, this is consistent with the known risk factors for 
CIN and cervical cancer.66 
 
There was no cytology testing prior to surgery on 354 women; these were more 
likely to be aged over 70.  This observation is compatible with the introduction of 
national screening in 1984, as this population of women would have been aged at 
least 50 and as such were a low priority.  No woman is compelled to have cervical 
screening and some women consistently exercise their right to opt-out of the 
national programme.  All women aged under 20 and over 90 years had not had any 
cervical screening prior to their hysterectomy, which is entirely consistent with 
national screening guidelines.16 
 
  
- 302 - 
When considering the result of the index test only 2.7% were classified as 
inadequate; the national average figures for inadequate rates in 2002 were 9.4%, 
thus the study figure was significantly lower.15  It is possible that some women had a 
previously inadequate test repeated prior to surgery to reduce the risk of missing 
potential cervical disease.  Alternatively, as these women would have been seen in 
a gynaecology outpatient clinic prior to surgery their index test may have been 
performed by a gynaecologist under optimum conditions (i.e. properly trained and 
appropriately equipped). 
 
Since the introduction of liquid based cytology techniques throughout the UK 
inadequate rates have subsequently fallen and in 2007-08 the national level stood at 
just 2.9%.15 
 
Women who had an index screening result of dyskaryosis’ were generally younger 
than those having had completely ‘normal’ or severely ‘abnormal’ results.  This 
finding is consistent with the natural history of cervical cancer, in that the changes of 
cervical intraepithelial neoplasia (CIN) take many years to develop into invasive 
cancer and pass through defined stages which may spontaneously regress, thus, 
cancers typically occur in older women with pre-invasive changes being detected 
earlier.2 
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Observed screening compared with anticipated screening 
An attempt was made to estimate how many cervical screening tests women were 
likely to have undergone at any given age, to permit comparison with the actual 
data.  This estimation was a combination of several factors:  firstly, the known 
screening guidelines that were in place at the time of the testing16; the known 
introduction of the national cervical screening programme (NHSCSP) and the fact 
that when pregnant and in the months subsequent to childbirth, cervical screening is 
not recommended.   
 
The estimates were generated completely separately from the study data but, when 
compared, showed a similar distribution of frequency (Chapter 6, figure 9) and an 
almost identical total number of tests undertaken.  However, women in the study 
had more screening tests at a younger age that the estimated model.  This is 
consistent with them having additional pathology compared with ‘normal’ women of 
a given age. 
 
White and Asian women typically had more cervical screening than women from 
other ethnic backgrounds (p=<0.001), however, even with the large study numbers 
the significance of this finding is uncertain as the rate of ethnicity recording was sub-
optimal.  Deprivation did not have a clinically significant impact on pre-operative 
screening in this population of women, although a negative correlation was 
observed (increased deprivation associated with less screening). 
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Entire preoperative screening history and the WMCIU algorithm 
As outlined in sections 4.4 and 5.5.4.4, women’s entire screening history was 
summarised using a modified version of an algorithm developed and used by the 
WMCIU.  The additional value of this coding is that any future work resulting from 
this study can use the same groupings to facilitate comparisons. 
 
The complex original coding was simplified into 13 groups for analysis.  Women, 
who had not ever undergone any cytology testing, were noted to be significantly 
older at the time of hysterectomy than all other women.  This may be because they 
presented late (i.e. the type of women who avoid any contact with healthcare 
personnel unless absolutely essential).  These unscreened women were also more 
likely to be from an ethnic grouping other than White British, which is consistent with 
findings of other studies169;172 and it is plausible that other barriers to access to 
healthcare may have accounted for their delay in having surgery (i.e. language or 
cultural factors), but this study was not able to investigate these further. 
 
Of note, 45.9% of women always had completely normal cervical screening results, 
6.19% never had any cervical screening but 9.85% had abnormal cytology prior to 
surgery.  Younger women and those living in more deprived areas were most likely 
to have ever had an abnormal cervical screening test results.66   
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7.3.3  Outcome of surgery:  which operation and what diagnosis? 
 
Hospital of surgery 
There were 16 hospitals in the West Midlands region which represented 86.64% of 
the study population:  median age at surgery varied from 47 to 50 years, a small 
difference.  Ethnicity and deprivation, however, varied widely across the region. 
 
A key finding was the significant variability in coding of ethnicity data between 
hospitals.  Several recorded ethnicity for over 90% of their hysterectomy patients; 
however, three hospitals recorded it in less than 40% of women.  In one hospital 
there was a clear indication that miscoding was occurring as there were no ‘white’ 
women documented, as this hospital represented over 10% of the study population 
this may have had a bearing on the distribution across ethnic groups as invariably 
the largest proportion would have been white. 
 
The plan to use hospital histopathology laboratory data to supplement the main 
study database had to be abandoned, as outlined in sections 3.4.2 and 4.6, thus 
was disappointing but served to highlight the major disadvantages of data linkage 
studies and contextualised the difficulties that the NHS is currently having in drawing 
together all its various information technology resources.173 
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Operation type 
Operation specific OPCS codes were used to divide women according to the type of 
hysterectomy operation, i.e. total or sub-total.  A very small number (n=8, 0.13%) 
could not have this information established, even from close scrutiny of their HES 
records as the only code applied was a non-specific ‘hysterectomy’ code and no 
other code was present to confirm the presence of the cervix uteri in the pathology 
specimen.  All vaginal hysterectomies were assumed to be total as it is not possible 
to remove the body of the uterus vaginally without also removing the cervix. 
 
92.77% of operations were coded as total hysterectomies, fewer than had been 
anticipated from the UK literature, where rates of over 97% had previously been 
noted.1;2  Women having a total hysterectomy were a little older than those 
undergoing the sub-total variant (median: 48.88 vs. 45.16yrs, p<0.001) and were 
slightly more likely to be of White ethnicity than Black or Chinese, although numbers 
were small.   
 
There was no association with operation type and duration of post operative stay, 
with both groups having a median stay of 5 days after surgery which is consistent 
with the literature.1  There was no association detected between deprivation status 
and operation type, thus no suggestion that women from different backgrounds are 
receiving different standards of service from the NHS. 
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Final diagnosis at surgery 
The diagnosis at the time of hysterectomy was established using ICD10 codes.  For 
each woman the ‘worst’ of all codes was selected as the main diagnosis, this was 
then compared with the result of the index test and if the index result was 
significantly worse than the hospital diagnosis then the index result took 
precedence.  This was because it was possible that colposcopic treatment had 
occurred between hysterectomy and index test, thus treating the significant 
abnormality that would, otherwise have been removed at hysterectomy.  Only 28 
women had their final diagnosis changed this way and thus even if this additional 
cross-checking had not been undertaken there would have been little change in the 
study findings. 
 
A malignancy was recorded in 11.61% of the study population; higher than had 
been anticipated.  However, this also included non-gynaecological disease and may 
reflect the overall trend for using less invasive treatments for managing benign 
conditions.  Intraepithelial neoplasia or carcinoma-in-situ was present in 3.00%; 
somewhat lower than had been anticipated (see sample size calculations Chapter 
3.5.1), which may represent success of colposcopy clinic excision.  The vast 
majority of women (82.90%) had benign diagnoses and a further 2.51% could not be 
classified into a meaningful diagnostic category. 
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The three main diagnosis groups were compared and, as anticipated, women with a 
cancer diagnosis were older than the other groups.  Most gynaecological cancers 
increase in incidence with increasing age, in particular, endometrial and ovarian 
cancer tend to present after the menopause, and squamous cervical cancer usually 
takes several decades to develop.174   
 
The intraepithelial neoplasia group was younger than the larger group of women 
who had benign disease.  This may be because the benign group would include 
older women who would be having hysterectomy surgery as treatment for prolapse 
and peri-menopausal vaginal bleeding concerns, whereas women having a 
diagnosis of CIN are likely to have been detected by routine cervical screening. 
 
There were no clear associations detected between deprivation or ethnicity and 
diagnostic category, as small numbers made it difficult to make meaningful 
comparisons.  However, it did appear that white women may be more likely to have 
a malignancy than the other groups.  Women with cancer diagnoses tended to stay 
in hospital longer than the other groups (median 6 compared with 4 days).  This was 
not unexpected as surgery to remove a known or suspected cancer is usually more 
extensive or ‘radical’ than routine surgery. 
 
The last cervical cytology test before surgery (the index test) was compared with the 
overall diagnosis as it had been postulated that women having had abnormal 
cytology would be more likely to have hysterectomy operations for non-benign 
reasons.   
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Whilst there was a very clear association between having an abnormal index result 
and having a hysterectomy for non benign indications (Pearson χ2 = 1,612.528, 
p=<0.001) the level of disagreement between them was also significant (McNemar = 
433.246, p=<0.001), thus although related, the index test result is not suitable as a 
predictor of future surgical diagnosis. 
 
Full screening history was also compared with the final diagnosis.  Again, there 
were clear associations detected, with women who had never been tested or having 
only had one pre-operative screening test being more likely to have a cancer 
diagnosis.  It is possible that these were women who may have actively avoided 
attending for screening until presenting with symptoms.81  It is known that 50% of 
cervical cancer cases in the UK occur in women who have never attended for 
routine cervical screening.151  Conversely, women who had several abnormal 
cytology tests were more also more likely to have CIN or carcinoma in situ at 
surgery. 
 
There was no clear association noted between operation type and final diagnosis.  It 
had been postulated that women with a cancer diagnosis would be very unlikely to 
have subtotal surgery as the objective would usually be full clearance of disease 
and staging, but this hypothesis was not proven. 
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Multiple regression analysis was used to establish if there were any pre-operative 
‘patient’ factors associated with an increased likelihood of having a total rather than 
a sub-total hysterectomy:  several factors were included in the model (age, 
deprivation, index test result) and both age and an abnormal index test result were 
found to be positively associated.  However, the various associations only 
accounted for 3% of the total and as such they do not have a meaningful bearing on 
the outcome.  Thus, there must be other factors at work; patient factors (i.e. 
presence of concomitant disease or patient preference) or doctor related factors (i.e. 
individual surgeon’s preference, expertise, staffing etc.) that could not be 
established from this type of research project. 
 
 
7.3.4  Follow-up after surgery by means of vaginal vault cytology tests:  which 
women are tested? 
 
7.3.4.1  Overview of women having vault cytology 
One of the key study objectives was to establish which women are having post 
operative vaginal vault cytology testing (vault smear tests).  The flowchart, Figure 37 
(an abridged version of the one in section 6.4), illustrates the numbers of women in 
the various groups.   
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Figure 37.  Study participants, operation type and use of vault cytology 
 
 
 
The main sub-group of interest within this study were women having a total 
hysterectomy (n=5,697) and the numbers were large enough to permit meaningful 
comparisons.  Having sorted the data into operation type (total or subtotal) and the 
various diagnostic groups and presence or absence of post operative cytology, it 
was finally possible to establish which women were followed up by vault cytology 
and to allocate a coding based on how appropriate this follow-up was, according to 
national guidelines.   
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This ‘appropriateness coding’, based on national guidelines where they existed, 
factored in changes to the guidance over time.  In-depth inspection of the numbers; 
was undertaken; of particular note, only 13 of 181 women with CIN at surgery had 
follow-up exactly according to guidelines (two vault tests within two years of 
surgery), a further 11 had testing but results were abnormal and so correct 
screening interval could not be assessed. 
 
For statistical analysis a more simplistic approach was taken using the premise that 
national guidelines are correct and that follow-up after hysterectomy for benign 
reasons is never indicated, whereas follow-up after hysterectomy for CIN should be 
performed.  Guidelines that were released after the data collection period of this 
research, suggest that women who have had less than ten years of routine cytology 
prior to undergoing a total hysterectomy should have one vault cytology test post-
operatively.  However, as this change was introduced in 2006 it was deliberately not 
factored into the main analysis, but was considered briefly.  
 
Another change introduced in 2006 was that follow-up after CIN should comprise 
two tests within two years of surgery where the disease was completely excised 
(assuming all results normal), whereas previously the guidelines had stated two 
tests within 18-months of surgery.  A decision was taken to consider vault cytology 
within 24-months of surgery as being done according to guidelines; this was 
intended be inclusive and reasonable. 
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If CIN is detected in the margins of a hysterectomy specimen, then screening should 
continue.16  Our data did not reveal the detail of disease-free margins in 
histopathological specimens and it was not factored into the analysis.  Had the 
hospital histopathology data been more useful then this may have provided data on 
disease-free margins. 
 
Coding the ‘appropriateness’ of vault cytology could not be applied to women who 
had a total hysterectomy for malignancy as there were no national guidelines to be 
applied.  Follow-up is currently left to the discretion of the surgeon responsible for 
the surgery and often involves colposcopic examination of the vagina, with vault 
cytology and/or guided biopsy of suspicious lesions.  From these findings it would 
appear that there is no local consensus or recommended standard on follow-up 
after gynaecological malignancy as, for these 678 women with a cancer diagnosis, 
just 20.50% were followed up by vault cytology (n=139) compared to 62.98% of 
women who had CIN. 
 
 
7.3.4.2  Demographic factors 
The demographic characteristics of women who had any post operative testing 
performed were compared with those who did not and several differences were 
detected:  Women having any post operative cytology tended to be younger, less 
deprived, non-white and have a shorter duration of post operative stay than those 
who were not tested.   
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As these findings were somewhat surprising, the subgroup of just those women who 
had a total hysterectomy was selected as this was a more appropriate group of 
women who may be eligible for vault cytology and the analysis re-run.  Again all the 
observations held true:  non-white, less deprived, younger women who stayed in 
hospital for less time, than their counterparts, were more likely to have vaginal vault 
cytology testing (all p=<0.001). 
 
The reasons for these findings may be complex.  It is plausible, but not proven, that 
women who are less deprived may be more assertive in their requests for follow-up 
testing.  Certainly, screening uptake is higher in this population routinely so this 
observation may just reflect the underlying phenomenon.  The increased use of 
vault cytology in non-white women is less explicable as these women are known to 
be less inclined to participate in all screening programmes.175;176   
 
The association with shorter hospital stay and vault cytology was surprising, one 
would anticipate that the need for screening would be associated with worsening 
pathology and worse prognosis which are both known to be related to increased 
duration of hospital stay. 
 
The finding that younger women are more likely to have post-operative screening is 
less surprising, as there have been high level discussions, nationally and 
internationally, concerning the appropriate role for cervical screening in younger 
women.   
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Following the year of this study, a new guideline was released suggesting that 
women who had less than ten years screening prior to hysterectomy should have 
one vault test post operatively.  Thus, it is plausible that this recommendation was 
being implemented ad hoc, particularly by some well informed hospital clinicians, 
prior to national roll-out. 
 
 
7.3.4.3  Pre-operative screening history 
It was postulated that women who had abnormal index cytology tests could be more 
likely to have vault cytology undertaken, irrespective of their final operative 
diagnosis.  Analysis confirmed this with Pearsons χ2=345.399 (p=<0.001).  Women’s 
entire screening history was then compared with vault cytology status and again 
strong associations were detected:  Pearsons χ2=369.972 (p=<0.001).  Thus, 
women with entirely normal pre-operative cytology or women who never had any 
pre-operative testing were highly unlikely to be screened post operatively, whereas 
those who had some abnormal screening results were more likely to have vault 
cytology undertaken.   
 
When patterns of entire screening histories were compared with each other, several 
differences were observed:  women who had ever received an abnormal cervical 
cytology result were significantly more likely to have post operative vault cytology 
than women who only had normal cervical screening results, Pearsons χ2=224.024, 
(p=<0.001).  These findings are all consistent with clinicians attempting to follow 
screening guidelines.  
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7.3.4.4  Diagnosis at time of surgery 
When final diagnosis at time of surgery was compared with the likelihood of having 
a vault cytology test a very strong association was detected; Pearsons χ2=503.311 
(p=<0.001).  This finding was anticipated because national guidelines suggest a 
place for vault cytology following total hysterectomy for CIN.  However, this was the 
only recommended use for vaginal vault cytology in the UK at the time of the study. 
 
Thus, it was anticipated that the great majority of women having CIN at 
hysterectomy (n=181) would have at least two vault cytology tests done within two 
years of surgery.  However, only 114 (62.98%) of these women ever had any vault 
cytology within four years of surgery, and of these, only 13 (7.18%) had screening 
done precisely ‘to protocol’ (defined as 2 tests within 2 years, both results normal):  
50 women (27.62%) had too many tests performed, 16 (8.84%) had testing done but 
later than the recommended interval and 11 had abnormal findings at vault testing 
and so guidelines ceased to apply.   
 
It is possible that other ‘factors’ had a greater influence on likelihood of adherence to 
national guidelines and that the scope of this research did not cover them.  
Alternatively it may be that these women were having colposcopic assessment and 
vaginal biopsy rather than cytology testing.  
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Overall these findings were disappointing.  Of the group of women who were 
definitely eligible for vault cytology post operatively, although over 60% were 
screened, very few were screened according to national guidelines (per protocol).  
The very large group of women who had a benign diagnosis at surgery included 
over 9% who had at least one subsequent vault cytology test.  This would suggest 
significant waste, both in terms of the emotional cost of undergoing screening17 and 
also financial cost to the NHS.  These observations are consistent with previously 
completed audit work by the author28 and confirm that there are ongoing problems 
with inappropriate over-use and under-use of vault cytology testing. 
 
It is not uncommon for guidelines to fail in practice177;178 however there are a range 
of evidence based, established strategies that may be adopted to maximise 
adoption of best practice.106;179  The guidelines for use of vault cytology are 
complex84 and changes introduced in 2004 were not disseminated effectively 
throughout the UK, thus it should not be surprising that they are not being adhered 
to. 
 
7.3.4.5  Patient factors associated with having vault cytology 
Multiple logistic regression analysis was undertaken in an attempt to establish which 
of the ‘patient factors’ had a significant bearing on whether or not a woman who had 
a total hysterectomy subsequently underwent any vault cytology screening.  
Younger age, less deprivation (lower IMD07 score), operative diagnosis (CIN or 
cancer) and abnormal result of the index test were all significantly associated with 
an increased likelihood of a woman subsequently having vault cytology.   
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Some of these findings had been anticipated i.e. result at operative diagnosis and 
index test result.  However, age and deprivation were somewhat surprising, 
although the odds ratios for these (age = 0.982, deprivation = 1.019) indicate that 
although potentially ‘significant’ in statistical terms, in reality their impact will be very 
small as their usefulness in clinical practice is doubtful. 
 
To explore possible ‘external’ factors influencing the likelihood of a woman having 
vault cytology, the hospital of the surgery was investigated and a clear association 
was detected (Pearson χ2=159.224 (15df, p=<0.001).  The percentage of women at 
each hospital subsequently having vault cytology ranged from 5.1% in a small 
hospital (137 hysterectomy operations in one year) to 25.7% in a large tertiary 
centre which would be anticipated to deal with a higher proportion of malignancies. 
 
However, there were several gaps in the hospitals data, with three major hospitals in 
the area not having any women coded as having had surgery there, which was 
probably a coding mismatch at HES.  Other women had surgery performed outside 
the West Midlands region or had invalid hospital codes.  There were too many 
institutions to permit the use of logistic regression analysis effectively and as such 
this is an area that may benefit from further research. 
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7.3.4.6  Factors associated with adherence to national screening guidelines 
 
In addition to establishing which women are having any vault cytology testing it was 
essential, for the study aims, to establish if national screening guidelines were being 
followed closely (adherence) and if the vault testing that took place was occurring 
according to protocol (appropriateness). 
 
National guidelines16 apply to those women having had a total hysterectomy for 
benign disease or for CIN, and where their test results are always normal the 
guidelines are clear and these two groups were explored.  However, if abnormalities 
are detected at vault testing the guidelines are not specific about the next steps that 
should be taken.  Thus, in the analysis, an uncertain classification was used for 
women who had post operative vault cytology where the results were inadequate, 
borderline or confusing or where guidelines could not be applied.  Additionally, there 
are no national guidelines concerning follow-up after malignant disease with vault 
cytology and so an assessment of appropriateness in these cases could not be 
made. 
 
National guidelines have been modified since the data collection period of this study 
(2004).89  Thus the decision as to whether or not a woman had been screened 
‘appropriately’ was based on the guidelines that were in place at the time of 
hysterectomy and the two subsequent years, rather that those currently in use.  
However, even if the analysis had been based on the latest guidelines there would 
have been little impact on the overall findings:   
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1.  Follow-up after hysterectomy with diagnosis of CIN 
Logistic regression analysis was undertaken and suggested that only the presence 
of an abnormal index test prior to hysterectomy was a statistically important 
predictor of having appropriate vault cytology testing and even this only made a very 
small difference, odds ratio of 3.14 but Nagelkerke R2 = 0.11 and a final fitted model 
of 67.6% with the starting point of 64.8%.   
 
2.  Follow-up after hysterectomy with benign diagnosis 
Following hysterectomy for benign disease, guidelines explicitly specify that vault 
cytology is not indicated.  However, of those women who had a total hysterectomy 
with benign results (n=4,695), 439 went on to have subsequent testing (9.35%).  
The overwhelming majority of these tested women (n=376 from 439) only ever had 
negative vault cytology, of these 23 had more than two tests taken. 
 
Logistic regression analysis was then run on just those women who had 
inappropriate vault cytology performed and it revealed several factors to be related 
to an increased likelihood of inappropriate use:  younger age, higher deprivation 
score (thus being less deprived), and the presence of an abnormal index test result, 
despite having benign diagnosis at surgery.  However, only the presence of an 
abnormal index test result had an odds ratio of greater then 1.5 and with Nagelkerke 
R2 = 0.048 and a final fitted model of 90.3% but unchanged from the starting point, 
thus the clinical significance and application of these findings is questionable.  There 
are clearly other non-patient factors at work which this study was not designed to 
explore.  
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7.3.4.7  Factors associated with having an abnormal vault cytology test result 
To establish the true value of vault cytology and make recommendations about its 
usefulness, it was important to distinguish between those women having normal and 
abnormal vault test results.   
 
Less than 3% of the vault tests returned an abnormal result; these were not related 
to age, deprivation, ethnicity or duration of hospital stay.  The only notable 
association was between the main operative diagnosis with those women who had 
cancers or CIN being more likely to return an abnormal vault cytology test result 
than women having a benign diagnosis (p=<0.001).  Thus current national 
guidelines, which target women who had CIN at hysterectomy, are supported by 
these findings.  This is the first UK study to establish this association. 
 
For women who had benign disease at hysterectomy and who had vault cytology 
(439), six had at least one abnormal vault test result (1.37%), however, 57 (12.98%) 
had results of uncertain significance.  Unlike those women with normal results 
where most only had the one test done, 46 of the women with ‘uncertain’ results had 
further testing done. 
 
The women who underwent a hysterectomy for malignant indications did not have 
any applicable national guidelines concerning their follow-up.  Thus, it was the 
responsibility of their consultant to determine whether or not vault cytology should 
be undertaken.   
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This study was not powered to look at cancer cases, however observations were 
made:  of the 135 women followed-up after a cancer was detected at surgery, only 
two (1.48%) had clearly abnormal results, 33 (24.44%) had results of uncertain 
significance and the great majority (74.07%) only ever had normal results.   
 
Without access to reliably linked hospital data it is not possible to assess the 
accuracy of the vault cytology findings, however, the increasing presence of results 
of uncertain significance with worsening diagnosis does bear further investigation. 
 
The systematic review undertaken by the author24 concluded that there is no 
demonstrable benefit in screening after hysterectomy for benign disease, the 
findings of this study support this, with very low rates of disease detection in those 
screened.  However in the absence of histopathology laboratory data or a case 
notes review to verify these results, some uncertainty remains.  The systematic 
review suggested that there is no evidence to suggest changing guidelines with 
respect to screening after CIN I/II, this study confirms this assertion as there were 
more abnormalities detected in this population. 
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7.4  SUMMARY OF STUDY FINDINGS  
 
Thus, this study has demonstrated that hysterectomy is still undertaken frequently 
and is not limited to certain ethnic groups.  There is no apparent age limit applied to 
women being able to undergo this major operation, although the 40-60 years range 
remains the most likely time for surgery, corresponding with the climacteric stage in 
a woman’s life. 
 
There was a clear association between hysterectomy and social disadvantage in 
England, with a significantly higher hysterectomy rate in those women living in more 
deprived areas. 
 
All major surgery carries risk; the in-patient death rate within this population was 1 
per 1,000 women having surgery for benign indications and 7 per 1,000 for women 
having malignant disease.  These are higher than current published RCOG figures. 
 
The great majority of women who have a hysterectomy will have had cervical 
screening at some time prior to surgery; usually they will have had more screening 
tests performed than the general population at any given age.  Younger women and 
those from White and Asian backgrounds had more testing that those from other 
ethnic backgrounds.  Younger women and those from more deprived areas were 
most likely to have had a history of abnormal cervical cytology. 
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Hysterectomy is known to be routinely carried out at 19 different hospitals across 
the West Midlands; individual surgeons ranged from performing just one or two 
procedures to over 150 procedures annually.  Sub-total hysterectomy was 
performed in over 7% of operations, significantly more than previous studies have 
shown, thus it would appear that this variant is being used more frequently.  Sub-
total surgery was used in younger women of Black or Chinese origin more 
frequently than in White women, however, there were no other associations with 
operation type.  Duration of post operative stay was not associated with operation 
variant. 
 
A malignancy was found in 11.61% of the study cohort, a higher proportion than was 
anticipated.  This may reflect an overall decrease in use of hysterectomy as a 
treatment for benign conditions, rather than a real increase in cases of malignant 
disease.  Malignancies tended to be found in older women, with CIN being found in 
the younger women; consistent with the natural history of these diseases.  
Diagnosis was not associated with deprivation or ethnicity. 
 
Logistic regression analysis of the factors associated with use of vault cytology post 
hysterectomy confirmed that post-operative vaginal vault cytology testing was 
undertaken more frequently in non-white, less deprived, younger women who 
stayed in hospital for a shorter period than their counterparts.  The reasons for these 
findings may be complex and require further research to understand and confirm.   
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Of the women eligible for vault cytology according to national guidelines, although 
over 60% are screened at some point, very few are screened exactly according to 
the specified protocol.   
 
A substantial minority of women who underwent a total hysterectomy for benign 
indications had vault cytology tests performed (9.35%, n=439), confirming that there 
is widespread inappropriate use of this test.  Women followed-up after malignant 
disease do not usually have vault cytology testing performed, but there is wide 
variation between hospitals with a range of 4.9 to 25.7% being followed up in this 
way.  This may reflect the lack of national guidelines or disagreement between 
specialists as to the value of the test. 
 
Logistic regression analysis of the factors associated with adherence to national 
guidelines, concerning vault cytology post hysterectomy for CIN, revealed that it is 
only the presence of an abnormal cervical screening test prior to surgery (the index 
test) that really influences this behaviour.  In women who had benign disease, 
inappropriate use of vault testing was more common in younger, less deprived 
women, in addition to those having had an abnormal index test result.  Non-
adherence to national guidelines is of concern but is consistent with findings from 
other research.106 
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Women who had CIN at surgery did appear more likely to have abnormal vault 
cytology results than those having benign diagnoses, suggesting that the national 
guidelines are targeting the right women. 
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7.5  RECOMMENDATIONS 
 
The findings of this study suggest that further research needs to be undertaken in 
several areas of uncertainty:   
 
Investigation into the accuracy of data concerning the ethnic distribution of 
hysterectomy could be explored by looking at more recent cohorts of HES data and 
linking it with one of the Primary Care databases which now routinely code ethnicity 
data.112   
 
 Hospital’s histopathology laboratory data should provide a rich source of research 
information if it can be linked with other electronic databases, if permission can be 
granted to use other patient identifiers this should be revisited.  When hospitals 
throughout the NHS embrace NHS number and standardise their coding of samples, 
this type of research could be undertaken successfully and in future will provide 
valuable comparisons for assessing the validity of HES and Exeter data recording. 
 
The demographic data presented has identified variability in the type of women 
having hysterectomy operations (deprivation and ethnicity).  Thus a larger scale 
study just considering HES data, perhaps spanning several years of data for the 
whole of the UK, would provide a rich data source and would confirm or refute these 
new observations. 
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Use of the WMCIU algorithm provided a standardised way of categorising women’s 
entire cervical screening history and it is suggested that this software should be 
used in future work of this nature:  this will allow for close analysis of cases and 
permit comparisons.  Further work, considering in some detail the cancer cases 
detected within this cohort, and using the algorithm, may generate valuable new 
associations for gynaecological and other malignancies in women. 
 
The unexpected finding that over 7% of hysterectomy operations leave some or all 
of the cervix in-situ deserves further investigation.  Thus a larger, more up to date, 
anonymous HES cohort could be identified (i.e. all of England) to see if this is a real 
change in practice and then look for confirmation of the associations with age and 
deprivation.  Additionally diagnosis should be investigated to see if this is related to 
having sub-total surgery.  With an increasingly obese society it is possible that 
physical patient factors could be a cause of the increase i.e. it is technically 
challenging and can prolong surgery to remove the cervix at the time of an 
abdominal hysterectomy in a very large patient.  To investigate this hypothesis it 
would be necessary to link HES data for sub-total hysterectomies with one of the 
primary care research databases. 
 
The finding of a higher rate of in-patient deaths than the published figures is a cause 
for concern and deserves urgent investigation.  To do this a further, up to date, large 
HES extract would need to be obtained but this time data concerning deaths could 
be requested from the General Register Office of the Home Office, based at 
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Southport, Liverpool.  Additionally a case-notes review of these cases could provide 
valuable data and identify the highest risk cases.  
 
Further research needs to be undertaken to examine the reasons why less 
deprived, younger women are more likely to have vaginal vault cytology post-
hysterectomy.  Additionally, it would be helpful to establish if there are any individual 
surgeon or hospital specific factors at work in determining which women undergo 
vault cytology and how appropriate this is. 
 
Having an abnormal vault cytology test result appears to be associated with 
worsening diagnosis at hysterectomy.  This result is intuitively correct but few 
studies have examined this subject in the past 15 years and as such ongoing audit 
of vault cytology will be helpful in confirming or refuting the findings of this study. 
 
Finally, it would appear that there is considerable confusion over the use of vaginal 
vault cytology testing and there is an argument that, where such uncertainty exists, 
the clinician responsible for the hysterectomy should have responsibility for any 
ongoing follow-up and thus vault cytology testing should become a secondary care 
initiated investigation, if it is used at all. 
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CHAPTER EIGHT:  CONCLUSIONS 
 
INTRODUCTION TO CHAPTER 
This concluding chapter summarises the important study findings whilst reminding 
the reader of the limitations and generalisability of this study then finally making 
recommendations for clinical practice and future research opportunities. 
 
 
8.1  SUMMARY OF FINDINGS 
 
Removal of the uterus is an operation that has been remarkably successful as a 
means of managing a diverse range of malignant and benign conditions affecting 
women.4;32  Although new technologies and techniques have been introduced that 
are replacing hysterectomy in some circumstances, it is still the most frequently 
performed major surgical procedure on women in the UK, North America, Australia 
and throughout Europe.53;54  
 
Cervical cytology screening has been highly successful in reducing the incidence of 
cervical cancer in those countries that have adopted it.  The UK has a national 
programme (NHSCSP) which is one of the most successful in the world; this is 
because it is free at the point of access, achieves full population coverage and has 
high uptake rates.15;66   
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However, use of vaginal vault cytology as a screening test in women following a 
total hysterectomy is only recommended for highly selected populations, as vaginal 
cancer is too rare to justify an organised screening programme.24  
 
It has been suggested that some vaginal vault cytology testing is being undertaken 
inappropriately, particularly in primary care,28 and so this study aimed to identify a 
cohort of women undergoing a hysterectomy and consider their entire screening 
history both before surgery and subsequently.127  The aims of this study were 
established as: 
 
 Primary:  to describe the variation in hysterectomy rates and subsequent 
follow-up by use of the vaginal vault cytology test in the West Midlands 
region. 
 Secondary:  to inform the development of national guidelines by generating 
high-quality evidence about current practice with respect to vaginal vault 
cytology. 
 
A pragmatic record linkage study was designed so that a cohort of women, having 
undergone a hysterectomy, could be identified from Hospital Episode Statistics.  
Then, their entire screening histories could be obtained from Open Exeter and 
merged with these data, supplementary data being obtained from individual 
histopathology laboratories where possible, using linkage techniques.  Thus 
routinely collected, high quality, patient data could be utilised without the need for 
individual patient consent.   
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The database was to be anonymised as soon as practicable after linkage, and 
before any analysis occurred to minimise the potential for any harm to patients from 
this transient breach of confidentiality. 
 
It transpired that HES and Exeter were rich sources of comprehensive, robust data.  
However, a combination of the PIAG stipulation that only NHS number could be 
used for linkage, inter-hospital variability and lack of reliable use of NHS number 
through the region, rendered the hospital data unsuitable for any more than very 
superficial description.   The final study dataset was cleaned and validated and 
contained data on 6,141 women from the West Midlands region who underwent a 
hysterectomy operation, their entire cervical screening records prior to surgery and 
any cytology results in the four years after surgery.   
 
The findings from this study are now summarised according to the original study 
objectives. 
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1.  To estimate incidence rates for hysterectomy operations in the West 
Midlands region of the UK 
 
The overall study demographics revealed an incidence of hysterectomy of 23 per 
10,000 women per annum, and a median age of surgery of 48 years with a wide 
range of 17 to 94 years.   
 
This incidence rate was lower than previous estimates1 but is consistent with a 
reduction in the use of hysterectomy for the management of some benign 
conditions, and still makes it a very commonly undertaken operation.  The average 
GP surgery of 6,000 patients will thus expect an average of seven women each year 
to have the operation.   
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2.  To describe variations in incidence of hysterectomy and establish those 
factors associated with variability 
 
The patient factors that were considered most likely to cause variability included 
age, deprivation, ethnicity and pre-existing medical problems including abnormal 
cervical screening and co-morbidities.  External factors that were considered most 
likely to influence incidence were hospital and surgeon of treatment.  Numbers were 
too small to investigate choice of surgeon and data was very limited on co-
morbidities but the other factors were explored. 
 
There was a very wide variation in hysterectomy incidence by age, with a peak 
incidence of 63 per 10,000 in the 45-49 years group, corresponding with the time of 
the menopause transition.  This was not surprising and was consistent with previous 
research findings.1  Age standardisation did not make any meaningful difference. 
 
The study population was significantly more deprived (IMD) than the population of 
England with 27% of the study population in the most deprived quintile and 14% in 
the least deprived.  However, deprivation scores were very similar to those for the 
West Midlands region,158 which is itself somewhat more deprived than England 
overall.  Age standardised incidence rates for hysterectomy varied significantly by 
deprivation score:  those most deprived had an incidence rate of 25 per 10,000, 
compared with 20, per 10,000 in the least deprived quintile.   
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These findings suggest that women in more deprived areas may have greater 
morbidity or receive a different standard of gynaecological care than those from less 
deprived areas, which is compatible with previous studies.12   
 
Ethnicity data, although only available for two thirds of the population, indicated that 
the study population had some differences from the background population of the 
West Midlands region.  Black women (encompassing Caribbean, African and other 
Black groups) had an incidence was as high as 33 per 10,000.  White women were 
the great majority and had an incidence of 23 per 10,000 (same as the overall 
population), in Chinese and mixed races numbers were too small to permit 
meaningful comment. 
 
Ten women died during their hospital admission, five of whom had malignant 
disease.  This represented 0.16% of the study population or a mortality rate of 1.6 
per 1,000 hysterectomy operations, however when separated by underlying 
diagnosis the mortality rates became 7 per 1,000 for hysterectomy in cases of 
malignancy and 1 per 1,000 for benign indications, which is still higher than the 
quoted incidence.9  This area requires further investigation. 
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3.  To describe cervical screening patterns prior to hysterectomy 
 
Preoperative cervical screening was undertaken on 5,787 women (94.23%) thus the 
great majority of the study population.  Those women who were ‘ever’ tested 
underwent a median of five tests each, although this varied significantly by age.  
One in six of the whole cohort subsequently had some post operative cytology.   
 
The result of the last cervical screening test before hysterectomy (the index test), 
was of interest with results suggesting cancer being more common in younger 
women and abnormal test results being more likely in women living in more 
deprived regions.  Ethnicity was not associated with index test result although being 
of a nationality other than White British was associated with never having attended 
for cervical screening. 
 
The index test was considered for use as a predictor of future diagnosis at surgery 
but, although obviously associated with operative findings, it is not sensitive or 
specific. 
 
The application of a complex coding algorithm, from the WMQARC, to the study 
data, allowed entire screening histories to be classified and compared.  The findings 
of this corroborated the data on deprivation and ethnicity even though the groups 
were created slightly differently from those using the raw study data. 
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4.  To describe the current indications for hysterectomy in West Midlands 
 
Malignant disease accounted for 11.6% of the study population, 3.0% for 
intraepithelial neoplasia but the great majority had surgery for benign indications 
(82.9%).  Women frequently had several diagnoses documented but for the study 
purposes the ‘worst’ of these was used.   CIN was noted more frequently in younger 
women. 
 
Women with malignant disease were more likely to be white and were significantly 
older than the rest of the study population.  Regression analysis of those factors 
associated with having a total or subtotal type of hysterectomy revealed significant 
associations with age and result of the index test, however these only accounted for 
a small proportion of the total and thus other factors may be more important, 
however, investigating these was beyond the scope of this study. 
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5.  To establish the current pattern of follow-up after total hysterectomy by 
means of vaginal vault cytology test 
 
Dividing the study participants according to hysterectomy type (using OPCS codes) 
allowed post operative cytology to be classified as vault cytology or continued 
cervical screening.  Total hysterectomy was performed in 92.77% 
 
The women who had total hysterectomies were considered further:  vault cytology 
was undertaken on 9.35% of women who had benign disease, this was clearly 
inappropriate.  Of women having a hysterectomy for carcinoma in situ or CIN, only 
63% had any vault cytology, thus in the one group of women who are explicitly 
recommended to have some post operative testing, over a third did not have any.   
 
Operative diagnosis was confirmed as the strongest predictor of having any vault 
cytology.  Women who had vault cytology undertaken were more likely to be 
younger, less deprived and non-White than those who did not have vault testing.  
Having an abnormal index test result was clearly associated with having post 
operative cytology as was having a history of any abnormal cytology preoperatively. 
 
Logistic regression analysis of ‘patient factors’ demonstrated that although age and 
deprivation score were associated with having vault cytology, the odds ratios were 
very small and the clinical usefulness of this observation is doubtful.  Hospital of 
surgery was also a significant ‘external’ factor but overall impacted little on the fitted 
model. 
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6.  To assess if vaginal vault cytology is being undertaken appropriately and 
establish those factors associated with inappropriate usage 
 
Women having a hysterectomy for CIN were scrutinised:  in addition to those not 
being tested at all (thus inappropriately not being tested), of those who were tested 
24 only had one test (too little testing), 16 had two tests but over too great a time 
frame (too infrequent), 50 had more than two consecutive normal results (excessive 
testing) and just 13 (7.18%) were followed-up exactly in accordance with the 
national guidelines.16  Thus, there was ample evidence of inappropriate over and 
under-use of vault cytology testing, even in the group of women that guidelines 
specifically single out for testing. 
 
When those women having a hysterectomy for benign disease were considered 
closely, and the latest guidance applied, (including the suggestion that vault 
cytology be undertaken if a woman has less than 10 years of pre-hysterectomy 
cervical screening) the proportions having inappropriate testing increased, with 
inappropriate screening in 721 of 4,695 = 15.36% (407 tested completely 
inappropriately, 298 not tested who could have been, 16 correctly had one test but 
then had further testing with normal results).89   
 
Regression analysis of those factors associated with inappropriate usage of vault 
cytology only identified index test result as being clinically important although age 
and deprivation score were related.   
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7.  To describe the results of vaginal vault cytology with respect to histology 
at hysterectomy and establish those factors associated with having an 
abnormal result 
 
With only 21 definitely abnormal vault test results (2.93%) in 717 women it was not 
possible to draw firm conclusions concerning factors predictive of abnormal vault 
cytology and regression analysis could not be undertaken.  The only factor clearly 
associated with an abnormal vault result was diagnosis at hysterectomy, with CIN or 
cancer being related to subsequent abnormal vault cytology.  
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8.  Additional findings of interest, supplementary to the original study aims 
 
HES and Open Exeter Linkage:  This study confirmed that linkage can be reliably 
undertaken even if just NHS number is available to the researcher, as a high ratio of 
perfect matching will be found.  Thus future projects may seek to just use this 
identifier to minimise breach of patient confidentiality, reduce beurocracy and limit 
costs.  Further research concerning data linkage studies would be facilitated by 
streamlining of ethical approvals processes, researchers contemplating similar 
research should be mindful of the many permissions required to obtain confidential 
data without explicit patient consent. 
 
Hospital pathology laboratory data:  This was a rich source of information but was 
difficult to translate between institutions, caution is recommended to researchers 
contemplating projects that may necessitate merging of data from a variety of 
hospitals that do not have similar software and coding standards.  In future this 
problem should be overcome by improvements and standards of NHS IT systems.  
Further research is recommended but with the caveat that more patient identifiers 
can be used for validation. 
 
West Midlands QARC Screening history algorithm:  This novel, bespoke software 
has the potential to standardise summarising entire cervical screening histories and 
has potential to be developed for other applications.  With only minor modification it 
was successfully used to code entire screening histories prior to hysterectomy and 
as such will allow for future collaborative research. 
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Inter-hospital variation:  This accounted for some of the poor ethnicity data with a 
few hospitals clearly using invalid coding whereas others had up to 98% of women’s 
ethnicity recorded.  This is an area that should be improved in future as accurate 
ethnicity recoding in NHS records has become a higher priority recently.   
 
Operation type:  This was established for all but eight of the participants; sub-total 
surgery was more common than had been anticipated and this was particularly 
noticeable in younger women and women of non-White ethnicity.  The reasons for 
this increase are not clear and warrant further study. 
 
Death rate:  During their hospital admission ten women died; a mortality rate of 16 
per 10,000 hysterectomy operations or one per 625 cases.  However, when split by 
diagnosis, five deaths were in women having a benign disease giving a mortality of 
five in 5,090 or one per 1,000, this is significantly worse than RCOG published risks 
of hysterectomy at one death in 4,000 operations.  For malignant disease it was five 
in 713, or seven per thousand.  There were no deaths in cases of CIN but numbers 
were small.  These findings warrant further investigation as a matter of urgency. 
 
Duration of post operative stay:  With a median of five and mode of four days, this 
was unremarkable.  However, data suggesting that 1.7% of women were sent home 
on the same day as major surgery requires further investigation.  This may 
represent miscoding or the fact that women were actually transferred to another 
hospital to recuperate (although this was not documented appropriately).  
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If some women are being discharged home quickly this has implications for practice 
and if demonstrated to be a safe option (with the appropriate clinical safeguards), 
this has the potential for increased throughput of patients. 
 
Overview of results 
Data linkage of confidential routinely collected data is possible but requires multiple 
ethical approvals.  Analysis of the study dataset confirms that hysterectomy is still 
commonly performed for a wide range of indications in the West Midlands.  Ethnicity 
and deprivation of the patient have some associations with incidence of surgery 
(higher incidence in Black women and women who are more deprived).   
 
Mortality appears to be worse than the currently quoted risks from surgery, at one 
death in 1,000 operations; this finding requires further validation and it is important 
that patient information and pre-operative consent should be amended to 
incorporate this figure if found to be accurate.   
 
Results from a woman’s preoperative screening history are associated with her 
likelihood of having subsequent post-operative vault cytology testing.  Typically 
women had a median of five cervical screening tests prior to hysterectomy.   
 
It has been confirmed that vault cytology testing is being undertaken inappropriately 
in a significant proportion of cases and national guidelines are not being followed 
closely.   
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For women with benign indications for surgery, over-testing was a concern, for 
those having CIN then testing too infrequently or not at all was the issue.  For 
women who had malignancy at the time of hysterectomy there was significant 
variation in the numbers who were followed up by vault cytology suggesting that 
there is no consensus amongst gynaecologists about the role of this test. 
 
Less than 3% of all women who underwent vault cytology ever had any abnormal 
results.  Thus the test is only detecting abnormality in a small proportion of women 
which reinforces concern about its usefulness or appropriateness of application. 
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8.2  CONCLUDING OBSERVATIONS 
 
Cervical screening 
Use of WMQARC algorithm for the classification of entire screening histories should 
become the gold standard for future research and audit in this field.  This will allow 
for valid comparisons between populations and make interpretation of study findings 
more generalisable. 
 
The high quality data contained in the Open Exeter system is a rich resource for 
research and, if it can be made more accessible by improvements to the software or 
transferring the data to a more ‘user-friendly’ format, then the usefulness outputs 
could be increased significantly. 
 
The UK cervical screening programme is a ‘jewel in the crown’ of the NHS and is an 
excellent demonstration of the positive impact that a well organised and funded 
screening programme may have.  However, success in one programme does not 
guarantee success in all areas and any potential screening test must fulfil many 
established criteria before it should be used.  
 
Use of vaginal vault cytology is currently outside the remit of NHSCSP; however, by 
suggesting a place for its use in its published guidelines, the NHSCSP has taken on 
responsibility for providing the highest standard of evidence based guidance to 
healthcare professionals.  There is clear evidence that these guidelines, like many 
others, are not being adhered to, this may be due, in part, to their complexity. 
  
- 346 - 
Hysterectomy 
Hysterectomy has been demonstrated to be declining in popularity.  This is likely to 
reflect the introduction of minimally invasive surgical techniques, less destructive 
endovascular treatments and an increase in pharmacological treatment options over 
the past three decades. 
 
Notwithstanding, the average GP surgery still has seven cases per annum 
(23/10,000 women pa) and in areas with of high density of women of Black ethnicity 
or a higher than usual proportion of peri-menopausal women, this incidence may be 
substantially greater. 
 
The death rate in women having hysterectomy is not insignificant:  1 per 1,000 
women having the operation for benign indications and 7 per 1,000 for those with 
malignancy.  These are higher than the quoted RCOG figures9 and this finding 
requires closer inspection as a matter of urgency so that in future women are 
realistically informed, prior to surgery, of the potential risks involved.  The presence 
of disseminated malignancy and significant co-morbidity obviously increase the risks 
of any surgery and if these women were excluded from this study then the mortality 
rates would be closer to the quoted figures, but still show a four-fold increase. 
 
Subtotal hysterectomy seems to be increasing in popularity in UK, a somewhat odd 
finding which does not have a good scientific backing.   
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Thus, this area requires further investigation to establish the reasons behind this 
observation:  are certain hospitals or individual specialists expressing their 
preference or is this a reflection of increased patient choice?  If this is a reflection of 
patient preference, then are women making a fully informed choice or is there a 
media driven effect?  Is it because patients are becoming increasingly obese and 
thus surgery is technically more challenging?  This topic should ideally be explored 
using qualitative methodologies; possibly starting with a questionnaire survey of 
women who had recently underwent a hysterectomy, then purposively interviewing 
those who had researched the subject or made a conscious decision to have a 
certain variant of the operation.  
 
 
Vault cytology 
This study has confirmed that vault cytology tests have a low rate of detection of 
abnormalities and makes a poor screening test as vaginal cancer is very rare.  
Cytological testing of the vaginal vault was never intended by Papanicolaou, when 
he developed his technique for examining a scraping of endothelial cells from the 
transformation zone of the cervix.73  More recently, the introduction of liquid based 
cytology techniques for analysing samples has exacerbated the situation as modern 
‘soft brush’ sampling devices are even less useful to obtain samples from the ill 
defined vaginal vault than the ‘extended tip’ Aylesbury spatula. 
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The study has confirmed that the national guidelines concerning vault cytology are 
not being closely adhered to by clinicians, even in women who may benefit from 
some form of follow-up.  
 
For women with a malignant diagnosis, opinion amongst gynaecologists is obviously 
divided as less than 20% of this population receive cytological follow-up.  If the test 
was felt by specialists to be of use then a significantly larger proportion of these 
women would have been expected to have undergone testing. 
 
To definitively answer the question of the value of vaginal vault cytology would 
require a very large prospective cohort study of women followed up for decades.  
This is unlikely to ever be possible in view of the extremely high cost of such studies 
and the limited potential benefit.  Thus, this study as a pragmatic alternative should 
be used to guide policy makers in the future. 
 
Further cost effective research, building on these findings, could include several 
areas:  it would be helpful to know what gynaecologists and primary healthcare 
professionals think is appropriate and would like to see happening with respect to 
follow-up after hysterectomy.  This could be achieved with a combination of 
questionnaire surveys and interviews.   
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In this climate of valuing patient choice, it is surprising that the literature does not 
address the issue of whether or not patients would value post operative testing.  
Thus, the viewpoint of patients having hysterectomy, for a variety of conditions, 
concerning their subsequent follow-up, should be sought.   
 
Given that vaginal vault cytology: is being used inappropriately (both over and under 
use) suggesting confusion by clinicians; has low rates of disease detection; 
sampling methods are no longer routinely taught to primary care clinicians at 
training updates and liquid based cytology techniques are not designed to facilitate 
adequate sample collection.  It is recommended that vaginal vault cytology should 
no longer be routinely undertaken in primary care.  
 
Instead, it is time for specialists responsible for undertaking hysterectomy 
operations to acknowledge the limitations of the test and to retain clinical 
responsibility for any ongoing surveillance.  Thus, the clinician undertaking or 
supervising the original operation will have a full picture of the individual patient and 
their risks and can weigh-up all these factors.  Additionally, if follow-up is undertaken 
via colposcopy services then the vaginal vault can be examined closely by the 
colposcope and stained to identify high risk areas for more accurate sampling or 
biopsy. 
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It would be helpful, to all responsible for undertaking cervical and vault cytology 
testing in both primary and secondary care, if the national guidelines were to be 
revised and amended to take account of this research and the suggestions herein.   
 
Thus, unnecessary testing could be minimised with consequent savings to women 
and the NHS:  psychological, physical and economic.  Additionally, those women 
who may genuinely benefit from ongoing vaginal vault cytological surveillance will 
receive more appropriate clinical care. 
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ABSTRACT 
 
Background:  Vaginal vault smears are used to detect persisting neoplasia of the 
lower genital tract after hysterectomy. Recent data suggest both widespread use 
and uncertain evidence of their effectiveness.  
 
Objectives:  To identify and synthesise evidence on the use and effectiveness of 
vaginal vault smears and to assess the quality. 
 
Search Strategy:  'vault smear’ OR  ‘vaginal vault smear’ OR ‘cervical vault smear’ 
OR (‘Hysterectomy’) AND (‘Follow up’ OR ‘Smear’). 
 
Selection Criteria:  Primary research, women who had a hysterectomy and were 
followed up by vault cytology. 
 
Data Collection and Analysis:  Systematic search (8 electronic databases), 
supplemented by contact with experts and review of bibliographies. Two 
independent reviewers determined eligibility/validity and extracted data concerning 
test performance characteristics. Quality was assessed according to established 
criteria. 
 
Results:  441 unique references, only 19 suitable. Quality of studies varied 
considerably and few were of ‘high’ methodological quality. Studies were 
geographically diverse and published over 40-years in 16 journals. From the higher 
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scoring papers there were 11 656 hysterectomies (6 546=benign, 76=CINI/CINII, 5 
037=CINIII). Proportions of abnormal vault smears and abnormal biopsies during 
follow-up increased with worsening histology at hysterectomy (p<0.0001 and 
p=0.0001). There was only one report of vaginal cancer subsequent to 
hysterectomy for CIN and insufficient data to allow for reliable meta-analysis. 
 
Conclusions:  Vault smears cause anxiety, consume resources and their value is 
largely unproven. Inconsistency of study design and limited methodological quality 
means that the value of vault smears could not be established. High quality 
research is required to ensure that guidelines are evidence based.  
 
 
Key Words:  Systematic Review; Vaginal vault smear 
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INTRODUCTION  
It has been suggested that too many vaginal vault smears are being undertaken 
both in the USA1 and the United Kingdom.2 The value of this test, in the follow-up of 
women after hysterectomy, has not been established and guidelines are based 
upon consensus opinion. 
 
By the age of 65 the proportion of women having a hysterectomy reaches a third in 
the USA3 and 20% in the UK (60 000 procedures annually).4 Subtotal surgery 
(sparing the cervix) is undertaken in less than 3% of the hysterectomies performed 
in the UK.5 Total hysterectomy includes removal of the cervix-uteri leaving the 
vagina as a blind ending pouch; since the cervix has been removed there is no 
possibility of the development of a primary cervical cancer and thus no indication for 
routine cervical screening. Papanicolaou (Pap) smear tests6 of the vaginal vault are 
a means of detecting recurrent invasive or pre-invasive disease of the lower female 
genital tract in women who do not have a cervix-uteri.7 
 
Benign indications (e.g. excessive bleeding or fibroid disease) account for over 90% 
of hysterectomies in the UK.5 The proportion of hysterectomies performed for 
cancer or pre-cancerous lesions has been reported to range from 6-10%.8 After 
surgery, current policy in the UK is to follow-up with vaginal vault smears those 
women who have had a hysterectomy for high-grade pre-invasive disease of the 
cervix.9  However, recent work suggests that practice varies amongst clinicians and 
many additional women may receive follow-up smears.2 
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The purpose of undertaking vault smears on asymptomatic women who had no 
abnormal cervical pathology at hysterectomy is to screen for vaginal intraepithelial 
neoplasia (VAIN) and prevent vaginal cancer. However, VAIN is 150 times less 
common than cervical intraepithelial neoplasia (CIN) and vaginal cancer is one of 
the rarest gynaecological malignancies (0.7 per 100 000 women in UK).10 
Recognised risk factors for VAIN include: CIN, immunosupression, genital warts / 
human papilloma virus (HPV) infection, radiation therapy and smoking.10 Besides 
VAIN, the only group of women appearing to be at increased risk of primary vaginal 
cancer are those whose mothers took diethylstilbestrol during pregnancy.11 
 
Opinion regarding the role of the vault smear has changed over time: In the 1950s 
there was enthusiasm for follow-up after hysterectomies demonstrating the 
presence of carcinoma-in-situ.12,13 Since the 1990s, this strategy has been 
questioned, and it has been suggested that too many vault smears may be being 
undertaken.1,3 In 2001, it was estimated that approximately 11 million vault smears 
per annum were being performed ‘unnecessarily’, out the 12.5 million women who 
had a hysterectomy and were continuing to have Pap smears1, in the USA, the 
study concluded that only 7-15% of women should require vault smears after 
hysterectomy (or cervical smears after sub-total/supracervical hysterectomy). If 
more than 80% of vault smears are unnecessary, this represents a huge waste of 
resources and may be the cause of unwarranted anxiety and inconvenience for 
women.14 
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In 1996 Pearce et al15 reported the results of screening a large cohort of women 
who had previously undergone hysterectomy for benign indications. The positive 
predictive value of the vault smear, as a means of screening women who have 
undergone hysterectomy for benign reasons is low16 and 10 years ago it was 
recommended that “the use of the Pap smear after hysterectomy, for benign 
disease, should become a thing of the past”.17  
 
This study aimed to establish the evidence base for the use of vaginal vault smears 
subsequent to hysterectomy for benign or pre-cancerous conditions. 
 
METHODS 
This systematic review16 aimed to identify all studies that either evaluated the vault 
smear test, or which reported the follow-up of a series of patients treated by 
hysterectomy for reasons other than malignancy, and contained data to enable the 
value of vault smears to be estimated. 
 
Searches were performed on the following electronic databases: Medline (from 
1966), Embase (from 1980), CINHAL (from 1982), CancerLit (from 1960) NHS 
Centre for Reviews and Dissemination, Database of Abstracts of Reviews of 
Effectiveness (NHSCRD – DARE), Turning Research into Practice (TRIP: from 
1986), Cochrane Collaboration Database, and Web of Science (WOS).  The search 
terms comprised ‘vault smear’ OR ‘vaginal vault smear’ OR ‘cervical vault smear’ 
OR (‘Hysterectomy’ AND (‘Follow up’ OR ‘Smear’). The specific search strategies 
(i.e. text words or index terms) were varied according to the search engine 
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(Appendix A).  Citations were downloaded into Reference Manager to facilitate 
identification of duplicate entries and for ease of handling. Electronic searching was 
supplemented by asking authors of papers relevant to the subject of this review to 
assist with the identification papers that pre-dated electronic search facilities, or of 
relevant unpublished data. 
 
Two authors independently scanned the titles and, where available, the abstracts of 
all articles identified by the electronic searches, excluding those that had no 
relevance. Complete copies of all remaining references and those where a decision 
could not be made on the basis of the title or abstract alone, were requested and 
two authors independently reviewed these to identify all eligible publications. Any 
disagreements were resolved by discussion with a third reviewer. 
 
Papers were ‘eligible’ for inclusion if they reported on a population of women who 
had undergone a hysterectomy and at least some of the population had vault smear 
tests. Case reports or expert opinion were excluded. Where the study population 
comprised a cohort of women with abnormal smears and where the number of 
women having had a hysterectomy was not stated (i.e. the rate of abnormal smears 
subsequent to hysterectomy could not be established) the publication was also 
excluded. All papers selected as eligible for inclusion had their bibliographies 
reviewed to identify any further papers of relevance to the review. Eligible papers 
were considered in full by two independent reviewers using a standardised pro-
forma (Appendix B) to determine the relevance of the papers to the aims of this 
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review. Two reviewers undertook independent data abstraction, any discrepancies 
in data abstraction were discussed and consensus reached.  
 
Included papers were scored, by two independent reviewers, for methodological 
quality. The scoring system was modified from the validated NHS Critical Appraisal 
Skills Programme (CASP) tool for assessing a diagnostic test18 (Appendix C). Again, 
any disagreement between the reviewers was resolved by consensus. The Quality 
Score (QS)19 was made up of points being awarded for a “Yes” response to different 
aspects of the methodology, resulting in a possible score of between zero and 10 for 
each. Papers having a QS greater than six were deemed to be of a ‘good’ 
methodological quality, however, even validated quality scoring systems can be 
criticised20 so the data from poorer quality papers was retained for comparison and 
three reviewers considered the methodological aspects of all studies at length.  
 
RESULTS 
 
The Literature Searches   
The systematic review identified 526 citations in total, 453 from electronic 
databases, seven from experts in the field and 66 from the bibliographies of 
included papers. There were 441 unique references once duplicates were excluded 
(371 from electronic sources, four from experts, 66 from bibliographies). Of these 
319 were excluded on the basis of title and abstract alone; a further 102 were 
excluded at eligibility assessment.  Thus, 20 research publications were eligible for 
inclusion. Of these, two reported the same piece of research and were published by 
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the same group in the same year;21,22 the more comprehensive was included.22  This 
gave a total of 19 studies:13 from electronic searches, one from experts and five 
from bibliographies. Table 1 summarises the source of publications. 
 
All identified studies utilised a form of cohort design and one had a control group23. 
The included papers were published between 1963 and 2000 in 16 different 
journals, with 11 published prior to 1990 (58%), (Table 2).  
 
Three of the papers contained information about women who had more than one 
histological diagnosis.23-25 Five papers followed up women after hysterectomy for 
benign disease.15,23,26-28 There were no papers concentrating exclusively on women 
who had CIN I or CIN II, the majority of papers considered follow up after 
carcinoma-in-situ or CIN III.22,24,29-39 
 
Data Extraction 
Table 2 summarizes the abstracted data from all 19 included papers. Cytological 
nomenclature has changed over time and reports from early studies have been 
‘translated’ into the currently accepted terminology to allow for comparison.40,41 The 
authors’ conclusions about the study, if related to the role of the vaginal vault smear, 
are reported along with our comments on the significance of the results. Quality 
scores (QS) ranged from 3.5 to 9 indicating wide variability in the methodological 
quality of the publications; only nine received a QS of ≥6.  
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The 19 studies were geographically diverse with six from North America, five from 
the UK, five from mainland Europe and two from New Zealand. One was a 
prospective cohort study, the rest were retrospective, and they were published in 16 
different journals. For each paper the number of women having a hysterectomy and 
the number subsequently followed up by means of a vault smear (N) is given (range 
4 to 5 682). All available outcomes data were abstracted including: (1) number of 
abnormal vault smears, (2) number of abnormal vaginal vault biopsies (i.e. 
histological confirmation of the presence of VAIN or other pre-malignant change but 
not frank malignancy), (3) number of vaginal cancers identified subsequent to 
hysterectomy. Tables 3i-iii summarise the numbers of ‘events’ documented in only 
the papers of better methodological quality (QS≥6).  
 
Narrative review 
The papers considered women with a variety of diagnoses at surgery, ranging from 
benign through to micro-invasive cancer, although the majority considered women 
with cervical intraepithelial neoplasia (CIN). The papers were divided into two main 
categories, women who had benign disease at hysterectomy and those who had 
CIN; these mainly comprised CINIII, a smaller number of papers also included 
cases of CIN I and II. 
 
Follow up after hysterectomy for benign histology:  Five studies were identified of 
which three were of better methodological quality. 15,26,28 Only one provided data 
suitable for life table analysis, this was a retrospective case note review and 
included women who had abnormal cytology before surgery but a benign diagnosis 
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at the time of surgery.28 All concluded that there is little benefit in follow up by vault 
smear screening: “The target condition is not common. . . less screening may be 
more desirable”,26 “there are currently no known scientific benefits from routine 
screening. . .and there can be possible risks”,28 “because of the low prevalence. . 
.and poor positive predictive value of the test routine screening. . .is probably not 
necessary”.15 
  
Follow up after hysterectomy for CIN III:  This diverse group of 15 papers only 
included six of better methodological quality.22,24,29,30,32,38 Three papers included 
cases of CIN I and CIN II, in addition to CIN III,24,25,32 one paper also included 
benign cases but comprised a population of women who were HIV positive – a 
population not comparable to the general population and therefore excluded from 
further analysis.23 
 
The six best quality papers were published over a 40 year span and their 
recommendations changed over time; in the earliest paper the conclusion was “of 
the utmost importance is thorough and long-term follow up”, whilst the most recent 
stated “The highest incidence of VAIN is found in the first two years after 
hysterectomy, after that incidence falls to that of the general pre-hysterectomy 
population.”32  
 
Analysis 
Outcomes after hysterectomy:  
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- Subsequent to benign indications (n=6543), 1.8%(117) of women had an abnormal 
smear, 0.12%(8) had an abnormal biopsy and no cancers were identified.  
- Subsequent to CIN I or II: 3.1% had an abnormal vault smear, 1.3% an abnormal 
biopsy and no cancers were detected.  
- Subsequent to CIN III, 14.1% of women had an abnormal smear, 1.7% an 
abnormal biopsy and one vaginal cancer (0.03%) was detected. This was the only 
report of invasive vaginal cancer, subsequent to hysterectomy for CIN III.  
Abnormal subsequent events (i.e. abnormal smear (2=522.6, 2df, p<0.0001) and 
abnormal biopsy (2=86.1, 2df, p=0.0001)) were positively associated with the 
histology at hysterectomy (benign, CINI/II, CINIII) i.e. more adverse outcomes with 
increased severity of disease. 
 
Follow up after hysterectomy for benign histology: Table 4i contains details of all 
studies reporting follow-up after hysterectomy for benign reasons with follow up 
information irrespective of methodological quality. Only one paper,26 (QS=6) 
included sufficient censoring and event data to enable estimation of a survival 
distribution. 
 
Follow up after CIN III: Events occurring during follow up after hysterectomy for 
CIN III are summarised in Table 4ii which includes all papers from the review, 
irrespective of QS. 
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DISCUSSION 
 
Summary of the evidence: 
Vaginal cancer is very rare.  This project aggregated data from studies following-up 
over 6800 women after hysterectomy for benign indications, CIN I and CIN II; 
despite up to 50 years follow-up, no cases of subsequent vaginal cancer were 
identified. Only one case of vaginal cancer was observed, three years after 
hysterectomy, in the cohort of 3 569 women having hysterectomy with reported 
evidence of CIN III. Unfortunately, all the studies following up women after 
hysterectomy with CIN III had significant methodological or reporting flaws. These 
results are compatible with the very low background incidence of primary vaginal 
cancer (approximately 7 per million women per annum).42 
 
There is little good quality evidence concerning the role of vaginal vault smears and 
there are insufficient data to enable the calculation of robust aggregated 
assessments of the sensitivity or specificity of the test.  Most of the observed events 
occurred within the first two years of follow-up; 46 of the 48 documented abnormal 
vault smears occurred within five years of hysterectomy. 
 
Of the six best quality studies, two considered data from women who had a 
hysterectomy for benign indications or CIN I/II and four studies considered women 
who had CIN III. The authors’ conclusions following hysterectomy for benign 
conditions were largely opposed to the use of the vault smear test for screening 
whereas recommendations following CIN III ranged from advising annual smears to 
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a more intensive regimen for two years followed by reversion to routine smears with 
the frequency recommended by the national screening programme (Table 2). 
 
Justification 
UK guidelines9 recommend that vault smears should only be undertaken where 
there is reasonable suspicion that their pre-existing cervical pathology has not been 
fully treated (i.e. For women on routine recall for at least 10 years prior to 
hysterectomy and no CIN in the sample at hysterectomy, no vault cytology is 
required; For women with less than 10 years routine recall and no CIN at 
hysterectomy, a sample should be taken 6 months after surgery and there should be 
no further cytology if it is negative; For women with completely excised CIN , a 
sample should be taken from the vault at 6 and 18 months after surgery, there 
should be no further cytological follow-up if both are negative). These guidelines are 
not based on gold standard evidence: they were derived from expert opinion. Thus, 
there is a need for good quality research to establish the evidence for continued 
surveillance and re-assess the appropriateness of current guidelines. This 
systematic review has aimed to address this need. 
 
Methods 
Pooled estimates of sensitivity and specificity for the vault smear test for each 
histological subgroup were anticipated outcomes of this review, but the variability in 
reference populations, incompleteness of data on censoring or confounding and 
large losses to follow up meant the data were insufficient for meta-analysis.   
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Searches of electronic databases and bibliographies of included papers provided 
the richest source of papers for inclusion, Medline provided almost half of the 
identified papers with bibliographies providing studies pre-dating electronic search 
engines and they were published in 16 different journals. The total number of 
women followed up by vault smears in all the studies was 13 338 (range 4–5 682; 
mean = 744; median = 220). 
 
Quality Scores 
Quality assessment scales for identifying trials of genuinely high quality are 
problematic20, however this limitation was considered from the outset and all data 
retained for consideration. Three reviewers all agreed with the study ‘quality’ based 
on the modified CASP score and so no deviation from this was deemed necessary. 
The mean quality score was 5.5 (range 3.5–9, SD=2.02), with only 6 papers having 
a QS greater than six and thus being deemed of ‘good’ methodological quality. 
There was no correlation between year of publication of the study and the quality 
score for that study, (Spearman correlation coefficient=0.133, p=0.588). The low 
quality scores reflect the fact that these data have been abstracted predominantly 
from studies that were not designed to provide data in the format required for this 
type of review. 
 
CONCLUSIONS and IMPLICATIONS 
This comprehensive, systematic review has collated and assessed the available 
literature relating to the appropriateness of follow-up subsequent to hysterectomy for 
indications other than cancer. The better quality studies had a combined study 
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population of 11 656 hysterectomies of which 6 543 were for benign disease, 76 for 
CIN I/II and 5 037 for CIN III. Nevertheless, incompleteness of follow up and 
recording prohibited meta-analysis of these data and it was not, therefore, possible 
to provide robust estimates of the value of the vaginal vault smear test in the follow 
up of women who have had a hysterectomy for reasons other than malignancy. 
 
Based on the available evidence the current UK guidelines9 appear reasonable. 
However this study confirms the need for definitive research to determine the 
appropriate duration and frequency of vaginal vault smears after hysterectomy for 
reasons other than cancer. Women’s views concerning the appropriateness of 
follow-up and a better understanding of the anxiety related to vault smears are also 
required if appropriate, acceptable and evidence-based guidelines are to be 
developed. 
 
As it is not practical to undertake a prospective randomised controlled trial (because 
vaginal cancer is rare and such a trial would have considerable ethical implications), 
epidemiological techniques continue to offer the most practical approach to 
answering some of these questions. A large, prospective audit of a cohort of women 
undergoing hysterectomy for reasons other than cancer could establish the 
frequency and characteristics of those who later develop VAIN and/or vaginal 
cancer. 
 
Any future decisions concerning the use of the vaginal vault smear must consider 
the potential harms of screening, including possible over-diagnosis (false positives) 
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and over-treatment, as well as the potential benefits. Women’s views concerning the 
appropriateness and duration of follow-up need to be established. It is known that in 
cancer screening programmes, false positive results cause a high level of anxiety.14 
 
This review has raised a number of important issues. Existing published research 
inadequately defines the clinical, financial and personal consequences of performing 
vault smears. The vaginal vault smear may be regarded as a ‘low priority area’ when 
compared with the large number of smears undertaken within cervical screening 
programmes. However, the public health services are required to justify all 
expenditure and further research in this subject is long overdue. 
 
Finally, we conclude that there is currently as there is no evidence to suggest that 
there is any demonstrable benefit in screening after hysterectomy for benign 
disease and, therefore, there is no evidence to support changing current guidelines 
for screening after CIN I/II. Screening after a diagnosis of cancer is outside the 
scope of this review. Screening after CIN III to five years is proposed by some 
authors, however, the data from this review indicate that 95% (46 of 48) abnormal 
smears occurred within two years and only one case of vaginal cancer was 
identified in all of the reported series. The value of the vaginal vault smear test as a 
screening tool after hysterectomy for reasons other than cancer is not supported by 
the existing literature. 
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Tables 
 
Table 1.  Evaluation of references by source  
Source of 
papers 
Total no 
of 
references 
  
No of 
unique  
references
No    (%) 
Excluded 
Papers 
Included  
references
 
Sensitivity 
of  
source 
Precision 
of  
source 
Medline 147 147  (33.3) 138 9 0.06 0.47 
Cancerlit 64 41    (9.3) 39 2 0.05 0.11 
EmBase 31 11    (2.5) 9 2 0.18 0.11 
NHSCRD  117 117  (26.5) 117 0 0 0 
Cochrane  44 35    (7.9) 35 0 0 0 
Trip 48 18    (4.1) 18 0 0 0 
Cinhal 2 2      (0.5) 2 0 0 0 
WOS 2 0      (0.0) 0 0 0 0 
Bibliographies 66 66    (15.0) 61 5 0.08 0.26 
Experts 7 4      (0.9) 3 1 0.25 0.05 
 
TOTALS 
 
526 
 
441 
 
422 
 
19 
 
- 
 
1.0 
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Table 2. Results table summarizing all papers finally included in the review 
Study 
 
Author, Region 
Method, Year 
Reference  
 
Study Population  
 
Number of women      Inclusion  
                                      details 
Results and Authors conclusions 
n1 = numbers of abnormal vault cytology tests* 
n2 = numbers of biopsy proven vaginal dysplasia 
n3 = numbers of invasive cancers 
Reviewers Comments 
 
Quality Score  QS  = (0-10)  
(score>6 = ‘good’ quality) 
Berget 
County of 
Maribo, 
Denmark 
Prospective 
population 
cohort study 
1972  
243 had a 
hysterectomy 
subsequent to a 
cervical abnormality: 
8 = Slight /  
Moderate atypia 
206 = CIS 
29 = Stage IA  
N = 237 had vault 
smears 
Followed up from 2-30 
months by vault smear plus 
clinical examination & 
questionnaire.  Excludes 13 
cases of pre-existing 
invasive disease 
 
237 followed up from 2-30 months by vault smear 
plus clinical examination & questionnaire  
n1 = 3:  4 actual abnormal smears but 1 awaiting 
data so excluded.  
n2 = 3: Carcinoma in situ   2/206 
             Stage 1a                1/29  
 
16/237 women regretted hysterectomy.  Therapeutic 
conization may be more appropriate for young 
women with stage 0. 
Follow up was short term only thus limiting usefulness of 
data.  
 
Incomplete information regarding proportion of patient 
followed-up. Possible that study underestimates true event 
rate.  
QS = 7.5 
Population offered 
free cytology service  
N=2849 had vault 
smears 
 
n2 = 24:  12 = recurrent, 12 = new cases 
3/24 = invasive ca, 19/24 = vaginal CIS 
2/24 = occult invasive disease 
 
14 within 5yrs, 22 within 10yrs, All within 15 yrs. 
Boyes 
British 
Columbia, 
Canada 
Cohort study  
1970  N = 159 followed up 
after micro-invasive 
disease detected 
70% of population had at 
least one smear during 
study period: 
1-5yrs = 1837 
6-15yrs = 993  
>16yrs = 19 
 
n2 = 4: detected 1-5 years,  
n3 = 1: detected at 20months 
 
Hysterectomy does not mean the end of follow-up 
as there is a significant risk of the development of 
subsequent disease in the vaginal vault. Patients 
require careful & prolonged cytological follow-up for 
the rest of their lives. 
An unknown number had a hysterectomy.  Large cohort 
study.  No definition of how recurrent or new disease is 
distinguished.  
 
Authors’ conclusions were influenced by higher rates of 
subsequent disease observed in sub-groups with micro-
invasion and occult disease. 
QS = 8 
Fawdry 
UK, SE Scotland 
Retrospective 
Cohort from 
cytology records  
1984  
1062 women had 
hysterectomies for 
confirmed 
carcinoma in-situ or 
severe dysplasia 
 
N = 810 had vault 
smears 
1035 = CIS 
27 = severe  
        dysplasia  
 
Follow up:  
253 regular vault smears, 
557 had some vault smears 
n1 = 64:   but 62 were only 'grade 2 smears',  
1 = unknown, 1 = presented symptomatically. 
n2 = 12:  Presented at:  8months (1), < 12months 
(8), 1-2years (2) 
n3 = 1  
 
With improved management it is hoped that early 
‘recurrences’ will be come less evident.  However, 
at least 2 smears in the 2years after hysterectomy 
seem essential. Subsequently, for most, the very 
low detection rate does not justify an annual hospital 
visit with its attendant anxieties.  
Comprehensive study, focusing on the follow-up of CIS.  
 
Losses to follow-up may underestimate the true event rate. 
QS = 7.5 
Gemmell 
UK, Tayside 
region of 
Scotland 
341 had a 
hysterectomy for 
CIN III 
 
All asked to attend for 
regular vault smears for at 
least 10 years 
 
n1 = 9  
n2 = 3:  at 9 & 46 months and 16 years.  
 
Incidence of VAIN following hysterectomy for CIN III 
Well-designed study with sufficient follow up. Losses to 
follow-up have been excluded from the denominator and 
may result in an over-estimate of the incidence of disease.   
QS = 9 
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Retrospective 
review (Cohort) 
1990  
 
N = 219 had vault 
smears 
was 0.91%...75% of abnormal vault smears reverted 
to normal without any active intervention... Little 
evidence to justify screening women who have 
undergone hysterectomy for CIN III any more 
frequently than the general population. Follow-up of 
women after hysterectomy for CIN III should involve 
6-monthly smears for the first year with a third 
smear at 2years. If these smears are normal the 
woman could revert to the national screening 
programme. 
Halberg 
Denmark 
Cohort, (unclear 
if retrospective 
or prospective) 
1969  
10,200 women 
undergoing a 
examination  
 
N = 49 had a 
hysterectomy for 
carcinoma in situ 
and were followed 
up by vault cytology 
 
 
 
n1 = 4 :  ‘atypical cells’ at 2; 5; 5; 6yrs  
n3 = 1:   invasive carcinoma with metastases at 
18months post hysterectomy  
 
Need improved measures of diagnosis. 
Study population, duration & frequency of follow up 
incompletely described.  Outcome of patients with atypia 
not documented. 
QS = 5 
Hellberg 
Sweden, 
Retrospective 
review of 
records 
1987  
90,000 fertile 
women served by a 
Swedish hospital  
 
N = 154   Had CINII 
or worse at 
hysterectomy and 
had vault smears 
Followed up with 
colposcopy and cytology 
twice a year for 2 years then 
annually 
 
Average duration of follow 
up = 10.3 years 
n2 = 4:  2 'within 1 year', 2 at 1-2 years  
1 = CINI, 2 = CINII, 1 = CINIII. 
n3 = 0  
 
The cure rate for hysterectomy is 99% (152/154). 
The results of conization are comparable to those 
for hysterectomy.  Disease may recur after as long 
as 15-20 years, and patients therefore need to be 
regularly followed up, probably a minimum of 10yrs. 
Study aimed to compare outcomes from conization, 
cryosurgery and hysterectomy.  Outcomes by initial 
histological diagnosis and completeness of follow-up not 
documented for sub-group treated by hysterectomy. 
Conclusions relate more to follow up after conization or 
destructive treatments of CIN, rather than after 
hysterectomy- data does not support the authors’ 
conclusions. 
QS = 3.5 
Kalogirou 
Greece 
Cohort study 
1997  
 
993 women 
undergoing 
hysterectomy for 
CIN III.  
 
N = 793 had vault 
smears 
All had CIN and 
completed 10 
years follow up: 6monthly 
for first year, annually 
thereafter 
n1 = 210  
n2 = 41:  VAIN  
Mean age at developing VAIN = 57 (35-75yrs) 
<1yr since hysterectomy = 6, 1-2years = 12, 2-5yrs 
= 20, >5yrs = 3 (up to 10yrs) 
 
Stage at detection:  VAIN I = 4, VAIN II = 10, VAIN 
III = 27.  In 21 (51%) cases the grade corresponded 
to original cervical lesion  
 
Incidence of VAIN in women who had completed 
10yrs follow up was 5.1%.  Vault cytology provides 
a suitable and acceptable test for detection . . . and 
is therefore indicated in follow up after hysterectomy 
for CIN.  Cost must be justified in terms of benefit . . 
. (vault smears) still cause considerable stress and 
anxiety to women. . .smears should be performed 
every six months for the first two years then 
annually to five years. Follow up should include 
colposcopic review on each examination. . . The 
Appropriately designed study with good follow-up. Limited 
information about characteristics of population. 
 
Lack of clarity as to whether entire study population was 
CIN III.  
QS = 7.5 
- A25 -  
highest incidence of VAIN is found in the first two 
years after hysterectomy, after two years the 
incidence similar to that of general pre-hysterectomy 
population - 0.7/1000. Patients with at history of CIN 
before hysterectomy represent a higher risk group. 
Kirkup 
UK, Sheffield 
Retrospective 
cohort 
1979  
N = 112 women had 
hysterectomy for 
CINIII and all were 
followed up with 
vault smears 
Followed up for a minimum 
of four years and where the 
first two post-operative 
smears were normal 
n1 = 0  
 
Recurrence of new lesions no higher than that in the 
general population . . . residual CIN after treatment 
should be detected by the first 2 post-operative 
smears. New lesions of CIN may occur but not more 
commonly than in the general populations and that 
the sudden occurrence of a possible ‘second type’ 
carcinoma. . . is rare. 
A highly selected population. Characteristics of population 
and number of excluded cases not provided.  
QS = 5.5 
Kurian 
UK, Edinburgh 
Retrospective 
cohort of 
computerised 
records 
1999  
N = 34 had a 
hysterectomy for 
glandular neoplasia 
of cervix and were 
followed up by 
cytology 
Women identified from 
pathology dept files, with 
glandular dysplasia, in-situ 
and invasive disease and 
treated by hysterectomy 
 
n1 and n2 = unknown.  
 
No recurrent abnormal glandular cells on follow-up 
for patients with LCGIN or micro invasive disease.  
CGIN is a precursor of invasive adenocarcinoma. 
Important to ensure adequate free margins for 
patients with glandular precursor lesions not treated 
by hysterectomy. 
Study included 80 cases treated by diathermy loop 
excision. Unable to disentangle those women who had a 
hysterectomy from the rest of the cohort. Time to 
identification of CIN not stated.  
QS = 5 
Liukko  
Finland, Turku 
Retrospective 
cohort, review of 
case-notes  
1978  
245 women with 
CIS treated at a 
University Hospital.  
 
N = 160 had vault 
smears 
Followed up for 5 to 10 
years 
n2 = 9:  2 dysplasia, 4 CIS, 3 invasive on biopsy. 
Recurrences all occurred between 3months - 4yrs  
Recurrence may also be a new epithelial lesion on 
the basis of a multi-focal mechanism of production. 
Cytologic and colposcopic follow up of these 
patients is thus necessary. 
Lack of clarity concerning subset of study population who 
were treated by hysterectomy.  
QS = 3.5 
 
McIndoe 
New Zealand, 
Aukland 
Retrospective 
cohort, case-
notes review 
1969  
539 women with 
cervical CIS. 
 
N = 175 had vault 
smears 
Followed up 1-17yrs (6.5 
mean) 
n1 = 9  
n2 = 4:  at 0,6,7,7years 
 
Our conservative attitude to diagnosis and treatment 
of CIS is reinforced by the rarity of invasive vaginal 
cancer in these cases.  No more . . .than periodic 
clinical, cytological and colposcopic examination is 
necessary. 
There is a lack of clarity with respect to study population 
and timing of abnormal smear results.  
QS = 3.5 
McIndoe 
New Zealand, 
Aukland 
Retrospective 
cohort, case-
notes review 
1984  
N = 250 women with 
CIS had a 
hysterectomy and 
all were followed up 
with vault smears 
Follow up for 5-28 years at  
3, 6 months & then annually 
n1 = 33 at 2 years (13.2%)  
n3 = 8 cases of invasive disease, 1 at 1year, 2 at 1-
5 years, 1 at 5-10 years and 4 at over 10 years. 
CIS cervix has significant invasive potential.  
Importance of observing patients for a long period is 
apparent. Patients with continuing abnormal 
cytology . . . are 24.8 times more likely to develop 
invasive carcinoma. 
Watch and wait policy and lack of intervention when 
abnormal smears occurred may have led to a higher than 
expected rate of invasive disease. Same series as 1969 
paper.  
QS = 5.5 
Michalkiewicz 
Poznan, Poland 
Retrospective 
cohort, case-
701 Women with 
epithelia dysplasia  
 
N = 172 had vault 
Follow up 3monthly for 
3years then 6monthly to 
5yrs. 
 
n2 = 2 recurrences  
2/160 = 1.25% after carcinoma in situ (11 & 22 
months).  
The most frequent cause of recurrence seemed to 
Not possible to determine grade of dysplasia.  
QS = 6 
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notes review  
1963  
smears Dysplasia = 12, Carcinoma 
in situ = 160 
be insufficiently radical treatment . . . The rarity of 
recurrence does not contraindicate conservative 
methods of treatment . . . Of the utmost importance 
is thorough and long-term follow-up. 
Miller 
USA 
Retrospective 
cohort, review of 
records 
1987  
3008 black women 
seen in a cancer-
screening clinic  
 
N = 775 
hysterectomy for 
'benign' reasons 
and had vault 
smears 
Followed up by vault smears 
annually.   
Time from hysterectomy 
ranged from 1yr to >30yrs, 
78% >5yrs previously 
n2 = 1:  vaginal dysplasia.  (0.13%)  
n3 = 0  
 
The absence of carcinoma in the post-hysterectomy 
group suggests that although an annual physical 
examination is indicated, the time interval between 
performances of the Pap test may be lengthened. 
If one asymptomatic cancer had been detected, the 
$10,000 cost would have been justified. 
Incomplete information on follow-up. Possible that all 
subsequent cases not traced or included.  
QS = 5 
Pearce 
New Orleans, 
USA 
Retrospective 
cohort 
1996  
6265 women who 
had vaginal smears 
at a large inner-city 
charity hospital.  
 
N = 5,682 had a 
hysterectomy for 
'benign disease' and 
had vault smears. 
99% = low socio-
economic class 
83% Black, 9% White, 5% 
Hispanic, 3% other race.   
 
The number of women with 
benign indications for 
hysterectomy was estimated 
from a sample of 150 cases 
n1 = 79  
n2 = 5  
n3 = 0  
 
Positive predictive value of pap smear for detecting 
vaginal cancer – 0%. For detecting VAIN 6.3% 
On average, 19yrs from hysterectomy to first 
abnormal smear.  
Because of the low prevalence of disease and poor 
PPV of the test, periodic, routine screening by 
vaginal Pap smears is probably not necessary for 
women who had hysterectomy for benign disease. 
Vault smears should be considered only for women 
with a history of cancer of the genital tract or CIN III 
because they have increased risk of disease. 
Hysterectomy number is an estimate based on review of 
only 150 records.   
 
Exact follow-up and length of follow-up not clear. No 
information on time from hysterectomy to each event. 
QS = 7 
Piscitelli  
North Carolina, 
USA 
Retrospective 
cohort, case 
notes review 
1995  
N = 697 
Hysterectomy for 
benign disease and 
had vault smears 
 
630 = had normal 
cervical smears pre 
hysterectomy 
63 = abnormal 
smears pre-
hysterectomy 
Followed up by vault smears 
for an average of 13.7years. 
 
1266 vault smears total 
(average 1.8 per patient) 
n1 = 33:  Slight atypia = 22, Mild dysplasia = 8, 
Moderate = 2, Severe = 1 
25 were found at the initial examination (0.25-
36yrs). 8 were found at a subsequent smear (2.25-
45yrs) 
n2 = 2  
 
The extremely low incidence of vaginal carcinoma 
combined with the lack of evidence supporting the 
effectiveness of screening patients after 
hysterectomy suggests that less screening may be 
more desirable. 
One of the few papers where the stated aim was to 
determine the relevance of vault smear tests. 
 
Incomplete description of the frequency and reasons for 
vaults smears.  
QS = 6 
Videlefsky 
Atlanta, USA 
Retrospective 
cohort  
1997  
2066 identified as 
eligible, random 
selection of 
N = 220. with a 
hysterectomy for 
benign conditions 
and vault smears 
 
All had one or more vault 
smears.  
 
1,211 smears (range 1-21) 
Mean interval =19.5months. 
Mean time from 
hysterectomy to first smear 
was 13.2months (range 0 -
n1 = 7:  4 no intervention, 3 treated. 
Long-term, 6 had normal vault smears and 1 had 
atypical squamous cells of undetermined 
significance. 5 were from the 164 with previously 
normal histology. 2 from the 56.with previously 
abnormal histology. 
n2 = 2  
The use of routinely collected computerized records at one 
centre and the absence of active follow up of study 
participants indicates the potential for under ascertainment 
of subsequent events. 
QS = 7.5 
- A27 -  
164 = no prior 
cytological 
abnormalities  
56 = prior 
abnormality: 12 - 
HPV induced 
changes / mild 
dysplasia 
44 - moderate / 
severe dysplasia 
155). 
 
Average duration of follow 
up 89 (3-175) months 
 
n3 = 0  
 
Most routine vaginal cuff cytology screening tests 
need not be performed in women who have had a 
hysterectomy for benign uterine conditions. . . There 
are currently no known scientific benefits from 
routine vaginal cuff smear screening, and there can 
be possible risks associated with performing 
unnecessary procedures. 
Wiener 
South 
Glamorgan, UK 
Retrospective 
Cohort of 
women identified 
from, ‘The 
Cardiff Cytology 
Study’ 
1992  
N = 195 women 
hysterectomy for 
pre-invasive disease 
of cervix (CIN or 
adenocarcinoma-in-
situ).  All had vault 
smears 
 
 
143 = >10yrs follow up  
95 = 15 years follow up 
43 =>20yrs  
 
A total of over, 2,800 
woman years followed up 
with vault smears 
n1 = 5:  in women who had CINIII originally, at 4, 4 
and 20 months, 12 & 16 years 
n2 = 3:  at 20months, 12 & 16 years 
n3 = 1:  at 16 years having been lost to follow up.  
 
Cytological screening of all women who had a 
hysterectomy with a history of CIN is indicated for 
the first two years after hysterectomy. Thereafter the 
estimated incidence of 0.7 per 1,000 woman years 
is higher than the general population but it is not a 
sufficient reason to screen more frequently. 
Selection of and distribution of disease in the cohort is not 
adequately described.  Events only occurred in cases with 
CIN III at hysterectomy but the proportion of the cohort 
with CIN III is not known.  Apparently no review of 
eligibility of cohort. At least one sub-total hysterectomy is 
included which may increase the likelihood of observing 
abnormal smears.  
QS = 4 
Williams 
USA 
Retrospective  
case – control 
study 
2000  
 
9 HIV positive 
(cases) and 43 HIV 
negative women 
hysterectomised 
(controls) 
 
N = 4 with cervical 
carcinoma in situ at 
hysterectomy and 
had vault smears 
Controls were matched for 
diagnosis date, race and 
age 
 
Only 5 HIV positive patients 
complied with any follow-up 
 
n1 = 3 abnormal smears at an average of 12 
months (6-24months) 
No recurrences in HIV negative controls  
 
Compliance with gynaecologic follow-up is very poor 
in this patient population . . .  we continue to 
recommend treating HIV positive women in the 
same manner as their non-infected counterparts. 
Incomplete information on the follow up and characteristics 
of control group.  
 
Event rates in HIV positive women are unlikely to be 
generalisable. 
QS = 5.5 
*  The term vault smears is used through the table instead of vault cytology tests as this was the accepted terminology at the time of publication. 
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Table 3i:  Numbers of abnormal vault smears per study, grouped by histology at time 
of hysterectomy (QS ≥6) 
Outcome Author 
 
Score Vault 
Smear N 
Events 
n  
Benign 
n / N 
CINI & II 
n/ N  
CINIII 
n / N  
Berget 7.5 237 4  0 / 8  2 / 206 
Fawdry 7.5 810 64   64 / 810 
Gemmell 9 219 9   9 / 219  
Kalogirou 7.5 793 210   210/793 
Pearce 7 5 682 79 79 / 5 682    
Piscitelli 6 697 33 33 / 697   
 
n1 = 
Abnormal 
vault smears 
 
Videlefsky 7.5 220 7 5 / 164 2/ 56   
TOTAL n1 
406 / 8 658 
4.7% 
  8 658 406 117 /  
    6 543 
1.8% 
2 / 64 
 
3.1% 
285 / 
    2 028 
14.1% 
 
 
Table 3ii:  Numbers of abnormal vaginal biopsies per study, grouped by histology at 
time of hysterectomy (QS ≥6) 
Outcome Author 
 
Score Vault 
Smear N 
Events 
n 
Benign 
n / N 
CINI, II 
n / N  
CINIII 
n / N  
Berget 7.5 214 2  0 / 8  2 / 206 
Boyes 8 2 849 24   24 / 2 849 
Fawdry 7.5 810 12   12 / 810 
Gemmell 9 219 3   3 / 219  
Kalogirou 7.5 793 41   41 / 793  
Michalkiewicz 6.5 172 2  0 / 12  2 / 160  
Pearce 7 5 682 5 5 /5 682   
Piscitelli 6 697 2 2 / 697   
 
n2 = 
Dysplasia - 
biopsy 
proven 
 
Videlefsky 7.5 220 2 1 / 164 1 / 56  
TOTAL n2 
93 / 11 656 
0.8% 
   
11 656 
 
93 
8 /  
  6 543 
0.12% 
1 / 76 
 
1.3% 
84 /  
  5 037 
1.7% 
 
 
Table 3iii:  Numbers of invasive vaginal cancers per study, grouped by histology at 
time of hysterectomy (QS ≥6) 
Outcome Author 
 
Score Vault Smear 
N 
Event
s 
n  
Benign 
n / N 
CINI & II 
n / N 
CINIII 
n / N 
Boyes 8 2 849 0  0 / 2 849 
Fawdry 7.5 810 1   1 / 810 
Pearce 7 5 682 0 0 / 5 682   
 
n3 = Invasive 
carcinoma 
 Videlefsky 7.5 220 0 0 / 164  0 / 56   
TOTAL n3 
1 / 9 561 
0.01% 
   
9 561 
 
1 
 
0% 
 
0% 
1/3 569 
0.03% 
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Table 4i:  Benign histology at hysterectomy - summary of all events with time 
Duration of  
Follow up 
N = Fup by 
vault 
smears 
 
Benign 
(events) 
Recurrence 
Rate 
 
Cumulative  
Rate 
 
Notes 
n1 = abnormal 
        smear 
n2= biopsy proven  
       recurrence 
Totals 
 
N = 7 318 
 
n1 =  
117 
n2 = 
9 
n1 =  
1.6% 
n2 =  
0.12% 
n1 =  
1.6% 
n2 = 
0.12% 
Miller, Pearce, 
Piscitelli, Videlefsky 
Time 
Unknown  
N = 6 457 
 
5 682 
79 
7 154 
8 
1.4% 0.1% 79/5 682 
1.4% 
8/7 154 
0.1% 
Pearce, Miller 
<1year N = 861 861 
2 
 0.2%  2/861 
0.2% 
 
1 – 2  858 
4 
 0.5%  6/861 
 
 
2 - 4.9  854 
4 
162 
1 
0.5% 0.6% 10/861 
 
1/162 
0.6% 
5 - 9.9  850 
7 
 0.7%  16/861  
10 - 14.9  844 
6 
 0.7%  24/861  
15 - 19.9  838 
11 
 1.3%  35/861  
20 - 24.9  668 
0 
 0%  35/861  
25 - 29.9  668 
1 
 0.1%  36/861  
30 - 34.9  667 
1 
 0.1%  37/861  
35 - 39.9  666 
0 
 0%  37/861  
40 - 44.9  666 
0 
 0%  N/A 37/861 
45 - 49.9  666 
1 
 0.1%  N/A 38/861 
Piscitelli & 
Videlefsky data 
 
Williams excluded as 
population too 
different from general 
population 
 
There were no 
cancers (n3), in this 
population. 
 
Table 4ii CIN III Histology at hysterectomy, summary of all events with time 
Duration of  
Follow up 
N2 = Fup by 
vault 
smears 
 
n = events 
CIN III Notes 
n1 = abnormal smear 
n2= biopsy proven  
       recurrence 
n3 = vaginal cancer 
Totals 
 
N= 5 822 n1 = 329 
5.7% 
n2 = 108 
1.9% 
n3 = 10 
0.2% 
Time 
Unknown  
 
 
287 8 0 
<1year 
 
 1 
1 – 2 
 
 
 
36 
2 - 4.9 
 
 1 
 
 
83  
3 
5 - 9.9 
 
 3 12 1 
10 - 14.9 
 
 1 3 2 
15 - 19.9 
 
 1 2 3 
Berget Boyes Fawdry 
Gemmell Halberg Hellberg 
Kalogirou Kirkup  Liukko 
McIndoe‘84 Michalkiewicz 
Weiner.   
 
Williams excluded as in 
Table 4i. 
 
Denominator data 
impossible to calculate from 
aggregate data thus 
columns omitted for clarity. 
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The electronic search strategies           Systematic review appendix A 
Searches that did not match any records when the main strategy was run (used for the 
Medline search) were simplified until matches were found, searches that produced a 
higher yield of matches were limited to human subjects and English language. 
 
Medline (from 1966) 
1.  Vaginal smear OR vaginal vault smear OR Papanicolaou smear OR vault smear 
2.  Limit 1 to human AND English language 
 
Embase (from 1980) 
1.  Vaginal smear OR vaginal vault smear OR Papanicolaou smear OR vault smear  
2.  Limit 1 to human AND English language 
 
CINHAL (from 1982) 
1.  Vaginal smear OR vaginal vault smear OR Papanicolaou smear OR vault smear 
 
CancerLit (from 1960)  
1.  Vaginal smear OR vaginal vault smear OR Papanicolaou smear OR vault smear 
 
NHS Centre for Reviews and Dissemination, Database of Abstracts of Reviews 
of Effectiveness (NHSCRD – DARE) 
1.  Vault smear/All fields OR hysterectomy and smear/All fields 
 
Turning Research into Practice (TRIP: from 1986) 
1.  Vaginal smear OR cervical smear OR hysterectomy 
 
Cochrane Collaboration Database (all Databases and Registers included) 
1. (VAULT and SMEAR) OR (VAGINAL and VAULT) OR (CERVICAL and VAULT) OR 
(HYSTERECTOMY and SMEAR) 
 
Web of Science (WOS, 1981)  
1. (Vaginal smear) OR (vaginal vault smear) OR (Papanicolaou smear) OR (vault 
smear)                
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VAULT SMEAR STUDY:  ELIGIBILITY & VALIDITY FORM       
Systematic review appendix B 
REVIEWER : FIRST AUTHOR : 
REFERENCE ID : YEAR PUBLISHED : 
COUNTRY : Study Years : 
Have some women had a hysterectomy?    YES n= 
 NO – EXCLUDE 
(if n= is unknown, exclude) 
Have some women been followed up by vault smear? YES n= 
 NO – EXCLUDE 
(if n= is unknown, exclude) 
Sample (ring all that apply)            BENIGN  CIN I     CIN II CIN III     
INVASIVE 
(if only INVASIVE, exclude) 
Description of Study Population: 
SAMPLE SIZE:  
OUTCOMES?   CANCER  RECURRENCE  OTHER 
_________  
FOLLOW–UP? VAULT SMEAR COLPOSCOPY OTHER _________ 
DURATION OF FOLLOW– UP? 
COMPLETENESS? 
RESULTS: 
 
 
 
 
 
If outcomes not directly attributed to population then EXCLUDE 
AUTHORS CONCLUSION:  
 
PTO - reviewers observations
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Systematic review appendix C 
Assessment tool (modified CASP) for assessment of cohort studies 
eligible for inclusion in the vaginal vault smears systematic review 
 
Author & Identifier:  
Question 
 
(score) 
Yes 
 
(1) 
No 
 
(0) 
Don’t 
Know 
(0) 
1 Are the aims clearly stated? 
 
 
   
2 Was an appropriate study design used? 
 
 
   
3 Do we know who exactly has been studied and was 
the population clearly described? 
(i.e. inclusion criteria, region, time frame, age, 
hysterectomy, histology) 
 
   
4 Was the cohort recruited in an acceptable way?  
(i.e. was there selection bias, does the cohort 
represent the study population, was everyone 
included that should have been) 
 
   
5 Was exposure accurately measured? 
(i.e. do we know if they had a hysterectomy and what 
was the histology at hysterectomy for whole cohort) 
 
   
6 Was follow up completely described? 
(i.e. duration and completeness) 
 
   
7 Did the numbers add up? 
(i.e. is everyone accounted for) 
 
   
8 Was outcome systematically measured? 
(i.e. same method for all women – is there a standard 
minimum done to assess all women, to minimize 
bias)   
 
   
9 Were the appropriate outcome measures? 
(i.e. histologically confirmed disease or recurrence) 
 
   
10 Have confounding factors been considered 
(i.e. HIV & HPV , accounted for in study design) 
 
   
 
 
TOTAL SCORE 
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Appendix B:  An audit of ten years of vault cytology testing. 
 
Vaginal vault cytology tests: Analysis of a decade of data from a UK tertiary 
centre 
 
Dr Helen Stokes-Lampard1, Prof Sue Wilson1, Dr Christine Waddell2, Mrs Linda 
Bentley2. 
 
1.  Department of Primary Care and General Practice, University of Birmingham, Primary Care 
Clinical Sciences Building, Edgbaston, Birmingham B15 2TT.   
2.  Cytology Laboratory, Birmingham Women’s NHS Foundation Trust, Metchley Park Road, 
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ABSTRACT 
 
Objectives:  To examine temporal trends in the use of vault cytology tests in 
primary and secondary care and the demographics of those women tested.   
 
Methods:  Retrospective analysis of routinely collected data concerning women 
who had a vault cytology test processed during a 10-year period (1 April 1995-31 
March 2005), at Birmingham Women's NHS Foundation Trust. 
 
Results:  8,457 vault cytology tests from 3,164 women (range 1-17 tests, 
median=2), were processed representing approximately 2% of the Department's 
cervical cytology workload.  There was a significant reduction in annual numbers 
processed (Pearson correlation -0.958, p<0.001).  Significant abnormalities (mild 
dyskaryosis or worse) were detected in 4.5%, with malignancy being detected in 
less than 0.1%.  The unsatisfactory cytology test rate was 10.7% overall. 
 There was a reduction in the numbers of vault cytology tests coming from the 
community, hospital outpatient clinics and operating theatres over time (χ2 for linear 
trend=139.53, 9df, P<0.0001).  Tests originating from community settings had 
lowest disease detection rates: no malignancies and only two severe abnormalities 
were detected from almost 4,000 primary care samples; abnormal results 
represented 2.8% (n=113), of which the majority (n=73) were borderline results.  All 
cancers (n=8) were detected in samples taken in gynaecology and colposcopy 
clinics. 
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Conclusions:  Vault cytology test usage appears to be reducing, particularly from 
out-patient clinics and primary care.  Community detection rates are very low.  
Further research is required to establish the true costs and benefits of vaginal vault 
cytology. 
 
 
 
 
 
 
MESH Keywords: Cervical screening, vaginal vault cytology, cervical 
cytology, clinical audit, Papanicolaou test. 
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INTRODUCTION  
 
Hysterectomy is the most commonly performed major gynaecological operation and 
approximately 20% of women in the UK have had a hysterectomy by the age of 65.  
In England, around 40,000 operations are performed every year.1   In the USA, a 
third of women have a hysterectomy, by the age of 65.2  Benign indications 
(excessive bleeding, fibroids, prolapse, endometriosis, pelvic pain etc.) account for 
over 94% of hysterectomies. About 6% are undertaken either as a consequence of 
abnormal cervical cytology, cervical or other gynaecological cancer.3 
 Total hysterectomy includes removal of the cervix and leaves the vagina as a 
blind ending pouch. Subtotal hysterectomy, where a part, or all, of the cervix 
remains intact is an indication for continued participation in the cervical screening 
programme, however subtotal surgery comprises less than 3% of the 
hysterectomies in the UK.4 Papanicolaou cytology tests of the vaginal vault (vault 
smears or, more correctly, vaginal vault cytology tests) are a means of detecting 
recurrent invasive or pre-invasive disease of the lower female genital tract in women 
who no longer have a cervix.5 
 Vault cytology testing may be undertaken on asymptomatic women who had 
no abnormal cervical pathology at hysterectomy, or prior to surgery, to screen for 
vaginal intraepithelial neoplasia (VaIN); VaIN being a precursor to vaginal cancer.  
However, VaIN is a hundred times less common than cervical intraepithelial 
neoplasia (CIN) and vaginal cancer is a rare malignancy with around seven cases 
per million women per annum.6   Besides the presence of VaIN, the only group of 
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women who appear to be at increased risk of developing primary vaginal cancer are 
women whose mothers took diethylstilbestrol during pregnancy.7 
 
Vaginal vault cytology tests fall outside the remit of the NHS cervical 
screening programme (NHSCSP), as they are not used to prevent cervical cancer.  
Recently the NHSCSP has confirmed that the call and recall system operated by 
primary care trusts will no longer be able to invite and recall women for vault 
cytology or record these results.8  However, national guidelines currently make the 
following recommendations for women who have had a hysterectomy: 
For women: 
(i) on routine recall for at least 10 year prior to hysterectomy and no CIN 
identified at hysterectomy, no vault cytology is required; 
(ii) with less than 10 years routine recall and no CIN at hysterectomy, vault 
cytology should be undertaken 6 months after surgery, with no further 
cytological follow-up if it is negative; 
(iii) with completely excised CIN at hysterectomy, vault cytology should be 
undertaken at 6 and 18 months after surgery with no further cytological 
follow-up if both are negative;   
(iv) with incomplete or uncertain excision of CIN, follow-up should be conducted 
as if the cervix were still in situ. 9, 10, 11 
 
Audit data suggested that too many vaginal cytology tests were being performed in 
South Birmingham, UK.  Half were being undertaken in primary care with extremely 
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poor detection rates (only one serious abnormality was detected in almost 2,500 
vault tests over five years).12 
 Very little data are available to inform estimates of the cost and benefits of 
routine screening, using vault cytology tests, for those women who had a 
hysterectomy for reasons other than cancer.13  A survey of primary healthcare 
professionals demonstrated an inverse relationship between practitioners’ perceived 
frequency of doing vault cytology tests and their level of knowledge about the test, 
with practitioner's knowledge generally being poor.14 No routine data are collected 
about the frequency of screening using vaginal vault tests and in future it will be 
increasingly difficult to do so in view of the recent changes to recording.8   
 This study aimed to describe temporal trends concerning the use of vault 
cytology tests in both primary and secondary / tertiary care (the term secondary care 
is used hereafter to refer to all non-community based care).  Its objectives were to 
describe which professionals were taking vault cytology samples, on whom and 
what the test results revealed. 
 
METHODS 
 
The pathology department and cytology laboratory, at the Birmingham Women's 
NHS Foundation Trust, has had computerised records since 1995.  These include 
personal details of women, their clinical details, and results of all histological and 
cytological specimens processed.   
 
Population: 
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All women who had one or more vault cytology tests processed during the period 1 
April 1995 to 31 March 2005, at the Birmingham Women's NHS Foundation Trust 
were included.  Vault cytology tests were identified by searching the local free text 
codes for the terms "VGSM" or "VGBR" (representing vaginal smear or vaginal 
brush samples), previous audits having confirmed this to be the most accurate 
indicator of cytology test type.15  Complete cytology and histopathology records, 
including SNOMED codes and demographic data, were extracted for all eligible 
women.  The cut off date of 31 March 2005 was chosen as the first point at which 10 
years worth of electronic data became available but it was also only a few months 
after liquid-based cytology (LBC) was introduced to the department, on a rolling 
programme.  Thus a small number of late samples may have been LBC but the vast 
majority were conventional. 
 
Ethical approval was granted by South Birmingham Local Research Ethics 
Committee (9 November 2004 - 04/Q2707/234).  Birmingham Women's NHS 
Foundation Trust provided R&D approval and NHS indemnity (Approval No 
02020506, Project Ref WAD001).  
 
Data handling and statistical analysis: 
Data were fully anonymised before analysis. Vault cytology results were categorised 
as: unsatisfactory, borderline (equivalent to atypical), negative/normal, mild 
dyskaryosis (equivalent to low-grade squamous intraepithelial lesion), moderate 
dyskaryosis (including mild-moderate), severe dyskaryosis (moderate and severe 
equivalent to high-grade squamous intraepithelial lesion) and malignancy/cancer. 
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Due to ongoing uncertainty about the clinical significance of borderline results, this 
group was retained as a separate classification for most of the analyses. In 
summary statistics that describe 'all abnormalities', borderline results are included; 
where 'significantly abnormal' results are discussed borderline results are omitted.  
Sample takers were categorised as: general practice, other community based (all 
family planning services and genitourinary medicine), gynaecology outpatients, 
colposcopy, other outpatient clinics (including oncology), wards (test usually taken in 
the operating theatre but attributed to ward on which patient stayed), private 
practice.  Data were processed using FoxPro 5.0, Excel and Access 2000 
(Microsoft), and analyses undertaken using StatsDirect v2.6.3 and SPSS v12.0.1. 
 
 
RESULTS 
 
When duplicate entries were removed, there were 8,457 records of separate vaginal 
vault cytology tests during the study period (Table 1 and Flowchart 1) representing 
3,164 different women.  
 
Numbers of vault cytology tests per woman: 
The number of vault cytology tests per woman ranged from one to 17, with 47% of 
women having one test and over 87% having five or fewer during the ten year study 
period, following an exponential decay pattern (mean=3.06, median=2, mode=1).   
 
Age of women having vault cytology tests: 
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Age at vault cytology followed a near normal distribution (range: 17 to 95 years, 
median=52 years. mean=53, mode=49).  The median age of women having vault 
cytology tests increased over time (Table 1, Pearson correlation 0.922, p<0.001). 
 
Source of vault cytology samples: 
General practice was the most common setting for vault cytology tests, followed by 
gynaecology outpatient clinics (Table 1, Graph 1).  Private hospitals contributed 3% 
of vault cytology tests but it should be noted that consultants at these hospitals may 
have sent pathology samples to other laboratories for analysis and this figure may 
be an underestimate. 
 
The source of vault cytology tests varied over time (Table 1, Graph 1) with a greater 
decline in GP, other community settings and outpatient clinics than from the 
colposcopy service (GP and community sources versus all other vault cytology 
tests: χ2 for linear trend=4.8 (9df, P=0.028); ward, theatre and out patient tests 
versus all other settings: χ2 (linear trend)=139.53 (9df, P<0.0001); colposcopy 
versus all other sources χ2 (linear trend)=87.33 (9df, P<0.0001). 
 
Trends over time: 
Analysis was based on financial years (1 April - 31 March).  There was a significant 
downward trend in total numbers of vault tests analysed each year (Table 1, 
Pearson correlation -0.958, p<0.001).  During the study period the cytopathology 
department processed almost 400,000 cervical cytology tests.16  The percentage 
workload that vault cytology represented fell from 2.81% in 95-96 to 0.9% in 
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2004/05 (χ2 for trend= 545.9, P<0.0001).  The total numbers of cytology tests, 
processed by the laboratory each year, fell from a high of 42,987 in 1995/6 to 
34,798 in 2005/6 (Table 1).16  
 
Cytology results of vault samples: 
The vault cytology test results for each complete data year are summarised in Table 
2.  Abnormalities were detected in 8.9% of tests, with malignancy being detected in 
less than 0.1%.  The unsatisfactory sample rate of 10.7% compares reasonably well 
with the cervical cytology unsatisfactory rate of 9.3% nationally in 2003-0416 prior to 
the introduction of LBC throughout the UK, and favourably with the in-house 
unsatisfactory rate of 11.6% during the study period.  
 Significant abnormality (mild, moderate, severe, invasive) was reported in 
4.4% of all samples, with invasion suspected in 0.1% (n=8).  National figures for 
cervical cytology, for the last year of the study (2004-05)16, suggest that these 
findings are somewhat worse than those for cervical screening where only 3.3% of 
tests give abnormal results (i.e. mild 2.1%, moderate 0.7% severe 0.5%, invasive 
0.0%). 
The eight tests indicating malignancy were performed on four women, one of 
whom had 14 vault tests taken during the 10 year study period, four of them 
indicating malignancy.  The pattern of results suggests that not only were fewer 
tests being done, as the years passed, but that lower grade abnormalities were 
being detected. 
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Comparison of vault cytology tests in the primary and secondary care setting: 
General practice and the community setting had particularly low detection rates for 
significant abnormality over the ten year study period:  No malignancies and only 
two severe abnormalities were detected from almost four thousand vault cytology 
tests taken in primary care (Table 3, Flowchart 1).   
 Abnormal test results (i.e. borderline, mild, moderate, severe or malignancy) 
represented 2.8% (113) of the total, with the majority (n=73) of these being 
'borderline' results; whereas for the hospital settings (clinics, wards and operating 
theatres) the proportion of abnormal test results was 14.5% (n=616).  Table 3 
demonstrates the results of the tests by setting.  All the cytology results that 
indicated cancer (n=8, from 4 women) were detected in tests taken in gynaecology 
or colposcopy clinics and all the women were aged over 60.  Of the 93 samples that 
demonstrated severe abnormalities only three were taken in the community setting.  
These 93 results came from 39 different women, with a range from one to 14 tests 
each, although, as one might predict, for each woman the results often varied over 
time, reflecting their ongoing treatment. 
 When comparing national findings for cervical cytology with our study 
findings16 by the source of sample (Table 4), proportions of all grades of significant 
result were different in our population from that found in the general population:  
mild 1.5% versus 2.1%, moderate 1.8% versus 0.7%, severe 1.1% versus 0.5%.  
However, when the age group 50-54 yrs of women whose samples came from 
primary care were considered (the majority of our study population) the study results 
were very similar to national findings for cervical cytology (mild 0.8% vs 0.7%, 
moderate 0.2% vs 0.2% severe 0.1%  vs 0.1%).16 
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DISCUSSION 
There was a steady fall in the number of vault cytology tests processed each year, 
which was particularly noticeable from primary care and gynaecology outpatient 
clinics.  The average age of women having vault cytology tests appeared to be 
increasing over time and the most significant abnormalities were, nearly all, 
detected in secondary care settings. 
Anonymising the data prior to analysis meant that crosschecking outlying 
data was not possible.  However, internal audits at the cytopathology laboratory 
enabled verification of histopathology data and the increasing, consistent use of the 
new unique ten digit NHS number reduced the possibility of failure to link cytology 
tests undertaken in the same women.  This study used all the available data for the 
specified period thus reducing the potential for bias associated with selecting a 
subset of data.  Clinical practice in this area may not be typical of other locations, 
however analysis of data over a 10-year period meant that a proportion of the 
clinical staff in both primary and secondary care changed (retirement or relocation) 
and there is no evidence to suggest that our findings are atypical.  Another issue 
that arises from the use of a single centre is the representativeness of the 
catchment population.  Birmingham Women's NHS Foundation Trust may not be 
representative of the wider UK population; however the hospital catchment area 
includes a wide spectrum of both ethnic diversity and deprivation, with some 
patients being referred to the tertiary centre for specialist management, and others 
for generalist gynaecology. 
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 National guidance concerning use of vault cytology tests was updated in 
2003; the interval between vault tests post hysterectomy for CIN changed from '6 
and 12 months after surgery' to '6 and 18months' and the requirement for a woman 
to completed 10 years of cervical screening prior to hysterectomy added.  Analysis 
of the data was not influenced by this change and, due to the long study period, we 
do not believe that this affected our findings.  
 It is possible that the inclusion of data from private patients could have 
skewed the results as that sector of the population may not be representative of the 
local population.  However, private vault cytology tests represented less than 3% of 
the total workload and the results obtained were consistent with those from both 
primary and secondary care. 
 Nationally there was some variation in total numbers of cervical cytology tests 
performed annually over the study period; however, the net result was a very small 
drop in numbers, representing only a 1.3% fall over the decade of this study.17  
Locally, however, there was a significant drop in the number of cytology tests 
processed; 2004-05 represented the start of the move to LBC  and implementation 
of the revised call/recall procedures in 2004 may also have had an impact, however 
these changes were not implemented fully until 2005-06. 
 The decline in the number of vault cytology tests during this period is far 
greater than the decline in the number of cervical cytology tests and cannot be 
explained by national or local trends.  Within the 10-year study period research 
undertaken by the authors (2001-2003) may have increased primary care 
practitioners awareness about inappropriate use of vault cytology tests,14 and may 
have contributed to the decline in vault tests undertaken in the community.  In March 
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2002 a letter was sent to all GP surgeries in the area reminding smear-takers of 
national vault cytology test guidelines.  These activities still do not explain the 
reduction in the number of vault cytology tests during the study period as the 
numbers had begun to fall in the period 1999/2000. 
 There were significant variations over the 10-year period in terms of slides 
being classified as inadequate for interpretation.  This finding is likely to be 
multifactorial: in 1998-1999 the wooden Ayres spatula was withdrawn from use 
locally and the wooden extended tip Aylesbury spatula was adopted for 100% 
usage. Anatomically, the Ayres sampler was better suited to taking vault cytology 
tests than the Aylesbury and its introduction was associated with an increase in the 
classification of tests as inadequate.18 Cytology tests became more difficult to read 
as blood and polymorphs obscured more of the field, this was particularly relevant to 
older women and those women undergoing vaginal vault cytology.  At this time there 
was also more stringent application of the adequacy criteria for classifying a test as 
'inadequate.19,20,21  However, during the study period national inadequate sample 
rates varied from 4.5% to 17.5% of all submitted cytology tests, averaging 6.9% 
overall (excluding laboratories that were pilot sites for LBC at that time).17 
Birmingham Women's NHS Foundation Trust had one of the highest levels of 
inadequate rates in 2003-04. However, after the full introduction of LBC, which 
included formal training in the use of the Cervex-Brush, this level fell to 1.6% in 
2005-06.22  This change commenced in September 2004 but was phased in 
gradually and started towards the end of the study period so should not have had a 
substantial impact on these data. 
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 According to national guidelines, vault cytology tests should be performed 
only on women who are at significantly higher risk of vaginal cytological abnormality 
than the general population of women having hysterectomy operations.  Vault 
cytology is not funded as part of the national cervical screening programme and 
does not fit the criteria for a screening test as vaginal cancer is very rare.  However, 
in this selected population of women having had a hysterectomy and then selected 
for vault cytology, thus defined by a clinician as being at higher risk, we found a very 
low rate of cellular abnormalities detected by vault cytology testing, with the vast 
majority of results being normal or of no clinical significance.  Over 84% were 
classified as not demonstrating any significant abnormality, with a further 10.7% 
being unsatisfactory for interpretation.  Of the 4.5% that did demonstrate a 
significant abnormality, most demonstrated either mild or moderate dyskaryosis 
(n=281).  Severe dyskaryosis or invasive disease was reported in 1.2% of all the 
tests (101 from 8,457 tests) from 1.4% of the women (43 from 3,164 women).   
 These results suggest that vault cytology tests were probably not being 
restricted to higher risk women as they are similar to nationally detected findings 
from general cervical screening.16  Thus, in our study population, this test appears to 
have low detection rates for disease.  In particular, those tests being done in the 
community setting were unlikely to detect any significant abnormalities, thus raising 
questions about the usefulness of the vault cytology test in the community setting.  
Rates of high grade abnormalities did not increase over time, as the total number of 
tests was falling, which supports the hypothesis that the tests are not being 
restricted to higher risk women.  This, raises the question of how VaIN and early 
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vaginal cancer are currently being detected and what role vault cytology testing now 
has.   
 
In summary, it would appear that use of vaginal vault cytology tests is declining, 
particularly those taken in outpatient clinics and the community setting.  This decline 
appears appropriate given the poor detection rates for significant disease in the 
community and that the call-recall system of the NHSCSP no longer includes 
women without a cervix.  It is now timely to open discussions amongst clinicians as 
to how they can best detect and diagnose VaIN? What is the place for vault 
cytology? and is there a role for better training or education of clinicians who take 
vault cytology samples?  To establish the true value of vaginal vault cytology tests it 
would be necessary to access more comprehensive data about women's screening 
histories, their hysterectomy pathology results and the results of any subsequent 
vault cytology tests and subsequent biopsies.  
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Table 1:  Trends over time in numbers of vault and cervical cytology tests and source of those tests 
 
Primary Care 
 
Secondary Care  
Year 
Vault 
tests 
p/a  
Change 
In 
vaults 
% p/a 
Cervical  
tests 
p/a 
Change  
in 
cervical 
% pa 
% of  
workload 
as vaults 
Odds 
ratios* 
 
Mean 
age** 
GP Community Ward, & 
out-
patients 
Colp 
Clinics
Private 
1995-96 1,206 
 
N/A 42,987 N/A 2.81 1.00 51.97 550 22 589 45 0 
1996-97 1,032 
 
- 14.4 40,747 - 5.2 2.53 0.90 52.61 460 21 408 143 0 
1997-98 1,048 
 
+ 1.6 38,091 - 6.5 2.75 0.98 52.40 441 15 385 164 43 
1998-99 1,047 
 
 0.0 38,829 + 1.9 2.70 0.96 52.41 469 19 357 163 39 
1999-2000 986 
 
- 5.8 37,962 - 2.2 2.60 0.92 53.67 466 7 339 146 28 
2000-01 858 
 
- 13.0 36,615 - 3.5 2.34 0.83 53.14 370 8 292 154 34 
2001-02 734 
 
- 14.5 40,419 + 10.4 1.82 0.64 53.91 309 5 245 133 42 
2002-03 671 
 
- 8.6 38,765 - 4.1 1.73 0.61 53.96 348 4 189 99 31 
2003-04 561 
 
- 16.3 36,963 - 4.6 1.52 0.53 53.71 289 0 147 101 24 
2004-05 
 
314 - 44.0 34,798 - 5.9 0.90 0.32 54.66 161 2 70 72 9 
3,863
45.7
%
103
1.2%
3,021
35.7%
1,220
14.45
250 
3.0% 
Total 
% 
8,457 - % 386,176 2.19%  53.01
46.9%   53.1% 
*  χ2 for trend = 545.9, P<0.0001  ** Pearson correlation -0.922, p<0.001 
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Table 2:  Variation in ‘Results’ codes over time  
 
Non significant 
 
Significant Totals Result: 
Yr: 
Unsatisf
actory 
Normal Borderline Mild 
 
Mod Severe Cancer 
95-96  n 
          % 
81 
6.7 
1,020 
84.6 
46
3.8
17
1.4
15
1.2
24 
2.0 
3
0.4
1,206
96-97 77 
7.5 
876 
84.9 
39
3.8
9
0.9
16
1.6
13 
1.3 
2
0.2
1,032
97-98 82 
7.8 
879 
83.9 
28
2.7
17
1.6
23
2.2
19 
1.8 
0
0
1,048
98-99 81 
7.7 
877 
83.8 
43
4.1
11
1.1
22
2.1
13 
1.2 
0
0
1,047
99-00 128 
13.0 
761 
77.2 
53
5.4
15
1.5
19
1.9
8 
0.8 
2
0.2
986
00-01 111 
12.9 
656 
76.5 
57
6.6
11
1.3
18
2.1
5 
0.6 
0
0
858
01-02 65 
8.9 
598 
81.5 
37
5.0
13
1.8
17
2.3
4 
0.5 
0
0
734
02-03 129 
9.2 
484 
72.1 
32
4.8
12
1.8
9
1.3
4 
0.6 
1
0.2
671
03-04 109 
19.4 
401 
71.5 
33
5.9
10
1.8
8
1.4
0 
0 
0
0
561
04-05 39 
12.4 
241 
76.8 
12
3.8
10
3.2
9
2.9
3 
1.0 
0
0
314
902 
10.7 
6793 
80.3 
380
4.5
125
1.5
156
1.8
93 
1.1 
8
0.1
   8,457 Total 
% 
95.5% 4.5% 
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Table 3:  Vault  cytology results by source (1995-2005) 
 
Result  
 
Source 
Unsatis 
factory 
Normal 
Border 
line 
Mild Mod Severe Cancer Totals 
General             N 
Practice             % 
                       OR* 
382 
(9.9%) 
1 
3,371 
(87.3%) 
1 
71 
(1.8%) 
1 
30 
(1.0%) 
1 
7 
(0.2%) 
1 
2 
(0.1%) 
1 
0 
(0%) 
- 
3,863 
(100%) 
 
Community       N 
                          % 
                        OR 
9 
(8.7%) 
0.9 
91 
(88.3%) 
1.0 
2 
(1.9%) 
0.9 
1 
(1.0%) 
1 
0 
(0%) 
- 
0 
(0%) 
- 
0 
(0%) 
- 
103 
(100%) 
Subtotal            N 
GP/Community  % 
391 
(9.8%) 
3,462 
(86.6%) 
73 
(1.8%) 
31 
(0.8%) 
7 
(0.2%) 
2 
(0.1%) 
0 
(0%) 
3996 
(100%) 
Out patients      N 
 or wards           % 
                        OR 
353 
(11.7%) 
1.2 
2,470 
(81.8%) 
0.9 
113 
(3.7%) 
0.5 
22 
(0.7%) 
0.7 
25 
(0.8%) 
4.0 
32 
(1.1%) 
11.0 
6 
(0.2%) 
- 
3,021 
(100%) 
Colposcopy      N 
                 % 
                    OR   
141 
(11.6%) 
1.2 
661 
(54.2%) 
0.6 
165 
(13.5%) 
7.3 
122 
(10.0%) 
10.0 
59 
(4.8%) 
24.0 
59 
(4.8%) 
48.0 
2 
(0.2%) 
- 
1,220 
(100%) 
Subtotal             N 
OPD / Colp        % 
494 
(11.6%) 
3,131 
(73.8%) 
278 
(6.6%) 
144 
(3.3%) 
87 
(2.1%) 
91 
(2.1%) 
8 
(0.2%) 
4,241 
(100%) 
Private               N 
 % 
 OR 
17 
(6.8%) 
0.7 
200 
(80.0%) 
0.9 
29 
(11.6%) 
6.3 
2 
(0.8%) 
0.8 
2 
(0.8%) 
4.0 
0 
(0%) 
- 
0 
(0%) 
- 
250 
(100%) 
Total 
 
902 
10.7% 
 
6,793 
80.3% 
380 
4.5% 
125 
1.5% 
156 
1.8% 
93 
1.1% 
8 
0.1% 
8,457 
*  Odds ratios calculated compared with General Practice as a source 
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Table 4:  Comparison of vault audit results with national cervical screening 
results from 2004/05 (percentages)* 
 
 
 Mild Moderate Severe Invasive 
All ages / All sources 
Study results 1.5 1.8 1.1 0.1 
National: all results 2.1 0.7 0.5 0 
GP & Community 
Study results 0.8 0.2 0.1 0.0 
National: all results 1.8 0.6 0.4 0.0 
National: aged 50-54 only** 0.7 0.2 0.1 0.0 
Hospital 
Study results 3.3 2.1 2.1 0.2 
National: all results 6.8 2.5 1.9 0.1 
*  National data taken from Table 14 of Cervical Screening Programme Bulletin:  Samples 
examined by pathology laboratories, by source of sample and result of test 2004-05. 
**  Age specific data taken from Table 15 of Cervical Screening Programme Bulletin:  GP & NHS 
Community Clinic samples examined by pathology laboratories, by result and age of women, 
2004-05. 
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Graph 1: Source of vault cytology tests, each year 
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8,457 vault tests 
from 3,164 women 
 
Primary Care = 3,966 
Secondary Care = 4,491 (53.1%)  
Normal / 
Unsatisfactory / 
Borderline 
= 8,075 (95.5%) 
 
Primary Care = 3,926 
Secondary Care = 4,149 
(51.4%) 
 
Mild 
 
= 125 (1.5%) 
 
Primary Care = 31 
Secondary Care = 94 
(75.2%) 
 
Cancer 
 
= 8 (0.1%) 
 
Primary Care = 0 
Secondary Care = 8 
(100%) 
Flowchart 1: Vault cytology tests data 
 
Severe 
 
= 93 (1.1%) 
 
Primary Care = 2 
Secondary Care = 91 
(97.8%) 
 
Moderate 
 
= 156 (1.8%) 
 
Primary Care = 7 
Secondary Care =149 
(95.5%) 
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Appendix C Modulus 11 algorithm for NHS number check digit   
 
The NHS number comprises 10 digits.  The first nine are the identifier and the tenth is a check digit used to 
confirm the number’s validity.  The check digit is calculated using the Modulus 11 algorithm.  There are four 
steps in the calculation: 
 
Step 1:  Multiply each of the first nine digits by a weighting factor as follows: 
 
Digit Position (starting from the left) Factor 
1 10 
2 9 
3 8 
4 7 
5 6 
6 5 
7 4 
8 3 
9 2 
 
Step 2:  Add the results of each multiplication together. 
Step 3:  Divide the total by 11 and establish the remainder. 
Step 4:  Subtract the remainder from 11 to give the check digit. 
There are two occasions where the check digit calculation process must be modified slightly: 
 If the result of step 4 is 11 then a check digit of 0 is used 
 If the result of step 4 is 10 then the number is invalid and not used 
 
Example:  Suppose the first nine digits of the number are 401 023 213 
Step 1 - apply weighting factors 
 
Digit Position Value Factor Result 
1 4 x 10 = 40 
2 0 x 9 = 0 
3 1 x 8 = 8 
4 0 x 7 = 0 
5 2 x 6 = 12 
6 3 x 5 = 15 
7 2 x 4 = 8 
8 1 x 3 = 3 
9 3 x 2 = 6 
 
Step 2 – add the results of each multiplication together 
40 + 0 + 8 + 0 + 12 + 15 + 8 + 3 + 6 = 92 
Step 3 – divide the total by 11    (92 / 11) = 8, remainder 4 
Step 4 – subtract the remainder from 11 to give the check digit  11 – 4 = 7 
 
The complete new NHS number in this example is therefore:   401 023 2137. 
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Appendix D to Appendix G 
 
Not available in the digital copy of this thesis  
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Appendix H:  Assumptions used in the WMQARC cervical screening 
status and history algorithms 
 
Criteria (per woman) Assumption 
Women born before 01/10/1984 
(aged 20 at first invitation) 
Should attend for their first screen within 6 months of 
their 20th birthday OR within 5.5 years of the start of the 
NHSCSP (30/06/1993) - whichever is latest 
Women born on or after 
01/10/1984 (aged ~ 25 at first 
invitation) 
Should attend for their first screen -2 / +6 months of their 
25th birthday 
Women aged 65 or over at 
diagnosis 
Not eligible for screening at time of diagnosis regardless 
of any tests taken after the woman’s 65th birthday 
Women aged under 20 at diagnosis 
(born before 01/10/1984) Not eligible for screening at time of diagnosis 
Women aged under 24 10/12 at 
diagnosis (born on or after 
01/10/1984) 
Not eligible for screening at time of diagnosis 
Women born before 01/01/1923 Have never been eligible for screening (regardless of whether they have attended for screening) 
Criteria (per test) Assumption 
Tests taken on or after date of 
diagnosis Always excluded from classification 
Tests with private hospital sender 
codes Always excluded from classification 
Tests with a hospital sender code 
Excluded from classification but recall number of months 
used if test is followed by a GP test recommending 
referral 
Tests with normal recall or early 
recall action codes 
Always included in classification regardless of intervals 
between tests 
Tests taken before 01/01/1988 Always included in classification 
Tests recommending referral 
Only included in classification if taken at appropriate time 
interval after last test OR the test is the woman's first test 
and fits into criteria described 
Tests taken when woman aged 
less than 24 10/12 (if born on or 
after 01/10/1984) 
Excluded from screening status and screening history 
(there should not be any).  Cases flagged as a QA issue 
Tests taken when woman aged 65 
or over 
Excluded from screening status but are included in 
history 
Number of months 
recommended recall 
Number of months assume woman should 
return for next screen 
36, 48 or 60 ± 6 
6 or 12 ± 3 
2 or 3 -1 and +3 
1 Should not attend early, but can attend up to 3 months late. 
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Appendix J:  Cancer and Gynaecological re-coding of ICD-10 
 
# Meaning of diagnosis codes  
 
Relevant ICD10 Codes 
01 No interest to project* All else: A00-A50, A65-A99, B00-B20, B22-
99,D50-D89, E-M,N: 0-64, N99, P, Q* 
02 Neoplasms, malignant, non gynae 
 
B21 (HIV) C00-C50, C60-C97 
03 Neoplasms, in-situ, non gynae 
 
D01-D05, D09 
05 Neoplasms, benign non gynae 
 
D00, D10-24, D29-D38, D40-D48  
10 Obstetric general 
 
O00, O10 - O99 
12 Neoplasms, malignant gynae 
 
C51-C58 
13 Neoplasms, in-situ, gynae 
 
D06-D07 
14 Neoplasms, intraepithelial neoplasia, gynae 
 
N87, N89.0-N89.3, N90.0-90.3 
15 Neoplasms, benign & unknown, gynae 
 
O01, D25-D28, D39 
16 Other gynae diagnoses: Inflammation 
 
N70 - N77 
17 Other gynae diagnoses: Infection 
 
A51-A64 
18 Other gynae diagnoses:  Bleeding, 
menstrual disorder and menopausal 
disorder 
N91 - N95 
19 Other gynae diagnoses NOS 
(Including endometriosis, prolapse, 
infertility, fistula, polyp, miscarriage) 
N80-86, N88, N89.4-N90, N90.4-N90.9, N96-
98, O02-O08 
88 Descriptive terms only (not true diagnosis), 
non gynae 
R00 - Z99 
99 Missing data (empty cells) 
 
- 
*Items in italics represent codes that are not diagnosis based.   
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Appendix K:  Full re-coding of screening history before hysterectomy 
 
Main 
Group 
Full 
Code 
Explanation 
 
Conversion notes 
11 Index abnormal, previous history 
includes abnormal tests 
If 4th digit = 1, 5th digit = 4  
or 4th dig 2/3/4/5/6 and 5th = 3 
13 Index abnormal, previous history 
only ever normal 
If 4th digit = 1, 5th digit = 2  
or 4th dig 2/3/4/5/6 and 5th = 4 
18 Index abnormal, previous history 
includes tests of uncertain 
significance 
If 4th digit = 1, 5th digit = 3 
or 4th dig 2/3/4/5/6 and 5th = 
1/2 
 
 
 
 
1 
19 Index abnormal, only one test 
pre-op 
Index 
abnormal 
(borderline 
or worse): 
3rd digit 
=3/4/5 
If 4th digit = 1, 5th digit = 1  
 
31 Index normal, previous history 
includes abnormal tests 
If 4th digit = 1, 5th digit = 4  
or 4th dig 2/3/4/5/6 and 5th = 3 
33 Index normal, previous history 
all normal 
If 4th digit = 1, 5th digit = 2  
or 4th dig 2/3/4/5/6 and 5th = 4 
38 Index normal, previous history 
includes tests of uncertain 
significance 
If 4th digit = 1, 5th digit = 3 
or 4th dig 2/3/4/5/6 and 5th = ½ 
 
 
 
 
2 
39 Index normal, only one test pre-
op 
Index 
normal: 
3rd digit=1 
If 4th digit = 1, 5th digit = 1  
 
81 Index of uncertain significance, 
previous history includes 
abnormal tests 
If 4th digit = 1, 5th digit = 4  
or 4th dig 2/3/4/5/6 and 5th = 3 
83 Index of uncertain significance, 
previous history only ever 
normal 
If 4th digit = 1, 5th digit = 2  
or 4th dig 2/3/4/5/6 and 5th = 4 
88 Index of uncertain significance, 
previous history includes 
uncertain test results 
If 4th digit = 1, 5th digit = 3 
or 4th dig 2/3/4/5/6 and 5th = 
1/2   
 
 
 
3 
89 Index of uncertain significance, 
only 1 pre-operative test 
Index 
uncertain 
(inadequate 
or recall 
suspended):
3rd digit=2/6 
If 4th digit = 1, 5th digit = 1  
 
4 99 Never had any pre-op testing, or 
at least nil recorded in Exeter or 
too old to have ever been 
detected in programme (even if 
did have smears) 
No index 
test 
All 5 digit code where first digit 
is 1,2,9  
or Any Single digit code 
starting 1,2,3,5,9  
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Appendix L:   Published study protocol 
 
 
Variation in NHS utilisation of vault smear tests in women post-hysterectomy:  
A study, using routinely collected datasets 
 
Helen J Stokes-Lampard*1, John Macleod2, Sue Wilson1 
 
1  Department of Primary Care and General Practice, University of Birmingham, Edgbaston, 
Birmingham, West Mids, UK, B15 2TT 
2  Department of Social Medicine, University of Bristol, Canynge Hall, Whiteladies Road, Bristol, 
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john.macleod@bristol.ac.uk; Sue Wilson  - s.wilson@bham.ac.uk 
* Corresponding author 
 
 
 
Abstract  
 
Background 
20% of women living in the UK have a hysterectomy during their lifetime, levels are 
higher in the USA, making it one of the most commonly performed major surgical 
procedures.  Understanding of the indications for hysterectomy and of the rationale 
for follow-up of women post hysterectomy is currently limited. Guidelines concerning 
follow-up by means of vaginal vault cytology tests exist but these are not based on 
'gold standard' evidence. Furthermore, the extent to which current practice reflects 
these guidelines is unclear.  This study aims to determine the factors associated 
with variability in hysterectomy rates and subsequent follow-up after surgery by use 
of the vaginal vault smear cytology test. 
 
Methods/Design 
All women resident in the West Midlands region, of the United Kingdom,  who had a 
hysterectomy operation between 1st April 2002 and 30th March 2003 will be 
identified from the Hospital Episodes Statistics database which also contains proxy 
data on deprivation status, derived from postcode and self declared ethnicity.  
These data will be linked to regional cervical screening records for each woman and 
histopathology laboratory records from the relevant hospitals.  Study objectives are 
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to describe: Indications for the hysterectomy operation, histology at hysterectomy, 
subsequent follow-up by use or non-use of vaginal vault cytology tests and variation 
between histological groups.  Additionally the data will be categorised according to a 
woman's cytology screening history prior to surgery (i.e. always normal, borderline, 
resolved abnormalities, CIN etc) and these different groups compared.  Variations in 
these outcomes according to age, deprivation and ethnic group will also be 
examined.  Analysis will be undertaken using SPSS. 
 
Discussion 
This study will clarify patterns of current practice in one large English region and 
determine whether this practice reflects existing guidelines.  The study will also 
strengthen the evidence base for future guidelines.  
 
Study registration:  National Research Register N0138173331 
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Background 
 
Surgical removal of the uterus (womb) is a ‘hysterectomy’ operation; over 98% 
women who have their uterus removed also have the cervix uteri or ‘neck’ of the 
uterus removed at the same time, a total hysterectomy[1].  This leaves the vagina 
as a pouch with a blind end at the site of amputation of the cervix.  There were 
around 39,000 hysterectomy procedures undertaken in the UK in 2005 [2], a 
cumulative lifetime incidence of 20% [3, 4], making it one of the most frequently 
performed major surgical procedures [5].   
 
The most common indication for a hysterectomy is menorrhagia which accounts for 
46% of all hysterectomies.  Prolapse accounts for a further 20%, and fibroids (or 
leiomyoma) another 18%-21% [6]; 90% of hysterectomies are performed for benign 
or noncancerous conditions [7]. 
 
Hysterectomy is inversely associated with social class and education with women 
from lower social classes being more likely to have a hysterectomy [3]. Several 
large cohort studies have examined the indications for hysterectomy in the UK, 
however none has published details of how these women are followed-up or the 
cost-effectiveness of the vaginal vault cytology test (known colloquially as a 'vault 
smear') in the population [3,4,6].  A vault smear is a cytological sample taken from 
the blind end of the vagina; the vault smear is used a means of identifying recurrent 
cervical cancer or the development of vaginal neoplasia.  Total hysterectomy is 
usually a reason for ceasing recall from the routine cervical screening programme, 
as the cervix is no longer present. 
 
No international consensus exists on the appropriate extent of cytological screening 
in women who have undergone hysterectomy, as evidence for the appropriate use 
of vaginal vault smears post-hysterectomy and the optimum period of follow-up is 
sparse.  The majority of published studies recommend the use of vaginal vault 
smears in the follow-up of women who have had a hysterectomy subsequent to the 
diagnosis of an invasive tumour of the cervix uteri, or where invasive disease is an 
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incidental finding at hysterectomy [8,9,10,11,12].  A systematic review of the 
literature [13] could identify no robust controlled trials that establish the value of the 
follow-up, by vault smears, for women who have had a hysterectomy for benign 
indications.  The available evidence does, however, suggest that the vault smear 
test has a very low positive predictive value when used as a screening tool in the 
absence of symptoms or clinical signs [8,9,14].  Therefore, most commentators 
recommend that vault smears for post-hysterectomy follow-up are only required for 
women who have had a histological diagnosis of Cervical Intraepithelial Neoplasia 
(CIN) III or frank malignancy [10,11,12].  Some go as far as to say that even in 
women with previous cytological abnormality, vault smears should be limited to 
those who present with symptoms or in whom an abnormality is detected clinically 
[15].   
 
Currently the UK National Health Service Cervical Screening Programme 
(NHSCSP) guidelines for the use of vaginal vault smears are: [16,17] 
(i) for women on routine recall for at least 10 years prior to hysterectomy, and 
no CIN in the histopathology sample at hysterectomy, no vault cytology is required. 
(ii) for women with less than 10 years' routine recall and no CIN at hysterectomy, 
a sample should be taken from the vaginal vault six months after surgery and there 
should be no further cytology follow-up if it is negative. 
(iii) for women with completely excised CIN at hysterectomy, a sample should be 
taken from the vault at 6 and 18months after surgery and there should be no further 
cytology follow-up if both samples are negative. 
(iii) for women with incomplete or uncertain excision of CIN follow-up should be 
conducted as if the cervix were still in situ (i.e as for low and high risk follow-up). 
 (iv) women who have undergone a hysterectomy but where the cervix is not 
completely excised are treated as if the cervix were still present and as such they 
remain in the normal cervical screening programme. 
 
In a survey of primary healthcare professionals in South Birmingham, UK, half of all 
vault smear tests were conducted in the primary care setting but primary healthcare 
professionals’ knowledge about the role of the test was poor [18]. Professionals 
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whose knowledge about the test was best, performed the test least often, and only 
one significant abnormality was detected in over 5,000 vault smear specimens[18].  
However, there is no recent reliable data on the patterns and variability in vault 
smear follow up and the extent of compliance with the national guidelines is 
unknown.   
 
No large-scale population studies have been undertaken to establish the actual 
patterns of follow-up, by use of vault smear tests, after hysterectomy.  One 
American study compared the results of vault smears with cervical smears, in 
matched controls, and noted that there was a significantly reduced risk of test 
abnormality in those followed up post-hysterectomy [19].  Vault smear tests 
undertaken in asymptomatic women can have a high false positive rate thus 
reducing the usefulness of the test[8].  Large-scale national cohort studies have 
reported on the socioeconomic distribution of patients undergoing hysterectomy [4] 
and the distribution of hysterectomy type (vaginal versus abdominal),[6] but none 
has examined the socioeconomic distribution of the histology results at surgery and 
the socioeconomic distribution of any subsequent follow-up by means of vault 
cytology. 
 
No international consensus exists as to the most appropriate follow up by vault 
smear test after hysterectomy [18]; the UK guidelines are not based upon ‘gold-
standard’ evidence [16, 17].  With the increasing pressure on diagnostic and 
treatment services, the evaluation of diagnostic services and identification of 
inappropriate testing are necessary prerequisites to improving the efficiency of 
service provision.  Thus there is a need for an adequately powered, population 
based study to consider the issue of hysterectomy follow up, the outcome of which 
may be used to inform national guidelines and encourage the teaching of best 
practice. 
 
Key objectives:  
-  Estimate age and socioeconomic specific incidence rates for hysterectomy, in the 
West Midlands. 
 - A115 -  
 
-  Describe indications for hysterectomy in West Midlands. 
-  Describe variations in incidence and establish those factors associated with 
variability. 
-  Establish the current pattern of follow-up after hysterectomy by means of vaginal 
vault cytology test. 
 
Methods/Design 
 
Study design: This retrospective population-based analysis of routinely collected 
data will link data, from three key sources and hence enable us to address the study 
objectives.  Figure 1 illustrates the main stages of the study. 
 
Hospital episode statistics (HES) is the national statistical data warehouse for 
England of the care provided by NHS hospitals and for NHS hospital patients 
treated elsewhere.  It is the data source for a wide range of healthcare analysis for 
the NHS, Government and many other organisations and individuals. For this study 
HES will be used to identify the population of women having a hysterectomy during 
the 2002 - 2003 fiscal year (1 April 2002 - 30 March 2003).  These women's cervical 
screening history records will be obtained from the local health authority cytology 
databases; complete records of cytology results for all women who have had 
cervical screening within a local catchment area, ten such areas cover the West 
Midlands Health Authority region.  All these cytology databases use the same suite 
of software and contribute to national statistics to ensure uniform reporting. These 
data will be linked and pseudo-anonymised to just NHS number:  A national, unique, 
ten-digit identifier that makes it possible to share patient information across the 
whole of the NHS) then supplemental data about specific diagnosis and laboratory 
advice will be added from hospital pathology laboratory records [20].  The dataset 
will be fully anonymised to ensure patient confidentiality. 
 
Selection and exclusion criteria:  The cohort will include all women resident in the 
West Midlands region who had a hysterectomy operation during the defined study 
period.   
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Population: The West Midlands conurbation of 5.2 million inhabitants covers a very 
diverse population:  It includes urban, suburban and rural areas ranging from some 
of the most to the least affluent wards in the country [21].  This represents a 10% 
sample of the population of England and Wales, (11% of England) and has, on 
average, a similar age, sex and socioeconomic profile to the UK as a whole [22]. 
 
Black and minority ethnic groups make up 11.3% of the West Midlands population, 
however the range within the region is quite striking with the 'Birmingham' Local 
Health Authority recording 29.6% of persons classifying themselves as being of 
black or minority ethnic group (second only to London) but the 'Staffordshire 
Moorlands' Health Authority figure is only 0.7% [22]. 
 
Study methodology:  The study depends upon the extraction of data, from three 
separate routinely collected datasets, which will then be combined into a relational 
database (Microsoft Access 2007) in a format suitable for analysis and fully 
anonymised.  Table 1 summarises all the data items to be requested and those that 
will be used to facilitate data linkage between the three databases. 
 
Data sources: 
The Hospital Episode Statistics (HES) dataset is managed by Northgate Information 
Solutions and access to sensitive confidential information requires permission to be 
granted by their security and confidentiality advisory group (SCAG) [23].  It is from 
this database that hospital in-patient data will be extracted:  Data about all 
hysterectomy operations will be requested and then categorised as ‘total’ and ‘sub-
total’ hysterectomies with the sub-total operations being excluded after verification. 
 
The NHS Information Authority (NHSIA) has control over the Exeter database:  The 
NHSIA is a ‘special health authority’ formed in 1999, the ‘Exeter’ system or now, 
more correctly the ‘National Health Applications and Infrastructure Service’ (NHAIS) 
is an integrated suite of software used by all health authorities at a regional level for 
holding administrative details of patients on GPs lists and used to manage patient 
 - A117 -  
 
registration, GP payments, breast and cervical screening programme [24].  The 
NHSIA will provide the following dataset:  All women, residing in the West Midlands 
region and identified from the HES dataset, who have ever had a smear test 
(cervical or vaginal).   
 
Currently there are 17 cytopathology units in the West Midlands region and over 20 
units where hysterectomy operations are performed routinely.  To obtain accurate 
data concerning the histology at hysterectomy, it will be necessary to access the 
histopathology records from some hospitals directly.  Since 1995 all histopathology 
laboratories in the West Midlands have had stand alone, computerised databases of 
their clinical records and thus data extraction will not require access to patient case 
notes, just to the electronic histopathology and cytopathology records.   
 
Once matching and merging of all three data sets is complete, all data will be 
anonymised to the level of unique study identifier, age at hysterectomy and 
deprivation index; thus NHS number, surname, date of birth and postcode will be 
replaced with less identifiable indices. 
 
The whole project was registered on the National Research Register in December 
2004 entry: N0138173331.  The approvals of both Multi Research Ethics Committee 
(MREC) and Patient Information Advisory Group (PIAG), have already been granted 
(MREC - West Mids MREC Approval granted on 27th April 2005 Ref: 05/MRE07/27, 
PIAG Full approval - 7th March 2006 Ref: 4-05(e)/2005).  SCAG of HES granted 
approval for access to their data on 11th April 2006, Ref:  ET0693. 
 
Ethical issues:  This project justifies the use of confidential patient data because the 
likely benefits to society outweigh the implications of that transient loss of 
confidentiality.  The outcome of this research may have significant implications for 
the general population of women thus it may be argued that it is in the public’s best 
interests for the research to be undertaken.  There is no intention to feed information 
back to the individuals involved or take any decision that affects them.  There are no 
practicable alternatives to access patient data of this quality that would be of equal 
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effectiveness.  Confidentiality has been planned from the outset of this study, and 
data will be anonymised as soon as is practicable after data validation has taken 
place. 
 
Power calculation/justification of sample size:  
This is a pragmatic sample of all women in the West Midlands Region who 
underwent a hysterectomy operation but sample size calculations were undertaken 
during protocol development to ensure the study will have sufficient power to detect 
important differences. 
 
The key groups of women are specified by their histology result at the time of 
surgery (benign / cervical intraepithelial neoplasia (CIN) / malignant) as this 
determines their recommended follow up according to national guidelines.  The data 
in Table 2 were used to provide the estimated proportions on the basis of previous 
research by the authors (Stokes-Lampard H, Wilson S, Waddell C, Bentley L, 
Vaginal vault smears:  10-years of data from a tertiary centre (Birmingham Women's 
Hospital NHS Trust),  awaiting publication.) 
 
Assumptions:   
 4,500 hysterectomies annually in West Midlands.   
 80% of hysterectomies undertaken for benign indications 
 10% for CIN 
 5% for cancer 
 5% will sub-total hysterectomies and excluded from analysis (approximately 
225 cases excluded).  
 
For the benign histology group, a sample of 1,800 women will be sufficient to 
estimate prevalence of follow up to within +/-1% (95% CI); for the CIN and cancer 
groups the estimate would be to within +/-4% (95%CI).  Thus the expected sample 
should be more than adequate and does not need to be expanded further. 
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Analysis: Will be undertaken using SPSS for Windows statistical software, with 
queries in Microsoft Access 2003® used to produce descriptive data.  A substantial 
amount of descriptive analysis of the data will be undertaken i.e. frequency 
distributions, cross tabulations and simple proportions, much of which will be 
amenable to visual formats. 
 
Comparison of the whole study population with the West Midlands and England 
populations (2001 census data) with respect to Index of Multiple Deprivation [22], 
age, and ethnicity will be undertaken initially and the results tabulated.  Then age-
specific incidence rates (5-year age bands) for hysterectomy will be calculated. 
 
Pre specified analysis will be used to describe and explore those factors potentially 
affecting variability within the three main research areas i.e. i. Indications for 
hysterectomy, ii. duration of hospital stay after hysterectomy and iii. follow up after 
hysterectomy by means of the vaginal vault smear cytology (vault smear test), 
 
Hospital diagnosis (obtained from HES records) will be used as a proxy for 
indication for hysterectomy. Indications for hysterectomy will be explored with 
respect to deprivation score, age, ethnicity and hospital where surgery took place.  
Duration of hospital stay will be described and explored with respect to age, 
ethnicity and deprivation score.  Each of these will be considered further by 
histology type; benign, CIN (further subdivided into CIN I, II & III) and malignant.  
Pre-hysterectomy cervical cytology data will be explored with respect to age, 
deprivation and ethnicity.  This data will be coded according to 'per protocol' and 
'non-protocol' patterns, according to UK guidelines, using an algorithm constructed 
by the cancer registry in the West Midlands, this is to ensure standardised results to 
facilitate future analysis.  Post-hysterectomy vault cytology will be explored with 
respect to age, histology type, deprivation and ethnicity.  Most of this descriptive 
analysis will be explored using χ2 and t-tests as appropriate. 
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Multiple regression analyses will aim to determine the relative importance of those 
factors (i.e. age, deprivation index, hospital of procedure and ethnicity) on the 
outcomes of interest.   
 
Finally, differences in the rates of vault smear cytology between the different 
histology sub-groups will be further explored using Kaplan-Meir survival analysis.  
The sub-groups will be compared with national guidelines to establish compliance. 
 
Outcome measures: 
-  Hysterectomy rates:  Age and deprivation index standardised rates; histology, 
consultant and unit specific rates. 
-  Proportion of women who have smear tests that undergo a hysterectomy 
procedure by histology and also by age, deprivation index, hospital and indication 
for surgery. 
-  Proportions of those women having a hysterectomy which results in the histology 
being reported as benign / CIN / malignant. 
-  Proportion of those having a hysterectomy that are followed up by vault smear 
tests, with respect to histology group (benign / CIN / malignant), age, deprivation 
index, hospital, origin of test (primary or secondary care) consultant and indication 
for surgery. 
-  Analysis of over / under use of vaginal vault smears with respect to current 
national guidelines. 
 
 
Discussion 
 
Pilot work suggests that too many vault smear tests are probably being undertaken 
and that this test has poor sensitivity to detect disease in low risk women.  These 
findings fit with some published work but there is a dearth of high quality research in 
this area. 
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This research will establish which women are currently having hysterectomy 
operations and determine when vault smear cytology tests are being done, both in 
terms of time elapsed post-operatively and histological indication for the test. Thus, 
compliance with current guidelines will be established and evidence to support the 
development of future guidelines will be generated. 
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Figure 1:  Study design 
 
 
 
HES Data:  
All Hysterectomy operations, 
W Mids, 2002-03. 
Cytology Records:  
Entire screening 
history, all results for 
up to 3 years post 
surgery  
Hospital 
Histopathology 
records:  Data about 
operation, other 
pathologies
Unique database: Women's 
hysterectomy details plus entire 
cytology screening history, operation 
histology and demographics. 
Ethics approval 
& PIAG 
approval 
Analysis:  Descriptive analysis of data, 
logistic regression analysis of factors 
associated with follow-up by vault smear test.  
Subgroup analysis by histology at 
hysterectomy. 
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Table 1:  Summary of extracted data and derived data items to be obtained 
from the three sources. 
 
 Hospital Episode 
Statistics (HES) 
'Exeter'  
Cervical Screening data 
Local Hospital 
Histopathology data 
Identifiers 
for linkage 
NHS Number, date of 
birth, postcode of home 
address. 
 
NHS Number, date of 
birth, postcode of home 
address. 
NHS Number. 
Data items Ethnicity, dates of 
hysterectomy operation, 
admission and discharge, 
surgical operation code(s) 
OPCS, diagnosis code(s) 
SNOMED morphology, 
hospital, consultant, GP 
and PCT of residence. 
 
Dates of all smear tests, 
results of those smear 
tests and recommended 
follow up, details of 
smear taker, registered 
GP, current cervical 
screening status and date 
of death (where 
applicable). 
 
Details of histology at 
hysterectomy, details of 
all specimens removed, 
details of results of 
analysis (morphology or 
diagnosis codes), full 
details of smear tests 
processed at the 
laboratory. 
 
Data to be 
thus 
derived or 
calculated 
Deprivation score (IMD), 
duration of stay, 
diagnostic grading of 
operation (benign vs pre-
malignant or malignant 
disease), age at surgery. 
Deprivation score (IMD), 
scoring of screening 
history using algorithm, 
whether any vault smears 
undertaken (also using 
operation date from 
HES). 
 
Confirmation of whether 
total or subtotal 
hysterectomy 
undertaken. 
Explanatory  
Notes 
Request full data on all 
West Midlands resident 
women who had a 
hysterectomy during the 
year, 1st April 2002 to 30th 
March 2003.  Requires 
approval of HES security 
and confidentiality 
advisory group. 
 
Request full cervical 
screening histories on all 
women identified in HES 
database.  Requires 
individual permission 
from each of 10 database 
controllers. 
Request full 
histopathology records 
on all women with NHS 
numbers identified in 
HES.  Requires 
permission from each 
of 17 hospitals ethics 
committees and heads 
of department. 
 
Table 2:  Estimated numbers of women in each histology category  
* with 5% excluded for being sub-total operations. 
 
  Sub-Total* 
(Excluded) 
Benign CIN All Cancers Totals 
Not followed up 
VS  
N/A 3240 
90% 
90 
20% 
23 
10% 
3,353 
Followed-up VS N/A 360 
10% 
360 
80% 
202 
90% 
922 
Totals 225 
5% 
3600   
80%  
450 
10% 
225 
5% 
4,275 
(95%)* 
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Appendix M:  Details of dissemination  
 
 
BACKGROUND WORK TO THIS STUDY, BY THE AUTHOR 
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Publications in Peer reviewed journals 
 H J Stokes-Lampard, S Wilson, T Allan, C Waddell, S Kehoe.  Vaginal vault 
smears –‘know more – do less’ a questionnaire survey of primary healthcare 
practitioners.  Cytopathology 2005,16,5,244-52. 
 
Conference Proceedings 
 H J Stokes-Lampard, S Wilson, C Mann, T Allen, S Kehoe, C Waddell, L 
Grovesnor.  Vaginal Vault Smears – Use and abuse in Primary Care.  
Parallel plenary session.  Nov 2003, UKFPCRN, Birmingham, UK 
 H J Stokes-Lampard, S Wilson, C Mann, T Allen, S Kehoe, C Waddell, L 
Grovesnor, R Todd.   Vaginal Vault Smears, are we doing them too often?  
Parallel plenary session. November 2002, NAPCRG, New Orleans, USA. 
 H J Stokes-Lampard, S Wilson, C Mann, T Allen, S Kehoe, C Waddell, L 
Grovesnor, R Todd.   Vaginal Vault Smears – When, Where & Why?  Parallel 
plenary session..  July 2002, SAPC, Birmingham, UK 
 
 
2.  Systematic review of literature concerning the use of vaginal vault smear 
tests 
 
Publications in Peer reviewed journals 
 Stokes-Lampard H, Wilson S, Waddell C, Ryan A, Holder R, Kehoe S.  
Vaginal vault smears after hysterectomy for reasons other than malignancy: a 
systematic review of the literature.  BJOG 2006; 113:1354-1365. 
      (Appendix A includes main results table) 
 
Conference Proceedings 
 H J Stokes-Lampard et al:  Vaginal vault smears, a systematic literature 
review and analysis of their usage after hysterectomy for indications other 
than invasive cancer.  October 2006 NAPCRG Tuscon, Arizona, USA.  
Parallel plenary 
 (Best Plenary of Conference prize winner):  H J Stokes-Lampard, S Wilson, C 
Waddell, S Kehoe, A Ryan, L Grovsenor, T Allan, R Holder, R Ryan.  Vaginal Vault 
Smears – An overview of their use (Incorporating:  A systematic review of the 
literature, a questionnaire survey, and an audit of current practice).  BSCCP 30 
March – 1st April 2006, London.  Plenary. 
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3.  Hospital Audit 
 
Publications in Peer reviewed journals (in press, see Appendix B) 
 H Stokes-Lampard, S Wilson, C Waddell, L Bentley.   Vaginal vault cytology 
tests: Analysis of a decade of data from a UK tertiary centre.   
 
 
Conference Proceedings 
 (Invited Plenary) H J Stokes-Lampard.  Follow-up after hysterectomy, a 
record linkage study. NIHR National Trainee Conference, Birmingham 18 
September 2007. 
 H J Stokes-Lampard.  Disentangling the data:  An analysis of 10 years of 
histopathology records from Birmingham Women’s Hospital NHS Trust. 
UKFPCRO 27 Nov -28 Nov 2006, Liverpool. 
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 H Stokes-Lampard, J Macleod, S Wilson   Who is having a hysterectomy 
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utilisation of vaginal vault cytology tests in women post-hysterectomy. SAPC 
Annual Conference. 8-10th July 2009, St Andrews, UK. 
 
 
Conference posters  
 H J Stokes-Lampard, J Macleod, S Wilson.  Which women are having 
hysterectomy operations and are they being followed up appropriately?  
Factors associated with variability in NHS utilisation of vaginal vault cytology 
tests in women post-hysterectomy; a data linkage study.  RCGP National 
conference, 4-7th November 2009, Glasgow, UK. 
 
 H J Stokes-Lampard, J Macleod, S Wilson.  Which women are having 
hysterectomy operations and are they being followed up appropriately?  
Factors associated with variability in NHS utilisation of vaginal vault cytology 
tests in women post-hysterectomy; a data linkage study.  NIHR Award 
holders conference, 22-23rd September 2009, Manchester, UK. 
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 H J Stokes-Lampard, S Wilson, J Macleod.  Factors associated with 
variability in NHS utilisation of vaginal vault cytology tests in women post 
hysterectomy:  Early results from a data linkage study (a work in progress).  
BSCCP Birmingham, 9-10th April 2008.  (Awarded a prize for Best Abstract). 
 
 
 
FURTHER PLANNED DISSEMINATION OF CURRENT STUDY FINDINGS 
 
 H J Stokes-Lampard, S Wilson, J Macleod, R Holder.  Follow-up after 
hysterectomy by vaginal vault cytology: a database linkage study of women 
having a hysterectomy operation in the West Midlands 2002-2003.  (Full 
research paper). 
 
 H J Stokes-Lampard, S Wilson, J Macleod, R Holder.  A socio-demographic 
analysis of the cohort of women having a hysterectomy in the West Midlands 
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histopathology laboratory data.  (Editorial). 
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tests in women post-hysterectomy; final conclusions from a data linkage 
study.  (will be submitted as an international conference presentation or 
poster to SAPC, NAPCRG, RCGP, BSCCP, in addition to presentation at 
various regional meetings). 
 
 
